#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Blunted ventral striatal responses to anticipated rewards foreshadow problematic drug use in novelty-seeking adolescents
#Text=Novelty-seeking tendencies in adolescents may promote innovation as well as problematic impulsive behaviour, including drug abuse.
1-1	0-7	Blunted	_	
1-2	8-15	ventral	_	
1-3	16-24	striatal	_	
1-4	25-34	responses	_	
1-5	35-37	to	_	
1-6	38-49	anticipated	_	
1-7	50-57	rewards	_	
1-8	58-68	foreshadow	_	
1-9	69-80	problematic	_	
1-10	81-85	drug	_	
1-11	86-89	use	_	
1-12	90-92	in	_	
1-13	93-108	novelty-seeking	_	
1-14	109-120	adolescents	_	
1-15	121-136	Novelty-seeking	_	
1-16	137-147	tendencies	_	
1-17	148-150	in	_	
1-18	151-162	adolescents	_	
1-19	163-166	may	_	
1-20	167-174	promote	_	
1-21	175-185	innovation	_	
1-22	186-188	as	_	
1-23	189-193	well	_	
1-24	194-196	as	_	
1-25	197-208	problematic	_	
1-26	209-218	impulsive	_	
1-27	219-228	behaviour	_	
1-28	228-229	,	_	
1-29	230-239	including	_	
1-30	240-244	drug	_	
1-31	245-250	abuse	_	
1-32	250-251	.	_	

#Text=Previous research has not clarified whether neural hyper- or hypo-responsiveness to anticipated rewards promotes vulnerability in these individuals.
2-1	252-260	Previous	_	
2-2	261-269	research	_	
2-3	270-273	has	_	
2-4	274-277	not	_	
2-5	278-287	clarified	_	
2-6	288-295	whether	_	
2-7	296-302	neural	_	
2-8	303-308	hyper	_	
2-9	308-309	-	_	
2-10	310-312	or	_	
2-11	313-332	hypo-responsiveness	_	
2-12	333-335	to	_	
2-13	336-347	anticipated	_	
2-14	348-355	rewards	_	
2-15	356-364	promotes	_	
2-16	365-378	vulnerability	_	
2-17	379-381	in	_	
2-18	382-387	these	_	
2-19	388-399	individuals	_	
2-20	399-400	.	_	

#Text=Here we use a longitudinal design to track 144 novelty-seeking adolescents at age 14 and 16 to determine whether neural activity in response to anticipated rewards predicts problematic drug use.
3-1	401-405	Here	_	
3-2	406-408	we	_	
3-3	409-412	use	_	
3-4	413-414	a	_	
3-5	415-427	longitudinal	_	
3-6	428-434	design	_	
3-7	435-437	to	_	
3-8	438-443	track	_	
3-9	444-447	144	_	
3-10	448-463	novelty-seeking	_	
3-11	464-475	adolescents	_	
3-12	476-478	at	_	
3-13	479-482	age	_	
3-14	483-485	14	_	
3-15	486-489	and	_	
3-16	490-492	16	_	
3-17	493-495	to	_	
3-18	496-505	determine	_	
3-19	506-513	whether	_	
3-20	514-520	neural	_	
3-21	521-529	activity	_	
3-22	530-532	in	_	
3-23	533-541	response	_	
3-24	542-544	to	_	
3-25	545-556	anticipated	_	
3-26	557-564	rewards	_	
3-27	565-573	predicts	_	
3-28	574-585	problematic	_	
3-29	586-590	drug	_	
3-30	591-594	use	_	
3-31	594-595	.	_	

#Text=We find that diminished BOLD activity in mesolimbic (ventral striatal and midbrain) and prefrontal cortical (dorsolateral prefrontal cortex) regions during reward anticipation at age 14 predicts problematic drug use at age 16.
4-1	596-598	We	_	
4-2	599-603	find	_	
4-3	604-608	that	_	
4-4	609-619	diminished	_	
4-5	620-624	BOLD	_	
4-6	625-633	activity	_	
4-7	634-636	in	_	
4-8	637-647	mesolimbic	_	
4-9	648-649	(	_	
4-10	649-656	ventral	_	
4-11	657-665	striatal	_	
4-12	666-669	and	_	
4-13	670-678	midbrain	_	
4-14	678-679	)	_	
4-15	680-683	and	_	
4-16	684-694	prefrontal	_	
4-17	695-703	cortical	_	
4-18	704-705	(	_	
4-19	705-717	dorsolateral	_	
4-20	718-728	prefrontal	_	
4-21	729-735	cortex	_	
4-22	735-736	)	_	
4-23	737-744	regions	_	
4-24	745-751	during	_	
4-25	752-758	reward	_	
4-26	759-771	anticipation	_	
4-27	772-774	at	_	
4-28	775-778	age	_	
4-29	779-781	14	_	
4-30	782-790	predicts	_	
4-31	791-802	problematic	_	
4-32	803-807	drug	_	
4-33	808-811	use	_	
4-34	812-814	at	_	
4-35	815-818	age	_	
4-36	819-821	16	_	
4-37	821-822	.	_	

#Text=Lower psychometric conscientiousness and steeper discounting of future rewards at age 14 also predicts problematic drug use at age 16, but the neural responses independently predict more variance than psychometric measures.
5-1	823-828	Lower	_	
5-2	829-841	psychometric	_	
5-3	842-859	conscientiousness	_	
5-4	860-863	and	_	
5-5	864-871	steeper	_	
5-6	872-883	discounting	_	
5-7	884-886	of	_	
5-8	887-893	future	_	
5-9	894-901	rewards	_	
5-10	902-904	at	_	
5-11	905-908	age	_	
5-12	909-911	14	_	
5-13	912-916	also	_	
5-14	917-925	predicts	_	
5-15	926-937	problematic	_	
5-16	938-942	drug	_	
5-17	943-946	use	_	
5-18	947-949	at	_	
5-19	950-953	age	_	
5-20	954-956	16	_	
5-21	956-957	,	_	
5-22	958-961	but	_	
5-23	962-965	the	_	
5-24	966-972	neural	_	
5-25	973-982	responses	_	
5-26	983-996	independently	_	
5-27	997-1004	predict	_	
5-28	1005-1009	more	_	
5-29	1010-1018	variance	_	
5-30	1019-1023	than	_	
5-31	1024-1036	psychometric	_	
5-32	1037-1045	measures	_	
5-33	1045-1046	.	_	

#Text=Together, these findings suggest that diminished neural responses to anticipated rewards in novelty-seeking adolescents may increase vulnerability to future problematic drug use.
6-1	1047-1055	Together	_	
6-2	1055-1056	,	_	
6-3	1057-1062	these	_	
6-4	1063-1071	findings	_	
6-5	1072-1079	suggest	_	
6-6	1080-1084	that	_	
6-7	1085-1095	diminished	_	
6-8	1096-1102	neural	_	
6-9	1103-1112	responses	_	
6-10	1113-1115	to	_	
6-11	1116-1127	anticipated	_	
6-12	1128-1135	rewards	_	
6-13	1136-1138	in	_	
6-14	1139-1154	novelty-seeking	_	
6-15	1155-1166	adolescents	_	
6-16	1167-1170	may	_	
6-17	1171-1179	increase	_	
6-18	1180-1193	vulnerability	_	
6-19	1194-1196	to	_	
6-20	1197-1203	future	_	
6-21	1204-1215	problematic	_	
6-22	1216-1220	drug	_	
6-23	1221-1224	use	_	
6-24	1224-1225	.	_	

#Text=Some adolescents seek novelty, but it is unknown whether the brain circuits underlying this behaviour can be used to predict later, problematic behaviour.
7-1	1226-1230	Some	_	
7-2	1231-1242	adolescents	_	
7-3	1243-1247	seek	_	
7-4	1248-1255	novelty	_	
7-5	1255-1256	,	_	
7-6	1257-1260	but	_	
7-7	1261-1263	it	_	
7-8	1264-1266	is	_	
7-9	1267-1274	unknown	_	
7-10	1275-1282	whether	_	
7-11	1283-1286	the	_	
7-12	1287-1292	brain	_	
7-13	1293-1301	circuits	_	
7-14	1302-1312	underlying	_	
7-15	1313-1317	this	_	
7-16	1318-1327	behaviour	_	
7-17	1328-1331	can	_	
7-18	1332-1334	be	_	
7-19	1335-1339	used	_	
7-20	1340-1342	to	_	
7-21	1343-1350	predict	_	
7-22	1351-1356	later	_	
7-23	1356-1357	,	_	
7-24	1358-1369	problematic	_	
7-25	1370-1379	behaviour	_	
7-26	1379-1380	.	_	

#Text=Here, authors show that diminished ventral striatal and prefrontal activity in response to anticipated rewards at age 14 in these individuals predicts problematic drug use at age 16.
8-1	1381-1385	Here	_	
8-2	1385-1386	,	_	
8-3	1387-1394	authors	_	
8-4	1395-1399	show	_	
8-5	1400-1404	that	_	
8-6	1405-1415	diminished	_	
8-7	1416-1423	ventral	_	
8-8	1424-1432	striatal	_	
8-9	1433-1436	and	_	
8-10	1437-1447	prefrontal	_	
8-11	1448-1456	activity	_	
8-12	1457-1459	in	_	
8-13	1460-1468	response	_	
8-14	1469-1471	to	_	
8-15	1472-1483	anticipated	_	
8-16	1484-1491	rewards	_	
8-17	1492-1494	at	_	
8-18	1495-1498	age	_	
8-19	1499-1501	14	_	
8-20	1502-1504	in	_	
8-21	1505-1510	these	_	
8-22	1511-1522	individuals	_	
8-23	1523-1531	predicts	_	
8-24	1532-1543	problematic	_	
8-25	1544-1548	drug	_	
8-26	1549-1552	use	_	
8-27	1553-1555	at	_	
8-28	1556-1559	age	_	
8-29	1560-1562	16	_	
8-30	1562-1563	.	_	

#Text=Individual differences in novelty seeking are associated with impulsive choice (or a preference for smaller but sooner over larger but later rewards).
9-1	1564-1574	Individual	_	
9-2	1575-1586	differences	_	
9-3	1587-1589	in	_	
9-4	1590-1597	novelty	_	
9-5	1598-1605	seeking	_	
9-6	1606-1609	are	_	
9-7	1610-1620	associated	_	
9-8	1621-1625	with	_	
9-9	1626-1635	impulsive	_	
9-10	1636-1642	choice	_	
9-11	1643-1644	(	_	
9-12	1644-1646	or	_	
9-13	1647-1648	a	_	
9-14	1649-1659	preference	_	
9-15	1660-1663	for	_	
9-16	1664-1671	smaller	_	
9-17	1672-1675	but	_	
9-18	1676-1682	sooner	_	
9-19	1683-1687	over	_	
9-20	1688-1694	larger	_	
9-21	1695-1698	but	_	
9-22	1699-1704	later	_	
9-23	1705-1712	rewards	_	
9-24	1712-1713	)	_	
9-25	1713-1714	.	_	

#Text=Specifically, novelty-seeking traits in adolescents can foreshadow later problematic behaviours including excessive drug use.
10-1	1715-1727	Specifically	_	
10-2	1727-1728	,	_	
10-3	1729-1744	novelty-seeking	_	
10-4	1745-1751	traits	_	
10-5	1752-1754	in	_	
10-6	1755-1766	adolescents	_	
10-7	1767-1770	can	_	
10-8	1771-1781	foreshadow	_	
10-9	1782-1787	later	_	
10-10	1788-1799	problematic	_	
10-11	1800-1810	behaviours	_	
10-12	1811-1820	including	_	
10-13	1821-1830	excessive	_	
10-14	1831-1835	drug	_	
10-15	1836-1839	use	_	
10-16	1839-1840	.	_	

#Text=Novelty seeking, in general, and impulsive choice, in particular, may recruit distinct neural systems that include a motivational circuit comprising mesolimbic dopamine projections from the ventral tegmental area of the midbrain to the ventral striatum (VS) as well as a countervailing cognitive control circuit comprising prefrontal cortical (PFC) regions.
11-1	1841-1848	Novelty	_	
11-2	1849-1856	seeking	_	
11-3	1856-1857	,	_	
11-4	1858-1860	in	_	
11-5	1861-1868	general	_	
11-6	1868-1869	,	_	
11-7	1870-1873	and	_	
11-8	1874-1883	impulsive	_	
11-9	1884-1890	choice	_	
11-10	1890-1891	,	_	
11-11	1892-1894	in	_	
11-12	1895-1905	particular	_	
11-13	1905-1906	,	_	
11-14	1907-1910	may	_	
11-15	1911-1918	recruit	_	
11-16	1919-1927	distinct	_	
11-17	1928-1934	neural	_	
11-18	1935-1942	systems	_	
11-19	1943-1947	that	_	
11-20	1948-1955	include	_	
11-21	1956-1957	a	_	
11-22	1958-1970	motivational	_	
11-23	1971-1978	circuit	_	
11-24	1979-1989	comprising	_	
11-25	1990-2000	mesolimbic	_	
11-26	2001-2009	dopamine	_	
11-27	2010-2021	projections	_	
11-28	2022-2026	from	_	
11-29	2027-2030	the	_	
11-30	2031-2038	ventral	_	
11-31	2039-2048	tegmental	_	
11-32	2049-2053	area	_	
11-33	2054-2056	of	_	
11-34	2057-2060	the	_	
11-35	2061-2069	midbrain	_	
11-36	2070-2072	to	_	
11-37	2073-2076	the	_	
11-38	2077-2084	ventral	_	
11-39	2085-2093	striatum	_	
11-40	2094-2095	(	_	
11-41	2095-2097	VS	_	
11-42	2097-2098	)	_	
11-43	2099-2101	as	_	
11-44	2102-2106	well	_	
11-45	2107-2109	as	_	
11-46	2110-2111	a	_	
11-47	2112-2126	countervailing	_	
11-48	2127-2136	cognitive	_	
11-49	2137-2144	control	_	
11-50	2145-2152	circuit	_	
11-51	2153-2163	comprising	_	
11-52	2164-2174	prefrontal	_	
11-53	2175-2183	cortical	_	
11-54	2184-2185	(	_	
11-55	2185-2188	PFC	_	
11-56	2188-2189	)	_	
11-57	2190-2197	regions	_	
11-58	2197-2198	.	_	

#Text=The balance of activity in these circuits may shift over development, consistent with evidence for earlier development of the motivational circuit than the cognitive control circuit in humans.
12-1	2199-2202	The	_	
12-2	2203-2210	balance	_	
12-3	2211-2213	of	_	
12-4	2214-2222	activity	_	
12-5	2223-2225	in	_	
12-6	2226-2231	these	_	
12-7	2232-2240	circuits	_	
12-8	2241-2244	may	_	
12-9	2245-2250	shift	_	
12-10	2251-2255	over	_	
12-11	2256-2267	development	_	
12-12	2267-2268	,	_	
12-13	2269-2279	consistent	_	
12-14	2280-2284	with	_	
12-15	2285-2293	evidence	_	
12-16	2294-2297	for	_	
12-17	2298-2305	earlier	_	
12-18	2306-2317	development	_	
12-19	2318-2320	of	_	
12-20	2321-2324	the	_	
12-21	2325-2337	motivational	_	
12-22	2338-2345	circuit	_	
12-23	2346-2350	than	_	
12-24	2351-2354	the	_	
12-25	2355-2364	cognitive	_	
12-26	2365-2372	control	_	
12-27	2373-2380	circuit	_	
12-28	2381-2383	in	_	
12-29	2384-2390	humans	_	
12-30	2390-2391	.	_	

#Text=Since dopaminergic modulation of these circuits can influence both motivation and cognitive control, delays in the development of these circuits and their relative activity could increase impulsive choice, including drug use.
13-1	2392-2397	Since	_	
13-2	2398-2410	dopaminergic	_	
13-3	2411-2421	modulation	_	
13-4	2422-2424	of	_	
13-5	2425-2430	these	_	
13-6	2431-2439	circuits	_	
13-7	2440-2443	can	_	
13-8	2444-2453	influence	_	
13-9	2454-2458	both	_	
13-10	2459-2469	motivation	_	
13-11	2470-2473	and	_	
13-12	2474-2483	cognitive	_	
13-13	2484-2491	control	_	
13-14	2491-2492	,	_	
13-15	2493-2499	delays	_	
13-16	2500-2502	in	_	
13-17	2503-2506	the	_	
13-18	2507-2518	development	_	
13-19	2519-2521	of	_	
13-20	2522-2527	these	_	
13-21	2528-2536	circuits	_	
13-22	2537-2540	and	_	
13-23	2541-2546	their	_	
13-24	2547-2555	relative	_	
13-25	2556-2564	activity	_	
13-26	2565-2570	could	_	
13-27	2571-2579	increase	_	
13-28	2580-2589	impulsive	_	
13-29	2590-2596	choice	_	
13-30	2596-2597	,	_	
13-31	2598-2607	including	_	
13-32	2608-2612	drug	_	
13-33	2613-2616	use	_	
13-34	2616-2617	.	_	

#Text=Theoretical accounts differ, however, with respect to exactly how activity in these motivational and control circuits can influence impulsive choice in adolescents.
14-1	2618-2629	Theoretical	_	
14-2	2630-2638	accounts	_	
14-3	2639-2645	differ	_	
14-4	2645-2646	,	_	
14-5	2647-2654	however	_	
14-6	2654-2655	,	_	
14-7	2656-2660	with	_	
14-8	2661-2668	respect	_	
14-9	2669-2671	to	_	
14-10	2672-2679	exactly	_	
14-11	2680-2683	how	_	
14-12	2684-2692	activity	_	
14-13	2693-2695	in	_	
14-14	2696-2701	these	_	
14-15	2702-2714	motivational	_	
14-16	2715-2718	and	_	
14-17	2719-2726	control	_	
14-18	2727-2735	circuits	_	
14-19	2736-2739	can	_	
14-20	2740-2749	influence	_	
14-21	2750-2759	impulsive	_	
14-22	2760-2766	choice	_	
14-23	2767-2769	in	_	
14-24	2770-2781	adolescents	_	
14-25	2781-2782	.	_	

#Text=On the one hand, impulsive choice in adolescents has been attributed to diminished motivation, such that drug abuse may reflect attempts to compensate for motivational deficits.
15-1	2783-2785	On	_	
15-2	2786-2789	the	_	
15-3	2790-2793	one	_	
15-4	2794-2798	hand	_	
15-5	2798-2799	,	_	
15-6	2800-2809	impulsive	_	
15-7	2810-2816	choice	_	
15-8	2817-2819	in	_	
15-9	2820-2831	adolescents	_	
15-10	2832-2835	has	_	
15-11	2836-2840	been	_	
15-12	2841-2851	attributed	_	
15-13	2852-2854	to	_	
15-14	2855-2865	diminished	_	
15-15	2866-2876	motivation	_	
15-16	2876-2877	,	_	
15-17	2878-2882	such	_	
15-18	2883-2887	that	_	
15-19	2888-2892	drug	_	
15-20	2893-2898	abuse	_	
15-21	2899-2902	may	_	
15-22	2903-2910	reflect	_	
15-23	2911-2919	attempts	_	
15-24	2920-2922	to	_	
15-25	2923-2933	compensate	_	
15-26	2934-2937	for	_	
15-27	2938-2950	motivational	_	
15-28	2951-2959	deficits	_	
15-29	2959-2960	.	_	

#Text=Support for this account has come from neuroimaging studies, suggesting that adolescents show diminished responses during anticipation of monetary rewards relative to adults, which are more pronounced in adolescents with contemporaneous drug use.
16-1	2961-2968	Support	_	
16-2	2969-2972	for	_	
16-3	2973-2977	this	_	
16-4	2978-2985	account	_	
16-5	2986-2989	has	_	
16-6	2990-2994	come	_	
16-7	2995-2999	from	_	
16-8	3000-3012	neuroimaging	_	
16-9	3013-3020	studies	_	
16-10	3020-3021	,	_	
16-11	3022-3032	suggesting	_	
16-12	3033-3037	that	_	
16-13	3038-3049	adolescents	_	
16-14	3050-3054	show	_	
16-15	3055-3065	diminished	_	
16-16	3066-3075	responses	_	
16-17	3076-3082	during	_	
16-18	3083-3095	anticipation	_	
16-19	3096-3098	of	_	
16-20	3099-3107	monetary	_	
16-21	3108-3115	rewards	_	
16-22	3116-3124	relative	_	
16-23	3125-3127	to	_	
16-24	3128-3134	adults	_	
16-25	3134-3135	,	_	
16-26	3136-3141	which	_	
16-27	3142-3145	are	_	
16-28	3146-3150	more	_	
16-29	3151-3161	pronounced	_	
16-30	3162-3164	in	_	
16-31	3165-3176	adolescents	_	
16-32	3177-3181	with	_	
16-33	3182-3197	contemporaneous	_	
16-34	3198-3202	drug	_	
16-35	3203-3206	use	_	
16-36	3206-3207	.	_	

#Text=On the other hand, impulsive behaviour in adolescents has also been attributed to excessive motivation, which could magnify the impact of received rewards and fuel subsequent impulsive choice.
17-1	3208-3210	On	_	
17-2	3211-3214	the	_	
17-3	3215-3220	other	_	
17-4	3221-3225	hand	_	
17-5	3225-3226	,	_	
17-6	3227-3236	impulsive	_	
17-7	3237-3246	behaviour	_	
17-8	3247-3249	in	_	
17-9	3250-3261	adolescents	_	
17-10	3262-3265	has	_	
17-11	3266-3270	also	_	
17-12	3271-3275	been	_	
17-13	3276-3286	attributed	_	
17-14	3287-3289	to	_	
17-15	3290-3299	excessive	_	
17-16	3300-3310	motivation	_	
17-17	3310-3311	,	_	
17-18	3312-3317	which	_	
17-19	3318-3323	could	_	
17-20	3324-3331	magnify	_	
17-21	3332-3335	the	_	
17-22	3336-3342	impact	_	
17-23	3343-3345	of	_	
17-24	3346-3354	received	_	
17-25	3355-3362	rewards	_	
17-26	3363-3366	and	_	
17-27	3367-3371	fuel	_	
17-28	3372-3382	subsequent	_	
17-29	3383-3392	impulsive	_	
17-30	3393-3399	choice	_	
17-31	3399-3400	.	_	

#Text=Support for this countervailing view comes from neuroimaging studies, indicating that adolescents show enhanced responses to monetarily rewarding outcomes relative to adults.
18-1	3401-3408	Support	_	
18-2	3409-3412	for	_	
18-3	3413-3417	this	_	
18-4	3418-3432	countervailing	_	
18-5	3433-3437	view	_	
18-6	3438-3443	comes	_	
18-7	3444-3448	from	_	
18-8	3449-3461	neuroimaging	_	
18-9	3462-3469	studies	_	
18-10	3469-3470	,	_	
18-11	3471-3481	indicating	_	
18-12	3482-3486	that	_	
18-13	3487-3498	adolescents	_	
18-14	3499-3503	show	_	
18-15	3504-3512	enhanced	_	
18-16	3513-3522	responses	_	
18-17	3523-3525	to	_	
18-18	3526-3536	monetarily	_	
18-19	3537-3546	rewarding	_	
18-20	3547-3555	outcomes	_	
18-21	3556-3564	relative	_	
18-22	3565-3567	to	_	
18-23	3568-3574	adults	_	
18-24	3574-3575	.	_	

#Text=More recent integrations of these findings can resolve these apparent discrepancies by clarifying that adolescents show both diminished responses during reward anticipation, as well as increased responses to reward outcomes, relative to adults.
19-1	3576-3580	More	_	
19-2	3581-3587	recent	_	
19-3	3588-3600	integrations	_	
19-4	3601-3603	of	_	
19-5	3604-3609	these	_	
19-6	3610-3618	findings	_	
19-7	3619-3622	can	_	
19-8	3623-3630	resolve	_	
19-9	3631-3636	these	_	
19-10	3637-3645	apparent	_	
19-11	3646-3659	discrepancies	_	
19-12	3660-3662	by	_	
19-13	3663-3673	clarifying	_	
19-14	3674-3678	that	_	
19-15	3679-3690	adolescents	_	
19-16	3691-3695	show	_	
19-17	3696-3700	both	_	
19-18	3701-3711	diminished	_	
19-19	3712-3721	responses	_	
19-20	3722-3728	during	_	
19-21	3729-3735	reward	_	
19-22	3736-3748	anticipation	_	
19-23	3748-3749	,	_	
19-24	3750-3752	as	_	
19-25	3753-3757	well	_	
19-26	3758-3760	as	_	
19-27	3761-3770	increased	_	
19-28	3771-3780	responses	_	
19-29	3781-3783	to	_	
19-30	3784-3790	reward	_	
19-31	3791-3799	outcomes	_	
19-32	3799-3800	,	_	
19-33	3801-3809	relative	_	
19-34	3810-3812	to	_	
19-35	3813-3819	adults	_	
19-36	3819-3820	.	_	

#Text=For novelty-seeking adolescents, impulsive choices may confer benefits as well as costs.
20-1	3821-3824	For	_	
20-2	3825-3840	novelty-seeking	_	
20-3	3841-3852	adolescents	_	
20-4	3852-3853	,	_	
20-5	3854-3863	impulsive	_	
20-6	3864-3871	choices	_	
20-7	3872-3875	may	_	
20-8	3876-3882	confer	_	
20-9	3883-3891	benefits	_	
20-10	3892-3894	as	_	
20-11	3895-3899	well	_	
20-12	3900-3902	as	_	
20-13	3903-3908	costs	_	
20-14	3908-3909	.	_	

#Text=Although novelty-seeking adolescents have been labelled as ‘reckless', ‘stupid', ‘irrational', ‘callous', ‘lazy' or even ‘violent', novelty seeking could confer either proximal or distal advantages.
21-1	3910-3918	Although	_	
21-2	3919-3934	novelty-seeking	_	
21-3	3935-3946	adolescents	_	
21-4	3947-3951	have	_	
21-5	3952-3956	been	_	
21-6	3957-3965	labelled	_	
21-7	3966-3968	as	_	
21-8	3969-3970	‘	_	
21-9	3970-3978	reckless	_	
21-10	3978-3979	'	_	
21-11	3979-3980	,	_	
21-12	3981-3982	‘	_	
21-13	3982-3988	stupid	_	
21-14	3988-3989	'	_	
21-15	3989-3990	,	_	
21-16	3991-3992	‘	_	
21-17	3992-4002	irrational	_	
21-18	4002-4003	'	_	
21-19	4003-4004	,	_	
21-20	4005-4006	‘	_	
21-21	4006-4013	callous	_	
21-22	4013-4014	'	_	
21-23	4014-4015	,	_	
21-24	4016-4017	‘	_	
21-25	4017-4021	lazy	_	
21-26	4021-4022	'	_	
21-27	4023-4025	or	_	
21-28	4026-4030	even	_	
21-29	4031-4032	‘	_	
21-30	4032-4039	violent	_	
21-31	4039-4040	'	_	
21-32	4040-4041	,	_	
21-33	4042-4049	novelty	_	
21-34	4050-4057	seeking	_	
21-35	4058-4063	could	_	
21-36	4064-4070	confer	_	
21-37	4071-4077	either	_	
21-38	4078-4086	proximal	_	
21-39	4087-4089	or	_	
21-40	4090-4096	distal	_	
21-41	4097-4107	advantages	_	
21-42	4107-4108	.	_	

#Text=For instance, novelty seeking encourages emigration away from relatives (which minimizes inbreeding), and can facilitate discovery and exploration of new opportunities and behaviours that might prove useful later in life.
22-1	4109-4112	For	_	
22-2	4113-4121	instance	_	
22-3	4121-4122	,	_	
22-4	4123-4130	novelty	_	
22-5	4131-4138	seeking	_	
22-6	4139-4149	encourages	_	
22-7	4150-4160	emigration	_	
22-8	4161-4165	away	_	
22-9	4166-4170	from	_	
22-10	4171-4180	relatives	_	
22-11	4181-4182	(	_	
22-12	4182-4187	which	_	
22-13	4188-4197	minimizes	_	
22-14	4198-4208	inbreeding	_	
22-15	4208-4209	)	_	
22-16	4209-4210	,	_	
22-17	4211-4214	and	_	
22-18	4215-4218	can	_	
22-19	4219-4229	facilitate	_	
22-20	4230-4239	discovery	_	
22-21	4240-4243	and	_	
22-22	4244-4255	exploration	_	
22-23	4256-4258	of	_	
22-24	4259-4262	new	_	
22-25	4263-4276	opportunities	_	
22-26	4277-4280	and	_	
22-27	4281-4291	behaviours	_	
22-28	4292-4296	that	_	
22-29	4297-4302	might	_	
22-30	4303-4308	prove	_	
22-31	4309-4315	useful	_	
22-32	4316-4321	later	_	
22-33	4322-4324	in	_	
22-34	4325-4329	life	_	
22-35	4329-4330	.	_	

#Text=Novelty seeking may also increase self-esteem when valued by peers, since peer influence increases over adolescence.
23-1	4331-4338	Novelty	_	
23-2	4339-4346	seeking	_	
23-3	4347-4350	may	_	
23-4	4351-4355	also	_	
23-5	4356-4364	increase	_	
23-6	4365-4376	self-esteem	_	
23-7	4377-4381	when	_	
23-8	4382-4388	valued	_	
23-9	4389-4391	by	_	
23-10	4392-4397	peers	_	
23-11	4397-4398	,	_	
23-12	4399-4404	since	_	
23-13	4405-4409	peer	_	
23-14	4410-4419	influence	_	
23-15	4420-4429	increases	_	
23-16	4430-4434	over	_	
23-17	4435-4446	adolescence	_	
23-18	4446-4447	.	_	

#Text=Finally, novelty seeking can elevate reproductive success in competitive environments in other species as well as humans, since others might perceive willingness to pursue novel options as a marker of ability.
24-1	4448-4455	Finally	_	
24-2	4455-4456	,	_	
24-3	4457-4464	novelty	_	
24-4	4465-4472	seeking	_	
24-5	4473-4476	can	_	
24-6	4477-4484	elevate	_	
24-7	4485-4497	reproductive	_	
24-8	4498-4505	success	_	
24-9	4506-4508	in	_	
24-10	4509-4520	competitive	_	
24-11	4521-4533	environments	_	
24-12	4534-4536	in	_	
24-13	4537-4542	other	_	
24-14	4543-4550	species	_	
24-15	4551-4553	as	_	
24-16	4554-4558	well	_	
24-17	4559-4561	as	_	
24-18	4562-4568	humans	_	
24-19	4568-4569	,	_	
24-20	4570-4575	since	_	
24-21	4576-4582	others	_	
24-22	4583-4588	might	_	
24-23	4589-4597	perceive	_	
24-24	4598-4609	willingness	_	
24-25	4610-4612	to	_	
24-26	4613-4619	pursue	_	
24-27	4620-4625	novel	_	
24-28	4626-4633	options	_	
24-29	4634-4636	as	_	
24-30	4637-4638	a	_	
24-31	4639-4645	marker	_	
24-32	4646-4648	of	_	
24-33	4649-4656	ability	_	
24-34	4656-4657	.	_	

#Text=For instance, in business, novelty seeking has been associated with creativity, entrepreneurial initiative and commercial success.
25-1	4658-4661	For	_	
25-2	4662-4670	instance	_	
25-3	4670-4671	,	_	
25-4	4672-4674	in	_	
25-5	4675-4683	business	_	
25-6	4683-4684	,	_	
25-7	4685-4692	novelty	_	
25-8	4693-4700	seeking	_	
25-9	4701-4704	has	_	
25-10	4705-4709	been	_	
25-11	4710-4720	associated	_	
25-12	4721-4725	with	_	
25-13	4726-4736	creativity	_	
25-14	4736-4737	,	_	
25-15	4738-4753	entrepreneurial	_	
25-16	4754-4764	initiative	_	
25-17	4765-4768	and	_	
25-18	4769-4779	commercial	_	
25-19	4780-4787	success	_	
25-20	4787-4788	.	_	

#Text=Thus, while novelty-seeking behaviour can both harm and help adolescents, it is currently unclear how or when novelty-seeking traits promote pathology versus promise.
26-1	4789-4793	Thus	_	
26-2	4793-4794	,	_	
26-3	4795-4800	while	_	
26-4	4801-4816	novelty-seeking	_	
26-5	4817-4826	behaviour	_	
26-6	4827-4830	can	_	
26-7	4831-4835	both	_	
26-8	4836-4840	harm	_	
26-9	4841-4844	and	_	
26-10	4845-4849	help	_	
26-11	4850-4861	adolescents	_	
26-12	4861-4862	,	_	
26-13	4863-4865	it	_	
26-14	4866-4868	is	_	
26-15	4869-4878	currently	_	
26-16	4879-4886	unclear	_	
26-17	4887-4890	how	_	
26-18	4891-4893	or	_	
26-19	4894-4898	when	_	
26-20	4899-4914	novelty-seeking	_	
26-21	4915-4921	traits	_	
26-22	4922-4929	promote	_	
26-23	4930-4939	pathology	_	
26-24	4940-4946	versus	_	
26-25	4947-4954	promise	_	
26-26	4954-4955	.	_	

#Text=In this research, we used a longitudinal design to identify which neural and behavioural factors predispose novelty-seeking adolescents to harmful outcomes specifically related to problematic drug use (PDU).
27-1	4956-4958	In	_	
27-2	4959-4963	this	_	
27-3	4964-4972	research	_	
27-4	4972-4973	,	_	
27-5	4974-4976	we	_	
27-6	4977-4981	used	_	
27-7	4982-4983	a	_	
27-8	4984-4996	longitudinal	_	
27-9	4997-5003	design	_	
27-10	5004-5006	to	_	
27-11	5007-5015	identify	_	
27-12	5016-5021	which	_	
27-13	5022-5028	neural	_	
27-14	5029-5032	and	_	
27-15	5033-5044	behavioural	_	
27-16	5045-5052	factors	_	
27-17	5053-5063	predispose	_	
27-18	5064-5079	novelty-seeking	_	
27-19	5080-5091	adolescents	_	
27-20	5092-5094	to	_	
27-21	5095-5102	harmful	_	
27-22	5103-5111	outcomes	_	
27-23	5112-5124	specifically	_	
27-24	5125-5132	related	_	
27-25	5133-5135	to	_	
27-26	5136-5147	problematic	_	
27-27	5148-5152	drug	_	
27-28	5153-5156	use	_	
27-29	5157-5158	(	_	
27-30	5158-5161	PDU	_	
27-31	5161-5162	)	_	
27-32	5162-5163	.	_	

#Text=This design could reveal whether functional or structural neural markers at age 14 preceded PDU at age 16.
28-1	5164-5168	This	_	
28-2	5169-5175	design	_	
28-3	5176-5181	could	_	
28-4	5182-5188	reveal	_	
28-5	5189-5196	whether	_	
28-6	5197-5207	functional	_	
28-7	5208-5210	or	_	
28-8	5211-5221	structural	_	
28-9	5222-5228	neural	_	
28-10	5229-5236	markers	_	
28-11	5237-5239	at	_	
28-12	5240-5243	age	_	
28-13	5244-5246	14	_	
28-14	5247-5255	preceded	_	
28-15	5256-5259	PDU	_	
28-16	5260-5262	at	_	
28-17	5263-5266	age	_	
28-18	5267-5269	16	_	
28-19	5269-5270	.	_	

#Text=We targeted motivational circuitry using a variant of a well-established neuroimaging task that reliably indexes individual differences in neural activity during reward anticipation (that is, the Monetary Incentive Delay Task).
29-1	5271-5273	We	_	
29-2	5274-5282	targeted	_	
29-3	5283-5295	motivational	_	
29-4	5296-5305	circuitry	_	
29-5	5306-5311	using	_	
29-6	5312-5313	a	_	
29-7	5314-5321	variant	_	
29-8	5322-5324	of	_	
29-9	5325-5326	a	_	
29-10	5327-5343	well-established	_	
29-11	5344-5356	neuroimaging	_	
29-12	5357-5361	task	_	
29-13	5362-5366	that	_	
29-14	5367-5375	reliably	_	
29-15	5376-5383	indexes	_	
29-16	5384-5394	individual	_	
29-17	5395-5406	differences	_	
29-18	5407-5409	in	_	
29-19	5410-5416	neural	_	
29-20	5417-5425	activity	_	
29-21	5426-5432	during	_	
29-22	5433-5439	reward	_	
29-23	5440-5452	anticipation	_	
29-24	5453-5454	(	_	
29-25	5454-5458	that	_	
29-26	5459-5461	is	_	
29-27	5461-5462	,	_	
29-28	5463-5466	the	_	
29-29	5467-5475	Monetary	_	
29-30	5476-5485	Incentive	_	
29-31	5486-5491	Delay	_	
29-32	5492-5496	Task	_	
29-33	5496-5497	)	_	
29-34	5497-5498	.	_	

#Text=Previous research has associated mesolimbic activity during reward anticipation with dopamine release as well as craving for drugs of abuse.
30-1	5499-5507	Previous	_	
30-2	5508-5516	research	_	
30-3	5517-5520	has	_	
30-4	5521-5531	associated	_	
30-5	5532-5542	mesolimbic	_	
30-6	5543-5551	activity	_	
30-7	5552-5558	during	_	
30-8	5559-5565	reward	_	
30-9	5566-5578	anticipation	_	
30-10	5579-5583	with	_	
30-11	5584-5592	dopamine	_	
30-12	5593-5600	release	_	
30-13	5601-5603	as	_	
30-14	5604-5608	well	_	
30-15	5609-5611	as	_	
30-16	5612-5619	craving	_	
30-17	5620-5623	for	_	
30-18	5624-5629	drugs	_	
30-19	5630-5632	of	_	
30-20	5633-5638	abuse	_	
30-21	5638-5639	.	_	

#Text=The current longitudinal design allowed us to test whether novelty-seeking adolescents with decreased neural responses during reward anticipation would be more likely to develop PDU (defined as the intake of increased amounts of licit and/or illicit drugs) over 2 years later.
31-1	5640-5643	The	_	
31-2	5644-5651	current	_	
31-3	5652-5664	longitudinal	_	
31-4	5665-5671	design	_	
31-5	5672-5679	allowed	_	
31-6	5680-5682	us	_	
31-7	5683-5685	to	_	
31-8	5686-5690	test	_	
31-9	5691-5698	whether	_	
31-10	5699-5714	novelty-seeking	_	
31-11	5715-5726	adolescents	_	
31-12	5727-5731	with	_	
31-13	5732-5741	decreased	_	
31-14	5742-5748	neural	_	
31-15	5749-5758	responses	_	
31-16	5759-5765	during	_	
31-17	5766-5772	reward	_	
31-18	5773-5785	anticipation	_	
31-19	5786-5791	would	_	
31-20	5792-5794	be	_	
31-21	5795-5799	more	_	
31-22	5800-5806	likely	_	
31-23	5807-5809	to	_	
31-24	5810-5817	develop	_	
31-25	5818-5821	PDU	_	
31-26	5822-5823	(	_	
31-27	5823-5830	defined	_	
31-28	5831-5833	as	_	
31-29	5834-5837	the	_	
31-30	5838-5844	intake	_	
31-31	5845-5847	of	_	
31-32	5848-5857	increased	_	
31-33	5858-5865	amounts	_	
31-34	5866-5868	of	_	
31-35	5869-5874	licit	_	
31-36	5875-5878	and	_	
31-37	5878-5879	/	_	
31-38	5879-5881	or	_	
31-39	5882-5889	illicit	_	
31-40	5890-5895	drugs	_	
31-41	5895-5896	)	_	
31-42	5897-5901	over	_	
31-43	5902-5903	2	_	
31-44	5904-5909	years	_	
31-45	5910-5915	later	_	
31-46	5915-5916	.	_	

#Text=This design also afforded a direct comparison of neural versus psychometric predictors of PDU.
32-1	5917-5921	This	_	
32-2	5922-5928	design	_	
32-3	5929-5933	also	_	
32-4	5934-5942	afforded	_	
32-5	5943-5944	a	_	
32-6	5945-5951	direct	_	
32-7	5952-5962	comparison	_	
32-8	5963-5965	of	_	
32-9	5966-5972	neural	_	
32-10	5973-5979	versus	_	
32-11	5980-5992	psychometric	_	
32-12	5993-6003	predictors	_	
32-13	6004-6006	of	_	
32-14	6007-6010	PDU	_	
32-15	6010-6011	.	_	

#Text=Based on previous findings implicating blunted neural responses during reward anticipation in adolescents with contemporaneous PDU, we hypothesized that decreased neural responses during reward anticipation might predict eventual PDU in novelty-seeking adolescents, and further, that these neural markers might augment predictions afforded by more conventional psychometric measures.
33-1	6012-6017	Based	_	
33-2	6018-6020	on	_	
33-3	6021-6029	previous	_	
33-4	6030-6038	findings	_	
33-5	6039-6050	implicating	_	
33-6	6051-6058	blunted	_	
33-7	6059-6065	neural	_	
33-8	6066-6075	responses	_	
33-9	6076-6082	during	_	
33-10	6083-6089	reward	_	
33-11	6090-6102	anticipation	_	
33-12	6103-6105	in	_	
33-13	6106-6117	adolescents	_	
33-14	6118-6122	with	_	
33-15	6123-6138	contemporaneous	_	
33-16	6139-6142	PDU	_	
33-17	6142-6143	,	_	
33-18	6144-6146	we	_	
33-19	6147-6159	hypothesized	_	
33-20	6160-6164	that	_	
33-21	6165-6174	decreased	_	
33-22	6175-6181	neural	_	
33-23	6182-6191	responses	_	
33-24	6192-6198	during	_	
33-25	6199-6205	reward	_	
33-26	6206-6218	anticipation	_	
33-27	6219-6224	might	_	
33-28	6225-6232	predict	_	
33-29	6233-6241	eventual	_	
33-30	6242-6245	PDU	_	
33-31	6246-6248	in	_	
33-32	6249-6264	novelty-seeking	_	
33-33	6265-6276	adolescents	_	
33-34	6276-6277	,	_	
33-35	6278-6281	and	_	
33-36	6282-6289	further	_	
33-37	6289-6290	,	_	
33-38	6291-6295	that	_	
33-39	6296-6301	these	_	
33-40	6302-6308	neural	_	
33-41	6309-6316	markers	_	
33-42	6317-6322	might	_	
33-43	6323-6330	augment	_	
33-44	6331-6342	predictions	_	
33-45	6343-6351	afforded	_	
33-46	6352-6354	by	_	
33-47	6355-6359	more	_	
33-48	6360-6372	conventional	_	
33-49	6373-6385	psychometric	_	
33-50	6386-6394	measures	_	
33-51	6394-6395	.	_	

#Text=Consistent with these hypotheses, we find that novelty-seeking adolescents who go on to develop PDU initially show reduced neural activity during reward anticipation (specifically, in the midbrain, VS and dorsolateral prefrontal cortex).
34-1	6396-6406	Consistent	_	
34-2	6407-6411	with	_	
34-3	6412-6417	these	_	
34-4	6418-6428	hypotheses	_	
34-5	6428-6429	,	_	
34-6	6430-6432	we	_	
34-7	6433-6437	find	_	
34-8	6438-6442	that	_	
34-9	6443-6458	novelty-seeking	_	
34-10	6459-6470	adolescents	_	
34-11	6471-6474	who	_	
34-12	6475-6477	go	_	
34-13	6478-6480	on	_	
34-14	6481-6483	to	_	
34-15	6484-6491	develop	_	
34-16	6492-6495	PDU	_	
34-17	6496-6505	initially	_	
34-18	6506-6510	show	_	
34-19	6511-6518	reduced	_	
34-20	6519-6525	neural	_	
34-21	6526-6534	activity	_	
34-22	6535-6541	during	_	
34-23	6542-6548	reward	_	
34-24	6549-6561	anticipation	_	
34-25	6562-6563	(	_	
34-26	6563-6575	specifically	_	
34-27	6575-6576	,	_	
34-28	6577-6579	in	_	
34-29	6580-6583	the	_	
34-30	6584-6592	midbrain	_	
34-31	6592-6593	,	_	
34-32	6594-6596	VS	_	
34-33	6597-6600	and	_	
34-34	6601-6613	dorsolateral	_	
34-35	6614-6624	prefrontal	_	
34-36	6625-6631	cortex	_	
34-37	6631-6632	)	_	
34-38	6632-6633	.	_	

#Text=These differences in neural activity cannot be accounted for by volumetric changes, and augment (or even exceed) predictions afforded by more conventional psychometric trait measures (specifically, temporal discounting and low conscientiousness).
35-1	6634-6639	These	_	
35-2	6640-6651	differences	_	
35-3	6652-6654	in	_	
35-4	6655-6661	neural	_	
35-5	6662-6670	activity	_	
35-6	6671-6677	cannot	_	
35-7	6678-6680	be	_	
35-8	6681-6690	accounted	_	
35-9	6691-6694	for	_	
35-10	6695-6697	by	_	
35-11	6698-6708	volumetric	_	
35-12	6709-6716	changes	_	
35-13	6716-6717	,	_	
35-14	6718-6721	and	_	
35-15	6722-6729	augment	_	
35-16	6730-6731	(	_	
35-17	6731-6733	or	_	
35-18	6734-6738	even	_	
35-19	6739-6745	exceed	_	
35-20	6745-6746	)	_	
35-21	6747-6758	predictions	_	
35-22	6759-6767	afforded	_	
35-23	6768-6770	by	_	
35-24	6771-6775	more	_	
35-25	6776-6788	conventional	_	
35-26	6789-6801	psychometric	_	
35-27	6802-6807	trait	_	
35-28	6808-6816	measures	_	
35-29	6817-6818	(	_	
35-30	6818-6830	specifically	_	
35-31	6830-6831	,	_	
35-32	6832-6840	temporal	_	
35-33	6841-6852	discounting	_	
35-34	6853-6856	and	_	
35-35	6857-6860	low	_	
35-36	6861-6878	conscientiousness	_	
35-37	6878-6879	)	_	
35-38	6879-6880	.	_	

#Text=In the future, neural markers of susceptibility to PDU may help researchers and clinicians to better target problematic symptoms and vulnerable individuals for intervention.
36-1	6881-6883	In	_	
36-2	6884-6887	the	_	
36-3	6888-6894	future	_	
36-4	6894-6895	,	_	
36-5	6896-6902	neural	_	
36-6	6903-6910	markers	_	
36-7	6911-6913	of	_	
36-8	6914-6928	susceptibility	_	
36-9	6929-6931	to	_	
36-10	6932-6935	PDU	_	
36-11	6936-6939	may	_	
36-12	6940-6944	help	_	
36-13	6945-6956	researchers	_	
36-14	6957-6960	and	_	
36-15	6961-6971	clinicians	_	
36-16	6972-6974	to	_	
36-17	6975-6981	better	_	
36-18	6982-6988	target	_	
36-19	6989-7000	problematic	_	
36-20	7001-7009	symptoms	_	
36-21	7010-7013	and	_	
36-22	7014-7024	vulnerable	_	
36-23	7025-7036	individuals	_	
36-24	7037-7040	for	_	
36-25	7041-7053	intervention	_	
36-26	7053-7054	.	_	

#Text=Results
#Text=Sample characteristics
#Text=Although the critical predictions focused on novelty-seeking adolescents, we first sought to verify that novelty seeking was associated with PDU.
37-1	7055-7062	Results	_	
37-2	7063-7069	Sample	_	
37-3	7070-7085	characteristics	_	
37-4	7086-7094	Although	_	
37-5	7095-7098	the	_	
37-6	7099-7107	critical	_	
37-7	7108-7119	predictions	_	
37-8	7120-7127	focused	_	
37-9	7128-7130	on	_	
37-10	7131-7146	novelty-seeking	_	
37-11	7147-7158	adolescents	_	
37-12	7158-7159	,	_	
37-13	7160-7162	we	_	
37-14	7163-7168	first	_	
37-15	7169-7175	sought	_	
37-16	7176-7178	to	_	
37-17	7179-7185	verify	_	
37-18	7186-7190	that	_	
37-19	7191-7198	novelty	_	
37-20	7199-7206	seeking	_	
37-21	7207-7210	was	_	
37-22	7211-7221	associated	_	
37-23	7222-7226	with	_	
37-24	7227-7230	PDU	_	
37-25	7230-7231	.	_	

#Text=In the target sample of subjects with high novelty-seeking scores (highest 25th percentile: n=283), 72 qualified as having PDU (25.4% PDU).
38-1	7232-7234	In	_	
38-2	7235-7238	the	_	
38-3	7239-7245	target	_	
38-4	7246-7252	sample	_	
38-5	7253-7255	of	_	
38-6	7256-7264	subjects	_	
38-7	7265-7269	with	_	
38-8	7270-7274	high	_	
38-9	7275-7290	novelty-seeking	_	
38-10	7291-7297	scores	_	
38-11	7298-7299	(	_	
38-12	7299-7306	highest	_	
38-13	7307-7311	25th	_	
38-14	7312-7322	percentile	_	
38-15	7322-7323	:	_	
38-16	7324-7325	n	_	
38-17	7325-7326	=	_	
38-18	7326-7329	283	_	
38-19	7329-7330	)	_	
38-20	7330-7331	,	_	
38-21	7332-7334	72	_	
38-22	7335-7344	qualified	_	
38-23	7345-7347	as	_	
38-24	7348-7354	having	_	
38-25	7355-7358	PDU	_	
38-26	7359-7360	(	_	
38-27	7360-7365	25.4%	_	
38-28	7366-7369	PDU	_	
38-29	7369-7370	)	_	
38-30	7370-7371	.	_	

#Text=Among adolescents in the middle 25–75% of novelty seekers (n=552), 102 qualified as having PDU (18.5% PDU), whereas in the lowest 25th percentile of novelty seekers (n=255), only 18 qualified as having PDU (7.1% PDU).
39-1	7372-7377	Among	_	
39-2	7378-7389	adolescents	_	
39-3	7390-7392	in	_	
39-4	7393-7396	the	_	
39-5	7397-7403	middle	_	
39-6	7404-7406	25	_	
39-7	7406-7407	–	_	
39-8	7407-7410	75%	_	
39-9	7411-7413	of	_	
39-10	7414-7421	novelty	_	
39-11	7422-7429	seekers	_	
39-12	7430-7431	(	_	
39-13	7431-7432	n	_	
39-14	7432-7433	=	_	
39-15	7433-7436	552	_	
39-16	7436-7437	)	_	
39-17	7437-7438	,	_	
39-18	7439-7442	102	_	
39-19	7443-7452	qualified	_	
39-20	7453-7455	as	_	
39-21	7456-7462	having	_	
39-22	7463-7466	PDU	_	
39-23	7467-7468	(	_	
39-24	7468-7473	18.5%	_	
39-25	7474-7477	PDU	_	
39-26	7477-7478	)	_	
39-27	7478-7479	,	_	
39-28	7480-7487	whereas	_	
39-29	7488-7490	in	_	
39-30	7491-7494	the	_	
39-31	7495-7501	lowest	_	
39-32	7502-7506	25th	_	
39-33	7507-7517	percentile	_	
39-34	7518-7520	of	_	
39-35	7521-7528	novelty	_	
39-36	7529-7536	seekers	_	
39-37	7537-7538	(	_	
39-38	7538-7539	n	_	
39-39	7539-7540	=	_	
39-40	7540-7543	255	_	
39-41	7543-7544	)	_	
39-42	7544-7545	,	_	
39-43	7546-7550	only	_	
39-44	7551-7553	18	_	
39-45	7554-7563	qualified	_	
39-46	7564-7566	as	_	
39-47	7567-7573	having	_	
39-48	7574-7577	PDU	_	
39-49	7578-7579	(	_	
39-50	7579-7583	7.1%	_	
39-51	7584-7587	PDU	_	
39-52	7587-7588	)	_	
39-53	7588-7589	.	_	

#Text=Incidence percentages thus supported the assumption that novelty-seeking traits appear relevant, but not sufficient, to confer vulnerability to PDU.
40-1	7590-7599	Incidence	_	
40-2	7600-7611	percentages	_	
40-3	7612-7616	thus	_	
40-4	7617-7626	supported	_	
40-5	7627-7630	the	_	
40-6	7631-7641	assumption	_	
40-7	7642-7646	that	_	
40-8	7647-7662	novelty-seeking	_	
40-9	7663-7669	traits	_	
40-10	7670-7676	appear	_	
40-11	7677-7685	relevant	_	
40-12	7685-7686	,	_	
40-13	7687-7690	but	_	
40-14	7691-7694	not	_	
40-15	7695-7705	sufficient	_	
40-16	7705-7706	,	_	
40-17	7707-7709	to	_	
40-18	7710-7716	confer	_	
40-19	7717-7730	vulnerability	_	
40-20	7731-7733	to	_	
40-21	7734-7737	PDU	_	
40-22	7737-7738	.	_	

#Text=Behavioural and psychometric data
#Text=Comparisons also verified that the PDU group showed significantly greater drug-taking scores than the control group at age 16 (n=72 controls 9.83±4.66, n=72 PDU group 20.24±5.43, F(1,142)=152.19, P<10−10, analysis of variance (ANOVA)), even though these differences were not evident at age 14 (n=72 controls 6.33±3.04, n=72 PDU group 6.93±4.97, F(1,142)=0.76, P=0.39, ANOVA; group (PDU versus control) by time point (age 14 versus age 16) interaction F(1,284)=81.33, P<2 × 10−16, ANOVA).
41-1	7739-7750	Behavioural	_	
41-2	7751-7754	and	_	
41-3	7755-7767	psychometric	_	
41-4	7768-7772	data	_	
41-5	7773-7784	Comparisons	_	
41-6	7785-7789	also	_	
41-7	7790-7798	verified	_	
41-8	7799-7803	that	_	
41-9	7804-7807	the	_	
41-10	7808-7811	PDU	_	
41-11	7812-7817	group	_	
41-12	7818-7824	showed	_	
41-13	7825-7838	significantly	_	
41-14	7839-7846	greater	_	
41-15	7847-7858	drug-taking	_	
41-16	7859-7865	scores	_	
41-17	7866-7870	than	_	
41-18	7871-7874	the	_	
41-19	7875-7882	control	_	
41-20	7883-7888	group	_	
41-21	7889-7891	at	_	
41-22	7892-7895	age	_	
41-23	7896-7898	16	_	
41-24	7899-7900	(	_	
41-25	7900-7901	n	_	
41-26	7901-7902	=	_	
41-27	7902-7904	72	_	
41-28	7905-7913	controls	_	
41-29	7914-7918	9.83	_	
41-30	7918-7919	±	_	
41-31	7919-7923	4.66	_	
41-32	7923-7924	,	_	
41-33	7925-7926	n	_	
41-34	7926-7927	=	_	
41-35	7927-7929	72	_	
41-36	7930-7933	PDU	_	
41-37	7934-7939	group	_	
41-38	7940-7945	20.24	_	
41-39	7945-7946	±	_	
41-40	7946-7950	5.43	_	
41-41	7950-7951	,	_	
41-42	7952-7953	F	_	
41-43	7953-7954	(	_	
41-44	7954-7959	1,142	_	
41-45	7959-7960	)	_	
41-46	7960-7961	=	_	
41-47	7961-7967	152.19	_	
41-48	7967-7968	,	_	
41-49	7969-7970	P	_	
41-50	7970-7971	<	_	
41-51	7971-7973	10	_	
41-52	7973-7974	−	_	
41-53	7974-7976	10	_	
41-54	7976-7977	,	_	
41-55	7978-7986	analysis	_	
41-56	7987-7989	of	_	
41-57	7990-7998	variance	_	
41-58	7999-8000	(	_	
41-59	8000-8005	ANOVA	_	
41-60	8005-8006	)	_	
41-61	8006-8007	)	_	
41-62	8007-8008	,	_	
41-63	8009-8013	even	_	
41-64	8014-8020	though	_	
41-65	8021-8026	these	_	
41-66	8027-8038	differences	_	
41-67	8039-8043	were	_	
41-68	8044-8047	not	_	
41-69	8048-8055	evident	_	
41-70	8056-8058	at	_	
41-71	8059-8062	age	_	
41-72	8063-8065	14	_	
41-73	8066-8067	(	_	
41-74	8067-8068	n	_	
41-75	8068-8069	=	_	
41-76	8069-8071	72	_	
41-77	8072-8080	controls	_	
41-78	8081-8085	6.33	_	
41-79	8085-8086	±	_	
41-80	8086-8090	3.04	_	
41-81	8090-8091	,	_	
41-82	8092-8093	n	_	
41-83	8093-8094	=	_	
41-84	8094-8096	72	_	
41-85	8097-8100	PDU	_	
41-86	8101-8106	group	_	
41-87	8107-8111	6.93	_	
41-88	8111-8112	±	_	
41-89	8112-8116	4.97	_	
41-90	8116-8117	,	_	
41-91	8118-8119	F	_	
41-92	8119-8120	(	_	
41-93	8120-8125	1,142	_	
41-94	8125-8126	)	_	
41-95	8126-8127	=	_	
41-96	8127-8131	0.76	_	
41-97	8131-8132	,	_	
41-98	8133-8134	P	_	
41-99	8134-8135	=	_	
41-100	8135-8139	0.39	_	
41-101	8139-8140	,	_	
41-102	8141-8146	ANOVA	_	
41-103	8146-8147	;	_	
41-104	8148-8153	group	_	
41-105	8154-8155	(	_	
41-106	8155-8158	PDU	_	
41-107	8159-8165	versus	_	
41-108	8166-8173	control	_	
41-109	8173-8174	)	_	
41-110	8175-8177	by	_	
41-111	8178-8182	time	_	
41-112	8183-8188	point	_	
41-113	8189-8190	(	_	
41-114	8190-8193	age	_	
41-115	8194-8196	14	_	
41-116	8197-8203	versus	_	
41-117	8204-8207	age	_	
41-118	8208-8210	16	_	
41-119	8210-8211	)	_	
41-120	8212-8223	interaction	_	
41-121	8224-8225	F	_	
41-122	8225-8226	(	_	
41-123	8226-8231	1,284	_	
41-124	8231-8232	)	_	
41-125	8232-8233	=	_	
41-126	8233-8238	81.33	_	
41-127	8238-8239	,	_	
41-128	8240-8241	P	_	
41-129	8241-8242	<	_	
41-130	8242-8243	2	_	
41-131	8244-8245	×	_	
41-132	8246-8248	10	_	
41-133	8248-8249	−	_	
41-134	8249-8251	16	_	
41-135	8251-8252	,	_	
41-136	8253-8258	ANOVA	_	
41-137	8258-8259	)	_	
41-138	8259-8260	.	_	

#Text=The PDU and control groups did not significantly differ with respect to pubertal status, age, gender, intelligence, novelty-seeking score, risk taking (CGT) or overall hit rate and reaction times in the Monetary Incentive Delay (MID) task (with the exception of the no gain condition; see Table 1) at age 14.
42-1	8261-8264	The	_	
42-2	8265-8268	PDU	_	
42-3	8269-8272	and	_	
42-4	8273-8280	control	_	
42-5	8281-8287	groups	_	
42-6	8288-8291	did	_	
42-7	8292-8295	not	_	
42-8	8296-8309	significantly	_	
42-9	8310-8316	differ	_	
42-10	8317-8321	with	_	
42-11	8322-8329	respect	_	
42-12	8330-8332	to	_	
42-13	8333-8341	pubertal	_	
42-14	8342-8348	status	_	
42-15	8348-8349	,	_	
42-16	8350-8353	age	_	
42-17	8353-8354	,	_	
42-18	8355-8361	gender	_	
42-19	8361-8362	,	_	
42-20	8363-8375	intelligence	_	
42-21	8375-8376	,	_	
42-22	8377-8392	novelty-seeking	_	
42-23	8393-8398	score	_	
42-24	8398-8399	,	_	
42-25	8400-8404	risk	_	
42-26	8405-8411	taking	_	
42-27	8412-8413	(	_	
42-28	8413-8416	CGT	_	
42-29	8416-8417	)	_	
42-30	8418-8420	or	_	
42-31	8421-8428	overall	_	
42-32	8429-8432	hit	_	
42-33	8433-8437	rate	_	
42-34	8438-8441	and	_	
42-35	8442-8450	reaction	_	
42-36	8451-8456	times	_	
42-37	8457-8459	in	_	
42-38	8460-8463	the	_	
42-39	8464-8472	Monetary	_	
42-40	8473-8482	Incentive	_	
42-41	8483-8488	Delay	_	
42-42	8489-8490	(	_	
42-43	8490-8493	MID	_	
42-44	8493-8494	)	_	
42-45	8495-8499	task	_	
42-46	8500-8501	(	_	
42-47	8501-8505	with	_	
42-48	8506-8509	the	_	
42-49	8510-8519	exception	_	
42-50	8520-8522	of	_	
42-51	8523-8526	the	_	
42-52	8527-8529	no	_	
42-53	8530-8534	gain	_	
42-54	8535-8544	condition	_	
42-55	8544-8545	;	_	
42-56	8546-8549	see	_	
42-57	8550-8555	Table	_	
42-58	8556-8557	1	_	
42-59	8557-8558	)	_	
42-60	8559-8561	at	_	
42-61	8562-8565	age	_	
42-62	8566-8568	14	_	
42-63	8568-8569	.	_	

#Text=The PDU group did, however, show steeper discounting of future rewards (log(discount rate); n=72 controls: −4.55±1.38, n=72 PDU: –3.99±1.53, F(1,142)=5.23, P=0.024; ANOVA) and scored lower in conscientiousness (n=72 controls: 25.44±6.20, n=72 PDU: 23.13±6.13, F(1,142)=5.09, P=0.026, ANOVA; see Table 1) at age 14.
43-1	8570-8573	The	_	
43-2	8574-8577	PDU	_	
43-3	8578-8583	group	_	
43-4	8584-8587	did	_	
43-5	8587-8588	,	_	
43-6	8589-8596	however	_	
43-7	8596-8597	,	_	
43-8	8598-8602	show	_	
43-9	8603-8610	steeper	_	
43-10	8611-8622	discounting	_	
43-11	8623-8625	of	_	
43-12	8626-8632	future	_	
43-13	8633-8640	rewards	_	
43-14	8641-8642	(	_	
43-15	8642-8645	log	_	
43-16	8645-8646	(	_	
43-17	8646-8654	discount	_	
43-18	8655-8659	rate	_	
43-19	8659-8660	)	_	
43-20	8660-8661	;	_	
43-21	8662-8663	n	_	
43-22	8663-8664	=	_	
43-23	8664-8666	72	_	
43-24	8667-8675	controls	_	
43-25	8675-8676	:	_	
43-26	8677-8678	−	_	
43-27	8678-8682	4.55	_	
43-28	8682-8683	±	_	
43-29	8683-8687	1.38	_	
43-30	8687-8688	,	_	
43-31	8689-8690	n	_	
43-32	8690-8691	=	_	
43-33	8691-8693	72	_	
43-34	8694-8697	PDU	_	
43-35	8697-8698	:	_	
43-36	8699-8700	–	_	
43-37	8700-8704	3.99	_	
43-38	8704-8705	±	_	
43-39	8705-8709	1.53	_	
43-40	8709-8710	,	_	
43-41	8711-8712	F	_	
43-42	8712-8713	(	_	
43-43	8713-8718	1,142	_	
43-44	8718-8719	)	_	
43-45	8719-8720	=	_	
43-46	8720-8724	5.23	_	
43-47	8724-8725	,	_	
43-48	8726-8727	P	_	
43-49	8727-8728	=	_	
43-50	8728-8733	0.024	_	
43-51	8733-8734	;	_	
43-52	8735-8740	ANOVA	_	
43-53	8740-8741	)	_	
43-54	8742-8745	and	_	
43-55	8746-8752	scored	_	
43-56	8753-8758	lower	_	
43-57	8759-8761	in	_	
43-58	8762-8779	conscientiousness	_	
43-59	8780-8781	(	_	
43-60	8781-8782	n	_	
43-61	8782-8783	=	_	
43-62	8783-8785	72	_	
43-63	8786-8794	controls	_	
43-64	8794-8795	:	_	
43-65	8796-8801	25.44	_	
43-66	8801-8802	±	_	
43-67	8802-8806	6.20	_	
43-68	8806-8807	,	_	
43-69	8808-8809	n	_	
43-70	8809-8810	=	_	
43-71	8810-8812	72	_	
43-72	8813-8816	PDU	_	
43-73	8816-8817	:	_	
43-74	8818-8823	23.13	_	
43-75	8823-8824	±	_	
43-76	8824-8828	6.13	_	
43-77	8828-8829	,	_	
43-78	8830-8831	F	_	
43-79	8831-8832	(	_	
43-80	8832-8837	1,142	_	
43-81	8837-8838	)	_	
43-82	8838-8839	=	_	
43-83	8839-8843	5.09	_	
43-84	8843-8844	,	_	
43-85	8845-8846	P	_	
43-86	8846-8847	=	_	
43-87	8847-8852	0.026	_	
43-88	8852-8853	,	_	
43-89	8854-8859	ANOVA	_	
43-90	8859-8860	;	_	
43-91	8861-8864	see	_	
43-92	8865-8870	Table	_	
43-93	8871-8872	1	_	
43-94	8872-8873	)	_	
43-95	8874-8876	at	_	
43-96	8877-8880	age	_	
43-97	8881-8883	14	_	
43-98	8883-8884	.	_	

#Text=Functional neuroimaging data
#Text=A first confirmatory voxel-wise analysis contrasted whole-brain activity during large versus small gain anticipation across both groups to verify main effects of reward anticipation at age 14.
44-1	8885-8895	Functional	_	
44-2	8896-8908	neuroimaging	_	
44-3	8909-8913	data	_	
44-4	8914-8915	A	_	
44-5	8916-8921	first	_	
44-6	8922-8934	confirmatory	_	
44-7	8935-8945	voxel-wise	_	
44-8	8946-8954	analysis	_	
44-9	8955-8965	contrasted	_	
44-10	8966-8977	whole-brain	_	
44-11	8978-8986	activity	_	
44-12	8987-8993	during	_	
44-13	8994-8999	large	_	
44-14	9000-9006	versus	_	
44-15	9007-9012	small	_	
44-16	9013-9017	gain	_	
44-17	9018-9030	anticipation	_	
44-18	9031-9037	across	_	
44-19	9038-9042	both	_	
44-20	9043-9049	groups	_	
44-21	9050-9052	to	_	
44-22	9053-9059	verify	_	
44-23	9060-9064	main	_	
44-24	9065-9072	effects	_	
44-25	9073-9075	of	_	
44-26	9076-9082	reward	_	
44-27	9083-9095	anticipation	_	
44-28	9096-9098	at	_	
44-29	9099-9102	age	_	
44-30	9103-9105	14	_	
44-31	9105-9106	.	_	

#Text=Across groups, large versus small gain anticipation elicited expected increases in activity in mesolimbic regions including the VS (n=144; peak x, y, z: 11, 5, −5 mm, Z=7.8, P=1.8E−13, corrected, t-test; −11, 5, −5 mm, Z=7.3, P=8.8E−12, corrected) and midbrain (peak x, y, z: 6, −25, −12 mm, Z=5.3, P=1.7E−6, corrected; −8, −24, −9 mm, Z=4.8, P=2.1E−5, corrected t-test; Fig. 1).
45-1	9107-9113	Across	_	
45-2	9114-9120	groups	_	
45-3	9120-9121	,	_	
45-4	9122-9127	large	_	
45-5	9128-9134	versus	_	
45-6	9135-9140	small	_	
45-7	9141-9145	gain	_	
45-8	9146-9158	anticipation	_	
45-9	9159-9167	elicited	_	
45-10	9168-9176	expected	_	
45-11	9177-9186	increases	_	
45-12	9187-9189	in	_	
45-13	9190-9198	activity	_	
45-14	9199-9201	in	_	
45-15	9202-9212	mesolimbic	_	
45-16	9213-9220	regions	_	
45-17	9221-9230	including	_	
45-18	9231-9234	the	_	
45-19	9235-9237	VS	_	
45-20	9238-9239	(	_	
45-21	9239-9240	n	_	
45-22	9240-9241	=	_	
45-23	9241-9244	144	_	
45-24	9244-9245	;	_	
45-25	9246-9250	peak	_	
45-26	9251-9252	x	_	
45-27	9252-9253	,	_	
45-28	9254-9255	y	_	
45-29	9255-9256	,	_	
45-30	9257-9258	z	_	
45-31	9258-9259	:	_	
45-32	9260-9262	11	_	
45-33	9262-9263	,	_	
45-34	9264-9265	5	_	
45-35	9265-9266	,	_	
45-36	9267-9268	−	_	
45-37	9268-9269	5	_	
45-38	9270-9272	mm	_	
45-39	9272-9273	,	_	
45-40	9274-9275	Z	_	
45-41	9275-9276	=	_	
45-42	9276-9279	7.8	_	
45-43	9279-9280	,	_	
45-44	9281-9282	P	_	
45-45	9282-9283	=	_	
45-46	9283-9287	1.8E	_	
45-47	9287-9288	−	_	
45-48	9288-9290	13	_	
45-49	9290-9291	,	_	
45-50	9292-9301	corrected	_	
45-51	9301-9302	,	_	
45-52	9303-9309	t-test	_	
45-53	9309-9310	;	_	
45-54	9311-9312	−	_	
45-55	9312-9314	11	_	
45-56	9314-9315	,	_	
45-57	9316-9317	5	_	
45-58	9317-9318	,	_	
45-59	9319-9320	−	_	
45-60	9320-9321	5	_	
45-61	9322-9324	mm	_	
45-62	9324-9325	,	_	
45-63	9326-9327	Z	_	
45-64	9327-9328	=	_	
45-65	9328-9331	7.3	_	
45-66	9331-9332	,	_	
45-67	9333-9334	P	_	
45-68	9334-9335	=	_	
45-69	9335-9339	8.8E	_	
45-70	9339-9340	−	_	
45-71	9340-9342	12	_	
45-72	9342-9343	,	_	
45-73	9344-9353	corrected	_	
45-74	9353-9354	)	_	
45-75	9355-9358	and	_	
45-76	9359-9367	midbrain	_	
45-77	9368-9369	(	_	
45-78	9369-9373	peak	_	
45-79	9374-9375	x	_	
45-80	9375-9376	,	_	
45-81	9377-9378	y	_	
45-82	9378-9379	,	_	
45-83	9380-9381	z	_	
45-84	9381-9382	:	_	
45-85	9383-9384	6	_	
45-86	9384-9385	,	_	
45-87	9386-9387	−	_	
45-88	9387-9389	25	_	
45-89	9389-9390	,	_	
45-90	9391-9392	−	_	
45-91	9392-9394	12	_	
45-92	9395-9397	mm	_	
45-93	9397-9398	,	_	
45-94	9399-9400	Z	_	
45-95	9400-9401	=	_	
45-96	9401-9404	5.3	_	
45-97	9404-9405	,	_	
45-98	9406-9407	P	_	
45-99	9407-9408	=	_	
45-100	9408-9412	1.7E	_	
45-101	9412-9413	−	_	
45-102	9413-9414	6	_	
45-103	9414-9415	,	_	
45-104	9416-9425	corrected	_	
45-105	9425-9426	;	_	
45-106	9427-9428	−	_	
45-107	9428-9429	8	_	
45-108	9429-9430	,	_	
45-109	9431-9432	−	_	
45-110	9432-9434	24	_	
45-111	9434-9435	,	_	
45-112	9436-9437	−	_	
45-113	9437-9438	9	_	
45-114	9439-9441	mm	_	
45-115	9441-9442	,	_	
45-116	9443-9444	Z	_	
45-117	9444-9445	=	_	
45-118	9445-9448	4.8	_	
45-119	9448-9449	,	_	
45-120	9450-9451	P	_	
45-121	9451-9452	=	_	
45-122	9452-9456	2.1E	_	
45-123	9456-9457	−	_	
45-124	9457-9458	5	_	
45-125	9458-9459	,	_	
45-126	9460-9469	corrected	_	
45-127	9470-9476	t-test	_	
45-128	9476-9477	;	_	
45-129	9478-9481	Fig	_	
45-130	9481-9482	.	_	
45-131	9483-9484	1	_	
45-132	9484-9485	)	_	
45-133	9485-9486	.	_	

#Text=The second targeted analysis contrasted activity in six predefined volumes of interest (see Methods) during large versus small gain anticipation in the PDU versus control groups at age 14 (Table 2; Figs 2 and 3; Supplementary Fig. 1).
46-1	9487-9490	The	_	
46-2	9491-9497	second	_	
46-3	9498-9506	targeted	_	
46-4	9507-9515	analysis	_	
46-5	9516-9526	contrasted	_	
46-6	9527-9535	activity	_	
46-7	9536-9538	in	_	
46-8	9539-9542	six	_	
46-9	9543-9553	predefined	_	
46-10	9554-9561	volumes	_	
46-11	9562-9564	of	_	
46-12	9565-9573	interest	_	
46-13	9574-9575	(	_	
46-14	9575-9578	see	_	
46-15	9579-9586	Methods	_	
46-16	9586-9587	)	_	
46-17	9588-9594	during	_	
46-18	9595-9600	large	_	
46-19	9601-9607	versus	_	
46-20	9608-9613	small	_	
46-21	9614-9618	gain	_	
46-22	9619-9631	anticipation	_	
46-23	9632-9634	in	_	
46-24	9635-9638	the	_	
46-25	9639-9642	PDU	_	
46-26	9643-9649	versus	_	
46-27	9650-9657	control	_	
46-28	9658-9664	groups	_	
46-29	9665-9667	at	_	
46-30	9668-9671	age	_	
46-31	9672-9674	14	_	
46-32	9675-9676	(	_	
46-33	9676-9681	Table	_	
46-34	9682-9683	2	_	
46-35	9683-9684	;	_	
46-36	9685-9689	Figs	_	
46-37	9690-9691	2	_	
46-38	9692-9695	and	_	
46-39	9696-9697	3	_	
46-40	9697-9698	;	_	
46-41	9699-9712	Supplementary	_	
46-42	9713-9716	Fig	_	
46-43	9716-9717	.	_	
46-44	9718-9719	1	_	
46-45	9719-9720	)	_	
46-46	9720-9721	.	_	

#Text=This analysis revealed significant group differences in activity in the right VS (n=144; t(126)=–2.66, P=0.004, uncorrected/P=0.027, corrected, t-test), the left midbrain (n=144; t(126)=–2.69, P=0.004, uncorrected/P=0.024, corrected, t-test) and right dorsolateral prefrontal cortex (n=144; t(126)=–2.48, P=0.007, uncorrected/P=0.044, corrected, t-test).
47-1	9722-9726	This	_	
47-2	9727-9735	analysis	_	
47-3	9736-9744	revealed	_	
47-4	9745-9756	significant	_	
47-5	9757-9762	group	_	
47-6	9763-9774	differences	_	
47-7	9775-9777	in	_	
47-8	9778-9786	activity	_	
47-9	9787-9789	in	_	
47-10	9790-9793	the	_	
47-11	9794-9799	right	_	
47-12	9800-9802	VS	_	
47-13	9803-9804	(	_	
47-14	9804-9805	n	_	
47-15	9805-9806	=	_	
47-16	9806-9809	144	_	
47-17	9809-9810	;	_	
47-18	9811-9812	t	_	
47-19	9812-9813	(	_	
47-20	9813-9816	126	_	
47-21	9816-9817	)	_	
47-22	9817-9818	=	_	
47-23	9818-9819	–	_	
47-24	9819-9823	2.66	_	
47-25	9823-9824	,	_	
47-26	9825-9826	P	_	
47-27	9826-9827	=	_	
47-28	9827-9832	0.004	_	
47-29	9832-9833	,	_	
47-30	9834-9845	uncorrected	_	
47-31	9845-9846	/	_	
47-32	9846-9847	P	_	
47-33	9847-9848	=	_	
47-34	9848-9853	0.027	_	
47-35	9853-9854	,	_	
47-36	9855-9864	corrected	_	
47-37	9864-9865	,	_	
47-38	9866-9872	t-test	_	
47-39	9872-9873	)	_	
47-40	9873-9874	,	_	
47-41	9875-9878	the	_	
47-42	9879-9883	left	_	
47-43	9884-9892	midbrain	_	
47-44	9893-9894	(	_	
47-45	9894-9895	n	_	
47-46	9895-9896	=	_	
47-47	9896-9899	144	_	
47-48	9899-9900	;	_	
47-49	9901-9902	t	_	
47-50	9902-9903	(	_	
47-51	9903-9906	126	_	
47-52	9906-9907	)	_	
47-53	9907-9908	=	_	
47-54	9908-9909	–	_	
47-55	9909-9913	2.69	_	
47-56	9913-9914	,	_	
47-57	9915-9916	P	_	
47-58	9916-9917	=	_	
47-59	9917-9922	0.004	_	
47-60	9922-9923	,	_	
47-61	9924-9935	uncorrected	_	
47-62	9935-9936	/	_	
47-63	9936-9937	P	_	
47-64	9937-9938	=	_	
47-65	9938-9943	0.024	_	
47-66	9943-9944	,	_	
47-67	9945-9954	corrected	_	
47-68	9954-9955	,	_	
47-69	9956-9962	t-test	_	
47-70	9962-9963	)	_	
47-71	9964-9967	and	_	
47-72	9968-9973	right	_	
47-73	9974-9986	dorsolateral	_	
47-74	9987-9997	prefrontal	_	
47-75	9998-10004	cortex	_	
47-76	10005-10006	(	_	
47-77	10006-10007	n	_	
47-78	10007-10008	=	_	
47-79	10008-10011	144	_	
47-80	10011-10012	;	_	
47-81	10013-10014	t	_	
47-82	10014-10015	(	_	
47-83	10015-10018	126	_	
47-84	10018-10019	)	_	
47-85	10019-10020	=	_	
47-86	10020-10021	–	_	
47-87	10021-10025	2.48	_	
47-88	10025-10026	,	_	
47-89	10027-10028	P	_	
47-90	10028-10029	=	_	
47-91	10029-10034	0.007	_	
47-92	10034-10035	,	_	
47-93	10036-10047	uncorrected	_	
47-94	10047-10048	/	_	
47-95	10048-10049	P	_	
47-96	10049-10050	=	_	
47-97	10050-10055	0.044	_	
47-98	10055-10056	,	_	
47-99	10057-10066	corrected	_	
47-100	10066-10067	,	_	
47-101	10068-10074	t-test	_	
47-102	10074-10075	)	_	
47-103	10075-10076	.	_	

#Text=Although this targeted analysis focused on high novelty-seeking adolescents, based on their documented vulnerability to future PDU, we further examined ventral striatal activity in subjects who scored in the middle quartiles and lower quartile on novelty-seeking traits.
48-1	10077-10085	Although	_	
48-2	10086-10090	this	_	
48-3	10091-10099	targeted	_	
48-4	10100-10108	analysis	_	
48-5	10109-10116	focused	_	
48-6	10117-10119	on	_	
48-7	10120-10124	high	_	
48-8	10125-10140	novelty-seeking	_	
48-9	10141-10152	adolescents	_	
48-10	10152-10153	,	_	
48-11	10154-10159	based	_	
48-12	10160-10162	on	_	
48-13	10163-10168	their	_	
48-14	10169-10179	documented	_	
48-15	10180-10193	vulnerability	_	
48-16	10194-10196	to	_	
48-17	10197-10203	future	_	
48-18	10204-10207	PDU	_	
48-19	10207-10208	,	_	
48-20	10209-10211	we	_	
48-21	10212-10219	further	_	
48-22	10220-10228	examined	_	
48-23	10229-10236	ventral	_	
48-24	10237-10245	striatal	_	
48-25	10246-10254	activity	_	
48-26	10255-10257	in	_	
48-27	10258-10266	subjects	_	
48-28	10267-10270	who	_	
48-29	10271-10277	scored	_	
48-30	10278-10280	in	_	
48-31	10281-10284	the	_	
48-32	10285-10291	middle	_	
48-33	10292-10301	quartiles	_	
48-34	10302-10305	and	_	
48-35	10306-10311	lower	_	
48-36	10312-10320	quartile	_	
48-37	10321-10323	on	_	
48-38	10324-10339	novelty-seeking	_	
48-39	10340-10346	traits	_	
48-40	10346-10347	.	_	

#Text=Decreased ventral striatal activity in the PDU group was only evident, however, in high novelty-seeking adolescents (Supplementary Figs 2 and 3).
49-1	10348-10357	Decreased	_	
49-2	10358-10365	ventral	_	
49-3	10366-10374	striatal	_	
49-4	10375-10383	activity	_	
49-5	10384-10386	in	_	
49-6	10387-10390	the	_	
49-7	10391-10394	PDU	_	
49-8	10395-10400	group	_	
49-9	10401-10404	was	_	
49-10	10405-10409	only	_	
49-11	10410-10417	evident	_	
49-12	10417-10418	,	_	
49-13	10419-10426	however	_	
49-14	10426-10427	,	_	
49-15	10428-10430	in	_	
49-16	10431-10435	high	_	
49-17	10436-10451	novelty-seeking	_	
49-18	10452-10463	adolescents	_	
49-19	10464-10465	(	_	
49-20	10465-10478	Supplementary	_	
49-21	10479-10483	Figs	_	
49-22	10484-10485	2	_	
49-23	10486-10489	and	_	
49-24	10490-10491	3	_	
49-25	10491-10492	)	_	
49-26	10492-10493	.	_	

#Text=A third exploratory voxel-wise analysis contrasted whole-brain activity during large versus small gain anticipation in the PDU versus control groups at age 14.
50-1	10494-10495	A	_	
50-2	10496-10501	third	_	
50-3	10502-10513	exploratory	_	
50-4	10514-10524	voxel-wise	_	
50-5	10525-10533	analysis	_	
50-6	10534-10544	contrasted	_	
50-7	10545-10556	whole-brain	_	
50-8	10557-10565	activity	_	
50-9	10566-10572	during	_	
50-10	10573-10578	large	_	
50-11	10579-10585	versus	_	
50-12	10586-10591	small	_	
50-13	10592-10596	gain	_	
50-14	10597-10609	anticipation	_	
50-15	10610-10612	in	_	
50-16	10613-10616	the	_	
50-17	10617-10620	PDU	_	
50-18	10621-10627	versus	_	
50-19	10628-10635	control	_	
50-20	10636-10642	groups	_	
50-21	10643-10645	at	_	
50-22	10646-10649	age	_	
50-23	10650-10652	14	_	
50-24	10652-10653	.	_	

#Text=Consistent with targeted findings, this analysis revealed group differences in activity in foci located in the bilateral VS (n=144; peak x, y, z: 15, −3, −9 mm, Z=–3.2, P=7.9E−4, uncorrected, t-test; peak x, y, z: −18, 0, −6 mm, Z=–2.9; P=0.002, uncorrected, t-test), left midbrain (peak x, y, z: −8, −21, −9 mm, Z=–3.1, P=9.0E−4, uncorrected, t-test), and right dorsolateral prefrontal cortex (peak x, y, z: 37, 5, 25 mm, Z=–4.2, P=1.7E−5, uncorrected; x, y, z: 18, 21, 36 mm, Z=–4.1, P=2.2E-5, uncorrected, t-test; Figs 2 and 3).
51-1	10654-10664	Consistent	_	
51-2	10665-10669	with	_	
51-3	10670-10678	targeted	_	
51-4	10679-10687	findings	_	
51-5	10687-10688	,	_	
51-6	10689-10693	this	_	
51-7	10694-10702	analysis	_	
51-8	10703-10711	revealed	_	
51-9	10712-10717	group	_	
51-10	10718-10729	differences	_	
51-11	10730-10732	in	_	
51-12	10733-10741	activity	_	
51-13	10742-10744	in	_	
51-14	10745-10749	foci	_	
51-15	10750-10757	located	_	
51-16	10758-10760	in	_	
51-17	10761-10764	the	_	
51-18	10765-10774	bilateral	_	
51-19	10775-10777	VS	_	
51-20	10778-10779	(	_	
51-21	10779-10780	n	_	
51-22	10780-10781	=	_	
51-23	10781-10784	144	_	
51-24	10784-10785	;	_	
51-25	10786-10790	peak	_	
51-26	10791-10792	x	_	
51-27	10792-10793	,	_	
51-28	10794-10795	y	_	
51-29	10795-10796	,	_	
51-30	10797-10798	z	_	
51-31	10798-10799	:	_	
51-32	10800-10802	15	_	
51-33	10802-10803	,	_	
51-34	10804-10805	−	_	
51-35	10805-10806	3	_	
51-36	10806-10807	,	_	
51-37	10808-10809	−	_	
51-38	10809-10810	9	_	
51-39	10811-10813	mm	_	
51-40	10813-10814	,	_	
51-41	10815-10816	Z	_	
51-42	10816-10817	=	_	
51-43	10817-10818	–	_	
51-44	10818-10821	3.2	_	
51-45	10821-10822	,	_	
51-46	10823-10824	P	_	
51-47	10824-10825	=	_	
51-48	10825-10829	7.9E	_	
51-49	10829-10830	−	_	
51-50	10830-10831	4	_	
51-51	10831-10832	,	_	
51-52	10833-10844	uncorrected	_	
51-53	10844-10845	,	_	
51-54	10846-10852	t-test	_	
51-55	10852-10853	;	_	
51-56	10854-10858	peak	_	
51-57	10859-10860	x	_	
51-58	10860-10861	,	_	
51-59	10862-10863	y	_	
51-60	10863-10864	,	_	
51-61	10865-10866	z	_	
51-62	10866-10867	:	_	
51-63	10868-10869	−	_	
51-64	10869-10871	18	_	
51-65	10871-10872	,	_	
51-66	10873-10874	0	_	
51-67	10874-10875	,	_	
51-68	10876-10877	−	_	
51-69	10877-10878	6	_	
51-70	10879-10881	mm	_	
51-71	10881-10882	,	_	
51-72	10883-10884	Z	_	
51-73	10884-10885	=	_	
51-74	10885-10886	–	_	
51-75	10886-10889	2.9	_	
51-76	10889-10890	;	_	
51-77	10891-10892	P	_	
51-78	10892-10893	=	_	
51-79	10893-10898	0.002	_	
51-80	10898-10899	,	_	
51-81	10900-10911	uncorrected	_	
51-82	10911-10912	,	_	
51-83	10913-10919	t-test	_	
51-84	10919-10920	)	_	
51-85	10920-10921	,	_	
51-86	10922-10926	left	_	
51-87	10927-10935	midbrain	_	
51-88	10936-10937	(	_	
51-89	10937-10941	peak	_	
51-90	10942-10943	x	_	
51-91	10943-10944	,	_	
51-92	10945-10946	y	_	
51-93	10946-10947	,	_	
51-94	10948-10949	z	_	
51-95	10949-10950	:	_	
51-96	10951-10952	−	_	
51-97	10952-10953	8	_	
51-98	10953-10954	,	_	
51-99	10955-10956	−	_	
51-100	10956-10958	21	_	
51-101	10958-10959	,	_	
51-102	10960-10961	−	_	
51-103	10961-10962	9	_	
51-104	10963-10965	mm	_	
51-105	10965-10966	,	_	
51-106	10967-10968	Z	_	
51-107	10968-10969	=	_	
51-108	10969-10970	–	_	
51-109	10970-10973	3.1	_	
51-110	10973-10974	,	_	
51-111	10975-10976	P	_	
51-112	10976-10977	=	_	
51-113	10977-10981	9.0E	_	
51-114	10981-10982	−	_	
51-115	10982-10983	4	_	
51-116	10983-10984	,	_	
51-117	10985-10996	uncorrected	_	
51-118	10996-10997	,	_	
51-119	10998-11004	t-test	_	
51-120	11004-11005	)	_	
51-121	11005-11006	,	_	
51-122	11007-11010	and	_	
51-123	11011-11016	right	_	
51-124	11017-11029	dorsolateral	_	
51-125	11030-11040	prefrontal	_	
51-126	11041-11047	cortex	_	
51-127	11048-11049	(	_	
51-128	11049-11053	peak	_	
51-129	11054-11055	x	_	
51-130	11055-11056	,	_	
51-131	11057-11058	y	_	
51-132	11058-11059	,	_	
51-133	11060-11061	z	_	
51-134	11061-11062	:	_	
51-135	11063-11065	37	_	
51-136	11065-11066	,	_	
51-137	11067-11068	5	_	
51-138	11068-11069	,	_	
51-139	11070-11072	25	_	
51-140	11073-11075	mm	_	
51-141	11075-11076	,	_	
51-142	11077-11078	Z	_	
51-143	11078-11079	=	_	
51-144	11079-11080	–	_	
51-145	11080-11083	4.2	_	
51-146	11083-11084	,	_	
51-147	11085-11086	P	_	
51-148	11086-11087	=	_	
51-149	11087-11091	1.7E	_	
51-150	11091-11092	−	_	
51-151	11092-11093	5	_	
51-152	11093-11094	,	_	
51-153	11095-11106	uncorrected	_	
51-154	11106-11107	;	_	
51-155	11108-11109	x	_	
51-156	11109-11110	,	_	
51-157	11111-11112	y	_	
51-158	11112-11113	,	_	
51-159	11114-11115	z	_	
51-160	11115-11116	:	_	
51-161	11117-11119	18	_	
51-162	11119-11120	,	_	
51-163	11121-11123	21	_	
51-164	11123-11124	,	_	
51-165	11125-11127	36	_	
51-166	11128-11130	mm	_	
51-167	11130-11131	,	_	
51-168	11132-11133	Z	_	
51-169	11133-11134	=	_	
51-170	11134-11135	–	_	
51-171	11135-11138	4.1	_	
51-172	11138-11139	,	_	
51-173	11140-11141	P	_	
51-174	11141-11142	=	_	
51-175	11142-11146	2.2E	_	
51-176	11146-11147	-	_	
51-177	11147-11148	5	_	
51-178	11148-11149	,	_	
51-179	11150-11161	uncorrected	_	
51-180	11161-11162	,	_	
51-181	11163-11169	t-test	_	
51-182	11169-11170	;	_	
51-183	11171-11175	Figs	_	
51-184	11176-11177	2	_	
51-185	11178-11181	and	_	
51-186	11182-11183	3	_	
51-187	11183-11184	)	_	
51-188	11184-11185	.	_	

#Text=Structural neuroimaging data
#Text=Reduced neural activity that precedes PDU could result from abnormal neural function, abnormal structure or both.
52-1	11186-11196	Structural	_	
52-2	11197-11209	neuroimaging	_	
52-3	11210-11214	data	_	
52-4	11215-11222	Reduced	_	
52-5	11223-11229	neural	_	
52-6	11230-11238	activity	_	
52-7	11239-11243	that	_	
52-8	11244-11252	precedes	_	
52-9	11253-11256	PDU	_	
52-10	11257-11262	could	_	
52-11	11263-11269	result	_	
52-12	11270-11274	from	_	
52-13	11275-11283	abnormal	_	
52-14	11284-11290	neural	_	
52-15	11291-11299	function	_	
52-16	11299-11300	,	_	
52-17	11301-11309	abnormal	_	
52-18	11310-11319	structure	_	
52-19	11320-11322	or	_	
52-20	11323-11327	both	_	
52-21	11327-11328	.	_	

#Text=Volume of interest analysis of voxel-based morphometry indices of grey matter density in the same six volumes used for functional comparisons revealed significant group differences after correcting for multiple comparisons (Table 3; Fig. 4a; Supplementary Fig. 4).
53-1	11329-11335	Volume	_	
53-2	11336-11338	of	_	
53-3	11339-11347	interest	_	
53-4	11348-11356	analysis	_	
53-5	11357-11359	of	_	
53-6	11360-11371	voxel-based	_	
53-7	11372-11383	morphometry	_	
53-8	11384-11391	indices	_	
53-9	11392-11394	of	_	
53-10	11395-11399	grey	_	
53-11	11400-11406	matter	_	
53-12	11407-11414	density	_	
53-13	11415-11417	in	_	
53-14	11418-11421	the	_	
53-15	11422-11426	same	_	
53-16	11427-11430	six	_	
53-17	11431-11438	volumes	_	
53-18	11439-11443	used	_	
53-19	11444-11447	for	_	
53-20	11448-11458	functional	_	
53-21	11459-11470	comparisons	_	
53-22	11471-11479	revealed	_	
53-23	11480-11491	significant	_	
53-24	11492-11497	group	_	
53-25	11498-11509	differences	_	
53-26	11510-11515	after	_	
53-27	11516-11526	correcting	_	
53-28	11527-11530	for	_	
53-29	11531-11539	multiple	_	
53-30	11540-11551	comparisons	_	
53-31	11552-11553	(	_	
53-32	11553-11558	Table	_	
53-33	11559-11560	3	_	
53-34	11560-11561	;	_	
53-35	11562-11565	Fig	_	
53-36	11565-11566	.	_	
53-37	11567-11569	4a	_	
53-38	11569-11570	;	_	
53-39	11571-11584	Supplementary	_	
53-40	11585-11588	Fig	_	
53-41	11588-11589	.	_	
53-42	11590-11591	4	_	
53-43	11591-11592	)	_	
53-44	11592-11593	.	_	

#Text=Specifically, at age 14, high novelty seekers who eventually developed PDU showed increased grey matter density in the left VS (n=144; t(126)=2.51, P=0.007, uncorrected/P=0.040, corrected, t-test), the left midbrain (n=144; t(126)=2.95, P=0.002, uncorrected/P=0.011, corrected, t-test) and bilateral dorsolateral prefrontal cortex (right: n=144; t(126)=3.62, P=0.001, uncorrected/P=0.001 corrected; left: t(126)=3.76, P=0.001, uncorrected/P=0.001, corrected, t-test).
54-1	11594-11606	Specifically	_	
54-2	11606-11607	,	_	
54-3	11608-11610	at	_	
54-4	11611-11614	age	_	
54-5	11615-11617	14	_	
54-6	11617-11618	,	_	
54-7	11619-11623	high	_	
54-8	11624-11631	novelty	_	
54-9	11632-11639	seekers	_	
54-10	11640-11643	who	_	
54-11	11644-11654	eventually	_	
54-12	11655-11664	developed	_	
54-13	11665-11668	PDU	_	
54-14	11669-11675	showed	_	
54-15	11676-11685	increased	_	
54-16	11686-11690	grey	_	
54-17	11691-11697	matter	_	
54-18	11698-11705	density	_	
54-19	11706-11708	in	_	
54-20	11709-11712	the	_	
54-21	11713-11717	left	_	
54-22	11718-11720	VS	_	
54-23	11721-11722	(	_	
54-24	11722-11723	n	_	
54-25	11723-11724	=	_	
54-26	11724-11727	144	_	
54-27	11727-11728	;	_	
54-28	11729-11730	t	_	
54-29	11730-11731	(	_	
54-30	11731-11734	126	_	
54-31	11734-11735	)	_	
54-32	11735-11736	=	_	
54-33	11736-11740	2.51	_	
54-34	11740-11741	,	_	
54-35	11742-11743	P	_	
54-36	11743-11744	=	_	
54-37	11744-11749	0.007	_	
54-38	11749-11750	,	_	
54-39	11751-11762	uncorrected	_	
54-40	11762-11763	/	_	
54-41	11763-11764	P	_	
54-42	11764-11765	=	_	
54-43	11765-11770	0.040	_	
54-44	11770-11771	,	_	
54-45	11772-11781	corrected	_	
54-46	11781-11782	,	_	
54-47	11783-11789	t-test	_	
54-48	11789-11790	)	_	
54-49	11790-11791	,	_	
54-50	11792-11795	the	_	
54-51	11796-11800	left	_	
54-52	11801-11809	midbrain	_	
54-53	11810-11811	(	_	
54-54	11811-11812	n	_	
54-55	11812-11813	=	_	
54-56	11813-11816	144	_	
54-57	11816-11817	;	_	
54-58	11818-11819	t	_	
54-59	11819-11820	(	_	
54-60	11820-11823	126	_	
54-61	11823-11824	)	_	
54-62	11824-11825	=	_	
54-63	11825-11829	2.95	_	
54-64	11829-11830	,	_	
54-65	11831-11832	P	_	
54-66	11832-11833	=	_	
54-67	11833-11838	0.002	_	
54-68	11838-11839	,	_	
54-69	11840-11851	uncorrected	_	
54-70	11851-11852	/	_	
54-71	11852-11853	P	_	
54-72	11853-11854	=	_	
54-73	11854-11859	0.011	_	
54-74	11859-11860	,	_	
54-75	11861-11870	corrected	_	
54-76	11870-11871	,	_	
54-77	11872-11878	t-test	_	
54-78	11878-11879	)	_	
54-79	11880-11883	and	_	
54-80	11884-11893	bilateral	_	
54-81	11894-11906	dorsolateral	_	
54-82	11907-11917	prefrontal	_	
54-83	11918-11924	cortex	_	
54-84	11925-11926	(	_	
54-85	11926-11931	right	_	
54-86	11931-11932	:	_	
54-87	11933-11934	n	_	
54-88	11934-11935	=	_	
54-89	11935-11938	144	_	
54-90	11938-11939	;	_	
54-91	11940-11941	t	_	
54-92	11941-11942	(	_	
54-93	11942-11945	126	_	
54-94	11945-11946	)	_	
54-95	11946-11947	=	_	
54-96	11947-11951	3.62	_	
54-97	11951-11952	,	_	
54-98	11953-11954	P	_	
54-99	11954-11955	=	_	
54-100	11955-11960	0.001	_	
54-101	11960-11961	,	_	
54-102	11962-11973	uncorrected	_	
54-103	11973-11974	/	_	
54-104	11974-11975	P	_	
54-105	11975-11976	=	_	
54-106	11976-11981	0.001	_	
54-107	11982-11991	corrected	_	
54-108	11991-11992	;	_	
54-109	11993-11997	left	_	
54-110	11997-11998	:	_	
54-111	11999-12000	t	_	
54-112	12000-12001	(	_	
54-113	12001-12004	126	_	
54-114	12004-12005	)	_	
54-115	12005-12006	=	_	
54-116	12006-12010	3.76	_	
54-117	12010-12011	,	_	
54-118	12012-12013	P	_	
54-119	12013-12014	=	_	
54-120	12014-12019	0.001	_	
54-121	12019-12020	,	_	
54-122	12021-12032	uncorrected	_	
54-123	12032-12033	/	_	
54-124	12033-12034	P	_	
54-125	12034-12035	=	_	
54-126	12035-12040	0.001	_	
54-127	12040-12041	,	_	
54-128	12042-12051	corrected	_	
54-129	12051-12052	,	_	
54-130	12053-12059	t-test	_	
54-131	12059-12060	)	_	
54-132	12060-12061	.	_	

#Text=The dorsolateral prefrontal region that showed structural differences showed some overlap with regions that showed group differences in functional activity (Fig. 4b).
55-1	12062-12065	The	_	
55-2	12066-12078	dorsolateral	_	
55-3	12079-12089	prefrontal	_	
55-4	12090-12096	region	_	
55-5	12097-12101	that	_	
55-6	12102-12108	showed	_	
55-7	12109-12119	structural	_	
55-8	12120-12131	differences	_	
55-9	12132-12138	showed	_	
55-10	12139-12143	some	_	
55-11	12144-12151	overlap	_	
55-12	12152-12156	with	_	
55-13	12157-12164	regions	_	
55-14	12165-12169	that	_	
55-15	12170-12176	showed	_	
55-16	12177-12182	group	_	
55-17	12183-12194	differences	_	
55-18	12195-12197	in	_	
55-19	12198-12208	functional	_	
55-20	12209-12217	activity	_	
55-21	12218-12219	(	_	
55-22	12219-12222	Fig	_	
55-23	12222-12223	.	_	
55-24	12224-12226	4b	_	
55-25	12226-12227	)	_	
55-26	12227-12228	.	_	

#Text=Behavioural and neural prediction of PDU
#Text=To compare the ability of psychological and neural variables of interest to predict the development of PDU, we further implemented a series of logistic regression models using statistically relevant psychometric and neural variables acquired at age 14 to predict PDU at age 16.
56-1	12229-12240	Behavioural	_	
56-2	12241-12244	and	_	
56-3	12245-12251	neural	_	
56-4	12252-12262	prediction	_	
56-5	12263-12265	of	_	
56-6	12266-12269	PDU	_	
56-7	12270-12272	To	_	
56-8	12273-12280	compare	_	
56-9	12281-12284	the	_	
56-10	12285-12292	ability	_	
56-11	12293-12295	of	_	
56-12	12296-12309	psychological	_	
56-13	12310-12313	and	_	
56-14	12314-12320	neural	_	
56-15	12321-12330	variables	_	
56-16	12331-12333	of	_	
56-17	12334-12342	interest	_	
56-18	12343-12345	to	_	
56-19	12346-12353	predict	_	
56-20	12354-12357	the	_	
56-21	12358-12369	development	_	
56-22	12370-12372	of	_	
56-23	12373-12376	PDU	_	
56-24	12376-12377	,	_	
56-25	12378-12380	we	_	
56-26	12381-12388	further	_	
56-27	12389-12400	implemented	_	
56-28	12401-12402	a	_	
56-29	12403-12409	series	_	
56-30	12410-12412	of	_	
56-31	12413-12421	logistic	_	
56-32	12422-12432	regression	_	
56-33	12433-12439	models	_	
56-34	12440-12445	using	_	
56-35	12446-12459	statistically	_	
56-36	12460-12468	relevant	_	
56-37	12469-12481	psychometric	_	
56-38	12482-12485	and	_	
56-39	12486-12492	neural	_	
56-40	12493-12502	variables	_	
56-41	12503-12511	acquired	_	
56-42	12512-12514	at	_	
56-43	12515-12518	age	_	
56-44	12519-12521	14	_	
56-45	12522-12524	to	_	
56-46	12525-12532	predict	_	
56-47	12533-12536	PDU	_	
56-48	12537-12539	at	_	
56-49	12540-12543	age	_	
56-50	12544-12546	16	_	
56-51	12546-12547	.	_	

#Text=Model comparison revealed that a model combining neural (activation in VS and dlPFC) with psychological variables (temporal discounting and Neuroticism-Extraversion-Openness Five-Factor Inventory conscientiousness) at age 14 best-predicted PDU at age 16 (n=144, Akaike Information criterion (AIC)=176, pseudo R2=0.20, logistic regression).
57-1	12548-12553	Model	_	
57-2	12554-12564	comparison	_	
57-3	12565-12573	revealed	_	
57-4	12574-12578	that	_	
57-5	12579-12580	a	_	
57-6	12581-12586	model	_	
57-7	12587-12596	combining	_	
57-8	12597-12603	neural	_	
57-9	12604-12605	(	_	
57-10	12605-12615	activation	_	
57-11	12616-12618	in	_	
57-12	12619-12621	VS	_	
57-13	12622-12625	and	_	
57-14	12626-12631	dlPFC	_	
57-15	12631-12632	)	_	
57-16	12633-12637	with	_	
57-17	12638-12651	psychological	_	
57-18	12652-12661	variables	_	
57-19	12662-12663	(	_	
57-20	12663-12671	temporal	_	
57-21	12672-12683	discounting	_	
57-22	12684-12687	and	_	
57-23	12688-12721	Neuroticism-Extraversion-Openness	_	
57-24	12722-12733	Five-Factor	_	
57-25	12734-12743	Inventory	_	
57-26	12744-12761	conscientiousness	_	
57-27	12761-12762	)	_	
57-28	12763-12765	at	_	
57-29	12766-12769	age	_	
57-30	12770-12772	14	_	
57-31	12773-12787	best-predicted	_	
57-32	12788-12791	PDU	_	
57-33	12792-12794	at	_	
57-34	12795-12798	age	_	
57-35	12799-12801	16	_	
57-36	12802-12803	(	_	
57-37	12803-12804	n	_	
57-38	12804-12805	=	_	
57-39	12805-12808	144	_	
57-40	12808-12809	,	_	
57-41	12810-12816	Akaike	_	
57-42	12817-12828	Information	_	
57-43	12829-12838	criterion	_	
57-44	12839-12840	(	_	
57-45	12840-12843	AIC	_	
57-46	12843-12844	)	_	
57-47	12844-12845	=	_	
57-48	12845-12848	176	_	
57-49	12848-12849	,	_	
57-50	12850-12856	pseudo	_	
57-51	12857-12859	R2	_	
57-52	12859-12860	=	_	
57-53	12860-12864	0.20	_	
57-54	12864-12865	,	_	
57-55	12866-12874	logistic	_	
57-56	12875-12885	regression	_	
57-57	12885-12886	)	_	
57-58	12886-12887	.	_	

#Text=Interestingly, the next most-predictive model included only neural variables (n=144, AIC=183, pseudo R2=0.15, logistic regression), followed by the model that included only psychological variables (n=144, AIC=195, pseudo R2=0.07, logistic regression).
58-1	12888-12901	Interestingly	_	
58-2	12901-12902	,	_	
58-3	12903-12906	the	_	
58-4	12907-12911	next	_	
58-5	12912-12927	most-predictive	_	
58-6	12928-12933	model	_	
58-7	12934-12942	included	_	
58-8	12943-12947	only	_	
58-9	12948-12954	neural	_	
58-10	12955-12964	variables	_	
58-11	12965-12966	(	_	
58-12	12966-12967	n	_	
58-13	12967-12968	=	_	
58-14	12968-12971	144	_	
58-15	12971-12972	,	_	
58-16	12973-12976	AIC	_	
58-17	12976-12977	=	_	
58-18	12977-12980	183	_	
58-19	12980-12981	,	_	
58-20	12982-12988	pseudo	_	
58-21	12989-12991	R2	_	
58-22	12991-12992	=	_	
58-23	12992-12996	0.15	_	
58-24	12996-12997	,	_	
58-25	12998-13006	logistic	_	
58-26	13007-13017	regression	_	
58-27	13017-13018	)	_	
58-28	13018-13019	,	_	
58-29	13020-13028	followed	_	
58-30	13029-13031	by	_	
58-31	13032-13035	the	_	
58-32	13036-13041	model	_	
58-33	13042-13046	that	_	
58-34	13047-13055	included	_	
58-35	13056-13060	only	_	
58-36	13061-13074	psychological	_	
58-37	13075-13084	variables	_	
58-38	13085-13086	(	_	
58-39	13086-13087	n	_	
58-40	13087-13088	=	_	
58-41	13088-13091	144	_	
58-42	13091-13092	,	_	
58-43	13093-13096	AIC	_	
58-44	13096-13097	=	_	
58-45	13097-13100	195	_	
58-46	13100-13101	,	_	
58-47	13102-13108	pseudo	_	
58-48	13109-13111	R2	_	
58-49	13111-13112	=	_	
58-50	13112-13116	0.07	_	
58-51	13116-13117	,	_	
58-52	13118-13126	logistic	_	
58-53	13127-13137	regression	_	
58-54	13137-13138	)	_	
58-55	13138-13139	.	_	

#Text=These findings suggest that neural and psychological variables may account for independent variance in predicting PDU.
59-1	13140-13145	These	_	
59-2	13146-13154	findings	_	
59-3	13155-13162	suggest	_	
59-4	13163-13167	that	_	
59-5	13168-13174	neural	_	
59-6	13175-13178	and	_	
59-7	13179-13192	psychological	_	
59-8	13193-13202	variables	_	
59-9	13203-13206	may	_	
59-10	13207-13214	account	_	
59-11	13215-13218	for	_	
59-12	13219-13230	independent	_	
59-13	13231-13239	variance	_	
59-14	13240-13242	in	_	
59-15	13243-13253	predicting	_	
59-16	13254-13257	PDU	_	
59-17	13257-13258	.	_	

#Text=Performing a formal classification using a linear support vector machine with threefold cross-validation implied that model predictions should generalize to other samples, and that classification accuracy was similar for the combined (neural and psychological) model (66% out of sample) and the model containing only neural variables (65% out of sample), but lower for the model containing only psychological variables (55% out of sample; Table 4).
60-1	13259-13269	Performing	_	
60-2	13270-13271	a	_	
60-3	13272-13278	formal	_	
60-4	13279-13293	classification	_	
60-5	13294-13299	using	_	
60-6	13300-13301	a	_	
60-7	13302-13308	linear	_	
60-8	13309-13316	support	_	
60-9	13317-13323	vector	_	
60-10	13324-13331	machine	_	
60-11	13332-13336	with	_	
60-12	13337-13346	threefold	_	
60-13	13347-13363	cross-validation	_	
60-14	13364-13371	implied	_	
60-15	13372-13376	that	_	
60-16	13377-13382	model	_	
60-17	13383-13394	predictions	_	
60-18	13395-13401	should	_	
60-19	13402-13412	generalize	_	
60-20	13413-13415	to	_	
60-21	13416-13421	other	_	
60-22	13422-13429	samples	_	
60-23	13429-13430	,	_	
60-24	13431-13434	and	_	
60-25	13435-13439	that	_	
60-26	13440-13454	classification	_	
60-27	13455-13463	accuracy	_	
60-28	13464-13467	was	_	
60-29	13468-13475	similar	_	
60-30	13476-13479	for	_	
60-31	13480-13483	the	_	
60-32	13484-13492	combined	_	
60-33	13493-13494	(	_	
60-34	13494-13500	neural	_	
60-35	13501-13504	and	_	
60-36	13505-13518	psychological	_	
60-37	13518-13519	)	_	
60-38	13520-13525	model	_	
60-39	13526-13527	(	_	
60-40	13527-13530	66%	_	
60-41	13531-13534	out	_	
60-42	13535-13537	of	_	
60-43	13538-13544	sample	_	
60-44	13544-13545	)	_	
60-45	13546-13549	and	_	
60-46	13550-13553	the	_	
60-47	13554-13559	model	_	
60-48	13560-13570	containing	_	
60-49	13571-13575	only	_	
60-50	13576-13582	neural	_	
60-51	13583-13592	variables	_	
60-52	13593-13594	(	_	
60-53	13594-13597	65%	_	
60-54	13598-13601	out	_	
60-55	13602-13604	of	_	
60-56	13605-13611	sample	_	
60-57	13611-13612	)	_	
60-58	13612-13613	,	_	
60-59	13614-13617	but	_	
60-60	13618-13623	lower	_	
60-61	13624-13627	for	_	
60-62	13628-13631	the	_	
60-63	13632-13637	model	_	
60-64	13638-13648	containing	_	
60-65	13649-13653	only	_	
60-66	13654-13667	psychological	_	
60-67	13668-13677	variables	_	
60-68	13678-13679	(	_	
60-69	13679-13682	55%	_	
60-70	13683-13686	out	_	
60-71	13687-13689	of	_	
60-72	13690-13696	sample	_	
60-73	13696-13697	;	_	
60-74	13698-13703	Table	_	
60-75	13704-13705	4	_	
60-76	13705-13706	)	_	
60-77	13706-13707	.	_	

#Text=Discussion
#Text=To identify factors that confer vulnerability to PDU, we longitudinally characterized and tracked a large sample of novelty-seeking adolescents.
61-1	13708-13718	Discussion	_	
61-2	13719-13721	To	_	
61-3	13722-13730	identify	_	
61-4	13731-13738	factors	_	
61-5	13739-13743	that	_	
61-6	13744-13750	confer	_	
61-7	13751-13764	vulnerability	_	
61-8	13765-13767	to	_	
61-9	13768-13771	PDU	_	
61-10	13771-13772	,	_	
61-11	13773-13775	we	_	
61-12	13776-13790	longitudinally	_	
61-13	13791-13804	characterized	_	
61-14	13805-13808	and	_	
61-15	13809-13816	tracked	_	
61-16	13817-13818	a	_	
61-17	13819-13824	large	_	
61-18	13825-13831	sample	_	
61-19	13832-13834	of	_	
61-20	13835-13850	novelty-seeking	_	
61-21	13851-13862	adolescents	_	
61-22	13862-13863	.	_	

#Text=We then compared individuals at age 14 who subsequently developed PDU at age 16 with those who did not.
62-1	13864-13866	We	_	
62-2	13867-13871	then	_	
62-3	13872-13880	compared	_	
62-4	13881-13892	individuals	_	
62-5	13893-13895	at	_	
62-6	13896-13899	age	_	
62-7	13900-13902	14	_	
62-8	13903-13906	who	_	
62-9	13907-13919	subsequently	_	
62-10	13920-13929	developed	_	
62-11	13930-13933	PDU	_	
62-12	13934-13936	at	_	
62-13	13937-13940	age	_	
62-14	13941-13943	16	_	
62-15	13944-13948	with	_	
62-16	13949-13954	those	_	
62-17	13955-13958	who	_	
62-18	13959-13962	did	_	
62-19	13963-13966	not	_	
62-20	13966-13967	.	_	

#Text=Importantly, these groups were carefully matched at age 14 on a range of relevant variables, including drug use.
63-1	13968-13979	Importantly	_	
63-2	13979-13980	,	_	
63-3	13981-13986	these	_	
63-4	13987-13993	groups	_	
63-5	13994-13998	were	_	
63-6	13999-14008	carefully	_	
63-7	14009-14016	matched	_	
63-8	14017-14019	at	_	
63-9	14020-14023	age	_	
63-10	14024-14026	14	_	
63-11	14027-14029	on	_	
63-12	14030-14031	a	_	
63-13	14032-14037	range	_	
63-14	14038-14040	of	_	
63-15	14041-14049	relevant	_	
63-16	14050-14059	variables	_	
63-17	14059-14060	,	_	
63-18	14061-14070	including	_	
63-19	14071-14075	drug	_	
63-20	14076-14079	use	_	
63-21	14079-14080	.	_	

#Text=Individuals who later transitioned to PDU showed decreased right ventral striatal, left midbrain and right dorsolateral prefrontal cortex activity during anticipation of large versus small gains at age 14.
64-1	14081-14092	Individuals	_	
64-2	14093-14096	who	_	
64-3	14097-14102	later	_	
64-4	14103-14115	transitioned	_	
64-5	14116-14118	to	_	
64-6	14119-14122	PDU	_	
64-7	14123-14129	showed	_	
64-8	14130-14139	decreased	_	
64-9	14140-14145	right	_	
64-10	14146-14153	ventral	_	
64-11	14154-14162	striatal	_	
64-12	14162-14163	,	_	
64-13	14164-14168	left	_	
64-14	14169-14177	midbrain	_	
64-15	14178-14181	and	_	
64-16	14182-14187	right	_	
64-17	14188-14200	dorsolateral	_	
64-18	14201-14211	prefrontal	_	
64-19	14212-14218	cortex	_	
64-20	14219-14227	activity	_	
64-21	14228-14234	during	_	
64-22	14235-14247	anticipation	_	
64-23	14248-14250	of	_	
64-24	14251-14256	large	_	
64-25	14257-14263	versus	_	
64-26	14264-14269	small	_	
64-27	14270-14275	gains	_	
64-28	14276-14278	at	_	
64-29	14279-14282	age	_	
64-30	14283-14285	14	_	
64-31	14285-14286	.	_	

#Text=Consistent with greater impulsivity, these vulnerable individuals also showed steeper discounting of future rewards and lower conscientiousness scores at age 14.
65-1	14287-14297	Consistent	_	
65-2	14298-14302	with	_	
65-3	14303-14310	greater	_	
65-4	14311-14322	impulsivity	_	
65-5	14322-14323	,	_	
65-6	14324-14329	these	_	
65-7	14330-14340	vulnerable	_	
65-8	14341-14352	individuals	_	
65-9	14353-14357	also	_	
65-10	14358-14364	showed	_	
65-11	14365-14372	steeper	_	
65-12	14373-14384	discounting	_	
65-13	14385-14387	of	_	
65-14	14388-14394	future	_	
65-15	14395-14402	rewards	_	
65-16	14403-14406	and	_	
65-17	14407-14412	lower	_	
65-18	14413-14430	conscientiousness	_	
65-19	14431-14437	scores	_	
65-20	14438-14440	at	_	
65-21	14441-14444	age	_	
65-22	14445-14447	14	_	
65-23	14447-14448	.	_	

#Text=Notably, comparison of neural and psychological measures revealed that the neural markers predicted PDU as well as or better than the psychological variables.
66-1	14449-14456	Notably	_	
66-2	14456-14457	,	_	
66-3	14458-14468	comparison	_	
66-4	14469-14471	of	_	
66-5	14472-14478	neural	_	
66-6	14479-14482	and	_	
66-7	14483-14496	psychological	_	
66-8	14497-14505	measures	_	
66-9	14506-14514	revealed	_	
66-10	14515-14519	that	_	
66-11	14520-14523	the	_	
66-12	14524-14530	neural	_	
66-13	14531-14538	markers	_	
66-14	14539-14548	predicted	_	
66-15	14549-14552	PDU	_	
66-16	14553-14555	as	_	
66-17	14556-14560	well	_	
66-18	14561-14563	as	_	
66-19	14564-14566	or	_	
66-20	14567-14573	better	_	
66-21	14574-14578	than	_	
66-22	14579-14582	the	_	
66-23	14583-14596	psychological	_	
66-24	14597-14606	variables	_	
66-25	14606-14607	.	_	

#Text=Consistent with the primary prediction, novelty-seeking subjects with less ventral striatal activity during reward anticipation at age 14 were more likely to develop PDU at age 16.
67-1	14608-14618	Consistent	_	
67-2	14619-14623	with	_	
67-3	14624-14627	the	_	
67-4	14628-14635	primary	_	
67-5	14636-14646	prediction	_	
67-6	14646-14647	,	_	
67-7	14648-14663	novelty-seeking	_	
67-8	14664-14672	subjects	_	
67-9	14673-14677	with	_	
67-10	14678-14682	less	_	
67-11	14683-14690	ventral	_	
67-12	14691-14699	striatal	_	
67-13	14700-14708	activity	_	
67-14	14709-14715	during	_	
67-15	14716-14722	reward	_	
67-16	14723-14735	anticipation	_	
67-17	14736-14738	at	_	
67-18	14739-14742	age	_	
67-19	14743-14745	14	_	
67-20	14746-14750	were	_	
67-21	14751-14755	more	_	
67-22	14756-14762	likely	_	
67-23	14763-14765	to	_	
67-24	14766-14773	develop	_	
67-25	14774-14777	PDU	_	
67-26	14778-14780	at	_	
67-27	14781-14784	age	_	
67-28	14785-14787	16	_	
67-29	14787-14788	.	_	

#Text=Reduced ventral striatal activity during gain anticipation has previously been observed in cross-sectional studies of substance abuse and other addictive behaviours, and coheres with non-human primate research, suggesting that repeated drug intake can reduce activity in the VS.
68-1	14789-14796	Reduced	_	
68-2	14797-14804	ventral	_	
68-3	14805-14813	striatal	_	
68-4	14814-14822	activity	_	
68-5	14823-14829	during	_	
68-6	14830-14834	gain	_	
68-7	14835-14847	anticipation	_	
68-8	14848-14851	has	_	
68-9	14852-14862	previously	_	
68-10	14863-14867	been	_	
68-11	14868-14876	observed	_	
68-12	14877-14879	in	_	
68-13	14880-14895	cross-sectional	_	
68-14	14896-14903	studies	_	
68-15	14904-14906	of	_	
68-16	14907-14916	substance	_	
68-17	14917-14922	abuse	_	
68-18	14923-14926	and	_	
68-19	14927-14932	other	_	
68-20	14933-14942	addictive	_	
68-21	14943-14953	behaviours	_	
68-22	14953-14954	,	_	
68-23	14955-14958	and	_	
68-24	14959-14966	coheres	_	
68-25	14967-14971	with	_	
68-26	14972-14981	non-human	_	
68-27	14982-14989	primate	_	
68-28	14990-14998	research	_	
68-29	14998-14999	,	_	
68-30	15000-15010	suggesting	_	
68-31	15011-15015	that	_	
68-32	15016-15024	repeated	_	
68-33	15025-15029	drug	_	
68-34	15030-15036	intake	_	
68-35	15037-15040	can	_	
68-36	15041-15047	reduce	_	
68-37	15048-15056	activity	_	
68-38	15057-15059	in	_	
68-39	15060-15063	the	_	
68-40	15064-15066	VS	_	
68-41	15066-15067	.	_	

#Text=Cross-sectional research, however, cannot clarify whether diminished neural responses to gain anticipation precede or result from substance abuse.
69-1	15068-15083	Cross-sectional	_	
69-2	15084-15092	research	_	
69-3	15092-15093	,	_	
69-4	15094-15101	however	_	
69-5	15101-15102	,	_	
69-6	15103-15109	cannot	_	
69-7	15110-15117	clarify	_	
69-8	15118-15125	whether	_	
69-9	15126-15136	diminished	_	
69-10	15137-15143	neural	_	
69-11	15144-15153	responses	_	
69-12	15154-15156	to	_	
69-13	15157-15161	gain	_	
69-14	15162-15174	anticipation	_	
69-15	15175-15182	precede	_	
69-16	15183-15185	or	_	
69-17	15186-15192	result	_	
69-18	15193-15197	from	_	
69-19	15198-15207	substance	_	
69-20	15208-15213	abuse	_	
69-21	15213-15214	.	_	

#Text=Some relevant evidence, however, comes from longitudinal studies of animals.
70-1	15215-15219	Some	_	
70-2	15220-15228	relevant	_	
70-3	15229-15237	evidence	_	
70-4	15237-15238	,	_	
70-5	15239-15246	however	_	
70-6	15246-15247	,	_	
70-7	15248-15253	comes	_	
70-8	15254-15258	from	_	
70-9	15259-15271	longitudinal	_	
70-10	15272-15279	studies	_	
70-11	15280-15282	of	_	
70-12	15283-15290	animals	_	
70-13	15290-15291	.	_	

#Text=For instance, one study implied that reduced dopamine D2 receptor availability in the striatum (assessed with positron emission tomography or PET) foreshadowed increased drug intake in primates.
71-1	15292-15295	For	_	
71-2	15296-15304	instance	_	
71-3	15304-15305	,	_	
71-4	15306-15309	one	_	
71-5	15310-15315	study	_	
71-6	15316-15323	implied	_	
71-7	15324-15328	that	_	
71-8	15329-15336	reduced	_	
71-9	15337-15345	dopamine	_	
71-10	15346-15348	D2	_	
71-11	15349-15357	receptor	_	
71-12	15358-15370	availability	_	
71-13	15371-15373	in	_	
71-14	15374-15377	the	_	
71-15	15378-15386	striatum	_	
71-16	15387-15388	(	_	
71-17	15388-15396	assessed	_	
71-18	15397-15401	with	_	
71-19	15402-15410	positron	_	
71-20	15411-15419	emission	_	
71-21	15420-15430	tomography	_	
71-22	15431-15433	or	_	
71-23	15434-15437	PET	_	
71-24	15437-15438	)	_	
71-25	15439-15451	foreshadowed	_	
71-26	15452-15461	increased	_	
71-27	15462-15466	drug	_	
71-28	15467-15473	intake	_	
71-29	15474-15476	in	_	
71-30	15477-15485	primates	_	
71-31	15485-15486	.	_	

#Text=Another study of rodents bred for impulsivity also indicated that reduced D2/D3 receptor availability in the striatum preceded increased drug intake.
72-1	15487-15494	Another	_	
72-2	15495-15500	study	_	
72-3	15501-15503	of	_	
72-4	15504-15511	rodents	_	
72-5	15512-15516	bred	_	
72-6	15517-15520	for	_	
72-7	15521-15532	impulsivity	_	
72-8	15533-15537	also	_	
72-9	15538-15547	indicated	_	
72-10	15548-15552	that	_	
72-11	15553-15560	reduced	_	
72-12	15561-15563	D2	_	
72-13	15563-15564	/	_	
72-14	15564-15566	D3	_	
72-15	15567-15575	receptor	_	
72-16	15576-15588	availability	_	
72-17	15589-15591	in	_	
72-18	15592-15595	the	_	
72-19	15596-15604	striatum	_	
72-20	15605-15613	preceded	_	
72-21	15614-15623	increased	_	
72-22	15624-15628	drug	_	
72-23	15629-15635	intake	_	
72-24	15635-15636	.	_	

#Text=This animal research highlights a critical role for longitudinal designs in clarifying causal pathways to substance abuse in humans.
73-1	15637-15641	This	_	
73-2	15642-15648	animal	_	
73-3	15649-15657	research	_	
73-4	15658-15668	highlights	_	
73-5	15669-15670	a	_	
73-6	15671-15679	critical	_	
73-7	15680-15684	role	_	
73-8	15685-15688	for	_	
73-9	15689-15701	longitudinal	_	
73-10	15702-15709	designs	_	
73-11	15710-15712	in	_	
73-12	15713-15723	clarifying	_	
73-13	15724-15730	causal	_	
73-14	15731-15739	pathways	_	
73-15	15740-15742	to	_	
73-16	15743-15752	substance	_	
73-17	15753-15758	abuse	_	
73-18	15759-15761	in	_	
73-19	15762-15768	humans	_	
73-20	15768-15769	.	_	

#Text=Consistent with animal results, the current findings demonstrate in a longitudinal sample of novelty-seeking adolescents that reduced activation of the VS and the midbrain at age 14 precedes PDU at age 16, thus implying that reduced recruitment of the mesolimbic circuit not only results from, but also can precede and predict PDU.
74-1	15770-15780	Consistent	_	
74-2	15781-15785	with	_	
74-3	15786-15792	animal	_	
74-4	15793-15800	results	_	
74-5	15800-15801	,	_	
74-6	15802-15805	the	_	
74-7	15806-15813	current	_	
74-8	15814-15822	findings	_	
74-9	15823-15834	demonstrate	_	
74-10	15835-15837	in	_	
74-11	15838-15839	a	_	
74-12	15840-15852	longitudinal	_	
74-13	15853-15859	sample	_	
74-14	15860-15862	of	_	
74-15	15863-15878	novelty-seeking	_	
74-16	15879-15890	adolescents	_	
74-17	15891-15895	that	_	
74-18	15896-15903	reduced	_	
74-19	15904-15914	activation	_	
74-20	15915-15917	of	_	
74-21	15918-15921	the	_	
74-22	15922-15924	VS	_	
74-23	15925-15928	and	_	
74-24	15929-15932	the	_	
74-25	15933-15941	midbrain	_	
74-26	15942-15944	at	_	
74-27	15945-15948	age	_	
74-28	15949-15951	14	_	
74-29	15952-15960	precedes	_	
74-30	15961-15964	PDU	_	
74-31	15965-15967	at	_	
74-32	15968-15971	age	_	
74-33	15972-15974	16	_	
74-34	15974-15975	,	_	
74-35	15976-15980	thus	_	
74-36	15981-15989	implying	_	
74-37	15990-15994	that	_	
74-38	15995-16002	reduced	_	
74-39	16003-16014	recruitment	_	
74-40	16015-16017	of	_	
74-41	16018-16021	the	_	
74-42	16022-16032	mesolimbic	_	
74-43	16033-16040	circuit	_	
74-44	16041-16044	not	_	
74-45	16045-16049	only	_	
74-46	16050-16057	results	_	
74-47	16058-16062	from	_	
74-48	16062-16063	,	_	
74-49	16064-16067	but	_	
74-50	16068-16072	also	_	
74-51	16073-16076	can	_	
74-52	16077-16084	precede	_	
74-53	16085-16088	and	_	
74-54	16089-16096	predict	_	
74-55	16097-16100	PDU	_	
74-56	16100-16101	.	_	

#Text=Theorists have linked reduced activity in the mesolimbic circuit to blunted motivation for reward.
75-1	16102-16111	Theorists	_	
75-2	16112-16116	have	_	
75-3	16117-16123	linked	_	
75-4	16124-16131	reduced	_	
75-5	16132-16140	activity	_	
75-6	16141-16143	in	_	
75-7	16144-16147	the	_	
75-8	16148-16158	mesolimbic	_	
75-9	16159-16166	circuit	_	
75-10	16167-16169	to	_	
75-11	16170-16177	blunted	_	
75-12	16178-16188	motivation	_	
75-13	16189-16192	for	_	
75-14	16193-16199	reward	_	
75-15	16199-16200	.	_	

#Text=Since organisms typically seek to increase states associated with positive outcomes, individuals with blunted neural responses during reward anticipation may require the promise of stronger rewards (for example, drugs of abuse) to elicit comparable levels of motivation.
76-1	16201-16206	Since	_	
76-2	16207-16216	organisms	_	
76-3	16217-16226	typically	_	
76-4	16227-16231	seek	_	
76-5	16232-16234	to	_	
76-6	16235-16243	increase	_	
76-7	16244-16250	states	_	
76-8	16251-16261	associated	_	
76-9	16262-16266	with	_	
76-10	16267-16275	positive	_	
76-11	16276-16284	outcomes	_	
76-12	16284-16285	,	_	
76-13	16286-16297	individuals	_	
76-14	16298-16302	with	_	
76-15	16303-16310	blunted	_	
76-16	16311-16317	neural	_	
76-17	16318-16327	responses	_	
76-18	16328-16334	during	_	
76-19	16335-16341	reward	_	
76-20	16342-16354	anticipation	_	
76-21	16355-16358	may	_	
76-22	16359-16366	require	_	
76-23	16367-16370	the	_	
76-24	16371-16378	promise	_	
76-25	16379-16381	of	_	
76-26	16382-16390	stronger	_	
76-27	16391-16398	rewards	_	
76-28	16399-16400	(	_	
76-29	16400-16403	for	_	
76-30	16404-16411	example	_	
76-31	16411-16412	,	_	
76-32	16413-16418	drugs	_	
76-33	16419-16421	of	_	
76-34	16422-16427	abuse	_	
76-35	16427-16428	)	_	
76-36	16429-16431	to	_	
76-37	16432-16438	elicit	_	
76-38	16439-16449	comparable	_	
76-39	16450-16456	levels	_	
76-40	16457-16459	of	_	
76-41	16460-16470	motivation	_	
76-42	16470-16471	.	_	

#Text=The reduced ventral striatal activation at age 14 observed in novelty-seeking adolescents at risk for PDU does not necessarily negate findings, suggesting that drug use may also reciprocally decrease ventral striatal activity.
77-1	16472-16475	The	_	
77-2	16476-16483	reduced	_	
77-3	16484-16491	ventral	_	
77-4	16492-16500	striatal	_	
77-5	16501-16511	activation	_	
77-6	16512-16514	at	_	
77-7	16515-16518	age	_	
77-8	16519-16521	14	_	
77-9	16522-16530	observed	_	
77-10	16531-16533	in	_	
77-11	16534-16549	novelty-seeking	_	
77-12	16550-16561	adolescents	_	
77-13	16562-16564	at	_	
77-14	16565-16569	risk	_	
77-15	16570-16573	for	_	
77-16	16574-16577	PDU	_	
77-17	16578-16582	does	_	
77-18	16583-16586	not	_	
77-19	16587-16598	necessarily	_	
77-20	16599-16605	negate	_	
77-21	16606-16614	findings	_	
77-22	16614-16615	,	_	
77-23	16616-16626	suggesting	_	
77-24	16627-16631	that	_	
77-25	16632-16636	drug	_	
77-26	16637-16640	use	_	
77-27	16641-16644	may	_	
77-28	16645-16649	also	_	
77-29	16650-16662	reciprocally	_	
77-30	16663-16671	decrease	_	
77-31	16672-16679	ventral	_	
77-32	16680-16688	striatal	_	
77-33	16689-16697	activity	_	
77-34	16697-16698	.	_	

#Text=Instead, in combination with previously noted cross-sectional observations of reduced mesolimbic activity associated with addictive behaviour, the present longitudinal findings raise the possibility of a vicious cycle in which novelty-seeking individuals with less responsive mesolimbic circuits seek increased exposure to drugs of abuse, which can further blunt mesolimbic responsiveness, and so maintain addiction.
78-1	16699-16706	Instead	_	
78-2	16706-16707	,	_	
78-3	16708-16710	in	_	
78-4	16711-16722	combination	_	
78-5	16723-16727	with	_	
78-6	16728-16738	previously	_	
78-7	16739-16744	noted	_	
78-8	16745-16760	cross-sectional	_	
78-9	16761-16773	observations	_	
78-10	16774-16776	of	_	
78-11	16777-16784	reduced	_	
78-12	16785-16795	mesolimbic	_	
78-13	16796-16804	activity	_	
78-14	16805-16815	associated	_	
78-15	16816-16820	with	_	
78-16	16821-16830	addictive	_	
78-17	16831-16840	behaviour	_	
78-18	16840-16841	,	_	
78-19	16842-16845	the	_	
78-20	16846-16853	present	_	
78-21	16854-16866	longitudinal	_	
78-22	16867-16875	findings	_	
78-23	16876-16881	raise	_	
78-24	16882-16885	the	_	
78-25	16886-16897	possibility	_	
78-26	16898-16900	of	_	
78-27	16901-16902	a	_	
78-28	16903-16910	vicious	_	
78-29	16911-16916	cycle	_	
78-30	16917-16919	in	_	
78-31	16920-16925	which	_	
78-32	16926-16941	novelty-seeking	_	
78-33	16942-16953	individuals	_	
78-34	16954-16958	with	_	
78-35	16959-16963	less	_	
78-36	16964-16974	responsive	_	
78-37	16975-16985	mesolimbic	_	
78-38	16986-16994	circuits	_	
78-39	16995-16999	seek	_	
78-40	17000-17009	increased	_	
78-41	17010-17018	exposure	_	
78-42	17019-17021	to	_	
78-43	17022-17027	drugs	_	
78-44	17028-17030	of	_	
78-45	17031-17036	abuse	_	
78-46	17036-17037	,	_	
78-47	17038-17043	which	_	
78-48	17044-17047	can	_	
78-49	17048-17055	further	_	
78-50	17056-17061	blunt	_	
78-51	17062-17072	mesolimbic	_	
78-52	17073-17087	responsiveness	_	
78-53	17087-17088	,	_	
78-54	17089-17092	and	_	
78-55	17093-17095	so	_	
78-56	17096-17104	maintain	_	
78-57	17105-17114	addiction	_	
78-58	17114-17115	.	_	

#Text=In neuroimaging tasks that elicit reward anticipation (for example, the Monetary Incentive Delay Task), researchers have reported that subjects show increased ventral striatal activity during the anticipation of large gains in comparison with small gains, no gains and even comparable losses.
79-1	17116-17118	In	_	
79-2	17119-17131	neuroimaging	_	
79-3	17132-17137	tasks	_	
79-4	17138-17142	that	_	
79-5	17143-17149	elicit	_	
79-6	17150-17156	reward	_	
79-7	17157-17169	anticipation	_	
79-8	17170-17171	(	_	
79-9	17171-17174	for	_	
79-10	17175-17182	example	_	
79-11	17182-17183	,	_	
79-12	17184-17187	the	_	
79-13	17188-17196	Monetary	_	
79-14	17197-17206	Incentive	_	
79-15	17207-17212	Delay	_	
79-16	17213-17217	Task	_	
79-17	17217-17218	)	_	
79-18	17218-17219	,	_	
79-19	17220-17231	researchers	_	
79-20	17232-17236	have	_	
79-21	17237-17245	reported	_	
79-22	17246-17250	that	_	
79-23	17251-17259	subjects	_	
79-24	17260-17264	show	_	
79-25	17265-17274	increased	_	
79-26	17275-17282	ventral	_	
79-27	17283-17291	striatal	_	
79-28	17292-17300	activity	_	
79-29	17301-17307	during	_	
79-30	17308-17311	the	_	
79-31	17312-17324	anticipation	_	
79-32	17325-17327	of	_	
79-33	17328-17333	large	_	
79-34	17334-17339	gains	_	
79-35	17340-17342	in	_	
79-36	17343-17353	comparison	_	
79-37	17354-17358	with	_	
79-38	17359-17364	small	_	
79-39	17365-17370	gains	_	
79-40	17370-17371	,	_	
79-41	17372-17374	no	_	
79-42	17375-17380	gains	_	
79-43	17381-17384	and	_	
79-44	17385-17389	even	_	
79-45	17390-17400	comparable	_	
79-46	17401-17407	losses	_	
79-47	17407-17408	.	_	

#Text=As in a previous cross-sectional study of adolescent smokers, at-risk adolescents showed reduced ventral striatal activity during gain anticipation, but not in response to gain outcomes.
80-1	17409-17411	As	_	
80-2	17412-17414	in	_	
80-3	17415-17416	a	_	
80-4	17417-17425	previous	_	
80-5	17426-17441	cross-sectional	_	
80-6	17442-17447	study	_	
80-7	17448-17450	of	_	
80-8	17451-17461	adolescent	_	
80-9	17462-17469	smokers	_	
80-10	17469-17470	,	_	
80-11	17471-17478	at-risk	_	
80-12	17479-17490	adolescents	_	
80-13	17491-17497	showed	_	
80-14	17498-17505	reduced	_	
80-15	17506-17513	ventral	_	
80-16	17514-17522	striatal	_	
80-17	17523-17531	activity	_	
80-18	17532-17538	during	_	
80-19	17539-17543	gain	_	
80-20	17544-17556	anticipation	_	
80-21	17556-17557	,	_	
80-22	17558-17561	but	_	
80-23	17562-17565	not	_	
80-24	17566-17568	in	_	
80-25	17569-17577	response	_	
80-26	17578-17580	to	_	
80-27	17581-17585	gain	_	
80-28	17586-17594	outcomes	_	
80-29	17594-17595	.	_	

#Text=Electrophysiological recordings in primates suggest that the firing of midbrain dopaminergic neurons increases proportional to anticipated gain magnitude, but that firing in response to gain outcomes instead reflects the inverse likelihood of previously anticipated gain (that is, the surprisingness of the gain outcome).
81-1	17596-17616	Electrophysiological	_	
81-2	17617-17627	recordings	_	
81-3	17628-17630	in	_	
81-4	17631-17639	primates	_	
81-5	17640-17647	suggest	_	
81-6	17648-17652	that	_	
81-7	17653-17656	the	_	
81-8	17657-17663	firing	_	
81-9	17664-17666	of	_	
81-10	17667-17675	midbrain	_	
81-11	17676-17688	dopaminergic	_	
81-12	17689-17696	neurons	_	
81-13	17697-17706	increases	_	
81-14	17707-17719	proportional	_	
81-15	17720-17722	to	_	
81-16	17723-17734	anticipated	_	
81-17	17735-17739	gain	_	
81-18	17740-17749	magnitude	_	
81-19	17749-17750	,	_	
81-20	17751-17754	but	_	
81-21	17755-17759	that	_	
81-22	17760-17766	firing	_	
81-23	17767-17769	in	_	
81-24	17770-17778	response	_	
81-25	17779-17781	to	_	
81-26	17782-17786	gain	_	
81-27	17787-17795	outcomes	_	
81-28	17796-17803	instead	_	
81-29	17804-17812	reflects	_	
81-30	17813-17816	the	_	
81-31	17817-17824	inverse	_	
81-32	17825-17835	likelihood	_	
81-33	17836-17838	of	_	
81-34	17839-17849	previously	_	
81-35	17850-17861	anticipated	_	
81-36	17862-17866	gain	_	
81-37	17867-17868	(	_	
81-38	17868-17872	that	_	
81-39	17873-17875	is	_	
81-40	17875-17876	,	_	
81-41	17877-17880	the	_	
81-42	17881-17895	surprisingness	_	
81-43	17896-17898	of	_	
81-44	17899-17902	the	_	
81-45	17903-17907	gain	_	
81-46	17908-17915	outcome	_	
81-47	17915-17916	)	_	
81-48	17916-17917	.	_	

#Text=More recently, optogenetic functional magnetic resonance imaging (fMRI) research on rats indicated that phasic optogenetic stimulation of midbrain dopamine neurons increases fMRI activity in the striatum.
82-1	17918-17922	More	_	
82-2	17923-17931	recently	_	
82-3	17931-17932	,	_	
82-4	17933-17944	optogenetic	_	
82-5	17945-17955	functional	_	
82-6	17956-17964	magnetic	_	
82-7	17965-17974	resonance	_	
82-8	17975-17982	imaging	_	
82-9	17983-17984	(	_	
82-10	17984-17988	fMRI	_	
82-11	17988-17989	)	_	
82-12	17990-17998	research	_	
82-13	17999-18001	on	_	
82-14	18002-18006	rats	_	
82-15	18007-18016	indicated	_	
82-16	18017-18021	that	_	
82-17	18022-18028	phasic	_	
82-18	18029-18040	optogenetic	_	
82-19	18041-18052	stimulation	_	
82-20	18053-18055	of	_	
82-21	18056-18064	midbrain	_	
82-22	18065-18073	dopamine	_	
82-23	18074-18081	neurons	_	
82-24	18082-18091	increases	_	
82-25	18092-18096	fMRI	_	
82-26	18097-18105	activity	_	
82-27	18106-18108	in	_	
82-28	18109-18112	the	_	
82-29	18113-18121	striatum	_	
82-30	18121-18122	.	_	

#Text=Thus, the present findings are consistent with an account in which ventral striatal activity during reward anticipation reflects phasic increases in dopamine firing and consequent release in the VS.
83-1	18123-18127	Thus	_	
83-2	18127-18128	,	_	
83-3	18129-18132	the	_	
83-4	18133-18140	present	_	
83-5	18141-18149	findings	_	
83-6	18150-18153	are	_	
83-7	18154-18164	consistent	_	
83-8	18165-18169	with	_	
83-9	18170-18172	an	_	
83-10	18173-18180	account	_	
83-11	18181-18183	in	_	
83-12	18184-18189	which	_	
83-13	18190-18197	ventral	_	
83-14	18198-18206	striatal	_	
83-15	18207-18215	activity	_	
83-16	18216-18222	during	_	
83-17	18223-18229	reward	_	
83-18	18230-18242	anticipation	_	
83-19	18243-18251	reflects	_	
83-20	18252-18258	phasic	_	
83-21	18259-18268	increases	_	
83-22	18269-18271	in	_	
83-23	18272-18280	dopamine	_	
83-24	18281-18287	firing	_	
83-25	18288-18291	and	_	
83-26	18292-18302	consequent	_	
83-27	18303-18310	release	_	
83-28	18311-18313	in	_	
83-29	18314-18317	the	_	
83-30	18318-18320	VS	_	
83-31	18320-18321	.	_	

#Text=More support for this account comes from a human study that combined the MID task with fMRI as well as [11C]raclopride PET to demonstrate that individuals who showed more fMRI activity during gain anticipation also showed more PET evidence of dopamine release to gain cues in the VS.
84-1	18322-18326	More	_	
84-2	18327-18334	support	_	
84-3	18335-18338	for	_	
84-4	18339-18343	this	_	
84-5	18344-18351	account	_	
84-6	18352-18357	comes	_	
84-7	18358-18362	from	_	
84-8	18363-18364	a	_	
84-9	18365-18370	human	_	
84-10	18371-18376	study	_	
84-11	18377-18381	that	_	
84-12	18382-18390	combined	_	
84-13	18391-18394	the	_	
84-14	18395-18398	MID	_	
84-15	18399-18403	task	_	
84-16	18404-18408	with	_	
84-17	18409-18413	fMRI	_	
84-18	18414-18416	as	_	
84-19	18417-18421	well	_	
84-20	18422-18424	as	_	
84-21	18425-18426	[	_	
84-22	18426-18429	11C	_	
84-23	18429-18430	]	_	
84-24	18430-18440	raclopride	_	
84-25	18441-18444	PET	_	
84-26	18445-18447	to	_	
84-27	18448-18459	demonstrate	_	
84-28	18460-18464	that	_	
84-29	18465-18476	individuals	_	
84-30	18477-18480	who	_	
84-31	18481-18487	showed	_	
84-32	18488-18492	more	_	
84-33	18493-18497	fMRI	_	
84-34	18498-18506	activity	_	
84-35	18507-18513	during	_	
84-36	18514-18518	gain	_	
84-37	18519-18531	anticipation	_	
84-38	18532-18536	also	_	
84-39	18537-18543	showed	_	
84-40	18544-18548	more	_	
84-41	18549-18552	PET	_	
84-42	18553-18561	evidence	_	
84-43	18562-18564	of	_	
84-44	18565-18573	dopamine	_	
84-45	18574-18581	release	_	
84-46	18582-18584	to	_	
84-47	18585-18589	gain	_	
84-48	18590-18594	cues	_	
84-49	18595-18597	in	_	
84-50	18598-18601	the	_	
84-51	18602-18604	VS	_	
84-52	18604-18605	.	_	

#Text=Correspondence across imaging modalities was not evident, however, in striatal responses to gain outcomes.
85-1	18606-18620	Correspondence	_	
85-2	18621-18627	across	_	
85-3	18628-18635	imaging	_	
85-4	18636-18646	modalities	_	
85-5	18647-18650	was	_	
85-6	18651-18654	not	_	
85-7	18655-18662	evident	_	
85-8	18662-18663	,	_	
85-9	18664-18671	however	_	
85-10	18671-18672	,	_	
85-11	18673-18675	in	_	
85-12	18676-18684	striatal	_	
85-13	18685-18694	responses	_	
85-14	18695-18697	to	_	
85-15	18698-18702	gain	_	
85-16	18703-18711	outcomes	_	
85-17	18711-18712	.	_	

#Text=In the present study, midbrain activity correlated robustly with ventral striatal activity during reward anticipation, and blunting of this anticipatory response predicted subsequent PDU at age 16 (Supplementary Table 1).
86-1	18713-18715	In	_	
86-2	18716-18719	the	_	
86-3	18720-18727	present	_	
86-4	18728-18733	study	_	
86-5	18733-18734	,	_	
86-6	18735-18743	midbrain	_	
86-7	18744-18752	activity	_	
86-8	18753-18763	correlated	_	
86-9	18764-18772	robustly	_	
86-10	18773-18777	with	_	
86-11	18778-18785	ventral	_	
86-12	18786-18794	striatal	_	
86-13	18795-18803	activity	_	
86-14	18804-18810	during	_	
86-15	18811-18817	reward	_	
86-16	18818-18830	anticipation	_	
86-17	18830-18831	,	_	
86-18	18832-18835	and	_	
86-19	18836-18844	blunting	_	
86-20	18845-18847	of	_	
86-21	18848-18852	this	_	
86-22	18853-18865	anticipatory	_	
86-23	18866-18874	response	_	
86-24	18875-18884	predicted	_	
86-25	18885-18895	subsequent	_	
86-26	18896-18899	PDU	_	
86-27	18900-18902	at	_	
86-28	18903-18906	age	_	
86-29	18907-18909	16	_	
86-30	18910-18911	(	_	
86-31	18911-18924	Supplementary	_	
86-32	18925-18930	Table	_	
86-33	18931-18932	1	_	
86-34	18932-18933	)	_	
86-35	18933-18934	.	_	

#Text=Although neuroimaging tasks less reliably elicit dorsolateral PFC activity than ventral striatal activity during reward anticipation, dlPFC regions also showed reduced activity during reward anticipation in novelty-seeking adolescents who went on to develop PDU.
87-1	18935-18943	Although	_	
87-2	18944-18956	neuroimaging	_	
87-3	18957-18962	tasks	_	
87-4	18963-18967	less	_	
87-5	18968-18976	reliably	_	
87-6	18977-18983	elicit	_	
87-7	18984-18996	dorsolateral	_	
87-8	18997-19000	PFC	_	
87-9	19001-19009	activity	_	
87-10	19010-19014	than	_	
87-11	19015-19022	ventral	_	
87-12	19023-19031	striatal	_	
87-13	19032-19040	activity	_	
87-14	19041-19047	during	_	
87-15	19048-19054	reward	_	
87-16	19055-19067	anticipation	_	
87-17	19067-19068	,	_	
87-18	19069-19074	dlPFC	_	
87-19	19075-19082	regions	_	
87-20	19083-19087	also	_	
87-21	19088-19094	showed	_	
87-22	19095-19102	reduced	_	
87-23	19103-19111	activity	_	
87-24	19112-19118	during	_	
87-25	19119-19125	reward	_	
87-26	19126-19138	anticipation	_	
87-27	19139-19141	in	_	
87-28	19142-19157	novelty-seeking	_	
87-29	19158-19169	adolescents	_	
87-30	19170-19173	who	_	
87-31	19174-19178	went	_	
87-32	19179-19181	on	_	
87-33	19182-19184	to	_	
87-34	19185-19192	develop	_	
87-35	19193-19196	PDU	_	
87-36	19196-19197	.	_	

#Text=Theorists have posited that impulsive adolescent choice may stem from imbalances in the activity of rapidly developing mesolimbic motivational circuits versus more slowly maturing prefrontal control circuits. dlPFC activity has specifically been associated with planning, behavioural control and goal implementation.
88-1	19198-19207	Theorists	_	
88-2	19208-19212	have	_	
88-3	19213-19220	posited	_	
88-4	19221-19225	that	_	
88-5	19226-19235	impulsive	_	
88-6	19236-19246	adolescent	_	
88-7	19247-19253	choice	_	
88-8	19254-19257	may	_	
88-9	19258-19262	stem	_	
88-10	19263-19267	from	_	
88-11	19268-19278	imbalances	_	
88-12	19279-19281	in	_	
88-13	19282-19285	the	_	
88-14	19286-19294	activity	_	
88-15	19295-19297	of	_	
88-16	19298-19305	rapidly	_	
88-17	19306-19316	developing	_	
88-18	19317-19327	mesolimbic	_	
88-19	19328-19340	motivational	_	
88-20	19341-19349	circuits	_	
88-21	19350-19356	versus	_	
88-22	19357-19361	more	_	
88-23	19362-19368	slowly	_	
88-24	19369-19377	maturing	_	
88-25	19378-19388	prefrontal	_	
88-26	19389-19396	control	_	
88-27	19397-19405	circuits	_	
88-28	19405-19406	.	_	
88-29	19407-19412	dlPFC	_	
88-30	19413-19421	activity	_	
88-31	19422-19425	has	_	
88-32	19426-19438	specifically	_	
88-33	19439-19443	been	_	
88-34	19444-19454	associated	_	
88-35	19455-19459	with	_	
88-36	19460-19468	planning	_	
88-37	19468-19469	,	_	
88-38	19470-19481	behavioural	_	
88-39	19482-19489	control	_	
88-40	19490-19493	and	_	
88-41	19494-19498	goal	_	
88-42	19499-19513	implementation	_	
88-43	19513-19514	.	_	

#Text=More extensive longitudinal assessments might clarify whether reduced prefrontal functional activity reflects a developmental delay or a lasting deficit in adolescents at risk for PDU.
89-1	19515-19519	More	_	
89-2	19520-19529	extensive	_	
89-3	19530-19542	longitudinal	_	
89-4	19543-19554	assessments	_	
89-5	19555-19560	might	_	
89-6	19561-19568	clarify	_	
89-7	19569-19576	whether	_	
89-8	19577-19584	reduced	_	
89-9	19585-19595	prefrontal	_	
89-10	19596-19606	functional	_	
89-11	19607-19615	activity	_	
89-12	19616-19624	reflects	_	
89-13	19625-19626	a	_	
89-14	19627-19640	developmental	_	
89-15	19641-19646	delay	_	
89-16	19647-19649	or	_	
89-17	19650-19651	a	_	
89-18	19652-19659	lasting	_	
89-19	19660-19667	deficit	_	
89-20	19668-19670	in	_	
89-21	19671-19682	adolescents	_	
89-22	19683-19685	at	_	
89-23	19686-19690	risk	_	
89-24	19691-19694	for	_	
89-25	19695-19698	PDU	_	
89-26	19698-19699	.	_	

#Text=Since ventral striatal regions connect to the prefrontal cortex through thalamic relays, which then reciprocally modulate the striatum, additional research might also clarify whether reduced ventral striatal activity precedes reduced prefrontal activity or the opposite.
90-1	19700-19705	Since	_	
90-2	19706-19713	ventral	_	
90-3	19714-19722	striatal	_	
90-4	19723-19730	regions	_	
90-5	19731-19738	connect	_	
90-6	19739-19741	to	_	
90-7	19742-19745	the	_	
90-8	19746-19756	prefrontal	_	
90-9	19757-19763	cortex	_	
90-10	19764-19771	through	_	
90-11	19772-19780	thalamic	_	
90-12	19781-19787	relays	_	
90-13	19787-19788	,	_	
90-14	19789-19794	which	_	
90-15	19795-19799	then	_	
90-16	19800-19812	reciprocally	_	
90-17	19813-19821	modulate	_	
90-18	19822-19825	the	_	
90-19	19826-19834	striatum	_	
90-20	19834-19835	,	_	
90-21	19836-19846	additional	_	
90-22	19847-19855	research	_	
90-23	19856-19861	might	_	
90-24	19862-19866	also	_	
90-25	19867-19874	clarify	_	
90-26	19875-19882	whether	_	
90-27	19883-19890	reduced	_	
90-28	19891-19898	ventral	_	
90-29	19899-19907	striatal	_	
90-30	19908-19916	activity	_	
90-31	19917-19925	precedes	_	
90-32	19926-19933	reduced	_	
90-33	19934-19944	prefrontal	_	
90-34	19945-19953	activity	_	
90-35	19954-19956	or	_	
90-36	19957-19960	the	_	
90-37	19961-19969	opposite	_	
90-38	19969-19970	.	_	

#Text=Since PDUrs showed higher (rather than lower) grey matter density in dorsolateral prefrontal cortex regions, the observed decreases in functional activity could not be attributed to decreased structural grey matter integrity (for example, as in the case of partial voluming).
91-1	19971-19976	Since	_	
91-2	19977-19982	PDUrs	_	
91-3	19983-19989	showed	_	
91-4	19990-19996	higher	_	
91-5	19997-19998	(	_	
91-6	19998-20004	rather	_	
91-7	20005-20009	than	_	
91-8	20010-20015	lower	_	
91-9	20015-20016	)	_	
91-10	20017-20021	grey	_	
91-11	20022-20028	matter	_	
91-12	20029-20036	density	_	
91-13	20037-20039	in	_	
91-14	20040-20052	dorsolateral	_	
91-15	20053-20063	prefrontal	_	
91-16	20064-20070	cortex	_	
91-17	20071-20078	regions	_	
91-18	20078-20079	,	_	
91-19	20080-20083	the	_	
91-20	20084-20092	observed	_	
91-21	20093-20102	decreases	_	
91-22	20103-20105	in	_	
91-23	20106-20116	functional	_	
91-24	20117-20125	activity	_	
91-25	20126-20131	could	_	
91-26	20132-20135	not	_	
91-27	20136-20138	be	_	
91-28	20139-20149	attributed	_	
91-29	20150-20152	to	_	
91-30	20153-20162	decreased	_	
91-31	20163-20173	structural	_	
91-32	20174-20178	grey	_	
91-33	20179-20185	matter	_	
91-34	20186-20195	integrity	_	
91-35	20196-20197	(	_	
91-36	20197-20200	for	_	
91-37	20201-20208	example	_	
91-38	20208-20209	,	_	
91-39	20210-20212	as	_	
91-40	20213-20215	in	_	
91-41	20216-20219	the	_	
91-42	20220-20224	case	_	
91-43	20225-20227	of	_	
91-44	20228-20235	partial	_	
91-45	20236-20244	voluming	_	
91-46	20244-20245	)	_	
91-47	20245-20246	.	_	

#Text=Observed increases in dorsolateral prefrontal grey matter density are consistent, however, with the notion of a structural developmental delay in prospective problematic drug users at age 14, since developmental studies suggest that PFC thickness continually decreases over adolescence, possibly as a result of synaptic pruning.
92-1	20247-20255	Observed	_	
92-2	20256-20265	increases	_	
92-3	20266-20268	in	_	
92-4	20269-20281	dorsolateral	_	
92-5	20282-20292	prefrontal	_	
92-6	20293-20297	grey	_	
92-7	20298-20304	matter	_	
92-8	20305-20312	density	_	
92-9	20313-20316	are	_	
92-10	20317-20327	consistent	_	
92-11	20327-20328	,	_	
92-12	20329-20336	however	_	
92-13	20336-20337	,	_	
92-14	20338-20342	with	_	
92-15	20343-20346	the	_	
92-16	20347-20353	notion	_	
92-17	20354-20356	of	_	
92-18	20357-20358	a	_	
92-19	20359-20369	structural	_	
92-20	20370-20383	developmental	_	
92-21	20384-20389	delay	_	
92-22	20390-20392	in	_	
92-23	20393-20404	prospective	_	
92-24	20405-20416	problematic	_	
92-25	20417-20421	drug	_	
92-26	20422-20427	users	_	
92-27	20428-20430	at	_	
92-28	20431-20434	age	_	
92-29	20435-20437	14	_	
92-30	20437-20438	,	_	
92-31	20439-20444	since	_	
92-32	20445-20458	developmental	_	
92-33	20459-20466	studies	_	
92-34	20467-20474	suggest	_	
92-35	20475-20479	that	_	
92-36	20480-20483	PFC	_	
92-37	20484-20493	thickness	_	
92-38	20494-20505	continually	_	
92-39	20506-20515	decreases	_	
92-40	20516-20520	over	_	
92-41	20521-20532	adolescence	_	
92-42	20532-20533	,	_	
92-43	20534-20542	possibly	_	
92-44	20543-20545	as	_	
92-45	20546-20547	a	_	
92-46	20548-20554	result	_	
92-47	20555-20557	of	_	
92-48	20558-20566	synaptic	_	
92-49	20567-20574	pruning	_	
92-50	20574-20575	.	_	

#Text=Therefore, relatively greater prefrontal grey matter density might reflect maturational delays in novelty-seeking adolescents that presage PDU.
93-1	20576-20585	Therefore	_	
93-2	20585-20586	,	_	
93-3	20587-20597	relatively	_	
93-4	20598-20605	greater	_	
93-5	20606-20616	prefrontal	_	
93-6	20617-20621	grey	_	
93-7	20622-20628	matter	_	
93-8	20629-20636	density	_	
93-9	20637-20642	might	_	
93-10	20643-20650	reflect	_	
93-11	20651-20663	maturational	_	
93-12	20664-20670	delays	_	
93-13	20671-20673	in	_	
93-14	20674-20689	novelty-seeking	_	
93-15	20690-20701	adolescents	_	
93-16	20702-20706	that	_	
93-17	20707-20714	presage	_	
93-18	20715-20718	PDU	_	
93-19	20718-20719	.	_	

#Text=Psychometric and behavioural measures have historically offered powerful tools for assessing individual differences in consideration of future rewards and long-term goals.
94-1	20720-20732	Psychometric	_	
94-2	20733-20736	and	_	
94-3	20737-20748	behavioural	_	
94-4	20749-20757	measures	_	
94-5	20758-20762	have	_	
94-6	20763-20775	historically	_	
94-7	20776-20783	offered	_	
94-8	20784-20792	powerful	_	
94-9	20793-20798	tools	_	
94-10	20799-20802	for	_	
94-11	20803-20812	assessing	_	
94-12	20813-20823	individual	_	
94-13	20824-20835	differences	_	
94-14	20836-20838	in	_	
94-15	20839-20852	consideration	_	
94-16	20853-20855	of	_	
94-17	20856-20862	future	_	
94-18	20863-20870	rewards	_	
94-19	20871-20874	and	_	
94-20	20875-20884	long-term	_	
94-21	20885-20890	goals	_	
94-22	20890-20891	.	_	

#Text=For instance, measures of temporal discounting index a preference for smaller sooner rewards over larger later rewards.
95-1	20892-20895	For	_	
95-2	20896-20904	instance	_	
95-3	20904-20905	,	_	
95-4	20906-20914	measures	_	
95-5	20915-20917	of	_	
95-6	20918-20926	temporal	_	
95-7	20927-20938	discounting	_	
95-8	20939-20944	index	_	
95-9	20945-20946	a	_	
95-10	20947-20957	preference	_	
95-11	20958-20961	for	_	
95-12	20962-20969	smaller	_	
95-13	20970-20976	sooner	_	
95-14	20977-20984	rewards	_	
95-15	20985-20989	over	_	
95-16	20990-20996	larger	_	
95-17	20997-21002	later	_	
95-18	21003-21010	rewards	_	
95-19	21010-21011	.	_	

#Text=Low temporal discounting powerfully predicts future educational and economic success, whereas high temporal discounting has instead been associated with addictive behaviour.
96-1	21012-21015	Low	_	
96-2	21016-21024	temporal	_	
96-3	21025-21036	discounting	_	
96-4	21037-21047	powerfully	_	
96-5	21048-21056	predicts	_	
96-6	21057-21063	future	_	
96-7	21064-21075	educational	_	
96-8	21076-21079	and	_	
96-9	21080-21088	economic	_	
96-10	21089-21096	success	_	
96-11	21096-21097	,	_	
96-12	21098-21105	whereas	_	
96-13	21106-21110	high	_	
96-14	21111-21119	temporal	_	
96-15	21120-21131	discounting	_	
96-16	21132-21135	has	_	
96-17	21136-21143	instead	_	
96-18	21144-21148	been	_	
96-19	21149-21159	associated	_	
96-20	21160-21164	with	_	
96-21	21165-21174	addictive	_	
96-22	21175-21184	behaviour	_	
96-23	21184-21185	.	_	

#Text=Consistent with this cross-sectional evidence, the present longitudinal findings indicate that high temporal discounting at age 14 was associated with PDU at age 16 in high novelty-seeking adolescents.
97-1	21186-21196	Consistent	_	
97-2	21197-21201	with	_	
97-3	21202-21206	this	_	
97-4	21207-21222	cross-sectional	_	
97-5	21223-21231	evidence	_	
97-6	21231-21232	,	_	
97-7	21233-21236	the	_	
97-8	21237-21244	present	_	
97-9	21245-21257	longitudinal	_	
97-10	21258-21266	findings	_	
97-11	21267-21275	indicate	_	
97-12	21276-21280	that	_	
97-13	21281-21285	high	_	
97-14	21286-21294	temporal	_	
97-15	21295-21306	discounting	_	
97-16	21307-21309	at	_	
97-17	21310-21313	age	_	
97-18	21314-21316	14	_	
97-19	21317-21320	was	_	
97-20	21321-21331	associated	_	
97-21	21332-21336	with	_	
97-22	21337-21340	PDU	_	
97-23	21341-21343	at	_	
97-24	21344-21347	age	_	
97-25	21348-21350	16	_	
97-26	21351-21353	in	_	
97-27	21354-21358	high	_	
97-28	21359-21374	novelty-seeking	_	
97-29	21375-21386	adolescents	_	
97-30	21386-21387	.	_	

#Text=Measures of conscientiousness index the tendency to follow socially prescribed norms for impulse control, whereas low conscientiousness has been associated with a wide range of addictive behaviours (including tobacco, alcohol and drug use).
98-1	21388-21396	Measures	_	
98-2	21397-21399	of	_	
98-3	21400-21417	conscientiousness	_	
98-4	21418-21423	index	_	
98-5	21424-21427	the	_	
98-6	21428-21436	tendency	_	
98-7	21437-21439	to	_	
98-8	21440-21446	follow	_	
98-9	21447-21455	socially	_	
98-10	21456-21466	prescribed	_	
98-11	21467-21472	norms	_	
98-12	21473-21476	for	_	
98-13	21477-21484	impulse	_	
98-14	21485-21492	control	_	
98-15	21492-21493	,	_	
98-16	21494-21501	whereas	_	
98-17	21502-21505	low	_	
98-18	21506-21523	conscientiousness	_	
98-19	21524-21527	has	_	
98-20	21528-21532	been	_	
98-21	21533-21543	associated	_	
98-22	21544-21548	with	_	
98-23	21549-21550	a	_	
98-24	21551-21555	wide	_	
98-25	21556-21561	range	_	
98-26	21562-21564	of	_	
98-27	21565-21574	addictive	_	
98-28	21575-21585	behaviours	_	
98-29	21586-21587	(	_	
98-30	21587-21596	including	_	
98-31	21597-21604	tobacco	_	
98-32	21604-21605	,	_	
98-33	21606-21613	alcohol	_	
98-34	21614-21617	and	_	
98-35	21618-21622	drug	_	
98-36	21623-21626	use	_	
98-37	21626-21627	)	_	
98-38	21627-21628	.	_	

#Text=The present findings additionally indicate that low conscientiousness at age 14 was associated with PDU at age 16 in high novelty-seeking adolescents.
99-1	21629-21632	The	_	
99-2	21633-21640	present	_	
99-3	21641-21649	findings	_	
99-4	21650-21662	additionally	_	
99-5	21663-21671	indicate	_	
99-6	21672-21676	that	_	
99-7	21677-21680	low	_	
99-8	21681-21698	conscientiousness	_	
99-9	21699-21701	at	_	
99-10	21702-21705	age	_	
99-11	21706-21708	14	_	
99-12	21709-21712	was	_	
99-13	21713-21723	associated	_	
99-14	21724-21728	with	_	
99-15	21729-21732	PDU	_	
99-16	21733-21735	at	_	
99-17	21736-21739	age	_	
99-18	21740-21742	16	_	
99-19	21743-21745	in	_	
99-20	21746-21750	high	_	
99-21	21751-21766	novelty-seeking	_	
99-22	21767-21778	adolescents	_	
99-23	21778-21779	.	_	

#Text=While both high temporal discounting and low conscientiousness have been linked to compromised PFC function, direct model comparisons indicated that reduced ventral striatal and dorsolateral PFC activity during reward anticipation might uniquely contribute to predictions of PDU in novelty-seeking adolescents—above and beyond contributions from these relevant psychometric measures.
100-1	21780-21785	While	_	
100-2	21786-21790	both	_	
100-3	21791-21795	high	_	
100-4	21796-21804	temporal	_	
100-5	21805-21816	discounting	_	
100-6	21817-21820	and	_	
100-7	21821-21824	low	_	
100-8	21825-21842	conscientiousness	_	
100-9	21843-21847	have	_	
100-10	21848-21852	been	_	
100-11	21853-21859	linked	_	
100-12	21860-21862	to	_	
100-13	21863-21874	compromised	_	
100-14	21875-21878	PFC	_	
100-15	21879-21887	function	_	
100-16	21887-21888	,	_	
100-17	21889-21895	direct	_	
100-18	21896-21901	model	_	
100-19	21902-21913	comparisons	_	
100-20	21914-21923	indicated	_	
100-21	21924-21928	that	_	
100-22	21929-21936	reduced	_	
100-23	21937-21944	ventral	_	
100-24	21945-21953	striatal	_	
100-25	21954-21957	and	_	
100-26	21958-21970	dorsolateral	_	
100-27	21971-21974	PFC	_	
100-28	21975-21983	activity	_	
100-29	21984-21990	during	_	
100-30	21991-21997	reward	_	
100-31	21998-22010	anticipation	_	
100-32	22011-22016	might	_	
100-33	22017-22025	uniquely	_	
100-34	22026-22036	contribute	_	
100-35	22037-22039	to	_	
100-36	22040-22051	predictions	_	
100-37	22052-22054	of	_	
100-38	22055-22058	PDU	_	
100-39	22059-22061	in	_	
100-40	22062-22077	novelty-seeking	_	
100-41	22078-22095	adolescents—above	_	
100-42	22096-22099	and	_	
100-43	22100-22106	beyond	_	
100-44	22107-22120	contributions	_	
100-45	22121-22125	from	_	
100-46	22126-22131	these	_	
100-47	22132-22140	relevant	_	
100-48	22141-22153	psychometric	_	
100-49	22154-22162	measures	_	
100-50	22162-22163	.	_	

#Text=Despite strengths of the study design in combining validated neuroimaging probes with substantial matched longitudinal samples, the design also has some limitations.
101-1	22164-22171	Despite	_	
101-2	22172-22181	strengths	_	
101-3	22182-22184	of	_	
101-4	22185-22188	the	_	
101-5	22189-22194	study	_	
101-6	22195-22201	design	_	
101-7	22202-22204	in	_	
101-8	22205-22214	combining	_	
101-9	22215-22224	validated	_	
101-10	22225-22237	neuroimaging	_	
101-11	22238-22244	probes	_	
101-12	22245-22249	with	_	
101-13	22250-22261	substantial	_	
101-14	22262-22269	matched	_	
101-15	22270-22282	longitudinal	_	
101-16	22283-22290	samples	_	
101-17	22290-22291	,	_	
101-18	22292-22295	the	_	
101-19	22296-22302	design	_	
101-20	22303-22307	also	_	
101-21	22308-22311	has	_	
101-22	22312-22316	some	_	
101-23	22317-22328	limitations	_	
101-24	22328-22329	.	_	

#Text=For instance, cutoff criteria for PDU necessarily depend upon specific substances under consideration.
102-1	22330-22333	For	_	
102-2	22334-22342	instance	_	
102-3	22342-22343	,	_	
102-4	22344-22350	cutoff	_	
102-5	22351-22359	criteria	_	
102-6	22360-22363	for	_	
102-7	22364-22367	PDU	_	
102-8	22368-22379	necessarily	_	
102-9	22380-22386	depend	_	
102-10	22387-22391	upon	_	
102-11	22392-22400	specific	_	
102-12	22401-22411	substances	_	
102-13	22412-22417	under	_	
102-14	22418-22431	consideration	_	
102-15	22431-22432	.	_	

#Text=In contrast to alcohol and cigarette consumption, in which a score compatible with daily use represented the cutoff, the threshold for other illicit drugs was instead defined based on lifetime use.
103-1	22433-22435	In	_	
103-2	22436-22444	contrast	_	
103-3	22445-22447	to	_	
103-4	22448-22455	alcohol	_	
103-5	22456-22459	and	_	
103-6	22460-22469	cigarette	_	
103-7	22470-22481	consumption	_	
103-8	22481-22482	,	_	
103-9	22483-22485	in	_	
103-10	22486-22491	which	_	
103-11	22492-22493	a	_	
103-12	22494-22499	score	_	
103-13	22500-22510	compatible	_	
103-14	22511-22515	with	_	
103-15	22516-22521	daily	_	
103-16	22522-22525	use	_	
103-17	22526-22537	represented	_	
103-18	22538-22541	the	_	
103-19	22542-22548	cutoff	_	
103-20	22548-22549	,	_	
103-21	22550-22553	the	_	
103-22	22554-22563	threshold	_	
103-23	22564-22567	for	_	
103-24	22568-22573	other	_	
103-25	22574-22581	illicit	_	
103-26	22582-22587	drugs	_	
103-27	22588-22591	was	_	
103-28	22592-22599	instead	_	
103-29	22600-22607	defined	_	
103-30	22608-22613	based	_	
103-31	22614-22616	on	_	
103-32	22617-22625	lifetime	_	
103-33	22626-22629	use	_	
103-34	22629-22630	.	_	

#Text=For this longitudinal sample, low thresholds were adopted (particularly for illicit drugs such as crack, cocaine and narcotics), relative to other studies of early use.
104-1	22631-22634	For	_	
104-2	22635-22639	this	_	
104-3	22640-22652	longitudinal	_	
104-4	22653-22659	sample	_	
104-5	22659-22660	,	_	
104-6	22661-22664	low	_	
104-7	22665-22675	thresholds	_	
104-8	22676-22680	were	_	
104-9	22681-22688	adopted	_	
104-10	22689-22690	(	_	
104-11	22690-22702	particularly	_	
104-12	22703-22706	for	_	
104-13	22707-22714	illicit	_	
104-14	22715-22720	drugs	_	
104-15	22721-22725	such	_	
104-16	22726-22728	as	_	
104-17	22729-22734	crack	_	
104-18	22734-22735	,	_	
104-19	22736-22743	cocaine	_	
104-20	22744-22747	and	_	
104-21	22748-22757	narcotics	_	
104-22	22757-22758	)	_	
104-23	22758-22759	,	_	
104-24	22760-22768	relative	_	
104-25	22769-22771	to	_	
104-26	22772-22777	other	_	
104-27	22778-22785	studies	_	
104-28	22786-22788	of	_	
104-29	22789-22794	early	_	
104-30	22795-22798	use	_	
104-31	22798-22799	.	_	

#Text=Only a few adolescents qualified for PDU at age 16 with respect to use of illicit drugs (Supplementary Figs 5 and 6), whereas most instead qualified based on the use of licit drugs (for example, alcohol, cigarette or cannabis).
105-1	22800-22804	Only	_	
105-2	22805-22806	a	_	
105-3	22807-22810	few	_	
105-4	22811-22822	adolescents	_	
105-5	22823-22832	qualified	_	
105-6	22833-22836	for	_	
105-7	22837-22840	PDU	_	
105-8	22841-22843	at	_	
105-9	22844-22847	age	_	
105-10	22848-22850	16	_	
105-11	22851-22855	with	_	
105-12	22856-22863	respect	_	
105-13	22864-22866	to	_	
105-14	22867-22870	use	_	
105-15	22871-22873	of	_	
105-16	22874-22881	illicit	_	
105-17	22882-22887	drugs	_	
105-18	22888-22889	(	_	
105-19	22889-22902	Supplementary	_	
105-20	22903-22907	Figs	_	
105-21	22908-22909	5	_	
105-22	22910-22913	and	_	
105-23	22914-22915	6	_	
105-24	22915-22916	)	_	
105-25	22916-22917	,	_	
105-26	22918-22925	whereas	_	
105-27	22926-22930	most	_	
105-28	22931-22938	instead	_	
105-29	22939-22948	qualified	_	
105-30	22949-22954	based	_	
105-31	22955-22957	on	_	
105-32	22958-22961	the	_	
105-33	22962-22965	use	_	
105-34	22966-22968	of	_	
105-35	22969-22974	licit	_	
105-36	22975-22980	drugs	_	
105-37	22981-22982	(	_	
105-38	22982-22985	for	_	
105-39	22986-22993	example	_	
105-40	22993-22994	,	_	
105-41	22995-23002	alcohol	_	
105-42	23002-23003	,	_	
105-43	23004-23013	cigarette	_	
105-44	23014-23016	or	_	
105-45	23017-23025	cannabis	_	
105-46	23025-23026	)	_	
105-47	23026-23027	.	_	

#Text=The validity of the adopted criteria was supported, however, by the fact that the criteria predicted future PDU.
106-1	23028-23031	The	_	
106-2	23032-23040	validity	_	
106-3	23041-23043	of	_	
106-4	23044-23047	the	_	
106-5	23048-23055	adopted	_	
106-6	23056-23064	criteria	_	
106-7	23065-23068	was	_	
106-8	23069-23078	supported	_	
106-9	23078-23079	,	_	
106-10	23080-23087	however	_	
106-11	23087-23088	,	_	
106-12	23089-23091	by	_	
106-13	23092-23095	the	_	
106-14	23096-23100	fact	_	
106-15	23101-23105	that	_	
106-16	23106-23109	the	_	
106-17	23110-23118	criteria	_	
106-18	23119-23128	predicted	_	
106-19	23129-23135	future	_	
106-20	23136-23139	PDU	_	
106-21	23139-23140	.	_	

#Text=Specifically, the percentage of adolescents qualifying for PDU at age 16 was highest for the top quarter of novelty seekers (25.4% PDU), lower for the middle two quarters of novelty seekers (18.5% PDU) and lowest for the bottom quarter of novelty seekers (7.1% PDU).
107-1	23141-23153	Specifically	_	
107-2	23153-23154	,	_	
107-3	23155-23158	the	_	
107-4	23159-23169	percentage	_	
107-5	23170-23172	of	_	
107-6	23173-23184	adolescents	_	
107-7	23185-23195	qualifying	_	
107-8	23196-23199	for	_	
107-9	23200-23203	PDU	_	
107-10	23204-23206	at	_	
107-11	23207-23210	age	_	
107-12	23211-23213	16	_	
107-13	23214-23217	was	_	
107-14	23218-23225	highest	_	
107-15	23226-23229	for	_	
107-16	23230-23233	the	_	
107-17	23234-23237	top	_	
107-18	23238-23245	quarter	_	
107-19	23246-23248	of	_	
107-20	23249-23256	novelty	_	
107-21	23257-23264	seekers	_	
107-22	23265-23266	(	_	
107-23	23266-23271	25.4%	_	
107-24	23272-23275	PDU	_	
107-25	23275-23276	)	_	
107-26	23276-23277	,	_	
107-27	23278-23283	lower	_	
107-28	23284-23287	for	_	
107-29	23288-23291	the	_	
107-30	23292-23298	middle	_	
107-31	23299-23302	two	_	
107-32	23303-23311	quarters	_	
107-33	23312-23314	of	_	
107-34	23315-23322	novelty	_	
107-35	23323-23330	seekers	_	
107-36	23331-23332	(	_	
107-37	23332-23337	18.5%	_	
107-38	23338-23341	PDU	_	
107-39	23341-23342	)	_	
107-40	23343-23346	and	_	
107-41	23347-23353	lowest	_	
107-42	23354-23357	for	_	
107-43	23358-23361	the	_	
107-44	23362-23368	bottom	_	
107-45	23369-23376	quarter	_	
107-46	23377-23379	of	_	
107-47	23380-23387	novelty	_	
107-48	23388-23395	seekers	_	
107-49	23396-23397	(	_	
107-50	23397-23401	7.1%	_	
107-51	23402-23405	PDU	_	
107-52	23405-23406	)	_	
107-53	23406-23407	.	_	

#Text=Based on previous research, we adopted a binary threshold criterion for PDU instead of a continuous outcome measure.
108-1	23408-23413	Based	_	
108-2	23414-23416	on	_	
108-3	23417-23425	previous	_	
108-4	23426-23434	research	_	
108-5	23434-23435	,	_	
108-6	23436-23438	we	_	
108-7	23439-23446	adopted	_	
108-8	23447-23448	a	_	
108-9	23449-23455	binary	_	
108-10	23456-23465	threshold	_	
108-11	23466-23475	criterion	_	
108-12	23476-23479	for	_	
108-13	23480-23483	PDU	_	
108-14	23484-23491	instead	_	
108-15	23492-23494	of	_	
108-16	23495-23496	a	_	
108-17	23497-23507	continuous	_	
108-18	23508-23515	outcome	_	
108-19	23516-23523	measure	_	
108-20	23523-23524	.	_	

#Text=This classification skirted correlational assumptions that the total amount of substance use maps linearly onto vulnerability.
109-1	23525-23529	This	_	
109-2	23530-23544	classification	_	
109-3	23545-23552	skirted	_	
109-4	23553-23566	correlational	_	
109-5	23567-23578	assumptions	_	
109-6	23579-23583	that	_	
109-7	23584-23587	the	_	
109-8	23588-23593	total	_	
109-9	23594-23600	amount	_	
109-10	23601-23603	of	_	
109-11	23604-23613	substance	_	
109-12	23614-23617	use	_	
109-13	23618-23622	maps	_	
109-14	23623-23631	linearly	_	
109-15	23632-23636	onto	_	
109-16	23637-23650	vulnerability	_	
109-17	23650-23651	.	_	

#Text=Such a correlational design might assume, for instance, that an individual who uses cigarettes, cannabis and alcohol should show a threefold difference in brain activity in predicted neural targets (for example, the VS) relative to an individual who uses only cannabis.
110-1	23652-23656	Such	_	
110-2	23657-23658	a	_	
110-3	23659-23672	correlational	_	
110-4	23673-23679	design	_	
110-5	23680-23685	might	_	
110-6	23686-23692	assume	_	
110-7	23692-23693	,	_	
110-8	23694-23697	for	_	
110-9	23698-23706	instance	_	
110-10	23706-23707	,	_	
110-11	23708-23712	that	_	
110-12	23713-23715	an	_	
110-13	23716-23726	individual	_	
110-14	23727-23730	who	_	
110-15	23731-23735	uses	_	
110-16	23736-23746	cigarettes	_	
110-17	23746-23747	,	_	
110-18	23748-23756	cannabis	_	
110-19	23757-23760	and	_	
110-20	23761-23768	alcohol	_	
110-21	23769-23775	should	_	
110-22	23776-23780	show	_	
110-23	23781-23782	a	_	
110-24	23783-23792	threefold	_	
110-25	23793-23803	difference	_	
110-26	23804-23806	in	_	
110-27	23807-23812	brain	_	
110-28	23813-23821	activity	_	
110-29	23822-23824	in	_	
110-30	23825-23834	predicted	_	
110-31	23835-23841	neural	_	
110-32	23842-23849	targets	_	
110-33	23850-23851	(	_	
110-34	23851-23854	for	_	
110-35	23855-23862	example	_	
110-36	23862-23863	,	_	
110-37	23864-23867	the	_	
110-38	23868-23870	VS	_	
110-39	23870-23871	)	_	
110-40	23872-23880	relative	_	
110-41	23881-23883	to	_	
110-42	23884-23886	an	_	
110-43	23887-23897	individual	_	
110-44	23898-23901	who	_	
110-45	23902-23906	uses	_	
110-46	23907-23911	only	_	
110-47	23912-23920	cannabis	_	
110-48	23920-23921	.	_	

#Text=These linear assumptions stand in contrast to the notion that substance abuse may reflect the expression of an addictive syndrome.
111-1	23922-23927	These	_	
111-2	23928-23934	linear	_	
111-3	23935-23946	assumptions	_	
111-4	23947-23952	stand	_	
111-5	23953-23955	in	_	
111-6	23956-23964	contrast	_	
111-7	23965-23967	to	_	
111-8	23968-23971	the	_	
111-9	23972-23978	notion	_	
111-10	23979-23983	that	_	
111-11	23984-23993	substance	_	
111-12	23994-23999	abuse	_	
111-13	24000-24003	may	_	
111-14	24004-24011	reflect	_	
111-15	24012-24015	the	_	
111-16	24016-24026	expression	_	
111-17	24027-24029	of	_	
111-18	24030-24032	an	_	
111-19	24033-24042	addictive	_	
111-20	24043-24051	syndrome	_	
111-21	24051-24052	.	_	

#Text=Consistent with such a categorical distinction, only in the high novelty-seeking group did blunted ventral striatal activity clearly foreshadow later PDU (Supplementary Fig. 2).
112-1	24053-24063	Consistent	_	
112-2	24064-24068	with	_	
112-3	24069-24073	such	_	
112-4	24074-24075	a	_	
112-5	24076-24087	categorical	_	
112-6	24088-24099	distinction	_	
112-7	24099-24100	,	_	
112-8	24101-24105	only	_	
112-9	24106-24108	in	_	
112-10	24109-24112	the	_	
112-11	24113-24117	high	_	
112-12	24118-24133	novelty-seeking	_	
112-13	24134-24139	group	_	
112-14	24140-24143	did	_	
112-15	24144-24151	blunted	_	
112-16	24152-24159	ventral	_	
112-17	24160-24168	striatal	_	
112-18	24169-24177	activity	_	
112-19	24178-24185	clearly	_	
112-20	24186-24196	foreshadow	_	
112-21	24197-24202	later	_	
112-22	24203-24206	PDU	_	
112-23	24207-24208	(	_	
112-24	24208-24221	Supplementary	_	
112-25	24222-24225	Fig	_	
112-26	24225-24226	.	_	
112-27	24227-24228	2	_	
112-28	24228-24229	)	_	
112-29	24229-24230	.	_	

#Text=Further, while stressors and related negative arousal may also potentiate impulsive behaviours including substance abuse in adolescents, the neuroimaging task employed in this study elicited gain but not loss anticipation, and so was primarily optimized to probe neural responses during anticipation of reward.
113-1	24231-24238	Further	_	
113-2	24238-24239	,	_	
113-3	24240-24245	while	_	
113-4	24246-24255	stressors	_	
113-5	24256-24259	and	_	
113-6	24260-24267	related	_	
113-7	24268-24276	negative	_	
113-8	24277-24284	arousal	_	
113-9	24285-24288	may	_	
113-10	24289-24293	also	_	
113-11	24294-24304	potentiate	_	
113-12	24305-24314	impulsive	_	
113-13	24315-24325	behaviours	_	
113-14	24326-24335	including	_	
113-15	24336-24345	substance	_	
113-16	24346-24351	abuse	_	
113-17	24352-24354	in	_	
113-18	24355-24366	adolescents	_	
113-19	24366-24367	,	_	
113-20	24368-24371	the	_	
113-21	24372-24384	neuroimaging	_	
113-22	24385-24389	task	_	
113-23	24390-24398	employed	_	
113-24	24399-24401	in	_	
113-25	24402-24406	this	_	
113-26	24407-24412	study	_	
113-27	24413-24421	elicited	_	
113-28	24422-24426	gain	_	
113-29	24427-24430	but	_	
113-30	24431-24434	not	_	
113-31	24435-24439	loss	_	
113-32	24440-24452	anticipation	_	
113-33	24452-24453	,	_	
113-34	24454-24457	and	_	
113-35	24458-24460	so	_	
113-36	24461-24464	was	_	
113-37	24465-24474	primarily	_	
113-38	24475-24484	optimized	_	
113-39	24485-24487	to	_	
113-40	24488-24493	probe	_	
113-41	24494-24500	neural	_	
113-42	24501-24510	responses	_	
113-43	24511-24517	during	_	
113-44	24518-24530	anticipation	_	
113-45	24531-24533	of	_	
113-46	24534-24540	reward	_	
113-47	24540-24541	.	_	

#Text=Future research using neuroimaging probes that elicit anticipation of punishment might better probe links between negative arousal and adolescent vulnerability to substance abuse.
114-1	24542-24548	Future	_	
114-2	24549-24557	research	_	
114-3	24558-24563	using	_	
114-4	24564-24576	neuroimaging	_	
114-5	24577-24583	probes	_	
114-6	24584-24588	that	_	
114-7	24589-24595	elicit	_	
114-8	24596-24608	anticipation	_	
114-9	24609-24611	of	_	
114-10	24612-24622	punishment	_	
114-11	24623-24628	might	_	
114-12	24629-24635	better	_	
114-13	24636-24641	probe	_	
114-14	24642-24647	links	_	
114-15	24648-24655	between	_	
114-16	24656-24664	negative	_	
114-17	24665-24672	arousal	_	
114-18	24673-24676	and	_	
114-19	24677-24687	adolescent	_	
114-20	24688-24701	vulnerability	_	
114-21	24702-24704	to	_	
114-22	24705-24714	substance	_	
114-23	24715-24720	abuse	_	
114-24	24720-24721	.	_	

#Text=In conclusion, these longitudinal findings in novelty-seeking adolescents demonstrate that diminished mesolimbic reward motivation along with impaired prefrontal control may confer risk for future PDU.
115-1	24722-24724	In	_	
115-2	24725-24735	conclusion	_	
115-3	24735-24736	,	_	
115-4	24737-24742	these	_	
115-5	24743-24755	longitudinal	_	
115-6	24756-24764	findings	_	
115-7	24765-24767	in	_	
115-8	24768-24783	novelty-seeking	_	
115-9	24784-24795	adolescents	_	
115-10	24796-24807	demonstrate	_	
115-11	24808-24812	that	_	
115-12	24813-24823	diminished	_	
115-13	24824-24834	mesolimbic	_	
115-14	24835-24841	reward	_	
115-15	24842-24852	motivation	_	
115-16	24853-24858	along	_	
115-17	24859-24863	with	_	
115-18	24864-24872	impaired	_	
115-19	24873-24883	prefrontal	_	
115-20	24884-24891	control	_	
115-21	24892-24895	may	_	
115-22	24896-24902	confer	_	
115-23	24903-24907	risk	_	
115-24	24908-24911	for	_	
115-25	24912-24918	future	_	
115-26	24919-24922	PDU	_	
115-27	24922-24923	.	_	

#Text=Importantly, these findings suggest that high novelty seeking alone does not necessarily lead to PDU, and that neuroimaging measures may augment psychometric measures in identifying vulnerability.
116-1	24924-24935	Importantly	_	
116-2	24935-24936	,	_	
116-3	24937-24942	these	_	
116-4	24943-24951	findings	_	
116-5	24952-24959	suggest	_	
116-6	24960-24964	that	_	
116-7	24965-24969	high	_	
116-8	24970-24977	novelty	_	
116-9	24978-24985	seeking	_	
116-10	24986-24991	alone	_	
116-11	24992-24996	does	_	
116-12	24997-25000	not	_	
116-13	25001-25012	necessarily	_	
116-14	25013-25017	lead	_	
116-15	25018-25020	to	_	
116-16	25021-25024	PDU	_	
116-17	25024-25025	,	_	
116-18	25026-25029	and	_	
116-19	25030-25034	that	_	
116-20	25035-25047	neuroimaging	_	
116-21	25048-25056	measures	_	
116-22	25057-25060	may	_	
116-23	25061-25068	augment	_	
116-24	25069-25081	psychometric	_	
116-25	25082-25090	measures	_	
116-26	25091-25093	in	_	
116-27	25094-25105	identifying	_	
116-28	25106-25119	vulnerability	_	
116-29	25119-25120	.	_	

#Text=Rather than limiting developmental possibilities, these findings may help clinicians to visualize modifiable markers that can eventually be therapeutically targeted to prevent vulnerability or even to promote flourishing as novelty seekers transition from adolescence to adulthood.
117-1	25121-25127	Rather	_	
117-2	25128-25132	than	_	
117-3	25133-25141	limiting	_	
117-4	25142-25155	developmental	_	
117-5	25156-25169	possibilities	_	
117-6	25169-25170	,	_	
117-7	25171-25176	these	_	
117-8	25177-25185	findings	_	
117-9	25186-25189	may	_	
117-10	25190-25194	help	_	
117-11	25195-25205	clinicians	_	
117-12	25206-25208	to	_	
117-13	25209-25218	visualize	_	
117-14	25219-25229	modifiable	_	
117-15	25230-25237	markers	_	
117-16	25238-25242	that	_	
117-17	25243-25246	can	_	
117-18	25247-25257	eventually	_	
117-19	25258-25260	be	_	
117-20	25261-25276	therapeutically	_	
117-21	25277-25285	targeted	_	
117-22	25286-25288	to	_	
117-23	25289-25296	prevent	_	
117-24	25297-25310	vulnerability	_	
117-25	25311-25313	or	_	
117-26	25314-25318	even	_	
117-27	25319-25321	to	_	
117-28	25322-25329	promote	_	
117-29	25330-25341	flourishing	_	
117-30	25342-25344	as	_	
117-31	25345-25352	novelty	_	
117-32	25353-25360	seekers	_	
117-33	25361-25371	transition	_	
117-34	25372-25376	from	_	
117-35	25377-25388	adolescence	_	
117-36	25389-25391	to	_	
117-37	25392-25401	adulthood	_	
117-38	25401-25402	.	_	

#Text=Methods
#Text=Subjects
#Text=Data for this study came from the IMAGEN project, and were collected at multiple sites across Europe.
118-1	25403-25410	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
118-2	25411-25419	Subjects	_	
118-3	25420-25424	Data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-4	25425-25428	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-5	25429-25433	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-6	25434-25439	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-7	25440-25444	came	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-8	25445-25449	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-9	25450-25453	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-10	25454-25460	IMAGEN	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-11	25461-25468	project	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-12	25468-25469	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-13	25470-25473	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-14	25474-25478	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-15	25479-25488	collected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-16	25489-25491	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-17	25492-25500	multiple	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-18	25501-25506	sites	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-19	25507-25513	across	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-20	25514-25520	Europe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
118-21	25520-25521	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	

#Text=At age 14, a large cohort of adolescents completed self-report and interview measures, in addition to structural and fMRI scans.
119-1	25522-25524	At	_	
119-2	25525-25528	age	_	
119-3	25529-25531	14	_	
119-4	25531-25532	,	_	
119-5	25533-25534	a	_	
119-6	25535-25540	large	_	
119-7	25541-25547	cohort	_	
119-8	25548-25550	of	_	
119-9	25551-25562	adolescents	_	
119-10	25563-25572	completed	_	
119-11	25573-25584	self-report	_	
119-12	25585-25588	and	_	
119-13	25589-25598	interview	_	
119-14	25599-25607	measures	_	
119-15	25607-25608	,	_	
119-16	25609-25611	in	_	
119-17	25612-25620	addition	_	
119-18	25621-25623	to	_	
119-19	25624-25634	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	
119-20	25635-25638	and	_	
119-21	25639-25643	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
119-22	25644-25649	scans	_	
119-23	25649-25650	.	_	

#Text=Parental report measures were also collected for some constructs.
120-1	25651-25659	Parental	_	
120-2	25660-25666	report	_	
120-3	25667-25675	measures	_	
120-4	25676-25680	were	_	
120-5	25681-25685	also	_	
120-6	25686-25695	collected	_	
120-7	25696-25699	for	_	
120-8	25700-25704	some	_	
120-9	25705-25715	constructs	_	
120-10	25715-25716	.	_	

#Text=Local ethics research committees approved the study at each site.
121-1	25717-25722	Local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
121-2	25723-25729	ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
121-3	25730-25738	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
121-4	25739-25749	committees	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
121-5	25750-25758	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
121-6	25759-25762	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
121-7	25763-25768	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
121-8	25769-25771	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
121-9	25772-25776	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
121-10	25777-25781	site	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
121-11	25781-25782	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	

#Text=On the day of assessment, written consent was obtained from each parent or guardian, and verbal assent was obtained from each adolescent.
122-1	25783-25785	On	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-2	25786-25789	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-3	25790-25793	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-4	25794-25796	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-5	25797-25807	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-6	25807-25808	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-7	25809-25816	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-8	25817-25824	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-9	25825-25828	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-10	25829-25837	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-11	25838-25842	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-12	25843-25847	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-13	25848-25854	parent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-14	25855-25857	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-15	25858-25866	guardian	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-16	25866-25867	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-17	25868-25871	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-18	25872-25878	verbal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-19	25879-25885	assent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-20	25886-25889	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-21	25890-25898	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-22	25899-25903	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-23	25904-25908	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-24	25909-25919	adolescent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
122-25	25919-25920	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	

#Text=Further details on recruitment, standardized instructions for administration of psychometric and cognitive behavioural measures, and other procedures are described in the Standard Operating Procedures for the IMAGEN project (http://www.imagen-europe.com/en/Publications_and_SOP.php).
123-1	25921-25928	Further	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-2	25929-25936	details	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-3	25937-25939	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-4	25940-25951	recruitment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-5	25951-25952	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-6	25953-25965	standardized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-7	25966-25978	instructions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-8	25979-25982	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-9	25983-25997	administration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-10	25998-26000	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-11	26001-26013	psychometric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-12	26014-26017	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-13	26018-26027	cognitive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-14	26028-26039	behavioural	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-15	26040-26048	measures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-16	26048-26049	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-17	26050-26053	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-18	26054-26059	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-19	26060-26070	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-20	26071-26074	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-21	26075-26084	described	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-22	26085-26087	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-23	26088-26091	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-24	26092-26100	Standard	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-25	26101-26110	Operating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-26	26111-26121	Procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-27	26122-26125	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-28	26126-26129	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-29	26130-26136	IMAGEN	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-30	26137-26144	project	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
123-31	26145-26146	(	_	
123-32	26146-26150	http	_	
123-33	26150-26151	:	_	
123-34	26151-26152	/	_	
123-35	26152-26153	/	_	
123-36	26153-26174	www.imagen-europe.com	_	
123-37	26174-26175	/	_	
123-38	26175-26177	en	_	
123-39	26177-26178	/	_	
123-40	26178-26202	Publications_and_SOP.php	_	
123-41	26202-26203	)	_	
123-42	26203-26204	.	_	

#Text=Subjects were included in the current study if they had valid data for all measures including the initial assessment at age 14 and follow-up at age 16 (see below).
124-1	26205-26213	Subjects	_	
124-2	26214-26218	were	_	
124-3	26219-26227	included	_	
124-4	26228-26230	in	_	
124-5	26231-26234	the	_	
124-6	26235-26242	current	_	
124-7	26243-26248	study	_	
124-8	26249-26251	if	_	
124-9	26252-26256	they	_	
124-10	26257-26260	had	_	
124-11	26261-26266	valid	_	
124-12	26267-26271	data	_	
124-13	26272-26275	for	_	
124-14	26276-26279	all	_	
124-15	26280-26288	measures	_	
124-16	26289-26298	including	_	
124-17	26299-26302	the	_	
124-18	26303-26310	initial	_	
124-19	26311-26321	assessment	_	
124-20	26322-26324	at	_	
124-21	26325-26328	age	_	
124-22	26329-26331	14	_	
124-23	26332-26335	and	_	
124-24	26336-26345	follow-up	_	
124-25	26346-26348	at	_	
124-26	26349-26352	age	_	
124-27	26353-26355	16	_	
124-28	26356-26357	(	_	
124-29	26357-26360	see	_	
124-30	26361-26366	below	_	
124-31	26366-26367	)	_	
124-32	26367-26368	.	_	

#Text=Based on these criteria, at the time of analysis, complete data were available for 1,090 adolescents.
125-1	26369-26374	Based	_	
125-2	26375-26377	on	_	
125-3	26378-26383	these	_	
125-4	26384-26392	criteria	_	
125-5	26392-26393	,	_	
125-6	26394-26396	at	_	
125-7	26397-26400	the	_	
125-8	26401-26405	time	_	
125-9	26406-26408	of	_	
125-10	26409-26417	analysis	_	
125-11	26417-26418	,	_	
125-12	26419-26427	complete	_	
125-13	26428-26432	data	_	
125-14	26433-26437	were	_	
125-15	26438-26447	available	_	
125-16	26448-26451	for	_	
125-17	26452-26457	1,090	_	
125-18	26458-26469	adolescents	_	
125-19	26469-26470	.	_	

#Text=Novelty seeking in this sample was initially assessed with the Novelty Seeking subscale of the Temperament and Character Inventory—Revised.
126-1	26471-26478	Novelty	_	
126-2	26479-26486	seeking	_	
126-3	26487-26489	in	_	
126-4	26490-26494	this	_	
126-5	26495-26501	sample	_	
126-6	26502-26505	was	_	
126-7	26506-26515	initially	_	
126-8	26516-26524	assessed	_	
126-9	26525-26529	with	_	
126-10	26530-26533	the	_	
126-11	26534-26541	Novelty	_	
126-12	26542-26549	Seeking	_	
126-13	26550-26558	subscale	_	
126-14	26559-26561	of	_	
126-15	26562-26565	the	_	
126-16	26566-26577	Temperament	_	
126-17	26578-26581	and	_	
126-18	26582-26591	Character	_	
126-19	26592-26609	Inventory—Revised	_	
126-20	26609-26610	.	_	

#Text=From the original sample of 1,090 with full data sets, individuals scoring in the top 25th percentile (n=283) of novelty seeking at the initial assessment at age 14 were selected.
127-1	26611-26615	From	_	
127-2	26616-26619	the	_	
127-3	26620-26628	original	_	
127-4	26629-26635	sample	_	
127-5	26636-26638	of	_	
127-6	26639-26644	1,090	_	
127-7	26645-26649	with	_	
127-8	26650-26654	full	_	
127-9	26655-26659	data	_	
127-10	26660-26664	sets	_	
127-11	26664-26665	,	_	
127-12	26666-26677	individuals	_	
127-13	26678-26685	scoring	_	
127-14	26686-26688	in	_	
127-15	26689-26692	the	_	
127-16	26693-26696	top	_	
127-17	26697-26701	25th	_	
127-18	26702-26712	percentile	_	
127-19	26713-26714	(	_	
127-20	26714-26715	n	_	
127-21	26715-26716	=	_	
127-22	26716-26719	283	_	
127-23	26719-26720	)	_	
127-24	26721-26723	of	_	
127-25	26724-26731	novelty	_	
127-26	26732-26739	seeking	_	
127-27	26740-26742	at	_	
127-28	26743-26746	the	_	
127-29	26747-26754	initial	_	
127-30	26755-26765	assessment	_	
127-31	26766-26768	at	_	
127-32	26769-26772	age	_	
127-33	26773-26775	14	_	
127-34	26776-26780	were	_	
127-35	26781-26789	selected	_	
127-36	26789-26790	.	_	

#Text=Based on the criteria described below, these subjects were then classified either as having PDU either at age 14 (excluded; n=20) or at age 16 (PDU group; n=72) or as not having PDU at either ages 14 or 16 (control group; n=191).
128-1	26791-26796	Based	_	
128-2	26797-26799	on	_	
128-3	26800-26803	the	_	
128-4	26804-26812	criteria	_	
128-5	26813-26822	described	_	
128-6	26823-26828	below	_	
128-7	26828-26829	,	_	
128-8	26830-26835	these	_	
128-9	26836-26844	subjects	_	
128-10	26845-26849	were	_	
128-11	26850-26854	then	_	
128-12	26855-26865	classified	_	
128-13	26866-26872	either	_	
128-14	26873-26875	as	_	
128-15	26876-26882	having	_	
128-16	26883-26886	PDU	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse	
128-17	26887-26893	either	_	
128-18	26894-26896	at	_	
128-19	26897-26900	age	_	
128-20	26901-26903	14	_	
128-21	26904-26905	(	_	
128-22	26905-26913	excluded	_	
128-23	26913-26914	;	_	
128-24	26915-26916	n	_	
128-25	26916-26917	=	_	
128-26	26917-26919	20	_	
128-27	26919-26920	)	_	
128-28	26921-26923	or	_	
128-29	26924-26926	at	_	
128-30	26927-26930	age	_	
128-31	26931-26933	16	_	
128-32	26934-26935	(	_	
128-33	26935-26938	PDU	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse	
128-34	26939-26944	group	_	
128-35	26944-26945	;	_	
128-36	26946-26947	n	_	
128-37	26947-26948	=	_	
128-38	26948-26950	72	_	
128-39	26950-26951	)	_	
128-40	26952-26954	or	_	
128-41	26955-26957	as	_	
128-42	26958-26961	not	_	
128-43	26962-26968	having	_	
128-44	26969-26972	PDU	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse	
128-45	26973-26975	at	_	
128-46	26976-26982	either	_	
128-47	26983-26987	ages	_	
128-48	26988-26990	14	_	
128-49	26991-26993	or	_	
128-50	26994-26996	16	_	
128-51	26997-26998	(	_	
128-52	26998-27005	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
128-53	27006-27011	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
128-54	27011-27012	;	_	
128-55	27013-27014	n	_	
128-56	27014-27015	=	_	
128-57	27015-27018	191	_	
128-58	27018-27019	)	_	
128-59	27019-27020	.	_	

#Text=Since we aimed to classify whether neural markers predict or result from drug use, we sought to directly compare the PDU group to the control group without statistically significant differences in PDU at age 14.
129-1	27021-27026	Since	_	
129-2	27027-27029	we	_	
129-3	27030-27035	aimed	_	
129-4	27036-27038	to	_	
129-5	27039-27047	classify	_	
129-6	27048-27055	whether	_	
129-7	27056-27062	neural	_	
129-8	27063-27070	markers	_	
129-9	27071-27078	predict	_	
129-10	27079-27081	or	_	
129-11	27082-27088	result	_	
129-12	27089-27093	from	_	
129-13	27094-27098	drug	_	
129-14	27099-27102	use	_	
129-15	27102-27103	,	_	
129-16	27104-27106	we	_	
129-17	27107-27113	sought	_	
129-18	27114-27116	to	_	
129-19	27117-27125	directly	_	
129-20	27126-27133	compare	_	
129-21	27134-27137	the	_	
129-22	27138-27141	PDU	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse	
129-23	27142-27147	group	_	
129-24	27148-27150	to	_	
129-25	27151-27154	the	_	
129-26	27155-27162	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
129-27	27163-27168	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
129-28	27169-27176	without	_	
129-29	27177-27190	statistically	_	
129-30	27191-27202	significant	_	
129-31	27203-27214	differences	_	
129-32	27215-27217	in	_	
129-33	27218-27221	PDU	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse	
129-34	27222-27224	at	_	
129-35	27225-27228	age	_	
129-36	27229-27231	14	_	
129-37	27231-27232	.	_	

#Text=Thus, we further matched both groups with respect to size and average drug intake at age 14 (as defined by each individual's total drug intake score, described below).
130-1	27233-27237	Thus	_	
130-2	27237-27238	,	_	
130-3	27239-27241	we	_	
130-4	27242-27249	further	_	
130-5	27250-27257	matched	_	
130-6	27258-27262	both	_	
130-7	27263-27269	groups	_	
130-8	27270-27274	with	_	
130-9	27275-27282	respect	_	
130-10	27283-27285	to	_	
130-11	27286-27290	size	_	
130-12	27291-27294	and	_	
130-13	27295-27302	average	_	
130-14	27303-27307	drug	_	
130-15	27308-27314	intake	_	
130-16	27315-27317	at	_	
130-17	27318-27321	age	_	
130-18	27322-27324	14	_	
130-19	27325-27326	(	_	
130-20	27326-27328	as	_	
130-21	27329-27336	defined	_	
130-22	27337-27339	by	_	
130-23	27340-27344	each	_	
130-24	27345-27357	individual's	_	
130-25	27358-27363	total	_	
130-26	27364-27368	drug	_	
130-27	27369-27375	intake	_	
130-28	27376-27381	score	_	
130-29	27381-27382	,	_	
130-30	27383-27392	described	_	
130-31	27393-27398	below	_	
130-32	27398-27399	)	_	
130-33	27399-27400	.	_	

#Text=This procedure yielded 72 subjects in the PDU group and 72 matched subjects in the control group (Table 1; Fig. 5).
131-1	27401-27405	This	_	
131-2	27406-27415	procedure	_	
131-3	27416-27423	yielded	_	
131-4	27424-27426	72	_	
131-5	27427-27435	subjects	_	
131-6	27436-27438	in	_	
131-7	27439-27442	the	_	
131-8	27443-27446	PDU	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse	
131-9	27447-27452	group	_	
131-10	27453-27456	and	_	
131-11	27457-27459	72	_	
131-12	27460-27467	matched	_	
131-13	27468-27476	subjects	_	
131-14	27477-27479	in	_	
131-15	27480-27483	the	_	
131-16	27484-27491	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
131-17	27492-27497	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
131-18	27498-27499	(	_	
131-19	27499-27504	Table	_	
131-20	27505-27506	1	_	
131-21	27506-27507	;	_	
131-22	27508-27511	Fig	_	
131-23	27511-27512	.	_	
131-24	27513-27514	5	_	
131-25	27514-27515	)	_	
131-26	27515-27516	.	_	

#Text=PDU criteria
#Text=PDU was operationally defined based on measures according to the European School Survey Project on Alcohol and Other Drugs (ESPAD).
132-1	27517-27520	PDU	_	
132-2	27521-27529	criteria	_	
132-3	27530-27533	PDU	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse	
132-4	27534-27537	was	_	
132-5	27538-27551	operationally	_	
132-6	27552-27559	defined	_	
132-7	27560-27565	based	_	
132-8	27566-27568	on	_	
132-9	27569-27577	measures	_	
132-10	27578-27587	according	_	
132-11	27588-27590	to	_	
132-12	27591-27594	the	_	
132-13	27595-27603	European	_	
132-14	27604-27610	School	_	
132-15	27611-27617	Survey	_	
132-16	27618-27625	Project	_	
132-17	27626-27628	on	_	
132-18	27629-27636	Alcohol	_	
132-19	27637-27640	and	_	
132-20	27641-27646	Other	_	
132-21	27647-27652	Drugs	_	
132-22	27653-27654	(	_	
132-23	27654-27659	ESPAD	_	
132-24	27659-27660	)	_	
132-25	27660-27661	.	_	

#Text=Unlike traditional clinical instruments (for example, the Diagnostic and Statistical Manual of Mental Disorders, version 5) these measures provided a preclinical index of drug use at ages 14 and 16.
133-1	27662-27668	Unlike	_	
133-2	27669-27680	traditional	_	
133-3	27681-27689	clinical	_	
133-4	27690-27701	instruments	_	
133-5	27702-27703	(	_	
133-6	27703-27706	for	_	
133-7	27707-27714	example	_	
133-8	27714-27715	,	_	
133-9	27716-27719	the	_	
133-10	27720-27730	Diagnostic	_	
133-11	27731-27734	and	_	
133-12	27735-27746	Statistical	_	
133-13	27747-27753	Manual	_	
133-14	27754-27756	of	_	
133-15	27757-27763	Mental	_	
133-16	27764-27773	Disorders	_	
133-17	27773-27774	,	_	
133-18	27775-27782	version	_	
133-19	27783-27784	5	_	
133-20	27784-27785	)	_	
133-21	27786-27791	these	_	
133-22	27792-27800	measures	_	
133-23	27801-27809	provided	_	
133-24	27810-27811	a	_	
133-25	27812-27823	preclinical	_	
133-26	27824-27829	index	_	
133-27	27830-27832	of	_	
133-28	27833-27837	drug	_	
133-29	27838-27841	use	_	
133-30	27842-27844	at	_	
133-31	27845-27849	ages	_	
133-32	27850-27852	14	_	
133-33	27853-27856	and	_	
133-34	27857-27859	16	_	
133-35	27859-27860	.	_	

#Text=Thus, cutoff criteria for PDU were defined to capture problematic use of various legal or illicit drugs.
134-1	27861-27865	Thus	_	
134-2	27865-27866	,	_	
134-3	27867-27873	cutoff	_	
134-4	27874-27882	criteria	_	
134-5	27883-27886	for	_	
134-6	27887-27890	PDU	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse	
134-7	27891-27895	were	_	
134-8	27896-27903	defined	_	
134-9	27904-27906	to	_	
134-10	27907-27914	capture	_	
134-11	27915-27926	problematic	_	
134-12	27927-27930	use	_	
134-13	27931-27933	of	_	
134-14	27934-27941	various	_	
134-15	27942-27947	legal	_	
134-16	27948-27950	or	_	
134-17	27951-27958	illicit	_	
134-18	27959-27964	drugs	_	
134-19	27964-27965	.	_	

#Text=With respect to legal drugs (alcohol and cigarettes), a threshold was set that indicated daily use.
135-1	27966-27970	With	_	
135-2	27971-27978	respect	_	
135-3	27979-27981	to	_	
135-4	27982-27987	legal	_	
135-5	27988-27993	drugs	_	
135-6	27994-27995	(	_	
135-7	27995-28002	alcohol	_	
135-8	28003-28006	and	_	
135-9	28007-28017	cigarettes	_	
135-10	28017-28018	)	_	
135-11	28018-28019	,	_	
135-12	28020-28021	a	_	
135-13	28022-28031	threshold	_	
135-14	28032-28035	was	_	
135-15	28036-28039	set	_	
135-16	28040-28044	that	_	
135-17	28045-28054	indicated	_	
135-18	28055-28060	daily	_	
135-19	28061-28064	use	_	
135-20	28064-28065	.	_	

#Text=In particular, a score of 3 or higher on smoking (0: ‘Not at all', 1: ‘Less than 1 cigarette per week', 2: ‘Less than 1 cigarette per day', 3: ‘1–5 cigarettes per day', 4: ‘6–10 cigarettes per day', 5: ‘11–20 cigarettes per day', 6: ‘More than 20 cigarettes per day') and a score of 5 or higher on alcohol consumption (0: ‘0 drinks per month', 1: ‘1–2 drinks per month', 2: ‘3–5 drinks per month', 3: ‘6–9', 4: ‘10–19', 5: ‘20–39' and 6: ‘40 or more') within the last 30 days were defined as PDU.
136-1	28066-28068	In	_	
136-2	28069-28079	particular	_	
136-3	28079-28080	,	_	
136-4	28081-28082	a	_	
136-5	28083-28088	score	_	
136-6	28089-28091	of	_	
136-7	28092-28093	3	_	
136-8	28094-28096	or	_	
136-9	28097-28103	higher	_	
136-10	28104-28106	on	_	
136-11	28107-28114	smoking	_	
136-12	28115-28116	(	_	
136-13	28116-28117	0	_	
136-14	28117-28118	:	_	
136-15	28119-28120	‘	_	
136-16	28120-28123	Not	_	
136-17	28124-28126	at	_	
136-18	28127-28130	all	_	
136-19	28130-28131	'	_	
136-20	28131-28132	,	_	
136-21	28133-28134	1	_	
136-22	28134-28135	:	_	
136-23	28136-28137	‘	_	
136-24	28137-28141	Less	_	
136-25	28142-28146	than	_	
136-26	28147-28148	1	_	
136-27	28149-28158	cigarette	_	
136-28	28159-28162	per	_	
136-29	28163-28167	week	_	
136-30	28167-28168	'	_	
136-31	28168-28169	,	_	
136-32	28170-28171	2	_	
136-33	28171-28172	:	_	
136-34	28173-28174	‘	_	
136-35	28174-28178	Less	_	
136-36	28179-28183	than	_	
136-37	28184-28185	1	_	
136-38	28186-28195	cigarette	_	
136-39	28196-28199	per	_	
136-40	28200-28203	day	_	
136-41	28203-28204	'	_	
136-42	28204-28205	,	_	
136-43	28206-28207	3	_	
136-44	28207-28208	:	_	
136-45	28209-28210	‘	_	
136-46	28210-28211	1	_	
136-47	28211-28212	–	_	
136-48	28212-28213	5	_	
136-49	28214-28224	cigarettes	_	
136-50	28225-28228	per	_	
136-51	28229-28232	day	_	
136-52	28232-28233	'	_	
136-53	28233-28234	,	_	
136-54	28235-28236	4	_	
136-55	28236-28237	:	_	
136-56	28238-28239	‘	_	
136-57	28239-28240	6	_	
136-58	28240-28241	–	_	
136-59	28241-28243	10	_	
136-60	28244-28254	cigarettes	_	
136-61	28255-28258	per	_	
136-62	28259-28262	day	_	
136-63	28262-28263	'	_	
136-64	28263-28264	,	_	
136-65	28265-28266	5	_	
136-66	28266-28267	:	_	
136-67	28268-28269	‘	_	
136-68	28269-28271	11	_	
136-69	28271-28272	–	_	
136-70	28272-28274	20	_	
136-71	28275-28285	cigarettes	_	
136-72	28286-28289	per	_	
136-73	28290-28293	day	_	
136-74	28293-28294	'	_	
136-75	28294-28295	,	_	
136-76	28296-28297	6	_	
136-77	28297-28298	:	_	
136-78	28299-28300	‘	_	
136-79	28300-28304	More	_	
136-80	28305-28309	than	_	
136-81	28310-28312	20	_	
136-82	28313-28323	cigarettes	_	
136-83	28324-28327	per	_	
136-84	28328-28331	day	_	
136-85	28331-28332	'	_	
136-86	28332-28333	)	_	
136-87	28334-28337	and	_	
136-88	28338-28339	a	_	
136-89	28340-28345	score	_	
136-90	28346-28348	of	_	
136-91	28349-28350	5	_	
136-92	28351-28353	or	_	
136-93	28354-28360	higher	_	
136-94	28361-28363	on	_	
136-95	28364-28371	alcohol	_	
136-96	28372-28383	consumption	_	
136-97	28384-28385	(	_	
136-98	28385-28386	0	_	
136-99	28386-28387	:	_	
136-100	28388-28389	‘	_	
136-101	28389-28390	0	_	
136-102	28391-28397	drinks	_	
136-103	28398-28401	per	_	
136-104	28402-28407	month	_	
136-105	28407-28408	'	_	
136-106	28408-28409	,	_	
136-107	28410-28411	1	_	
136-108	28411-28412	:	_	
136-109	28413-28414	‘	_	
136-110	28414-28415	1	_	
136-111	28415-28416	–	_	
136-112	28416-28417	2	_	
136-113	28418-28424	drinks	_	
136-114	28425-28428	per	_	
136-115	28429-28434	month	_	
136-116	28434-28435	'	_	
136-117	28435-28436	,	_	
136-118	28437-28438	2	_	
136-119	28438-28439	:	_	
136-120	28440-28441	‘	_	
136-121	28441-28442	3	_	
136-122	28442-28443	–	_	
136-123	28443-28444	5	_	
136-124	28445-28451	drinks	_	
136-125	28452-28455	per	_	
136-126	28456-28461	month	_	
136-127	28461-28462	'	_	
136-128	28462-28463	,	_	
136-129	28464-28465	3	_	
136-130	28465-28466	:	_	
136-131	28467-28468	‘	_	
136-132	28468-28469	6	_	
136-133	28469-28470	–	_	
136-134	28470-28471	9	_	
136-135	28471-28472	'	_	
136-136	28472-28473	,	_	
136-137	28474-28475	4	_	
136-138	28475-28476	:	_	
136-139	28477-28478	‘	_	
136-140	28478-28480	10	_	
136-141	28480-28481	–	_	
136-142	28481-28483	19	_	
136-143	28483-28484	'	_	
136-144	28484-28485	,	_	
136-145	28486-28487	5	_	
136-146	28487-28488	:	_	
136-147	28489-28490	‘	_	
136-148	28490-28492	20	_	
136-149	28492-28493	–	_	
136-150	28493-28495	39	_	
136-151	28495-28496	'	_	
136-152	28497-28500	and	_	
136-153	28501-28502	6	_	
136-154	28502-28503	:	_	
136-155	28504-28505	‘	_	
136-156	28505-28507	40	_	
136-157	28508-28510	or	_	
136-158	28511-28515	more	_	
136-159	28515-28516	'	_	
136-160	28516-28517	)	_	
136-161	28518-28524	within	_	
136-162	28525-28528	the	_	
136-163	28529-28533	last	_	
136-164	28534-28536	30	_	
136-165	28537-28541	days	_	
136-166	28542-28546	were	_	
136-167	28547-28554	defined	_	
136-168	28555-28557	as	_	
136-169	28558-28561	PDU	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse	
136-170	28561-28562	.	_	

#Text=With respect to illicit drugs, PDU thresholds were based on lifetime use.
137-1	28563-28567	With	_	
137-2	28568-28575	respect	_	
137-3	28576-28578	to	_	
137-4	28579-28586	illicit	_	
137-5	28587-28592	drugs	_	
137-6	28592-28593	,	_	
137-7	28594-28597	PDU	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse	
137-8	28598-28608	thresholds	_	
137-9	28609-28613	were	_	
137-10	28614-28619	based	_	
137-11	28620-28622	on	_	
137-12	28623-28631	lifetime	_	
137-13	28632-28635	use	_	
137-14	28635-28636	.	_	

#Text=Apart from cannabis, where the threshold was set to 39 lifetime occasions, the threshold for other drugs (glue, tranquilizers, amphetamine, lysergic acid diethylamide (LSD), hallucinogenic mushrooms, 3,4 methylenedioxymethamphetamine (MDMA), ketamine or liquid ecstasy) was set to 3–5 occasions or more.
138-1	28637-28642	Apart	_	
138-2	28643-28647	from	_	
138-3	28648-28656	cannabis	_	
138-4	28656-28657	,	_	
138-5	28658-28663	where	_	
138-6	28664-28667	the	_	
138-7	28668-28677	threshold	_	
138-8	28678-28681	was	_	
138-9	28682-28685	set	_	
138-10	28686-28688	to	_	
138-11	28689-28691	39	_	
138-12	28692-28700	lifetime	_	
138-13	28701-28710	occasions	_	
138-14	28710-28711	,	_	
138-15	28712-28715	the	_	
138-16	28716-28725	threshold	_	
138-17	28726-28729	for	_	
138-18	28730-28735	other	_	
138-19	28736-28741	drugs	_	
138-20	28742-28743	(	_	
138-21	28743-28747	glue	_	
138-22	28747-28748	,	_	
138-23	28749-28762	tranquilizers	_	
138-24	28762-28763	,	_	
138-25	28764-28775	amphetamine	_	
138-26	28775-28776	,	_	
138-27	28777-28785	lysergic	_	
138-28	28786-28790	acid	_	
138-29	28791-28803	diethylamide	_	
138-30	28804-28805	(	_	
138-31	28805-28808	LSD	_	
138-32	28808-28809	)	_	
138-33	28809-28810	,	_	
138-34	28811-28825	hallucinogenic	_	
138-35	28826-28835	mushrooms	_	
138-36	28835-28836	,	_	
138-37	28837-28840	3,4	_	
138-38	28841-28870	methylenedioxymethamphetamine	_	
138-39	28871-28872	(	_	
138-40	28872-28876	MDMA	_	
138-41	28876-28877	)	_	
138-42	28877-28878	,	_	
138-43	28879-28887	ketamine	_	
138-44	28888-28890	or	_	
138-45	28891-28897	liquid	_	
138-46	28898-28905	ecstasy	_	
138-47	28905-28906	)	_	
138-48	28907-28910	was	_	
138-49	28911-28914	set	_	
138-50	28915-28917	to	_	
138-51	28918-28919	3	_	
138-52	28919-28920	–	_	
138-53	28920-28921	5	_	
138-54	28922-28931	occasions	_	
138-55	28932-28934	or	_	
138-56	28935-28939	more	_	
138-57	28939-28940	.	_	

#Text=Use of a lifetime score and therefore a lower threshold criterion for these drugs was justified by the fact that early use of these drugs robustly predicts PDU later in life (for example, a threefold risk after early cannabis use).
139-1	28941-28944	Use	_	
139-2	28945-28947	of	_	
139-3	28948-28949	a	_	
139-4	28950-28958	lifetime	_	
139-5	28959-28964	score	_	
139-6	28965-28968	and	_	
139-7	28969-28978	therefore	_	
139-8	28979-28980	a	_	
139-9	28981-28986	lower	_	
139-10	28987-28996	threshold	_	
139-11	28997-29006	criterion	_	
139-12	29007-29010	for	_	
139-13	29011-29016	these	_	
139-14	29017-29022	drugs	_	
139-15	29023-29026	was	_	
139-16	29027-29036	justified	_	
139-17	29037-29039	by	_	
139-18	29040-29043	the	_	
139-19	29044-29048	fact	_	
139-20	29049-29053	that	_	
139-21	29054-29059	early	_	
139-22	29060-29063	use	_	
139-23	29064-29066	of	_	
139-24	29067-29072	these	_	
139-25	29073-29078	drugs	_	
139-26	29079-29087	robustly	_	
139-27	29088-29096	predicts	_	
139-28	29097-29100	PDU	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse	
139-29	29101-29106	later	_	
139-30	29107-29109	in	_	
139-31	29110-29114	life	_	
139-32	29115-29116	(	_	
139-33	29116-29119	for	_	
139-34	29120-29127	example	_	
139-35	29127-29128	,	_	
139-36	29129-29130	a	_	
139-37	29131-29140	threefold	_	
139-38	29141-29145	risk	_	
139-39	29146-29151	after	_	
139-40	29152-29157	early	_	
139-41	29158-29166	cannabis	_	
139-42	29167-29170	use	_	
139-43	29170-29171	)	_	
139-44	29171-29172	.	_	

#Text=Finally, the threshold for illicit drugs (for example, crack, cocaine, heroin and narcotics) was set to 1–2 or more occasions (Supplementary Figs 5 and 6 depict the distribution of scores for both groups at age 14 and 16, and cutoffs for each substance).
140-1	29173-29180	Finally	_	
140-2	29180-29181	,	_	
140-3	29182-29185	the	_	
140-4	29186-29195	threshold	_	
140-5	29196-29199	for	_	
140-6	29200-29207	illicit	_	
140-7	29208-29213	drugs	_	
140-8	29214-29215	(	_	
140-9	29215-29218	for	_	
140-10	29219-29226	example	_	
140-11	29226-29227	,	_	
140-12	29228-29233	crack	_	
140-13	29233-29234	,	_	
140-14	29235-29242	cocaine	_	
140-15	29242-29243	,	_	
140-16	29244-29250	heroin	_	
140-17	29251-29254	and	_	
140-18	29255-29264	narcotics	_	
140-19	29264-29265	)	_	
140-20	29266-29269	was	_	
140-21	29270-29273	set	_	
140-22	29274-29276	to	_	
140-23	29277-29278	1	_	
140-24	29278-29279	–	_	
140-25	29279-29280	2	_	
140-26	29281-29283	or	_	
140-27	29284-29288	more	_	
140-28	29289-29298	occasions	_	
140-29	29299-29300	(	_	
140-30	29300-29313	Supplementary	_	
140-31	29314-29318	Figs	_	
140-32	29319-29320	5	_	
140-33	29321-29324	and	_	
140-34	29325-29326	6	_	
140-35	29327-29333	depict	_	
140-36	29334-29337	the	_	
140-37	29338-29350	distribution	_	
140-38	29351-29353	of	_	
140-39	29354-29360	scores	_	
140-40	29361-29364	for	_	
140-41	29365-29369	both	_	
140-42	29370-29376	groups	_	
140-43	29377-29379	at	_	
140-44	29380-29383	age	_	
140-45	29384-29386	14	_	
140-46	29387-29390	and	_	
140-47	29391-29393	16	_	
140-48	29393-29394	,	_	
140-49	29395-29398	and	_	
140-50	29399-29406	cutoffs	_	
140-51	29407-29410	for	_	
140-52	29411-29415	each	_	
140-53	29416-29425	substance	_	
140-54	29425-29426	)	_	
140-55	29426-29427	.	_	

#Text=None of the subjects in either group fell above the threshold for use of any substance at age 14 (Supplementary Fig. 5).
141-1	29428-29432	None	_	
141-2	29433-29435	of	_	
141-3	29436-29439	the	_	
141-4	29440-29448	subjects	_	
141-5	29449-29451	in	_	
141-6	29452-29458	either	_	
141-7	29459-29464	group	_	
141-8	29465-29469	fell	_	
141-9	29470-29475	above	_	
141-10	29476-29479	the	_	
141-11	29480-29489	threshold	_	
141-12	29490-29493	for	_	
141-13	29494-29497	use	_	
141-14	29498-29500	of	_	
141-15	29501-29504	any	_	
141-16	29505-29514	substance	_	
141-17	29515-29517	at	_	
141-18	29518-29521	age	_	
141-19	29522-29524	14	_	
141-20	29525-29526	(	_	
141-21	29526-29539	Supplementary	_	
141-22	29540-29543	Fig	_	
141-23	29543-29544	.	_	
141-24	29545-29546	5	_	
141-25	29546-29547	)	_	
141-26	29547-29548	.	_	

#Text=Furthermore, most subjects were classified as PDU by means of daily cigarette use, followed by alcohol and cannabis—only a few were classified as PDU based on their use of other illicit drugs (for example, MDMA and amphetamines; Supplementary Figs 5 and 6).
142-1	29549-29560	Furthermore	_	
142-2	29560-29561	,	_	
142-3	29562-29566	most	_	
142-4	29567-29575	subjects	_	
142-5	29576-29580	were	_	
142-6	29581-29591	classified	_	
142-7	29592-29594	as	_	
142-8	29595-29598	PDU	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse	
142-9	29599-29601	by	_	
142-10	29602-29607	means	_	
142-11	29608-29610	of	_	
142-12	29611-29616	daily	_	
142-13	29617-29626	cigarette	_	
142-14	29627-29630	use	_	
142-15	29630-29631	,	_	
142-16	29632-29640	followed	_	
142-17	29641-29643	by	_	
142-18	29644-29651	alcohol	_	
142-19	29652-29655	and	_	
142-20	29656-29669	cannabis—only	_	
142-21	29670-29671	a	_	
142-22	29672-29675	few	_	
142-23	29676-29680	were	_	
142-24	29681-29691	classified	_	
142-25	29692-29694	as	_	
142-26	29695-29698	PDU	_	
142-27	29699-29704	based	_	
142-28	29705-29707	on	_	
142-29	29708-29713	their	_	
142-30	29714-29717	use	_	
142-31	29718-29720	of	_	
142-32	29721-29726	other	_	
142-33	29727-29734	illicit	_	
142-34	29735-29740	drugs	_	
142-35	29741-29742	(	_	
142-36	29742-29745	for	_	
142-37	29746-29753	example	_	
142-38	29753-29754	,	_	
142-39	29755-29759	MDMA	_	
142-40	29760-29763	and	_	
142-41	29764-29776	amphetamines	_	
142-42	29776-29777	;	_	
142-43	29778-29791	Supplementary	_	
142-44	29792-29796	Figs	_	
142-45	29797-29798	5	_	
142-46	29799-29802	and	_	
142-47	29803-29804	6	_	
142-48	29804-29805	)	_	
142-49	29805-29806	.	_	

#Text=Personality and psychopathology measures
#Text=Novelty seeking was assessed using a subscale of the Temperament and Character Inventory—Revised.
143-1	29807-29818	Personality	_	
143-2	29819-29822	and	_	
143-3	29823-29838	psychopathology	_	
143-4	29839-29847	measures	_	
143-5	29848-29855	Novelty	_	
143-6	29856-29863	seeking	_	
143-7	29864-29867	was	_	
143-8	29868-29876	assessed	_	
143-9	29877-29882	using	_	
143-10	29883-29884	a	_	
143-11	29885-29893	subscale	_	
143-12	29894-29896	of	_	
143-13	29897-29900	the	_	
143-14	29901-29912	Temperament	_	
143-15	29913-29916	and	_	
143-16	29917-29926	Character	_	
143-17	29927-29944	Inventory—Revised	_	
143-18	29944-29945	.	_	

#Text=Dimensions of personality were assessed using the 60-item Neuroticism-Extraversion-Openness Five-Factor Inventory, which indexes dimensions of Extraversion, Agreeableness, Conscientiousness, Neuroticism, and Openness to Experience, as described by the Five-Factor Model of personality.
144-1	29946-29956	Dimensions	_	
144-2	29957-29959	of	_	
144-3	29960-29971	personality	_	
144-4	29972-29976	were	_	
144-5	29977-29985	assessed	_	
144-6	29986-29991	using	_	
144-7	29992-29995	the	_	
144-8	29996-29998	60	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[8]	
144-9	29998-29999	-	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[8]	
144-10	29999-30003	item	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[8]	
144-11	30004-30037	Neuroticism-Extraversion-Openness	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[8]	
144-12	30038-30049	Five-Factor	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[8]	
144-13	30050-30059	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[8]	
144-14	30059-30060	,	_	
144-15	30061-30066	which	_	
144-16	30067-30074	indexes	_	
144-17	30075-30085	dimensions	_	
144-18	30086-30088	of	_	
144-19	30089-30101	Extraversion	_	
144-20	30101-30102	,	_	
144-21	30103-30116	Agreeableness	_	
144-22	30116-30117	,	_	
144-23	30118-30135	Conscientiousness	_	
144-24	30135-30136	,	_	
144-25	30137-30148	Neuroticism	_	
144-26	30148-30149	,	_	
144-27	30150-30153	and	_	
144-28	30154-30162	Openness	_	
144-29	30163-30165	to	_	
144-30	30166-30176	Experience	_	
144-31	30176-30177	,	_	
144-32	30178-30180	as	_	
144-33	30181-30190	described	_	
144-34	30191-30193	by	_	
144-35	30194-30197	the	_	
144-36	30198-30209	Five-Factor	_	
144-37	30210-30215	Model	_	
144-38	30216-30218	of	_	
144-39	30219-30230	personality	_	
144-40	30230-30231	.	_	

#Text=Adolescent psychiatric symptoms and their impact were assessed with the Development and Well-Being Assessment, which generates probabilities that individuals qualify for Diagnostic and Statistical Manual of Mental Disorders (version 4) psychiatric diagnoses.
145-1	30232-30242	Adolescent	_	
145-2	30243-30254	psychiatric	_	
145-3	30255-30263	symptoms	_	
145-4	30264-30267	and	_	
145-5	30268-30273	their	_	
145-6	30274-30280	impact	_	
145-7	30281-30285	were	_	
145-8	30286-30294	assessed	_	
145-9	30295-30299	with	_	
145-10	30300-30303	the	_	
145-11	30304-30315	Development	_	
145-12	30316-30319	and	_	
145-13	30320-30330	Well-Being	_	
145-14	30331-30341	Assessment	_	
145-15	30341-30342	,	_	
145-16	30343-30348	which	_	
145-17	30349-30358	generates	_	
145-18	30359-30372	probabilities	_	
145-19	30373-30377	that	_	
145-20	30378-30389	individuals	_	
145-21	30390-30397	qualify	_	
145-22	30398-30401	for	_	
145-23	30402-30412	Diagnostic	_	
145-24	30413-30416	and	_	
145-25	30417-30428	Statistical	_	
145-26	30429-30435	Manual	_	
145-27	30436-30438	of	_	
145-28	30439-30445	Mental	_	
145-29	30446-30455	Disorders	_	
145-30	30456-30457	(	_	
145-31	30457-30464	version	_	
145-32	30465-30466	4	_	
145-33	30466-30467	)	_	
145-34	30468-30479	psychiatric	_	
145-35	30480-30489	diagnoses	_	
145-36	30489-30490	.	_	

#Text=Cognitive measures
#Text=Subjects completed a version of the Wechsler Intelligence Scale for Children-IV, which included the Perceptual Reasoning, Matrix Reasoning and Similarities, and Vocabulary scales to index intelligence.
146-1	30491-30500	Cognitive	_	
146-2	30501-30509	measures	_	
146-3	30510-30518	Subjects	_	
146-4	30519-30528	completed	_	
146-5	30529-30530	a	_	
146-6	30531-30538	version	_	
146-7	30539-30541	of	_	
146-8	30542-30545	the	_	
146-9	30546-30554	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[9]	
146-10	30555-30567	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[9]	
146-11	30568-30573	Scale	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[9]	
146-12	30574-30577	for	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[9]	
146-13	30578-30589	Children-IV	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[9]	
146-14	30589-30590	,	_	
146-15	30591-30596	which	_	
146-16	30597-30605	included	_	
146-17	30606-30609	the	_	
146-18	30610-30620	Perceptual	_	
146-19	30621-30630	Reasoning	_	
146-20	30630-30631	,	_	
146-21	30632-30638	Matrix	_	
146-22	30639-30648	Reasoning	_	
146-23	30649-30652	and	_	
146-24	30653-30665	Similarities	_	
146-25	30665-30666	,	_	
146-26	30667-30670	and	_	
146-27	30671-30681	Vocabulary	_	
146-28	30682-30688	scales	_	
146-29	30689-30691	to	_	
146-30	30692-30697	index	_	
146-31	30698-30710	intelligence	_	
146-32	30710-30711	.	_	

#Text=The Monetary-Choice Questionnaire (MCQ) was administered to assess delay discounting—or individual differences in the tendency to choose sooner but smaller over later but larger rewards (this index correlates well with more precise but also more time-consuming measures).
147-1	30712-30715	The	_	
147-2	30716-30731	Monetary-Choice	http://www.case.edu/ProvCaRe/provcare#Questionnaire[10]	
147-3	30732-30745	Questionnaire	http://www.case.edu/ProvCaRe/provcare#Questionnaire[10]	
147-4	30746-30747	(	http://www.case.edu/ProvCaRe/provcare#Questionnaire[10]	
147-5	30747-30750	MCQ	http://www.case.edu/ProvCaRe/provcare#Questionnaire[10]	
147-6	30750-30751	)	http://www.case.edu/ProvCaRe/provcare#Questionnaire[10]	
147-7	30752-30755	was	_	
147-8	30756-30768	administered	_	
147-9	30769-30771	to	_	
147-10	30772-30778	assess	_	
147-11	30779-30784	delay	_	
147-12	30785-30799	discounting—or	_	
147-13	30800-30810	individual	_	
147-14	30811-30822	differences	_	
147-15	30823-30825	in	_	
147-16	30826-30829	the	_	
147-17	30830-30838	tendency	_	
147-18	30839-30841	to	_	
147-19	30842-30848	choose	_	
147-20	30849-30855	sooner	_	
147-21	30856-30859	but	_	
147-22	30860-30867	smaller	_	
147-23	30868-30872	over	_	
147-24	30873-30878	later	_	
147-25	30879-30882	but	_	
147-26	30883-30889	larger	_	
147-27	30890-30897	rewards	_	
147-28	30898-30899	(	_	
147-29	30899-30903	this	_	
147-30	30904-30909	index	_	
147-31	30910-30920	correlates	_	
147-32	30921-30925	well	_	
147-33	30926-30930	with	_	
147-34	30931-30935	more	_	
147-35	30936-30943	precise	_	
147-36	30944-30947	but	_	
147-37	30948-30952	also	_	
147-38	30953-30957	more	_	
147-39	30958-30972	time-consuming	_	
147-40	30973-30981	measures	_	
147-41	30981-30982	)	_	
147-42	30982-30983	.	_	

#Text=Subjects also completed the Cambridge Gambling Task (CGT), as a behavioural measure of risk seeking.
148-1	30984-30992	Subjects	_	
148-2	30993-30997	also	_	
148-3	30998-31007	completed	_	
148-4	31008-31011	the	_	
148-5	31012-31021	Cambridge	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[11]	
148-6	31022-31030	Gambling	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[11]	
148-7	31031-31035	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[11]	
148-8	31036-31037	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[11]	
148-9	31037-31040	CGT	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[11]	
148-10	31040-31041	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[11]	
148-11	31041-31042	,	_	
148-12	31043-31045	as	_	
148-13	31046-31047	a	_	
148-14	31048-31059	behavioural	_	
148-15	31060-31067	measure	_	
148-16	31068-31070	of	_	
148-17	31071-31075	risk	_	
148-18	31076-31083	seeking	_	
148-19	31083-31084	.	_	

#Text=Demographics
#Text=The Puberty Development Scale assessed each subject's pubertal status.
149-1	31085-31097	Demographics	_	
149-2	31098-31101	The	_	
149-3	31102-31109	Puberty	_	
149-4	31110-31121	Development	_	
149-5	31122-31127	Scale	_	
149-6	31128-31136	assessed	_	
149-7	31137-31141	each	_	
149-8	31142-31151	subject's	_	
149-9	31152-31160	pubertal	_	
149-10	31161-31167	status	_	
149-11	31167-31168	.	_	

#Text=Socioeconomic status scores were assessed using a composite score that indexed the weighted sum of the following variables: Mother's Education Score, Father's Education Score, Family Stress Unemployment Score, Financial Difficulties Score, Home Inadequacy Score, Neighborhood Score, Financial Crisis Score, Mother Employed Score, Father Employed Score.
150-1	31169-31182	Socioeconomic	http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus[12]	
150-2	31183-31189	status	http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus[12]	
150-3	31190-31196	scores	_	
150-4	31197-31201	were	_	
150-5	31202-31210	assessed	_	
150-6	31211-31216	using	_	
150-7	31217-31218	a	_	
150-8	31219-31228	composite	_	
150-9	31229-31234	score	_	
150-10	31235-31239	that	_	
150-11	31240-31247	indexed	_	
150-12	31248-31251	the	_	
150-13	31252-31260	weighted	_	
150-14	31261-31264	sum	_	
150-15	31265-31267	of	_	
150-16	31268-31271	the	_	
150-17	31272-31281	following	_	
150-18	31282-31291	variables	_	
150-19	31291-31292	:	_	
150-20	31293-31301	Mother's	_	
150-21	31302-31311	Education	_	
150-22	31312-31317	Score	_	
150-23	31317-31318	,	_	
150-24	31319-31327	Father's	_	
150-25	31328-31337	Education	_	
150-26	31338-31343	Score	_	
150-27	31343-31344	,	_	
150-28	31345-31351	Family	_	
150-29	31352-31358	Stress	_	
150-30	31359-31371	Unemployment	_	
150-31	31372-31377	Score	_	
150-32	31377-31378	,	_	
150-33	31379-31388	Financial	_	
150-34	31389-31401	Difficulties	_	
150-35	31402-31407	Score	_	
150-36	31407-31408	,	_	
150-37	31409-31413	Home	_	
150-38	31414-31424	Inadequacy	_	
150-39	31425-31430	Score	_	
150-40	31430-31431	,	_	
150-41	31432-31444	Neighborhood	_	
150-42	31445-31450	Score	_	
150-43	31450-31451	,	_	
150-44	31452-31461	Financial	_	
150-45	31462-31468	Crisis	_	
150-46	31469-31474	Score	_	
150-47	31474-31475	,	_	
150-48	31476-31482	Mother	_	
150-49	31483-31491	Employed	_	
150-50	31492-31497	Score	_	
150-51	31497-31498	,	_	
150-52	31499-31505	Father	_	
150-53	31506-31514	Employed	_	
150-54	31515-31520	Score	_	
150-55	31520-31521	.	_	

#Text=Negative (that is, high risk) scores were reverse-coded.
151-1	31522-31530	Negative	_	
151-2	31531-31532	(	_	
151-3	31532-31536	that	_	
151-4	31537-31539	is	_	
151-5	31539-31540	,	_	
151-6	31541-31545	high	_	
151-7	31546-31550	risk	_	
151-8	31550-31551	)	_	
151-9	31552-31558	scores	_	
151-10	31559-31563	were	_	
151-11	31564-31577	reverse-coded	_	
151-12	31577-31578	.	_	

#Text=Functional neuroimaging data acquisition and analysis
#Text=The task used to probe neural activity during reward anticipation was a modified version of the MID task, which required subjects to respond after seeing a cue to a briefly presented target by pressing one of two buttons as rapidly as possible to indicate whether the target appeared on the left or the right side of the screen (Fig. 6).
152-1	31579-31589	Functional	_	
152-2	31590-31602	neuroimaging	_	
152-3	31603-31607	data	_	
152-4	31608-31619	acquisition	_	
152-5	31620-31623	and	_	
152-6	31624-31632	analysis	_	
152-7	31633-31636	The	_	
152-8	31637-31641	task	_	
152-9	31642-31646	used	_	
152-10	31647-31649	to	_	
152-11	31650-31655	probe	_	
152-12	31656-31662	neural	_	
152-13	31663-31671	activity	_	
152-14	31672-31678	during	_	
152-15	31679-31685	reward	_	
152-16	31686-31698	anticipation	_	
152-17	31699-31702	was	_	
152-18	31703-31704	a	_	
152-19	31705-31713	modified	_	
152-20	31714-31721	version	_	
152-21	31722-31724	of	_	
152-22	31725-31728	the	_	
152-23	31729-31732	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[13]	
152-24	31733-31737	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[13]	
152-25	31737-31738	,	_	
152-26	31739-31744	which	_	
152-27	31745-31753	required	_	
152-28	31754-31762	subjects	_	
152-29	31763-31765	to	_	
152-30	31766-31773	respond	_	
152-31	31774-31779	after	_	
152-32	31780-31786	seeing	_	
152-33	31787-31788	a	_	
152-34	31789-31792	cue	_	
152-35	31793-31795	to	_	
152-36	31796-31797	a	_	
152-37	31798-31805	briefly	_	
152-38	31806-31815	presented	_	
152-39	31816-31822	target	_	
152-40	31823-31825	by	_	
152-41	31826-31834	pressing	_	
152-42	31835-31838	one	_	
152-43	31839-31841	of	_	
152-44	31842-31845	two	_	
152-45	31846-31853	buttons	_	
152-46	31854-31856	as	_	
152-47	31857-31864	rapidly	_	
152-48	31865-31867	as	_	
152-49	31868-31876	possible	_	
152-50	31877-31879	to	_	
152-51	31880-31888	indicate	_	
152-52	31889-31896	whether	_	
152-53	31897-31900	the	_	
152-54	31901-31907	target	_	
152-55	31908-31916	appeared	_	
152-56	31917-31919	on	_	
152-57	31920-31923	the	_	
152-58	31924-31928	left	_	
152-59	31929-31931	or	_	
152-60	31932-31935	the	_	
152-61	31936-31941	right	_	
152-62	31942-31946	side	_	
152-63	31947-31949	of	_	
152-64	31950-31953	the	_	
152-65	31954-31960	screen	_	
152-66	31961-31962	(	_	
152-67	31962-31965	Fig	_	
152-68	31965-31966	.	_	
152-69	31967-31968	6	_	
152-70	31968-31969	)	_	
152-71	31969-31970	.	_	

#Text=If subjects responded while the target was on the screen, they received points, but if they responded before or after the target's disappearance, they received no points.
153-1	31971-31973	If	_	
153-2	31974-31982	subjects	_	
153-3	31983-31992	responded	_	
153-4	31993-31998	while	_	
153-5	31999-32002	the	_	
153-6	32003-32009	target	_	
153-7	32010-32013	was	_	
153-8	32014-32016	on	_	
153-9	32017-32020	the	_	
153-10	32021-32027	screen	_	
153-11	32027-32028	,	_	
153-12	32029-32033	they	_	
153-13	32034-32042	received	_	
153-14	32043-32049	points	_	
153-15	32049-32050	,	_	
153-16	32051-32054	but	_	
153-17	32055-32057	if	_	
153-18	32058-32062	they	_	
153-19	32063-32072	responded	_	
153-20	32073-32079	before	_	
153-21	32080-32082	or	_	
153-22	32083-32088	after	_	
153-23	32089-32092	the	_	
153-24	32093-32101	target's	_	
153-25	32102-32115	disappearance	_	
153-26	32115-32116	,	_	
153-27	32117-32121	they	_	
153-28	32122-32130	received	_	
153-29	32131-32133	no	_	
153-30	32134-32140	points	_	
153-31	32140-32141	.	_	

#Text=Cues signalled each trial's onset, and reliably indicated the position of the target as well as the number of points to be awarded for a successful response.
154-1	32142-32146	Cues	_	
154-2	32147-32156	signalled	_	
154-3	32157-32161	each	_	
154-4	32162-32169	trial's	_	
154-5	32170-32175	onset	_	
154-6	32175-32176	,	_	
154-7	32177-32180	and	_	
154-8	32181-32189	reliably	_	
154-9	32190-32199	indicated	_	
154-10	32200-32203	the	_	
154-11	32204-32212	position	_	
154-12	32213-32215	of	_	
154-13	32216-32219	the	_	
154-14	32220-32226	target	_	
154-15	32227-32229	as	_	
154-16	32230-32234	well	_	
154-17	32235-32237	as	_	
154-18	32238-32241	the	_	
154-19	32242-32248	number	_	
154-20	32249-32251	of	_	
154-21	32252-32258	points	_	
154-22	32259-32261	to	_	
154-23	32262-32264	be	_	
154-24	32265-32272	awarded	_	
154-25	32273-32276	for	_	
154-26	32277-32278	a	_	
154-27	32279-32289	successful	_	
154-28	32290-32298	response	_	
154-29	32298-32299	.	_	

#Text=Cues took one of three forms: a triangle indicated no points (‘No Gain'), a circle with one line indicated 2 points (‘Small Gain') and a circle with three lines indicated 10 points (‘Large Gain') at stake.
155-1	32300-32304	Cues	_	
155-2	32305-32309	took	_	
155-3	32310-32313	one	_	
155-4	32314-32316	of	_	
155-5	32317-32322	three	_	
155-6	32323-32328	forms	_	
155-7	32328-32329	:	_	
155-8	32330-32331	a	_	
155-9	32332-32340	triangle	_	
155-10	32341-32350	indicated	_	
155-11	32351-32353	no	_	
155-12	32354-32360	points	_	
155-13	32361-32362	(	_	
155-14	32362-32363	‘	_	
155-15	32363-32365	No	_	
155-16	32366-32370	Gain	_	
155-17	32370-32371	'	_	
155-18	32371-32372	)	_	
155-19	32372-32373	,	_	
155-20	32374-32375	a	_	
155-21	32376-32382	circle	_	
155-22	32383-32387	with	_	
155-23	32388-32391	one	_	
155-24	32392-32396	line	_	
155-25	32397-32406	indicated	_	
155-26	32407-32408	2	_	
155-27	32409-32415	points	_	
155-28	32416-32417	(	_	
155-29	32417-32418	‘	_	
155-30	32418-32423	Small	_	
155-31	32424-32428	Gain	_	
155-32	32428-32429	'	_	
155-33	32429-32430	)	_	
155-34	32431-32434	and	_	
155-35	32435-32436	a	_	
155-36	32437-32443	circle	_	
155-37	32444-32448	with	_	
155-38	32449-32454	three	_	
155-39	32455-32460	lines	_	
155-40	32461-32470	indicated	_	
155-41	32471-32473	10	_	
155-42	32474-32480	points	_	
155-43	32481-32482	(	_	
155-44	32482-32483	‘	_	
155-45	32483-32488	Large	_	
155-46	32489-32493	Gain	_	
155-47	32493-32494	'	_	
155-48	32494-32495	)	_	
155-49	32496-32498	at	_	
155-50	32499-32504	stake	_	
155-51	32504-32505	.	_	

#Text=Behavioural data from this modified MID task included the proportion of hits on gain trials and hit reaction times.
156-1	32506-32517	Behavioural	_	
156-2	32518-32522	data	_	
156-3	32523-32527	from	_	
156-4	32528-32532	this	_	
156-5	32533-32541	modified	_	
156-6	32542-32545	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[14]	
156-7	32546-32550	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[14]	
156-8	32551-32559	included	_	
156-9	32560-32563	the	_	
156-10	32564-32574	proportion	_	
156-11	32575-32577	of	_	
156-12	32578-32582	hits	_	
156-13	32583-32585	on	_	
156-14	32586-32590	gain	_	
156-15	32591-32597	trials	_	
156-16	32598-32601	and	_	
156-17	32602-32605	hit	_	
156-18	32606-32614	reaction	_	
156-19	32615-32620	times	_	
156-20	32620-32621	.	_	

#Text=At all sites, scanning was performed with 3 T whole-body magnetic resonance scanners produced by a variety of manufacturers (Siemens, Philips, General Electric and Bruker).
157-1	32622-32624	At	_	
157-2	32625-32628	all	_	
157-3	32629-32634	sites	_	
157-4	32634-32635	,	_	
157-5	32636-32644	scanning	_	
157-6	32645-32648	was	_	
157-7	32649-32658	performed	_	
157-8	32659-32663	with	_	
157-9	32664-32665	3	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[15]	
157-10	32666-32667	T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[15]	
157-11	32668-32678	whole-body	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[15]	
157-12	32679-32687	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[15]	
157-13	32688-32697	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[15]	
157-14	32698-32706	scanners	_	
157-15	32707-32715	produced	_	
157-16	32716-32718	by	_	
157-17	32719-32720	a	_	
157-18	32721-32728	variety	_	
157-19	32729-32731	of	_	
157-20	32732-32745	manufacturers	_	
157-21	32746-32747	(	_	
157-22	32747-32754	Siemens	_	
157-23	32754-32755	,	_	
157-24	32756-32763	Philips	_	
157-25	32763-32764	,	_	
157-26	32765-32772	General	_	
157-27	32773-32781	Electric	_	
157-28	32782-32785	and	_	
157-29	32786-32792	Bruker	_	
157-30	32792-32793	)	_	
157-31	32793-32794	.	_	

#Text=For functional imaging, we acquired 300 volumes with 40 slices in descending order (2.4 mm slice thickness with 1 mm gap) using a gradient-echo T2*-weighted pulse sequence (EPI).
158-1	32795-32798	For	_	
158-2	32799-32809	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[16]	
158-3	32810-32817	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[16]	
158-4	32817-32818	,	_	
158-5	32819-32821	we	_	
158-6	32822-32830	acquired	_	
158-7	32831-32834	300	_	
158-8	32835-32842	volumes	_	
158-9	32843-32847	with	_	
158-10	32848-32850	40	_	
158-11	32851-32857	slices	_	
158-12	32858-32860	in	_	
158-13	32861-32871	descending	_	
158-14	32872-32877	order	_	
158-15	32878-32879	(	_	
158-16	32879-32882	2.4	_	
158-17	32883-32885	mm	_	
158-18	32886-32891	slice	_	
158-19	32892-32901	thickness	_	
158-20	32902-32906	with	_	
158-21	32907-32908	1	_	
158-22	32909-32911	mm	_	
158-23	32912-32915	gap	_	
158-24	32915-32916	)	_	
158-25	32917-32922	using	_	
158-26	32923-32924	a	_	
158-27	32925-32938	gradient-echo	_	
158-28	32939-32941	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[17]	
158-29	32941-32942	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[17]	
158-30	32942-32943	-	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[17]	
158-31	32943-32951	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[17]	
158-32	32952-32957	pulse	_	
158-33	32958-32966	sequence	_	
158-34	32967-32968	(	_	
158-35	32968-32971	EPI	_	
158-36	32971-32972	)	_	
158-37	32972-32973	.	_	

#Text=The time to repetition for volume acquisition was set to 2,200 ms and the time to echo to 30 ms.
159-1	32974-32977	The	_	
159-2	32978-32982	time	_	
159-3	32983-32985	to	_	
159-4	32986-32996	repetition	_	
159-5	32997-33000	for	_	
159-6	33001-33007	volume	_	
159-7	33008-33019	acquisition	_	
159-8	33020-33023	was	_	
159-9	33024-33027	set	_	
159-10	33028-33030	to	_	
159-11	33031-33036	2,200	_	
159-12	33037-33039	ms	_	
159-13	33040-33043	and	_	
159-14	33044-33047	the	_	
159-15	33048-33052	time	_	
159-16	33053-33055	to	_	
159-17	33056-33060	echo	_	
159-18	33061-33063	to	_	
159-19	33064-33066	30	_	
159-20	33067-33069	ms	_	
159-21	33069-33070	.	_	

#Text=In-plane resolution was 64 × 64 with a field of view of 220 × 220 mm.
160-1	33071-33079	In-plane	_	
160-2	33080-33090	resolution	_	
160-3	33091-33094	was	_	
160-4	33095-33097	64	_	
160-5	33098-33099	×	_	
160-6	33100-33102	64	_	
160-7	33103-33107	with	_	
160-8	33108-33109	a	_	
160-9	33110-33115	field	_	
160-10	33116-33118	of	_	
160-11	33119-33123	view	_	
160-12	33124-33126	of	_	
160-13	33127-33130	220	_	
160-14	33131-33132	×	_	
160-15	33133-33136	220	_	
160-16	33137-33139	mm	_	
160-17	33139-33140	.	_	

#Text=The plane of acquisition was tilted to parallel the anterior–posterior commissure line.
161-1	33141-33144	The	_	
161-2	33145-33150	plane	_	
161-3	33151-33153	of	_	
161-4	33154-33165	acquisition	_	
161-5	33166-33169	was	_	
161-6	33170-33176	tilted	_	
161-7	33177-33179	to	_	
161-8	33180-33188	parallel	_	
161-9	33189-33192	the	_	
161-10	33193-33211	anterior–posterior	_	
161-11	33212-33222	commissure	_	
161-12	33223-33227	line	_	
161-13	33227-33228	.	_	

#Text=For anatomical reference, a three-dimensional magnetization prepared gradient-echo sequence of the whole brain was obtained with time to repetition of 6.8 ms and a time to echo of 3.2 ms.
162-1	33229-33232	For	_	
162-2	33233-33243	anatomical	_	
162-3	33244-33253	reference	_	
162-4	33253-33254	,	_	
162-5	33255-33256	a	_	
162-6	33257-33274	three-dimensional	_	
162-7	33275-33288	magnetization	_	
162-8	33289-33297	prepared	_	
162-9	33298-33311	gradient-echo	_	
162-10	33312-33320	sequence	_	
162-11	33321-33323	of	_	
162-12	33324-33327	the	_	
162-13	33328-33333	whole	_	
162-14	33334-33339	brain	_	
162-15	33340-33343	was	_	
162-16	33344-33352	obtained	_	
162-17	33353-33357	with	_	
162-18	33358-33362	time	_	
162-19	33363-33365	to	_	
162-20	33366-33376	repetition	_	
162-21	33377-33379	of	_	
162-22	33380-33383	6.8	_	
162-23	33384-33386	ms	_	
162-24	33387-33390	and	_	
162-25	33391-33392	a	_	
162-26	33393-33397	time	_	
162-27	33398-33400	to	_	
162-28	33401-33405	echo	_	
162-29	33406-33408	of	_	
162-30	33409-33412	3.2	_	
162-31	33413-33415	ms	_	
162-32	33415-33416	.	_	

#Text=These imaging parameters were chosen to ensure comparability of data across different scanners.
163-1	33417-33422	These	_	
163-2	33423-33430	imaging	_	
163-3	33431-33441	parameters	_	
163-4	33442-33446	were	_	
163-5	33447-33453	chosen	_	
163-6	33454-33456	to	_	
163-7	33457-33463	ensure	_	
163-8	33464-33477	comparability	_	
163-9	33478-33480	of	_	
163-10	33481-33485	data	_	
163-11	33486-33492	across	_	
163-12	33493-33502	different	_	
163-13	33503-33511	scanners	_	
163-14	33511-33512	.	_	

#Text=Further details of the image acquisition protocols and quality control procedures have been described previously, including an extensive period of standardization across magnetic resonance scanners.
164-1	33513-33520	Further	_	
164-2	33521-33528	details	_	
164-3	33529-33531	of	_	
164-4	33532-33535	the	_	
164-5	33536-33541	image	_	
164-6	33542-33553	acquisition	_	
164-7	33554-33563	protocols	_	
164-8	33564-33567	and	_	
164-9	33568-33575	quality	_	
164-10	33576-33583	control	_	
164-11	33584-33594	procedures	_	
164-12	33595-33599	have	_	
164-13	33600-33604	been	_	
164-14	33605-33614	described	_	
164-15	33615-33625	previously	_	
164-16	33625-33626	,	_	
164-17	33627-33636	including	_	
164-18	33637-33639	an	_	
164-19	33640-33649	extensive	_	
164-20	33650-33656	period	_	
164-21	33657-33659	of	_	
164-22	33660-33675	standardization	_	
164-23	33676-33682	across	_	
164-24	33683-33691	magnetic	_	
164-25	33692-33701	resonance	_	
164-26	33702-33710	scanners	_	
164-27	33710-33711	.	_	

#Text=Image preprocessing and analyses were performed with SPM8 and SPM12 software (Wellcome Trust Centre for Neuroimaging, London).
165-1	33712-33717	Image	_	
165-2	33718-33731	preprocessing	_	
165-3	33732-33735	and	_	
165-4	33736-33744	analyses	_	
165-5	33745-33749	were	_	
165-6	33750-33759	performed	_	
165-7	33760-33764	with	_	
165-8	33765-33769	SPM8	_	
165-9	33770-33773	and	_	
165-10	33774-33779	SPM12	_	
165-11	33780-33788	software	_	
165-12	33789-33790	(	_	
165-13	33790-33798	Wellcome	_	
165-14	33799-33804	Trust	_	
165-15	33805-33811	Centre	_	
165-16	33812-33815	for	_	
165-17	33816-33828	Neuroimaging	_	
165-18	33828-33829	,	_	
165-19	33830-33836	London	_	
165-20	33836-33837	)	_	
165-21	33837-33838	.	_	

#Text=For structural preprocessing, we normalized individually segmented T1-weighted scans to a template generated by the first 552 adolescents in the sample using the DARTEL toolbox as implemented in SPM8.
166-1	33839-33842	For	_	
166-2	33843-33853	structural	_	
166-3	33854-33867	preprocessing	_	
166-4	33867-33868	,	_	
166-5	33869-33871	we	_	
166-6	33872-33882	normalized	_	
166-7	33883-33895	individually	_	
166-8	33896-33905	segmented	_	
166-9	33906-33908	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[18]	
166-10	33908-33909	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[18]	
166-11	33909-33917	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[18]	
166-12	33918-33923	scans	_	
166-13	33924-33926	to	_	
166-14	33927-33928	a	_	
166-15	33929-33937	template	_	
166-16	33938-33947	generated	_	
166-17	33948-33950	by	_	
166-18	33951-33954	the	_	
166-19	33955-33960	first	_	
166-20	33961-33964	552	_	
166-21	33965-33976	adolescents	_	
166-22	33977-33979	in	_	
166-23	33980-33983	the	_	
166-24	33984-33990	sample	_	
166-25	33991-33996	using	_	
166-26	33997-34000	the	_	
166-27	34001-34007	DARTEL	_	
166-28	34008-34015	toolbox	_	
166-29	34016-34018	as	_	
166-30	34019-34030	implemented	_	
166-31	34031-34033	in	_	
166-32	34034-34038	SPM8	_	
166-33	34038-34039	.	_	

#Text=For fMRI whole-brain analyses, single-subject echo-planar images were coregistered with their associated T1-weighted structural images.
167-1	34040-34043	For	_	
167-2	34044-34048	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
167-3	34049-34060	whole-brain	_	
167-4	34061-34069	analyses	_	
167-5	34069-34070	,	_	
167-6	34071-34085	single-subject	_	
167-7	34086-34097	echo-planar	_	
167-8	34098-34104	images	_	
167-9	34105-34109	were	_	
167-10	34110-34122	coregistered	_	
167-11	34123-34127	with	_	
167-12	34128-34133	their	_	
167-13	34134-34144	associated	_	
167-14	34145-34147	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[19]	
167-15	34147-34148	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[19]	
167-16	34148-34156	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[19]	
167-17	34157-34167	structural	_	
167-18	34168-34174	images	_	
167-19	34174-34175	.	_	

#Text=Functional images were then realigned and resliced to the first volume.
168-1	34176-34186	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[20]	
168-2	34187-34193	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[20]	
168-3	34194-34198	were	_	
168-4	34199-34203	then	_	
168-5	34204-34213	realigned	_	
168-6	34214-34217	and	_	
168-7	34218-34226	resliced	_	
168-8	34227-34229	to	_	
168-9	34230-34233	the	_	
168-10	34234-34239	first	_	
168-11	34240-34246	volume	_	
168-12	34246-34247	.	_	

#Text=Single-subject statistical models analysed the resliced data using the following regressors: (1) anticipation of large gain; (2) anticipation of small gain; (3) anticipation of no gain; (4) feedback indicating large gain; (5) feedback indicating small gain; (6) and feedback indicating no gain.
169-1	34248-34262	Single-subject	_	
169-2	34263-34274	statistical	_	
169-3	34275-34281	models	_	
169-4	34282-34290	analysed	_	
169-5	34291-34294	the	_	
169-6	34295-34303	resliced	_	
169-7	34304-34308	data	_	
169-8	34309-34314	using	_	
169-9	34315-34318	the	_	
169-10	34319-34328	following	_	
169-11	34329-34339	regressors	_	
169-12	34339-34340	:	_	
169-13	34341-34342	(	_	
169-14	34342-34343	1	_	
169-15	34343-34344	)	_	
169-16	34345-34357	anticipation	_	
169-17	34358-34360	of	_	
169-18	34361-34366	large	_	
169-19	34367-34371	gain	_	
169-20	34371-34372	;	_	
169-21	34373-34374	(	_	
169-22	34374-34375	2	_	
169-23	34375-34376	)	_	
169-24	34377-34389	anticipation	_	
169-25	34390-34392	of	_	
169-26	34393-34398	small	_	
169-27	34399-34403	gain	_	
169-28	34403-34404	;	_	
169-29	34405-34406	(	_	
169-30	34406-34407	3	_	
169-31	34407-34408	)	_	
169-32	34409-34421	anticipation	_	
169-33	34422-34424	of	_	
169-34	34425-34427	no	_	
169-35	34428-34432	gain	_	
169-36	34432-34433	;	_	
169-37	34434-34435	(	_	
169-38	34435-34436	4	_	
169-39	34436-34437	)	_	
169-40	34438-34446	feedback	_	
169-41	34447-34457	indicating	_	
169-42	34458-34463	large	_	
169-43	34464-34468	gain	_	
169-44	34468-34469	;	_	
169-45	34470-34471	(	_	
169-46	34471-34472	5	_	
169-47	34472-34473	)	_	
169-48	34474-34482	feedback	_	
169-49	34483-34493	indicating	_	
169-50	34494-34499	small	_	
169-51	34500-34504	gain	_	
169-52	34504-34505	;	_	
169-53	34506-34507	(	_	
169-54	34507-34508	6	_	
169-55	34508-34509	)	_	
169-56	34510-34513	and	_	
169-57	34514-34522	feedback	_	
169-58	34523-34533	indicating	_	
169-59	34534-34536	no	_	
169-60	34537-34541	gain	_	
169-61	34541-34542	.	_	

#Text=Each regressor was defined separately for successful (that is, ‘hits') as well as unsuccessful (that is, ‘misses') response trials.
170-1	34543-34547	Each	_	
170-2	34548-34557	regressor	_	
170-3	34558-34561	was	_	
170-4	34562-34569	defined	_	
170-5	34570-34580	separately	_	
170-6	34581-34584	for	_	
170-7	34585-34595	successful	_	
170-8	34596-34597	(	_	
170-9	34597-34601	that	_	
170-10	34602-34604	is	_	
170-11	34604-34605	,	_	
170-12	34606-34607	‘	_	
170-13	34607-34611	hits	_	
170-14	34611-34612	'	_	
170-15	34612-34613	)	_	
170-16	34614-34616	as	_	
170-17	34617-34621	well	_	
170-18	34622-34624	as	_	
170-19	34625-34637	unsuccessful	_	
170-20	34638-34639	(	_	
170-21	34639-34643	that	_	
170-22	34644-34646	is	_	
170-23	34646-34647	,	_	
170-24	34648-34649	‘	_	
170-25	34649-34655	misses	_	
170-26	34655-34656	'	_	
170-27	34656-34657	)	_	
170-28	34658-34666	response	_	
170-29	34667-34673	trials	_	
170-30	34673-34674	.	_	

#Text=Thus, each model included a total of 12 orthogonal regressors.
171-1	34675-34679	Thus	_	
171-2	34679-34680	,	_	
171-3	34681-34685	each	_	
171-4	34686-34691	model	_	
171-5	34692-34700	included	_	
171-6	34701-34702	a	_	
171-7	34703-34708	total	_	
171-8	34709-34711	of	_	
171-9	34712-34714	12	_	
171-10	34715-34725	orthogonal	_	
171-11	34726-34736	regressors	_	
171-12	34736-34737	.	_	

#Text=Trials in which subjects failed to respond were modelled similarly but separately as error trials.
172-1	34738-34744	Trials	_	
172-2	34745-34747	in	_	
172-3	34748-34753	which	_	
172-4	34754-34762	subjects	_	
172-5	34763-34769	failed	_	
172-6	34770-34772	to	_	
172-7	34773-34780	respond	_	
172-8	34781-34785	were	_	
172-9	34786-34794	modelled	_	
172-10	34795-34804	similarly	_	
172-11	34805-34808	but	_	
172-12	34809-34819	separately	_	
172-13	34820-34822	as	_	
172-14	34823-34828	error	_	
172-15	34829-34835	trials	_	
172-16	34835-34836	.	_	

#Text=Rigid body movement parameters from the realignment procedure were included as six additional covariates.
173-1	34837-34842	Rigid	_	
173-2	34843-34847	body	_	
173-3	34848-34856	movement	_	
173-4	34857-34867	parameters	_	
173-5	34868-34872	from	_	
173-6	34873-34876	the	_	
173-7	34877-34888	realignment	_	
173-8	34889-34898	procedure	_	
173-9	34899-34903	were	_	
173-10	34904-34912	included	_	
173-11	34913-34915	as	_	
173-12	34916-34919	six	_	
173-13	34920-34930	additional	_	
173-14	34931-34941	covariates	_	
173-15	34941-34942	.	_	

#Text=Next, contrast images of the parameter estimates were created for each subject.
174-1	34943-34947	Next	_	
174-2	34947-34948	,	_	
174-3	34949-34957	contrast	_	
174-4	34958-34964	images	_	
174-5	34965-34967	of	_	
174-6	34968-34971	the	_	
174-7	34972-34981	parameter	_	
174-8	34982-34991	estimates	_	
174-9	34992-34996	were	_	
174-10	34997-35004	created	_	
174-11	35005-35008	for	_	
174-12	35009-35013	each	_	
174-13	35014-35021	subject	_	
174-14	35021-35022	.	_	

#Text=The present analyses focused on the gain anticipation phase.
175-1	35023-35026	The	_	
175-2	35027-35034	present	_	
175-3	35035-35043	analyses	_	
175-4	35044-35051	focused	_	
175-5	35052-35054	on	_	
175-6	35055-35058	the	_	
175-7	35059-35063	gain	_	
175-8	35064-35076	anticipation	_	
175-9	35077-35082	phase	_	
175-10	35082-35083	.	_	

#Text=Analyses specifically contrasted neural responses during anticipation of large versus small gain, since motor responses did not differ across incentivized conditions between groups (but were slightly lower in vulnerable subjects for no gain trials; Table 1).
176-1	35084-35092	Analyses	_	
176-2	35093-35105	specifically	_	
176-3	35106-35116	contrasted	_	
176-4	35117-35123	neural	_	
176-5	35124-35133	responses	_	
176-6	35134-35140	during	_	
176-7	35141-35153	anticipation	_	
176-8	35154-35156	of	_	
176-9	35157-35162	large	_	
176-10	35163-35169	versus	_	
176-11	35170-35175	small	_	
176-12	35176-35180	gain	_	
176-13	35180-35181	,	_	
176-14	35182-35187	since	_	
176-15	35188-35193	motor	_	
176-16	35194-35203	responses	_	
176-17	35204-35207	did	_	
176-18	35208-35211	not	_	
176-19	35212-35218	differ	_	
176-20	35219-35225	across	_	
176-21	35226-35238	incentivized	_	
176-22	35239-35249	conditions	_	
176-23	35250-35257	between	_	
176-24	35258-35264	groups	_	
176-25	35265-35266	(	_	
176-26	35266-35269	but	_	
176-27	35270-35274	were	_	
176-28	35275-35283	slightly	_	
176-29	35284-35289	lower	_	
176-30	35290-35292	in	_	
176-31	35293-35303	vulnerable	_	
176-32	35304-35312	subjects	_	
176-33	35313-35316	for	_	
176-34	35317-35319	no	_	
176-35	35320-35324	gain	_	
176-36	35325-35331	trials	_	
176-37	35331-35332	;	_	
176-38	35333-35338	Table	_	
176-39	35339-35340	1	_	
176-40	35340-35341	)	_	
176-41	35341-35342	.	_	

#Text=Single-subject contrast images were created by applying the DARTEL deformations to the contrast images, which were subsequently smoothed with a Gaussian kernel of 8 mm full width at half maximum.
177-1	35343-35357	Single-subject	_	
177-2	35358-35366	contrast	_	
177-3	35367-35373	images	_	
177-4	35374-35378	were	_	
177-5	35379-35386	created	_	
177-6	35387-35389	by	_	
177-7	35390-35398	applying	_	
177-8	35399-35402	the	_	
177-9	35403-35409	DARTEL	_	
177-10	35410-35422	deformations	_	
177-11	35423-35425	to	_	
177-12	35426-35429	the	_	
177-13	35430-35438	contrast	_	
177-14	35439-35445	images	_	
177-15	35445-35446	,	_	
177-16	35447-35452	which	_	
177-17	35453-35457	were	_	
177-18	35458-35470	subsequently	_	
177-19	35471-35479	smoothed	_	
177-20	35480-35484	with	_	
177-21	35485-35486	a	_	
177-22	35487-35495	Gaussian	_	
177-23	35496-35502	kernel	_	
177-24	35503-35505	of	_	
177-25	35506-35507	8	_	
177-26	35508-35510	mm	_	
177-27	35511-35515	full	_	
177-28	35516-35521	width	_	
177-29	35522-35524	at	_	
177-30	35525-35529	half	_	
177-31	35530-35537	maximum	_	
177-32	35537-35538	.	_	

#Text=Normalized and smoothed single-subject contrast images were then entered into a second-level random-effects analysis (two-sample t-test contrasting PDU subjects versus controls).
178-1	35539-35549	Normalized	_	
178-2	35550-35553	and	_	
178-3	35554-35562	smoothed	_	
178-4	35563-35577	single-subject	_	
178-5	35578-35586	contrast	_	
178-6	35587-35593	images	_	
178-7	35594-35598	were	_	
178-8	35599-35603	then	_	
178-9	35604-35611	entered	_	
178-10	35612-35616	into	_	
178-11	35617-35618	a	_	
178-12	35619-35631	second-level	_	
178-13	35632-35646	random-effects	_	
178-14	35647-35655	analysis	_	
178-15	35656-35657	(	_	
178-16	35657-35667	two-sample	_	
178-17	35668-35674	t-test	_	
178-18	35675-35686	contrasting	_	
178-19	35687-35690	PDU	_	
178-20	35691-35699	subjects	_	
178-21	35700-35706	versus	_	
178-22	35707-35715	controls	_	
178-23	35715-35716	)	_	
178-24	35716-35717	.	_	

#Text=Although both groups were matched for gender, pubertal status, intelligence estimate, ESPAD composite score, novelty-seeking score and scanning site at the first assessment, we included those variables as covariates to account for residual variance between and within groups.
179-1	35718-35726	Although	_	
179-2	35727-35731	both	_	
179-3	35732-35738	groups	_	
179-4	35739-35743	were	_	
179-5	35744-35751	matched	_	
179-6	35752-35755	for	_	
179-7	35756-35762	gender	_	
179-8	35762-35763	,	_	
179-9	35764-35772	pubertal	_	
179-10	35773-35779	status	_	
179-11	35779-35780	,	_	
179-12	35781-35793	intelligence	_	
179-13	35794-35802	estimate	_	
179-14	35802-35803	,	_	
179-15	35804-35809	ESPAD	_	
179-16	35810-35819	composite	_	
179-17	35820-35825	score	_	
179-18	35825-35826	,	_	
179-19	35827-35842	novelty-seeking	_	
179-20	35843-35848	score	_	
179-21	35849-35852	and	_	
179-22	35853-35861	scanning	_	
179-23	35862-35866	site	_	
179-24	35867-35869	at	_	
179-25	35870-35873	the	_	
179-26	35874-35879	first	_	
179-27	35880-35890	assessment	_	
179-28	35890-35891	,	_	
179-29	35892-35894	we	_	
179-30	35895-35903	included	_	
179-31	35904-35909	those	_	
179-32	35910-35919	variables	_	
179-33	35920-35922	as	_	
179-34	35923-35933	covariates	_	
179-35	35934-35936	to	_	
179-36	35937-35944	account	_	
179-37	35945-35948	for	_	
179-38	35949-35957	residual	_	
179-39	35958-35966	variance	_	
179-40	35967-35974	between	_	
179-41	35975-35978	and	_	
179-42	35979-35985	within	_	
179-43	35986-35992	groups	_	
179-44	35992-35993	.	_	

#Text=For whole-brain analyses, which were primarily intended to verify main effects of the neuroimaging task across groups and group differences in predicted regions, the threshold was set to P<0.05, corrected for multiple comparisons.
180-1	35994-35997	For	_	
180-2	35998-36009	whole-brain	_	
180-3	36010-36018	analyses	_	
180-4	36018-36019	,	_	
180-5	36020-36025	which	_	
180-6	36026-36030	were	_	
180-7	36031-36040	primarily	_	
180-8	36041-36049	intended	_	
180-9	36050-36052	to	_	
180-10	36053-36059	verify	_	
180-11	36060-36064	main	_	
180-12	36065-36072	effects	_	
180-13	36073-36075	of	_	
180-14	36076-36079	the	_	
180-15	36080-36092	neuroimaging	_	
180-16	36093-36097	task	_	
180-17	36098-36104	across	_	
180-18	36105-36111	groups	_	
180-19	36112-36115	and	_	
180-20	36116-36121	group	_	
180-21	36122-36133	differences	_	
180-22	36134-36136	in	_	
180-23	36137-36146	predicted	_	
180-24	36147-36154	regions	_	
180-25	36154-36155	,	_	
180-26	36156-36159	the	_	
180-27	36160-36169	threshold	_	
180-28	36170-36173	was	_	
180-29	36174-36177	set	_	
180-30	36178-36180	to	_	
180-31	36181-36182	P	_	
180-32	36182-36183	<	_	
180-33	36183-36187	0.05	_	
180-34	36187-36188	,	_	
180-35	36189-36198	corrected	_	
180-36	36199-36202	for	_	
180-37	36203-36211	multiple	_	
180-38	36212-36223	comparisons	_	
180-39	36223-36224	.	_	

#Text=For targeted analyses that tested the critical hypotheses, bilateral ventral striatal spherical (12 mm diameter) volumes of interest (VOIs) were centred on Montreal Neurological Institute coordinates ±14, 8, –8 (ref.), as documented in previous research on reward anticipation.
181-1	36225-36228	For	_	
181-2	36229-36237	targeted	_	
181-3	36238-36246	analyses	_	
181-4	36247-36251	that	_	
181-5	36252-36258	tested	_	
181-6	36259-36262	the	_	
181-7	36263-36271	critical	_	
181-8	36272-36282	hypotheses	_	
181-9	36282-36283	,	_	
181-10	36284-36293	bilateral	_	
181-11	36294-36301	ventral	_	
181-12	36302-36310	striatal	_	
181-13	36311-36320	spherical	_	
181-14	36321-36322	(	_	
181-15	36322-36324	12	_	
181-16	36325-36327	mm	_	
181-17	36328-36336	diameter	_	
181-18	36336-36337	)	_	
181-19	36338-36345	volumes	_	
181-20	36346-36348	of	_	
181-21	36349-36357	interest	_	
181-22	36358-36359	(	_	
181-23	36359-36363	VOIs	_	
181-24	36363-36364	)	_	
181-25	36365-36369	were	_	
181-26	36370-36377	centred	_	
181-27	36378-36380	on	_	
181-28	36381-36389	Montreal	_	
181-29	36390-36402	Neurological	_	
181-30	36403-36412	Institute	_	
181-31	36413-36424	coordinates	_	
181-32	36425-36426	±	_	
181-33	36426-36428	14	_	
181-34	36428-36429	,	_	
181-35	36430-36431	8	_	
181-36	36431-36432	,	_	
181-37	36433-36434	–	_	
181-38	36434-36435	8	_	
181-39	36436-36437	(	_	
181-40	36437-36440	ref	_	
181-41	36440-36441	.	_	
181-42	36441-36442	)	_	
181-43	36442-36443	,	_	
181-44	36444-36446	as	_	
181-45	36447-36457	documented	_	
181-46	36458-36460	in	_	
181-47	36461-36469	previous	_	
181-48	36470-36478	research	_	
181-49	36479-36481	on	_	
181-50	36482-36488	reward	_	
181-51	36489-36501	anticipation	_	
181-52	36501-36502	.	_	

#Text=Similarly, bilateral midbrain spherical (12 mm diameter) VOIs were centred on coordinates ±9, –15, –15 (ref.), as documented in previous research on reward anticipation.
182-1	36503-36512	Similarly	_	
182-2	36512-36513	,	_	
182-3	36514-36523	bilateral	_	
182-4	36524-36532	midbrain	_	
182-5	36533-36542	spherical	_	
182-6	36543-36544	(	_	
182-7	36544-36546	12	_	
182-8	36547-36549	mm	_	
182-9	36550-36558	diameter	_	
182-10	36558-36559	)	_	
182-11	36560-36564	VOIs	_	
182-12	36565-36569	were	_	
182-13	36570-36577	centred	_	
182-14	36578-36580	on	_	
182-15	36581-36592	coordinates	_	
182-16	36593-36594	±	_	
182-17	36594-36595	9	_	
182-18	36595-36596	,	_	
182-19	36597-36598	–	_	
182-20	36598-36600	15	_	
182-21	36600-36601	,	_	
182-22	36602-36603	–	_	
182-23	36603-36605	15	_	
182-24	36606-36607	(	_	
182-25	36607-36610	ref	_	
182-26	36610-36611	.	_	
182-27	36611-36612	)	_	
182-28	36612-36613	,	_	
182-29	36614-36616	as	_	
182-30	36617-36627	documented	_	
182-31	36628-36630	in	_	
182-32	36631-36639	previous	_	
182-33	36640-36648	research	_	
182-34	36649-36651	on	_	
182-35	36652-36658	reward	_	
182-36	36659-36671	anticipation	_	
182-37	36671-36672	.	_	

#Text=Bilateral dorsolateral PFC spherical (40 mm diameter) VOIs were centred on coordinates ±35, 36, 32 (ref.), based on previous research on executive control.
183-1	36673-36682	Bilateral	_	
183-2	36683-36695	dorsolateral	_	
183-3	36696-36699	PFC	_	
183-4	36700-36709	spherical	_	
183-5	36710-36711	(	_	
183-6	36711-36713	40	_	
183-7	36714-36716	mm	_	
183-8	36717-36725	diameter	_	
183-9	36725-36726	)	_	
183-10	36727-36731	VOIs	_	
183-11	36732-36736	were	_	
183-12	36737-36744	centred	_	
183-13	36745-36747	on	_	
183-14	36748-36759	coordinates	_	
183-15	36760-36761	±	_	
183-16	36761-36763	35	_	
183-17	36763-36764	,	_	
183-18	36765-36767	36	_	
183-19	36767-36768	,	_	
183-20	36769-36771	32	_	
183-21	36772-36773	(	_	
183-22	36773-36776	ref	_	
183-23	36776-36777	.	_	
183-24	36777-36778	)	_	
183-25	36778-36779	,	_	
183-26	36780-36785	based	_	
183-27	36786-36788	on	_	
183-28	36789-36797	previous	_	
183-29	36798-36806	research	_	
183-30	36807-36809	on	_	
183-31	36810-36819	executive	_	
183-32	36820-36827	control	_	
183-33	36827-36828	.	_	

#Text=Tests for associations of activity in these VOIs at age 14 with eventual PDU versus healthy status at age 16 were Bonferroni-corrected for multiple comparisons (P<0.05/6=P<0.008).
184-1	36829-36834	Tests	_	
184-2	36835-36838	for	_	
184-3	36839-36851	associations	_	
184-4	36852-36854	of	_	
184-5	36855-36863	activity	_	
184-6	36864-36866	in	_	
184-7	36867-36872	these	_	
184-8	36873-36877	VOIs	_	
184-9	36878-36880	at	_	
184-10	36881-36884	age	_	
184-11	36885-36887	14	_	
184-12	36888-36892	with	_	
184-13	36893-36901	eventual	_	
184-14	36902-36905	PDU	_	
184-15	36906-36912	versus	_	
184-16	36913-36920	healthy	_	
184-17	36921-36927	status	_	
184-18	36928-36930	at	_	
184-19	36931-36934	age	_	
184-20	36935-36937	16	_	
184-21	36938-36942	were	_	
184-22	36943-36963	Bonferroni-corrected	_	
184-23	36964-36967	for	_	
184-24	36968-36976	multiple	_	
184-25	36977-36988	comparisons	_	
184-26	36989-36990	(	_	
184-27	36990-36991	P	_	
184-28	36991-36992	<	_	
184-29	36992-36996	0.05	_	
184-30	36996-36997	/	_	
184-31	36997-36998	6	_	
184-32	36998-36999	=	_	
184-33	36999-37000	P	_	
184-34	37000-37001	<	_	
184-35	37001-37006	0.008	_	
184-36	37006-37007	)	_	
184-37	37007-37008	.	_	

#Text=In figures, results are displayed at a threshold of P<0.005 uncorrected with clusters including at least 10 contiguous voxels and projected onto the mean structural scan of all subjects, but these VOIs are superimposed for visualization purposes (Figs 2, 3, 4).
185-1	37009-37011	In	_	
185-2	37012-37019	figures	_	
185-3	37019-37020	,	_	
185-4	37021-37028	results	_	
185-5	37029-37032	are	_	
185-6	37033-37042	displayed	_	
185-7	37043-37045	at	_	
185-8	37046-37047	a	_	
185-9	37048-37057	threshold	_	
185-10	37058-37060	of	_	
185-11	37061-37062	P	_	
185-12	37062-37063	<	_	
185-13	37063-37068	0.005	_	
185-14	37069-37080	uncorrected	_	
185-15	37081-37085	with	_	
185-16	37086-37094	clusters	_	
185-17	37095-37104	including	_	
185-18	37105-37107	at	_	
185-19	37108-37113	least	_	
185-20	37114-37116	10	_	
185-21	37117-37127	contiguous	_	
185-22	37128-37134	voxels	_	
185-23	37135-37138	and	_	
185-24	37139-37148	projected	_	
185-25	37149-37153	onto	_	
185-26	37154-37157	the	_	
185-27	37158-37162	mean	_	
185-28	37163-37173	structural	_	
185-29	37174-37178	scan	_	
185-30	37179-37181	of	_	
185-31	37182-37185	all	_	
185-32	37186-37194	subjects	_	
185-33	37194-37195	,	_	
185-34	37196-37199	but	_	
185-35	37200-37205	these	_	
185-36	37206-37210	VOIs	_	
185-37	37211-37214	are	_	
185-38	37215-37227	superimposed	_	
185-39	37228-37231	for	_	
185-40	37232-37245	visualization	_	
185-41	37246-37254	purposes	_	
185-42	37255-37256	(	_	
185-43	37256-37260	Figs	_	
185-44	37261-37262	2	_	
185-45	37262-37263	,	_	
185-46	37264-37265	3	_	
185-47	37265-37266	,	_	
185-48	37267-37268	4	_	
185-49	37268-37269	)	_	
185-50	37269-37270	.	_	

#Text=Since the average adolescent brain at age 14 is smaller than the adult brain, we refrained from transforming individual brains into adult MNI space.
186-1	37271-37276	Since	_	
186-2	37277-37280	the	_	
186-3	37281-37288	average	_	
186-4	37289-37299	adolescent	_	
186-5	37300-37305	brain	_	
186-6	37306-37308	at	_	
186-7	37309-37312	age	_	
186-8	37313-37315	14	_	
186-9	37316-37318	is	_	
186-10	37319-37326	smaller	_	
186-11	37327-37331	than	_	
186-12	37332-37335	the	_	
186-13	37336-37341	adult	_	
186-14	37342-37347	brain	_	
186-15	37347-37348	,	_	
186-16	37349-37351	we	_	
186-17	37352-37361	refrained	_	
186-18	37362-37366	from	_	
186-19	37367-37379	transforming	_	
186-20	37380-37390	individual	_	
186-21	37391-37397	brains	_	
186-22	37398-37402	into	_	
186-23	37403-37408	adult	_	
186-24	37409-37412	MNI	_	
186-25	37413-37418	space	_	
186-26	37418-37419	.	_	

#Text=However, since the predictions came from studies that reported data in MNI space, we estimated the parameters for linear transformation from MNI space to the space of our DARTEL template (that is, X=0.892,·XMNI=−0.008,·YMNI=+0.004,·ZMNI=+0.385; Y=0.017,·XMNI=+0.930,·YMNI=+0.025,·ZMNI=−6.799; Z=0.009,·XMNI=−0.005,·YMNI=+0.838,·ZMNI=−0.093).
187-1	37420-37427	However	_	
187-2	37427-37428	,	_	
187-3	37429-37434	since	_	
187-4	37435-37438	the	_	
187-5	37439-37450	predictions	_	
187-6	37451-37455	came	_	
187-7	37456-37460	from	_	
187-8	37461-37468	studies	_	
187-9	37469-37473	that	_	
187-10	37474-37482	reported	_	
187-11	37483-37487	data	_	
187-12	37488-37490	in	_	
187-13	37491-37494	MNI	_	
187-14	37495-37500	space	_	
187-15	37500-37501	,	_	
187-16	37502-37504	we	_	
187-17	37505-37514	estimated	_	
187-18	37515-37518	the	_	
187-19	37519-37529	parameters	_	
187-20	37530-37533	for	_	
187-21	37534-37540	linear	_	
187-22	37541-37555	transformation	_	
187-23	37556-37560	from	_	
187-24	37561-37564	MNI	_	
187-25	37565-37570	space	_	
187-26	37571-37573	to	_	
187-27	37574-37577	the	_	
187-28	37578-37583	space	_	
187-29	37584-37586	of	_	
187-30	37587-37590	our	_	
187-31	37591-37597	DARTEL	_	
187-32	37598-37606	template	_	
187-33	37607-37608	(	_	
187-34	37608-37612	that	_	
187-35	37613-37615	is	_	
187-36	37615-37616	,	_	
187-37	37617-37618	X	_	
187-38	37618-37619	=	_	
187-39	37619-37624	0.892	_	
187-40	37624-37625	,	_	
187-41	37625-37626	·	_	
187-42	37626-37630	XMNI	_	
187-43	37630-37631	=	_	
187-44	37631-37632	−	_	
187-45	37632-37637	0.008	_	
187-46	37637-37638	,	_	
187-47	37638-37639	·	_	
187-48	37639-37643	YMNI	_	
187-49	37643-37644	=	_	
187-50	37644-37645	+	_	
187-51	37645-37650	0.004	_	
187-52	37650-37651	,	_	
187-53	37651-37652	·	_	
187-54	37652-37656	ZMNI	_	
187-55	37656-37657	=	_	
187-56	37657-37658	+	_	
187-57	37658-37663	0.385	_	
187-58	37663-37664	;	_	
187-59	37665-37666	Y	_	
187-60	37666-37667	=	_	
187-61	37667-37672	0.017	_	
187-62	37672-37673	,	_	
187-63	37673-37674	·	_	
187-64	37674-37678	XMNI	_	
187-65	37678-37679	=	_	
187-66	37679-37680	+	_	
187-67	37680-37685	0.930	_	
187-68	37685-37686	,	_	
187-69	37686-37687	·	_	
187-70	37687-37691	YMNI	_	
187-71	37691-37692	=	_	
187-72	37692-37693	+	_	
187-73	37693-37698	0.025	_	
187-74	37698-37699	,	_	
187-75	37699-37700	·	_	
187-76	37700-37704	ZMNI	_	
187-77	37704-37705	=	_	
187-78	37705-37706	−	_	
187-79	37706-37711	6.799	_	
187-80	37711-37712	;	_	
187-81	37713-37714	Z	_	
187-82	37714-37715	=	_	
187-83	37715-37720	0.009	_	
187-84	37720-37721	,	_	
187-85	37721-37722	·	_	
187-86	37722-37726	XMNI	_	
187-87	37726-37727	=	_	
187-88	37727-37728	−	_	
187-89	37728-37733	0.005	_	
187-90	37733-37734	,	_	
187-91	37734-37735	·	_	
187-92	37735-37739	YMNI	_	
187-93	37739-37740	=	_	
187-94	37740-37741	+	_	
187-95	37741-37746	0.838	_	
187-96	37746-37747	,	_	
187-97	37747-37748	·	_	
187-98	37748-37752	ZMNI	_	
187-99	37752-37753	=	_	
187-100	37753-37754	−	_	
187-101	37754-37759	0.093	_	
187-102	37759-37760	)	_	
187-103	37760-37761	.	_	

#Text=Structural neuroimaging data analysis
#Text=Voxel-based morphometry analyses compared spatially normalized structural scans on a voxel-by-voxel basis.
188-1	37762-37772	Structural	_	
188-2	37773-37785	neuroimaging	_	
188-3	37786-37790	data	_	
188-4	37791-37799	analysis	_	
188-5	37800-37811	Voxel-based	_	
188-6	37812-37823	morphometry	_	
188-7	37824-37832	analyses	_	
188-8	37833-37841	compared	_	
188-9	37842-37851	spatially	_	
188-10	37852-37862	normalized	_	
188-11	37863-37873	structural	_	
188-12	37874-37879	scans	_	
188-13	37880-37882	on	_	
188-14	37883-37884	a	_	
188-15	37885-37899	voxel-by-voxel	_	
188-16	37900-37905	basis	_	
188-17	37905-37906	.	_	

#Text=Instead of directly comparing image intensity, however, structural scans were segmented into grey and white matter, smoothed, and then the grey matter partition was subjected to a voxel-by-voxel statistical test.
189-1	37907-37914	Instead	_	
189-2	37915-37917	of	_	
189-3	37918-37926	directly	_	
189-4	37927-37936	comparing	_	
189-5	37937-37942	image	_	
189-6	37943-37952	intensity	_	
189-7	37952-37953	,	_	
189-8	37954-37961	however	_	
189-9	37961-37962	,	_	
189-10	37963-37973	structural	_	
189-11	37974-37979	scans	_	
189-12	37980-37984	were	_	
189-13	37985-37994	segmented	_	
189-14	37995-37999	into	_	
189-15	38000-38004	grey	_	
189-16	38005-38008	and	_	
189-17	38009-38014	white	_	
189-18	38015-38021	matter	_	
189-19	38021-38022	,	_	
189-20	38023-38031	smoothed	_	
189-21	38031-38032	,	_	
189-22	38033-38036	and	_	
189-23	38037-38041	then	_	
189-24	38042-38045	the	_	
189-25	38046-38050	grey	_	
189-26	38051-38057	matter	_	
189-27	38058-38067	partition	_	
189-28	38068-38071	was	_	
189-29	38072-38081	subjected	_	
189-30	38082-38084	to	_	
189-31	38085-38086	a	_	
189-32	38087-38101	voxel-by-voxel	_	
189-33	38102-38113	statistical	_	
189-34	38114-38118	test	_	
189-35	38118-38119	.	_	

#Text=Thus, T1 images were segmented using the ‘new segment' routine as implemented in SPM8, then modulated and spatially normalized with DARTEL (see above).
190-1	38120-38124	Thus	_	
190-2	38124-38125	,	_	
190-3	38126-38128	T1	_	
190-4	38129-38135	images	_	
190-5	38136-38140	were	_	
190-6	38141-38150	segmented	_	
190-7	38151-38156	using	_	
190-8	38157-38160	the	_	
190-9	38161-38162	‘	_	
190-10	38162-38165	new	_	
190-11	38166-38173	segment	_	
190-12	38173-38174	'	_	
190-13	38175-38182	routine	_	
190-14	38183-38185	as	_	
190-15	38186-38197	implemented	_	
190-16	38198-38200	in	_	
190-17	38201-38205	SPM8	_	
190-18	38205-38206	,	_	
190-19	38207-38211	then	_	
190-20	38212-38221	modulated	_	
190-21	38222-38225	and	_	
190-22	38226-38235	spatially	_	
190-23	38236-38246	normalized	_	
190-24	38247-38251	with	_	
190-25	38252-38258	DARTEL	_	
190-26	38259-38260	(	_	
190-27	38260-38263	see	_	
190-28	38264-38269	above	_	
190-29	38269-38270	)	_	
190-30	38270-38271	.	_	

#Text=Resulting images were smoothed with a Gaussian kernel of 8 mm full width at half maximum.
191-1	38272-38281	Resulting	_	
191-2	38282-38288	images	_	
191-3	38289-38293	were	_	
191-4	38294-38302	smoothed	_	
191-5	38303-38307	with	_	
191-6	38308-38309	a	_	
191-7	38310-38318	Gaussian	_	
191-8	38319-38325	kernel	_	
191-9	38326-38328	of	_	
191-10	38329-38330	8	_	
191-11	38331-38333	mm	_	
191-12	38334-38338	full	_	
191-13	38339-38344	width	_	
191-14	38345-38347	at	_	
191-15	38348-38352	half	_	
191-16	38353-38360	maximum	_	
191-17	38360-38361	.	_	

#Text=Statistical analyses mirrored those applied to the fMRI contrasts (that is, two-sample t-test contrasting PDU subjects versus controls, with gender, pubertal status, intelligence quotient estimate, ESPAD score, novelty-seeking score and scanning site entered as covariates of no interest).
192-1	38362-38373	Statistical	_	
192-2	38374-38382	analyses	_	
192-3	38383-38391	mirrored	_	
192-4	38392-38397	those	_	
192-5	38398-38405	applied	_	
192-6	38406-38408	to	_	
192-7	38409-38412	the	_	
192-8	38413-38417	fMRI	_	
192-9	38418-38427	contrasts	_	
192-10	38428-38429	(	_	
192-11	38429-38433	that	_	
192-12	38434-38436	is	_	
192-13	38436-38437	,	_	
192-14	38438-38448	two-sample	_	
192-15	38449-38455	t-test	_	
192-16	38456-38467	contrasting	_	
192-17	38468-38471	PDU	_	
192-18	38472-38480	subjects	_	
192-19	38481-38487	versus	_	
192-20	38488-38496	controls	_	
192-21	38496-38497	,	_	
192-22	38498-38502	with	_	
192-23	38503-38509	gender	_	
192-24	38509-38510	,	_	
192-25	38511-38519	pubertal	_	
192-26	38520-38526	status	_	
192-27	38526-38527	,	_	
192-28	38528-38540	intelligence	_	
192-29	38541-38549	quotient	_	
192-30	38550-38558	estimate	_	
192-31	38558-38559	,	_	
192-32	38560-38565	ESPAD	_	
192-33	38566-38571	score	_	
192-34	38571-38572	,	_	
192-35	38573-38588	novelty-seeking	_	
192-36	38589-38594	score	_	
192-37	38595-38598	and	_	
192-38	38599-38607	scanning	_	
192-39	38608-38612	site	_	
192-40	38613-38620	entered	_	
192-41	38621-38623	as	_	
192-42	38624-38634	covariates	_	
192-43	38635-38637	of	_	
192-44	38638-38640	no	_	
192-45	38641-38649	interest	_	
192-46	38649-38650	)	_	
192-47	38650-38651	.	_	

#Text=Targeted analyses compared grey matter density within the same VOIs that were constructed to compare functional activity.
193-1	38652-38660	Targeted	_	
193-2	38661-38669	analyses	_	
193-3	38670-38678	compared	_	
193-4	38679-38683	grey	_	
193-5	38684-38690	matter	_	
193-6	38691-38698	density	_	
193-7	38699-38705	within	_	
193-8	38706-38709	the	_	
193-9	38710-38714	same	_	
193-10	38715-38719	VOIs	_	
193-11	38720-38724	that	_	
193-12	38725-38729	were	_	
193-13	38730-38741	constructed	_	
193-14	38742-38744	to	_	
193-15	38745-38752	compare	_	
193-16	38753-38763	functional	_	
193-17	38764-38772	activity	_	
193-18	38772-38773	.	_	

#Text=Behavioural and neural prediction of PDU
#Text=After verifying key psychometric and neural variables at age 14, these variables' relative ability to predict problematic abuse at age 16 was evaluated using a series of logistic regression models that included psychometric variables only, neural variables only (maximum peaks from VOIs), and the combination of psychometric and neural variables.
194-1	38774-38785	Behavioural	_	
194-2	38786-38789	and	_	
194-3	38790-38796	neural	_	
194-4	38797-38807	prediction	_	
194-5	38808-38810	of	_	
194-6	38811-38814	PDU	_	
194-7	38815-38820	After	_	
194-8	38821-38830	verifying	_	
194-9	38831-38834	key	_	
194-10	38835-38847	psychometric	_	
194-11	38848-38851	and	_	
194-12	38852-38858	neural	_	
194-13	38859-38868	variables	_	
194-14	38869-38871	at	_	
194-15	38872-38875	age	_	
194-16	38876-38878	14	_	
194-17	38878-38879	,	_	
194-18	38880-38885	these	_	
194-19	38886-38895	variables	_	
194-20	38895-38896	'	_	
194-21	38897-38905	relative	_	
194-22	38906-38913	ability	_	
194-23	38914-38916	to	_	
194-24	38917-38924	predict	_	
194-25	38925-38936	problematic	_	
194-26	38937-38942	abuse	_	
194-27	38943-38945	at	_	
194-28	38946-38949	age	_	
194-29	38950-38952	16	_	
194-30	38953-38956	was	_	
194-31	38957-38966	evaluated	_	
194-32	38967-38972	using	_	
194-33	38973-38974	a	_	
194-34	38975-38981	series	_	
194-35	38982-38984	of	_	
194-36	38985-38993	logistic	_	
194-37	38994-39004	regression	_	
194-38	39005-39011	models	_	
194-39	39012-39016	that	_	
194-40	39017-39025	included	_	
194-41	39026-39038	psychometric	_	
194-42	39039-39048	variables	_	
194-43	39049-39053	only	_	
194-44	39053-39054	,	_	
194-45	39055-39061	neural	_	
194-46	39062-39071	variables	_	
194-47	39072-39076	only	_	
194-48	39077-39078	(	_	
194-49	39078-39085	maximum	_	
194-50	39086-39091	peaks	_	
194-51	39092-39096	from	_	
194-52	39097-39101	VOIs	_	
194-53	39101-39102	)	_	
194-54	39102-39103	,	_	
194-55	39104-39107	and	_	
194-56	39108-39111	the	_	
194-57	39112-39123	combination	_	
194-58	39124-39126	of	_	
194-59	39127-39139	psychometric	_	
194-60	39140-39143	and	_	
194-61	39144-39150	neural	_	
194-62	39151-39160	variables	_	
194-63	39160-39161	.	_	

#Text=Since data checks of pair-wise correlations revealed that activity in midbrain and bilateral ventral striatal VOIs was highly correlated (Supplementary Fig. 7), and based on previous evidence reliably implicating ventral striatal activity in reward anticipation, we included coefficients for the right ventral striatal VOI in the models.
195-1	39162-39167	Since	_	
195-2	39168-39172	data	_	
195-3	39173-39179	checks	_	
195-4	39180-39182	of	_	
195-5	39183-39192	pair-wise	_	
195-6	39193-39205	correlations	_	
195-7	39206-39214	revealed	_	
195-8	39215-39219	that	_	
195-9	39220-39228	activity	_	
195-10	39229-39231	in	_	
195-11	39232-39240	midbrain	_	
195-12	39241-39244	and	_	
195-13	39245-39254	bilateral	_	
195-14	39255-39262	ventral	_	
195-15	39263-39271	striatal	_	
195-16	39272-39276	VOIs	_	
195-17	39277-39280	was	_	
195-18	39281-39287	highly	_	
195-19	39288-39298	correlated	_	
195-20	39299-39300	(	_	
195-21	39300-39313	Supplementary	_	
195-22	39314-39317	Fig	_	
195-23	39317-39318	.	_	
195-24	39319-39320	7	_	
195-25	39320-39321	)	_	
195-26	39321-39322	,	_	
195-27	39323-39326	and	_	
195-28	39327-39332	based	_	
195-29	39333-39335	on	_	
195-30	39336-39344	previous	_	
195-31	39345-39353	evidence	_	
195-32	39354-39362	reliably	_	
195-33	39363-39374	implicating	_	
195-34	39375-39382	ventral	_	
195-35	39383-39391	striatal	_	
195-36	39392-39400	activity	_	
195-37	39401-39403	in	_	
195-38	39404-39410	reward	_	
195-39	39411-39423	anticipation	_	
195-40	39423-39424	,	_	
195-41	39425-39427	we	_	
195-42	39428-39436	included	_	
195-43	39437-39449	coefficients	_	
195-44	39450-39453	for	_	
195-45	39454-39457	the	_	
195-46	39458-39463	right	_	
195-47	39464-39471	ventral	_	
195-48	39472-39480	striatal	_	
195-49	39481-39484	VOI	_	
195-50	39485-39487	in	_	
195-51	39488-39491	the	_	
195-52	39492-39498	models	_	
195-53	39498-39499	.	_	

#Text=Similarly, since activity in the two dorsolateral prefrontal VOIs was highly correlated, the prefrontal region whose activity was most closely associated with future PDU was included in the models.
196-1	39500-39509	Similarly	_	
196-2	39509-39510	,	_	
196-3	39511-39516	since	_	
196-4	39517-39525	activity	_	
196-5	39526-39528	in	_	
196-6	39529-39532	the	_	
196-7	39533-39536	two	_	
196-8	39537-39549	dorsolateral	_	
196-9	39550-39560	prefrontal	_	
196-10	39561-39565	VOIs	_	
196-11	39566-39569	was	_	
196-12	39570-39576	highly	_	
196-13	39577-39587	correlated	_	
196-14	39587-39588	,	_	
196-15	39589-39592	the	_	
196-16	39593-39603	prefrontal	_	
196-17	39604-39610	region	_	
196-18	39611-39616	whose	_	
196-19	39617-39625	activity	_	
196-20	39626-39629	was	_	
196-21	39630-39634	most	_	
196-22	39635-39642	closely	_	
196-23	39643-39653	associated	_	
196-24	39654-39658	with	_	
196-25	39659-39665	future	_	
196-26	39666-39669	PDU	_	
196-27	39670-39673	was	_	
196-28	39674-39682	included	_	
196-29	39683-39685	in	_	
196-30	39686-39689	the	_	
196-31	39690-39696	models	_	
196-32	39696-39697	.	_	

#Text=This initial variable selection averted collinearity and resulting instability that might arise from including highly correlated variables in the same model.
197-1	39698-39702	This	_	
197-2	39703-39710	initial	_	
197-3	39711-39719	variable	_	
197-4	39720-39729	selection	_	
197-5	39730-39737	averted	_	
197-6	39738-39750	collinearity	_	
197-7	39751-39754	and	_	
197-8	39755-39764	resulting	_	
197-9	39765-39776	instability	_	
197-10	39777-39781	that	_	
197-11	39782-39787	might	_	
197-12	39788-39793	arise	_	
197-13	39794-39798	from	_	
197-14	39799-39808	including	_	
197-15	39809-39815	highly	_	
197-16	39816-39826	correlated	_	
197-17	39827-39836	variables	_	
197-18	39837-39839	in	_	
197-19	39840-39843	the	_	
197-20	39844-39848	same	_	
197-21	39849-39854	model	_	
197-22	39854-39855	.	_	

#Text=Cross-validation analyses verified that these variables could classify future PDU out of sample in each model.
198-1	39856-39872	Cross-validation	_	
198-2	39873-39881	analyses	_	
198-3	39882-39890	verified	_	
198-4	39891-39895	that	_	
198-5	39896-39901	these	_	
198-6	39902-39911	variables	_	
198-7	39912-39917	could	_	
198-8	39918-39926	classify	_	
198-9	39927-39933	future	_	
198-10	39934-39937	PDU	_	
198-11	39938-39941	out	_	
198-12	39942-39944	of	_	
198-13	39945-39951	sample	_	
198-14	39952-39954	in	_	
198-15	39955-39959	each	_	
198-16	39960-39965	model	_	
198-17	39965-39966	.	_	

#Text=Classification was determined using 10-fold cross-validation over fits of a linear support vector machine, with 50% classification representing chance.
199-1	39967-39981	Classification	_	
199-2	39982-39985	was	_	
199-3	39986-39996	determined	_	
199-4	39997-40002	using	_	
199-5	40003-40005	10	_	
199-6	40005-40006	-	_	
199-7	40006-40010	fold	_	
199-8	40011-40027	cross-validation	_	
199-9	40028-40032	over	_	
199-10	40033-40037	fits	_	
199-11	40038-40040	of	_	
199-12	40041-40042	a	_	
199-13	40043-40049	linear	_	
199-14	40050-40057	support	_	
199-15	40058-40064	vector	_	
199-16	40065-40072	machine	_	
199-17	40072-40073	,	_	
199-18	40074-40078	with	_	
199-19	40079-40082	50%	_	
199-20	40083-40097	classification	_	
199-21	40098-40110	representing	_	
199-22	40111-40117	chance	_	
199-23	40117-40118	.	_	

#Text=Data availability
#Text=Data are available via application to the IMAGEN project (http://www.imagen-europe.com).
200-1	40119-40123	Data	_	
200-2	40124-40136	availability	_	
200-3	40137-40141	Data	_	
200-4	40142-40145	are	_	
200-5	40146-40155	available	_	
200-6	40156-40159	via	_	
200-7	40160-40171	application	_	
200-8	40172-40174	to	_	
200-9	40175-40178	the	_	
200-10	40179-40185	IMAGEN	_	
200-11	40186-40193	project	_	
200-12	40194-40195	(	_	
200-13	40195-40199	http	_	
200-14	40199-40200	:	_	
200-15	40200-40201	/	_	
200-16	40201-40202	/	_	
200-17	40202-40223	www.imagen-europe.com	_	
200-18	40223-40224	)	_	
200-19	40224-40225	.	_	

#Text=Additional information
#Text=How to cite this article: Büchel, C. et al.
201-1	40226-40236	Additional	_	
201-2	40237-40248	information	_	
201-3	40249-40252	How	_	
201-4	40253-40255	to	_	
201-5	40256-40260	cite	_	
201-6	40261-40265	this	_	
201-7	40266-40273	article	_	
201-8	40273-40274	:	_	
201-9	40275-40281	Büchel	_	
201-10	40281-40282	,	_	
201-11	40283-40284	C	_	
201-12	40284-40285	.	_	
201-13	40286-40288	et	_	
201-14	40289-40291	al	_	
201-15	40291-40292	.	_	

#Text=Blunted ventral striatal responses to anticipated rewards foreshadow problematic drug use in novelty-seeking adolescents.
202-1	40293-40300	Blunted	_	
202-2	40301-40308	ventral	_	
202-3	40309-40317	striatal	_	
202-4	40318-40327	responses	_	
202-5	40328-40330	to	_	
202-6	40331-40342	anticipated	_	
202-7	40343-40350	rewards	_	
202-8	40351-40361	foreshadow	_	
202-9	40362-40373	problematic	_	
202-10	40374-40378	drug	_	
202-11	40379-40382	use	_	
202-12	40383-40385	in	_	
202-13	40386-40401	novelty-seeking	_	
202-14	40402-40413	adolescents	_	
202-15	40413-40414	.	_	

#Text=Nat.
203-1	40415-40418	Nat	_	
203-2	40418-40419	.	_	

#Text=Commun. 8, 14140 doi: 10.1038/ncomms14140 (2017).
204-1	40420-40426	Commun	_	
204-2	40426-40427	.	_	
204-3	40428-40429	8	_	
204-4	40429-40430	,	_	
204-5	40431-40436	14140	_	
204-6	40437-40440	doi	_	
204-7	40440-40441	:	_	
204-8	40442-40449	10.1038	_	
204-9	40449-40450	/	_	
204-10	40450-40461	ncomms14140	_	
204-11	40462-40463	(	_	
204-12	40463-40467	2017	_	
204-13	40467-40468	)	_	
204-14	40468-40469	.	_	

#Text=Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
205-1	40470-40481	Publisher's	_	
205-2	40482-40486	note	_	
205-3	40486-40487	:	_	
205-4	40488-40496	Springer	_	
205-5	40497-40503	Nature	_	
205-6	40504-40511	remains	_	
205-7	40512-40519	neutral	_	
205-8	40520-40524	with	_	
205-9	40525-40531	regard	_	
205-10	40532-40534	to	_	
205-11	40535-40549	jurisdictional	_	
205-12	40550-40556	claims	_	
205-13	40557-40559	in	_	
205-14	40560-40569	published	_	
205-15	40570-40574	maps	_	
205-16	40575-40578	and	_	
205-17	40579-40592	institutional	_	
205-18	40593-40605	affiliations	_	
205-19	40605-40606	.	_	

#Text=Supplementary Material
#Text=The IMAGEN Consortium
#Text=Mercedes Arroyo23, Eric Artiges9, Semiha Aydin14, Christine Bach15, Alexis Barbot9, Gareth Barker5, Ruediger Bruehl14, Anna Cattrell5, Patrick Constant26, Hans Crombag27, Katharina Czech13, Jeffrey Dalley23, Benjamin Decideur9, Sylvane Desrivieres5, Tahmine Fadai1, Mira Fauth-Buhler15, Jianfeng Feng28, Irinia Filippi16,17, Vincent Frouin9, Birgit Fuchs29, Isabel Gemmeke13, Alexander Genauck13, Eanna Hanratty5, Bert Heinrichs30, Nadja Heym20, Thomas Hubner24, Albrecht Ihlenfeld14, Alex Ing5, James Ireland31, Tianye Jia5, Jennifer Jones4, Sarah Jurk24, Mehri Kaviani20, Arno Klaassen32, Johann Kruschwitz13, Christophe Lalanne9, Dirk Lanzerath30, Mark Lathrop33, Claire Lawrence20, Hervé Lemaitre16,17, Christine Macare5, Catherine Mallik5, Adam Mar23, Lourdes Martinez-Medina5, Eva Mennigen24, Fabiana Mesquita de Carvahlo5, Xavier Mignon26, Sabina Millenet15, Ruben Miranda16,17, Kathrin Müller24, Charlotte Nymberg5, Caroline Parchetka13, Yolanda Pena-Oliver27, Jani Pentilla16,17, Jean-Baptiste Poline9, Erin Burke Quinlan5, Michael Rapp13, Stephan Ripke24, Tamzin Ripley27, Gabriel Robert5, John Rogers31, Alexander Romanowski13, Barbara Ruggeri5, Christine Schmäl15, Dirk Schmidt24, Sophia Schneider1, Florian Schubert14, Yannick Schwartz9, Wolfgang Sommer15, Rainer Spanagel15, Claudia Speiser29, Tade Spranger30, Alicia Stedman20, Dai Stephens27, Nicole Strache13, Andreas Ströhle13, Maren Struve15, Naresh Subramaniam23, David Theobald23, Nora Vetter24, Helene Vulser16,17, Katharina Weiss13, Robert Whelan4, Steve Williams5, Bing Xu5, Juliana Yacubian1, Tao Yu5, Veronika Ziesch24
#Text=26PERTIMM, 92600 Asnieres-Sur-Seine, France, 28Warwick University, Coventry CV4 7AL, UK, 29GABO:milliarium mbH & Co.
206-1	40607-40620	Supplementary	_	
206-2	40621-40629	Material	_	
206-3	40630-40633	The	_	
206-4	40634-40640	IMAGEN	_	
206-5	40641-40651	Consortium	_	
206-6	40652-40660	Mercedes	_	
206-7	40661-40669	Arroyo23	_	
206-8	40669-40670	,	_	
206-9	40671-40675	Eric	_	
206-10	40676-40684	Artiges9	_	
206-11	40684-40685	,	_	
206-12	40686-40692	Semiha	_	
206-13	40693-40700	Aydin14	_	
206-14	40700-40701	,	_	
206-15	40702-40711	Christine	_	
206-16	40712-40718	Bach15	_	
206-17	40718-40719	,	_	
206-18	40720-40726	Alexis	_	
206-19	40727-40734	Barbot9	_	
206-20	40734-40735	,	_	
206-21	40736-40742	Gareth	_	
206-22	40743-40750	Barker5	_	
206-23	40750-40751	,	_	
206-24	40752-40760	Ruediger	_	
206-25	40761-40769	Bruehl14	_	
206-26	40769-40770	,	_	
206-27	40771-40775	Anna	_	
206-28	40776-40785	Cattrell5	_	
206-29	40785-40786	,	_	
206-30	40787-40794	Patrick	_	
206-31	40795-40805	Constant26	_	
206-32	40805-40806	,	_	
206-33	40807-40811	Hans	_	
206-34	40812-40821	Crombag27	_	
206-35	40821-40822	,	_	
206-36	40823-40832	Katharina	_	
206-37	40833-40840	Czech13	_	
206-38	40840-40841	,	_	
206-39	40842-40849	Jeffrey	_	
206-40	40850-40858	Dalley23	_	
206-41	40858-40859	,	_	
206-42	40860-40868	Benjamin	_	
206-43	40869-40878	Decideur9	_	
206-44	40878-40879	,	_	
206-45	40880-40887	Sylvane	_	
206-46	40888-40900	Desrivieres5	_	
206-47	40900-40901	,	_	
206-48	40902-40909	Tahmine	_	
206-49	40910-40916	Fadai1	_	
206-50	40916-40917	,	_	
206-51	40918-40922	Mira	_	
206-52	40923-40937	Fauth-Buhler15	_	
206-53	40937-40938	,	_	
206-54	40939-40947	Jianfeng	_	
206-55	40948-40954	Feng28	_	
206-56	40954-40955	,	_	
206-57	40956-40962	Irinia	_	
206-58	40963-40975	Filippi16,17	_	
206-59	40975-40976	,	_	
206-60	40977-40984	Vincent	_	
206-61	40985-40992	Frouin9	_	
206-62	40992-40993	,	_	
206-63	40994-41000	Birgit	_	
206-64	41001-41008	Fuchs29	_	
206-65	41008-41009	,	_	
206-66	41010-41016	Isabel	_	
206-67	41017-41026	Gemmeke13	_	
206-68	41026-41027	,	_	
206-69	41028-41037	Alexander	_	
206-70	41038-41047	Genauck13	_	
206-71	41047-41048	,	_	
206-72	41049-41054	Eanna	_	
206-73	41055-41064	Hanratty5	_	
206-74	41064-41065	,	_	
206-75	41066-41070	Bert	_	
206-76	41071-41082	Heinrichs30	_	
206-77	41082-41083	,	_	
206-78	41084-41089	Nadja	_	
206-79	41090-41096	Heym20	_	
206-80	41096-41097	,	_	
206-81	41098-41104	Thomas	_	
206-82	41105-41113	Hubner24	_	
206-83	41113-41114	,	_	
206-84	41115-41123	Albrecht	_	
206-85	41124-41135	Ihlenfeld14	_	
206-86	41135-41136	,	_	
206-87	41137-41141	Alex	_	
206-88	41142-41146	Ing5	_	
206-89	41146-41147	,	_	
206-90	41148-41153	James	_	
206-91	41154-41163	Ireland31	_	
206-92	41163-41164	,	_	
206-93	41165-41171	Tianye	_	
206-94	41172-41176	Jia5	_	
206-95	41176-41177	,	_	
206-96	41178-41186	Jennifer	_	
206-97	41187-41193	Jones4	_	
206-98	41193-41194	,	_	
206-99	41195-41200	Sarah	_	
206-100	41201-41207	Jurk24	_	
206-101	41207-41208	,	_	
206-102	41209-41214	Mehri	_	
206-103	41215-41224	Kaviani20	_	
206-104	41224-41225	,	_	
206-105	41226-41230	Arno	_	
206-106	41231-41241	Klaassen32	_	
206-107	41241-41242	,	_	
206-108	41243-41249	Johann	_	
206-109	41250-41262	Kruschwitz13	_	
206-110	41262-41263	,	_	
206-111	41264-41274	Christophe	_	
206-112	41275-41283	Lalanne9	_	
206-113	41283-41284	,	_	
206-114	41285-41289	Dirk	_	
206-115	41290-41301	Lanzerath30	_	
206-116	41301-41302	,	_	
206-117	41303-41307	Mark	_	
206-118	41308-41317	Lathrop33	_	
206-119	41317-41318	,	_	
206-120	41319-41325	Claire	_	
206-121	41326-41336	Lawrence20	_	
206-122	41336-41337	,	_	
206-123	41338-41343	Hervé	_	
206-124	41344-41357	Lemaitre16,17	_	
206-125	41357-41358	,	_	
206-126	41359-41368	Christine	_	
206-127	41369-41376	Macare5	_	
206-128	41376-41377	,	_	
206-129	41378-41387	Catherine	_	
206-130	41388-41395	Mallik5	_	
206-131	41395-41396	,	_	
206-132	41397-41401	Adam	_	
206-133	41402-41407	Mar23	_	
206-134	41407-41408	,	_	
206-135	41409-41416	Lourdes	_	
206-136	41417-41433	Martinez-Medina5	_	
206-137	41433-41434	,	_	
206-138	41435-41438	Eva	_	
206-139	41439-41449	Mennigen24	_	
206-140	41449-41450	,	_	
206-141	41451-41458	Fabiana	_	
206-142	41459-41467	Mesquita	_	
206-143	41468-41470	de	_	
206-144	41471-41480	Carvahlo5	_	
206-145	41480-41481	,	_	
206-146	41482-41488	Xavier	_	
206-147	41489-41497	Mignon26	_	
206-148	41497-41498	,	_	
206-149	41499-41505	Sabina	_	
206-150	41506-41516	Millenet15	_	
206-151	41516-41517	,	_	
206-152	41518-41523	Ruben	_	
206-153	41524-41536	Miranda16,17	_	
206-154	41536-41537	,	_	
206-155	41538-41545	Kathrin	_	
206-156	41546-41554	Müller24	_	
206-157	41554-41555	,	_	
206-158	41556-41565	Charlotte	_	
206-159	41566-41574	Nymberg5	_	
206-160	41574-41575	,	_	
206-161	41576-41584	Caroline	_	
206-162	41585-41596	Parchetka13	_	
206-163	41596-41597	,	_	
206-164	41598-41605	Yolanda	_	
206-165	41606-41619	Pena-Oliver27	_	
206-166	41619-41620	,	_	
206-167	41621-41625	Jani	_	
206-168	41626-41639	Pentilla16,17	_	
206-169	41639-41640	,	_	
206-170	41641-41654	Jean-Baptiste	_	
206-171	41655-41662	Poline9	_	
206-172	41662-41663	,	_	
206-173	41664-41668	Erin	_	
206-174	41669-41674	Burke	_	
206-175	41675-41683	Quinlan5	_	
206-176	41683-41684	,	_	
206-177	41685-41692	Michael	_	
206-178	41693-41699	Rapp13	_	
206-179	41699-41700	,	_	
206-180	41701-41708	Stephan	_	
206-181	41709-41716	Ripke24	_	
206-182	41716-41717	,	_	
206-183	41718-41724	Tamzin	_	
206-184	41725-41733	Ripley27	_	
206-185	41733-41734	,	_	
206-186	41735-41742	Gabriel	_	
206-187	41743-41750	Robert5	_	
206-188	41750-41751	,	_	
206-189	41752-41756	John	_	
206-190	41757-41765	Rogers31	_	
206-191	41765-41766	,	_	
206-192	41767-41776	Alexander	_	
206-193	41777-41789	Romanowski13	_	
206-194	41789-41790	,	_	
206-195	41791-41798	Barbara	_	
206-196	41799-41807	Ruggeri5	_	
206-197	41807-41808	,	_	
206-198	41809-41818	Christine	_	
206-199	41819-41827	Schmäl15	_	
206-200	41827-41828	,	_	
206-201	41829-41833	Dirk	_	
206-202	41834-41843	Schmidt24	_	
206-203	41843-41844	,	_	
206-204	41845-41851	Sophia	_	
206-205	41852-41862	Schneider1	_	
206-206	41862-41863	,	_	
206-207	41864-41871	Florian	_	
206-208	41872-41882	Schubert14	_	
206-209	41882-41883	,	_	
206-210	41884-41891	Yannick	_	
206-211	41892-41901	Schwartz9	_	
206-212	41901-41902	,	_	
206-213	41903-41911	Wolfgang	_	
206-214	41912-41920	Sommer15	_	
206-215	41920-41921	,	_	
206-216	41922-41928	Rainer	_	
206-217	41929-41939	Spanagel15	_	
206-218	41939-41940	,	_	
206-219	41941-41948	Claudia	_	
206-220	41949-41958	Speiser29	_	
206-221	41958-41959	,	_	
206-222	41960-41964	Tade	_	
206-223	41965-41975	Spranger30	_	
206-224	41975-41976	,	_	
206-225	41977-41983	Alicia	_	
206-226	41984-41993	Stedman20	_	
206-227	41993-41994	,	_	
206-228	41995-41998	Dai	_	
206-229	41999-42009	Stephens27	_	
206-230	42009-42010	,	_	
206-231	42011-42017	Nicole	_	
206-232	42018-42027	Strache13	_	
206-233	42027-42028	,	_	
206-234	42029-42036	Andreas	_	
206-235	42037-42046	Ströhle13	_	
206-236	42046-42047	,	_	
206-237	42048-42053	Maren	_	
206-238	42054-42062	Struve15	_	
206-239	42062-42063	,	_	
206-240	42064-42070	Naresh	_	
206-241	42071-42084	Subramaniam23	_	
206-242	42084-42085	,	_	
206-243	42086-42091	David	_	
206-244	42092-42102	Theobald23	_	
206-245	42102-42103	,	_	
206-246	42104-42108	Nora	_	
206-247	42109-42117	Vetter24	_	
206-248	42117-42118	,	_	
206-249	42119-42125	Helene	_	
206-250	42126-42137	Vulser16,17	_	
206-251	42137-42138	,	_	
206-252	42139-42148	Katharina	_	
206-253	42149-42156	Weiss13	_	
206-254	42156-42157	,	_	
206-255	42158-42164	Robert	_	
206-256	42165-42172	Whelan4	_	
206-257	42172-42173	,	_	
206-258	42174-42179	Steve	_	
206-259	42180-42189	Williams5	_	
206-260	42189-42190	,	_	
206-261	42191-42195	Bing	_	
206-262	42196-42199	Xu5	_	
206-263	42199-42200	,	_	
206-264	42201-42208	Juliana	_	
206-265	42209-42218	Yacubian1	_	
206-266	42218-42219	,	_	
206-267	42220-42223	Tao	_	
206-268	42224-42227	Yu5	_	
206-269	42227-42228	,	_	
206-270	42229-42237	Veronika	_	
206-271	42238-42246	Ziesch24	_	
206-272	42247-42256	26PERTIMM	_	
206-273	42256-42257	,	_	
206-274	42258-42263	92600	_	
206-275	42264-42282	Asnieres-Sur-Seine	_	
206-276	42282-42283	,	_	
206-277	42284-42290	France	_	
206-278	42290-42291	,	_	
206-279	42292-42301	28Warwick	_	
206-280	42302-42312	University	_	
206-281	42312-42313	,	_	
206-282	42314-42322	Coventry	_	
206-283	42323-42326	CV4	_	
206-284	42327-42330	7AL	_	
206-285	42330-42331	,	_	
206-286	42332-42334	UK	_	
206-287	42334-42335	,	_	
206-288	42336-42342	29GABO	_	
206-289	42342-42343	:	_	
206-290	42343-42353	milliarium	_	
206-291	42354-42357	mbH	_	
206-292	42358-42359	&	_	
206-293	42360-42362	Co	_	
206-294	42362-42363	.	_	

#Text=KG 80333 Munich, Germany, 30Deutsches Referenzzentrum fur Ethik, D53113 Bonn, Germany, 31Delosis, Twickenham, Middlesex TW1 4AE, UK, 32Scito, F-75020 Paris, France, 33Centre National de Genotypage, 91057 Evry, France
#Text=Determinants of early alcohol use in healthy adolescents: the differential contribution of neuroimaging and psychological factors
#Text=Behavioral endophenotypes of drug addiction: Etiological insights from neuroimaging studies
#Text=Neuropsychosocial profiles of current and future adolescent alcohol misusers
#Text=Age differences in sensation seeking and impulsivity as indexed by behavior and self-report: evidence for a dual systems model
#Text=Personality profile and drug of choice; a multivariate analysis using Cloninger's TCI on heroin addicts, alcoholics, and a random population group
#Text=Novelty seeking, risk taking, and related constructs as predictors of adolescent substance use: an application of Cloninger's theory
#Text=Earlier development of the accumbens relative to orbitofrontal cortex might underlie risk-taking behavior in adolescents
#Text=A social neuroscience perspective on adolescent risk-taking
#Text=The triadic model perspective for the study of adolescent motivated behavior
#Text=The reward circuit: linking primate anatomy and human imaging
#Text=Dynamic mapping of human cortical development during childhood through early adulthood
#Text=Structural MRI of pediatric brain development: what have we learned and where are we going?
207-1	42364-42366	KG	_	
207-2	42367-42372	80333	_	
207-3	42373-42379	Munich	_	
207-4	42379-42380	,	_	
207-5	42381-42388	Germany	_	
207-6	42388-42389	,	_	
207-7	42390-42401	30Deutsches	_	
207-8	42402-42417	Referenzzentrum	_	
207-9	42418-42421	fur	_	
207-10	42422-42427	Ethik	_	
207-11	42427-42428	,	_	
207-12	42429-42435	D53113	_	
207-13	42436-42440	Bonn	_	
207-14	42440-42441	,	_	
207-15	42442-42449	Germany	_	
207-16	42449-42450	,	_	
207-17	42451-42460	31Delosis	_	
207-18	42460-42461	,	_	
207-19	42462-42472	Twickenham	_	
207-20	42472-42473	,	_	
207-21	42474-42483	Middlesex	_	
207-22	42484-42487	TW1	_	
207-23	42488-42491	4AE	_	
207-24	42491-42492	,	_	
207-25	42493-42495	UK	_	
207-26	42495-42496	,	_	
207-27	42497-42504	32Scito	_	
207-28	42504-42505	,	_	
207-29	42506-42507	F	_	
207-30	42507-42508	-	_	
207-31	42508-42513	75020	_	
207-32	42514-42519	Paris	_	
207-33	42519-42520	,	_	
207-34	42521-42527	France	_	
207-35	42527-42528	,	_	
207-36	42529-42537	33Centre	_	
207-37	42538-42546	National	_	
207-38	42547-42549	de	_	
207-39	42550-42560	Genotypage	_	
207-40	42560-42561	,	_	
207-41	42562-42567	91057	_	
207-42	42568-42572	Evry	_	
207-43	42572-42573	,	_	
207-44	42574-42580	France	_	
207-45	42581-42593	Determinants	_	
207-46	42594-42596	of	_	
207-47	42597-42602	early	_	
207-48	42603-42610	alcohol	_	
207-49	42611-42614	use	_	
207-50	42615-42617	in	_	
207-51	42618-42625	healthy	_	
207-52	42626-42637	adolescents	_	
207-53	42637-42638	:	_	
207-54	42639-42642	the	_	
207-55	42643-42655	differential	_	
207-56	42656-42668	contribution	_	
207-57	42669-42671	of	_	
207-58	42672-42684	neuroimaging	_	
207-59	42685-42688	and	_	
207-60	42689-42702	psychological	_	
207-61	42703-42710	factors	_	
207-62	42711-42721	Behavioral	_	
207-63	42722-42736	endophenotypes	_	
207-64	42737-42739	of	_	
207-65	42740-42744	drug	_	
207-66	42745-42754	addiction	_	
207-67	42754-42755	:	_	
207-68	42756-42767	Etiological	_	
207-69	42768-42776	insights	_	
207-70	42777-42781	from	_	
207-71	42782-42794	neuroimaging	_	
207-72	42795-42802	studies	_	
207-73	42803-42820	Neuropsychosocial	_	
207-74	42821-42829	profiles	_	
207-75	42830-42832	of	_	
207-76	42833-42840	current	_	
207-77	42841-42844	and	_	
207-78	42845-42851	future	_	
207-79	42852-42862	adolescent	_	
207-80	42863-42870	alcohol	_	
207-81	42871-42879	misusers	_	
207-82	42880-42883	Age	_	
207-83	42884-42895	differences	_	
207-84	42896-42898	in	_	
207-85	42899-42908	sensation	_	
207-86	42909-42916	seeking	_	
207-87	42917-42920	and	_	
207-88	42921-42932	impulsivity	_	
207-89	42933-42935	as	_	
207-90	42936-42943	indexed	_	
207-91	42944-42946	by	_	
207-92	42947-42955	behavior	_	
207-93	42956-42959	and	_	
207-94	42960-42971	self-report	_	
207-95	42971-42972	:	_	
207-96	42973-42981	evidence	_	
207-97	42982-42985	for	_	
207-98	42986-42987	a	_	
207-99	42988-42992	dual	_	
207-100	42993-43000	systems	_	
207-101	43001-43006	model	_	
207-102	43007-43018	Personality	_	
207-103	43019-43026	profile	_	
207-104	43027-43030	and	_	
207-105	43031-43035	drug	_	
207-106	43036-43038	of	_	
207-107	43039-43045	choice	_	
207-108	43045-43046	;	_	
207-109	43047-43048	a	_	
207-110	43049-43061	multivariate	_	
207-111	43062-43070	analysis	_	
207-112	43071-43076	using	_	
207-113	43077-43088	Cloninger's	_	
207-114	43089-43092	TCI	_	
207-115	43093-43095	on	_	
207-116	43096-43102	heroin	_	
207-117	43103-43110	addicts	_	
207-118	43110-43111	,	_	
207-119	43112-43122	alcoholics	_	
207-120	43122-43123	,	_	
207-121	43124-43127	and	_	
207-122	43128-43129	a	_	
207-123	43130-43136	random	_	
207-124	43137-43147	population	_	
207-125	43148-43153	group	_	
207-126	43154-43161	Novelty	_	
207-127	43162-43169	seeking	_	
207-128	43169-43170	,	_	
207-129	43171-43175	risk	_	
207-130	43176-43182	taking	_	
207-131	43182-43183	,	_	
207-132	43184-43187	and	_	
207-133	43188-43195	related	_	
207-134	43196-43206	constructs	_	
207-135	43207-43209	as	_	
207-136	43210-43220	predictors	_	
207-137	43221-43223	of	_	
207-138	43224-43234	adolescent	_	
207-139	43235-43244	substance	_	
207-140	43245-43248	use	_	
207-141	43248-43249	:	_	
207-142	43250-43252	an	_	
207-143	43253-43264	application	_	
207-144	43265-43267	of	_	
207-145	43268-43279	Cloninger's	_	
207-146	43280-43286	theory	_	
207-147	43287-43294	Earlier	_	
207-148	43295-43306	development	_	
207-149	43307-43309	of	_	
207-150	43310-43313	the	_	
207-151	43314-43323	accumbens	_	
207-152	43324-43332	relative	_	
207-153	43333-43335	to	_	
207-154	43336-43349	orbitofrontal	_	
207-155	43350-43356	cortex	_	
207-156	43357-43362	might	_	
207-157	43363-43371	underlie	_	
207-158	43372-43383	risk-taking	_	
207-159	43384-43392	behavior	_	
207-160	43393-43395	in	_	
207-161	43396-43407	adolescents	_	
207-162	43408-43409	A	_	
207-163	43410-43416	social	_	
207-164	43417-43429	neuroscience	_	
207-165	43430-43441	perspective	_	
207-166	43442-43444	on	_	
207-167	43445-43455	adolescent	_	
207-168	43456-43467	risk-taking	_	
207-169	43468-43471	The	_	
207-170	43472-43479	triadic	_	
207-171	43480-43485	model	_	
207-172	43486-43497	perspective	_	
207-173	43498-43501	for	_	
207-174	43502-43505	the	_	
207-175	43506-43511	study	_	
207-176	43512-43514	of	_	
207-177	43515-43525	adolescent	_	
207-178	43526-43535	motivated	_	
207-179	43536-43544	behavior	_	
207-180	43545-43548	The	_	
207-181	43549-43555	reward	_	
207-182	43556-43563	circuit	_	
207-183	43563-43564	:	_	
207-184	43565-43572	linking	_	
207-185	43573-43580	primate	_	
207-186	43581-43588	anatomy	_	
207-187	43589-43592	and	_	
207-188	43593-43598	human	_	
207-189	43599-43606	imaging	_	
207-190	43607-43614	Dynamic	_	
207-191	43615-43622	mapping	_	
207-192	43623-43625	of	_	
207-193	43626-43631	human	_	
207-194	43632-43640	cortical	_	
207-195	43641-43652	development	_	
207-196	43653-43659	during	_	
207-197	43660-43669	childhood	_	
207-198	43670-43677	through	_	
207-199	43678-43683	early	_	
207-200	43684-43693	adulthood	_	
207-201	43694-43704	Structural	_	
207-202	43705-43708	MRI	_	
207-203	43709-43711	of	_	
207-204	43712-43721	pediatric	_	
207-205	43722-43727	brain	_	
207-206	43728-43739	development	_	
207-207	43739-43740	:	_	
207-208	43741-43745	what	_	
207-209	43746-43750	have	_	
207-210	43751-43753	we	_	
207-211	43754-43761	learned	_	
207-212	43762-43765	and	_	
207-213	43766-43771	where	_	
207-214	43772-43775	are	_	
207-215	43776-43778	we	_	
207-216	43779-43784	going	_	
207-217	43784-43785	?	_	

#Text=Maturation of limbic corticostriatal activation and connectivity associated with developmental changes in temporal discounting
#Text=The neural basis of puberty and adolescence
#Text=Inverted-U-shaped dopamine actions on human working memory and cognitive control
#Text=Imaging brain response to reward in addictive disorders
#Text=Reward deficiency syndrome
#Text=The dopamine hypothesis of drug addiction: hypodopaminergic state
#Text=Incentive-elicited brain activation in adolescents: similarities and differences from young adults
#Text=Adolescents, adults and rewards: comparing motivational neurocircuitry recruitment using fMRI
#Text=Longitudinal study of striatal activation to reward and loss anticipation from mid-adolescence into late adolescence/early adulthood
#Text=Lower ventral striatal activation during reward anticipation in adolescent smokers
#Text=Amygdala and nucleus accumbens in responses to receipt and omission of gains in adults and adolescents
#Text=Striatal ups and downs: their roles in vulnerability to addictions in humans
#Text=Adolescent risky decision-making: Neurocognitive development of reward and control regions
#Text=Immaturities in reward processing and its influence on inhibitory control in adolescence
#Text=Different developmental trajectories for anticipation and receipt of reward during adolescence
#Text=Risk taking in adolescence: a decision-making perspective
#Text=Does the adolescent brain make risk taking inevitable?
208-1	43786-43796	Maturation	_	
208-2	43797-43799	of	_	
208-3	43800-43806	limbic	_	
208-4	43807-43822	corticostriatal	_	
208-5	43823-43833	activation	_	
208-6	43834-43837	and	_	
208-7	43838-43850	connectivity	_	
208-8	43851-43861	associated	_	
208-9	43862-43866	with	_	
208-10	43867-43880	developmental	_	
208-11	43881-43888	changes	_	
208-12	43889-43891	in	_	
208-13	43892-43900	temporal	_	
208-14	43901-43912	discounting	_	
208-15	43913-43916	The	_	
208-16	43917-43923	neural	_	
208-17	43924-43929	basis	_	
208-18	43930-43932	of	_	
208-19	43933-43940	puberty	_	
208-20	43941-43944	and	_	
208-21	43945-43956	adolescence	_	
208-22	43957-43974	Inverted-U-shaped	_	
208-23	43975-43983	dopamine	_	
208-24	43984-43991	actions	_	
208-25	43992-43994	on	_	
208-26	43995-44000	human	_	
208-27	44001-44008	working	_	
208-28	44009-44015	memory	_	
208-29	44016-44019	and	_	
208-30	44020-44029	cognitive	_	
208-31	44030-44037	control	_	
208-32	44038-44045	Imaging	_	
208-33	44046-44051	brain	_	
208-34	44052-44060	response	_	
208-35	44061-44063	to	_	
208-36	44064-44070	reward	_	
208-37	44071-44073	in	_	
208-38	44074-44083	addictive	_	
208-39	44084-44093	disorders	_	
208-40	44094-44100	Reward	_	
208-41	44101-44111	deficiency	_	
208-42	44112-44120	syndrome	_	
208-43	44121-44124	The	_	
208-44	44125-44133	dopamine	_	
208-45	44134-44144	hypothesis	_	
208-46	44145-44147	of	_	
208-47	44148-44152	drug	_	
208-48	44153-44162	addiction	_	
208-49	44162-44163	:	_	
208-50	44164-44180	hypodopaminergic	_	
208-51	44181-44186	state	_	
208-52	44187-44205	Incentive-elicited	_	
208-53	44206-44211	brain	_	
208-54	44212-44222	activation	_	
208-55	44223-44225	in	_	
208-56	44226-44237	adolescents	_	
208-57	44237-44238	:	_	
208-58	44239-44251	similarities	_	
208-59	44252-44255	and	_	
208-60	44256-44267	differences	_	
208-61	44268-44272	from	_	
208-62	44273-44278	young	_	
208-63	44279-44285	adults	_	
208-64	44286-44297	Adolescents	_	
208-65	44297-44298	,	_	
208-66	44299-44305	adults	_	
208-67	44306-44309	and	_	
208-68	44310-44317	rewards	_	
208-69	44317-44318	:	_	
208-70	44319-44328	comparing	_	
208-71	44329-44341	motivational	_	
208-72	44342-44356	neurocircuitry	_	
208-73	44357-44368	recruitment	_	
208-74	44369-44374	using	_	
208-75	44375-44379	fMRI	_	
208-76	44380-44392	Longitudinal	_	
208-77	44393-44398	study	_	
208-78	44399-44401	of	_	
208-79	44402-44410	striatal	_	
208-80	44411-44421	activation	_	
208-81	44422-44424	to	_	
208-82	44425-44431	reward	_	
208-83	44432-44435	and	_	
208-84	44436-44440	loss	_	
208-85	44441-44453	anticipation	_	
208-86	44454-44458	from	_	
208-87	44459-44474	mid-adolescence	_	
208-88	44475-44479	into	_	
208-89	44480-44484	late	_	
208-90	44485-44496	adolescence	_	
208-91	44496-44497	/	_	
208-92	44497-44502	early	_	
208-93	44503-44512	adulthood	_	
208-94	44513-44518	Lower	_	
208-95	44519-44526	ventral	_	
208-96	44527-44535	striatal	_	
208-97	44536-44546	activation	_	
208-98	44547-44553	during	_	
208-99	44554-44560	reward	_	
208-100	44561-44573	anticipation	_	
208-101	44574-44576	in	_	
208-102	44577-44587	adolescent	_	
208-103	44588-44595	smokers	_	
208-104	44596-44604	Amygdala	_	
208-105	44605-44608	and	_	
208-106	44609-44616	nucleus	_	
208-107	44617-44626	accumbens	_	
208-108	44627-44629	in	_	
208-109	44630-44639	responses	_	
208-110	44640-44642	to	_	
208-111	44643-44650	receipt	_	
208-112	44651-44654	and	_	
208-113	44655-44663	omission	_	
208-114	44664-44666	of	_	
208-115	44667-44672	gains	_	
208-116	44673-44675	in	_	
208-117	44676-44682	adults	_	
208-118	44683-44686	and	_	
208-119	44687-44698	adolescents	_	
208-120	44699-44707	Striatal	_	
208-121	44708-44711	ups	_	
208-122	44712-44715	and	_	
208-123	44716-44721	downs	_	
208-124	44721-44722	:	_	
208-125	44723-44728	their	_	
208-126	44729-44734	roles	_	
208-127	44735-44737	in	_	
208-128	44738-44751	vulnerability	_	
208-129	44752-44754	to	_	
208-130	44755-44765	addictions	_	
208-131	44766-44768	in	_	
208-132	44769-44775	humans	_	
208-133	44776-44786	Adolescent	_	
208-134	44787-44792	risky	_	
208-135	44793-44808	decision-making	_	
208-136	44808-44809	:	_	
208-137	44810-44824	Neurocognitive	_	
208-138	44825-44836	development	_	
208-139	44837-44839	of	_	
208-140	44840-44846	reward	_	
208-141	44847-44850	and	_	
208-142	44851-44858	control	_	
208-143	44859-44866	regions	_	
208-144	44867-44879	Immaturities	_	
208-145	44880-44882	in	_	
208-146	44883-44889	reward	_	
208-147	44890-44900	processing	_	
208-148	44901-44904	and	_	
208-149	44905-44908	its	_	
208-150	44909-44918	influence	_	
208-151	44919-44921	on	_	
208-152	44922-44932	inhibitory	_	
208-153	44933-44940	control	_	
208-154	44941-44943	in	_	
208-155	44944-44955	adolescence	_	
208-156	44956-44965	Different	_	
208-157	44966-44979	developmental	_	
208-158	44980-44992	trajectories	_	
208-159	44993-44996	for	_	
208-160	44997-45009	anticipation	_	
208-161	45010-45013	and	_	
208-162	45014-45021	receipt	_	
208-163	45022-45024	of	_	
208-164	45025-45031	reward	_	
208-165	45032-45038	during	_	
208-166	45039-45050	adolescence	_	
208-167	45051-45055	Risk	_	
208-168	45056-45062	taking	_	
208-169	45063-45065	in	_	
208-170	45066-45077	adolescence	_	
208-171	45077-45078	:	_	
208-172	45079-45080	a	_	
208-173	45081-45096	decision-making	_	
208-174	45097-45108	perspective	_	
208-175	45109-45113	Does	_	
208-176	45114-45117	the	_	
208-177	45118-45128	adolescent	_	
208-178	45129-45134	brain	_	
208-179	45135-45139	make	_	
208-180	45140-45144	risk	_	
208-181	45145-45151	taking	_	
208-182	45152-45162	inevitable	_	
208-183	45162-45163	?	_	

#Text=A skeptical appraisal
#Text=The adolescent brain and age-related behavioral manifestations
#Text=The social re-orientation of adolescence: a neuroscience perspective on the process and its relation to psychopathology
#Text=Competitiveness, risk taking, and violence: the young male syndrome
#Text=Disaggregating entrepreneurial orientation: the non-linear impact of innovativeness, proactiveness and risk-taking on SME performance
#Text=FMRI visualization of brain activity during a monetary incentive delay task
#Text=Affective traits link to reliable neural markers of incentive anticipation
#Text=Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release
#Text=Dysfunction of reward processing correlates with alcohol craving in detoxified alcoholics
#Text=Risk taking and the adolescent reward system: A potential common link to substance abuse
#Text=Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects
#Text=Pathological gambling is linked to reduced activation of the mesolimbic reward system
#Text=PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys
#Text=Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement
#Text=Dissociable systems for gain- and loss-related value predictions and errors of prediction in the human brain
#Text=Adaptive coding of reward value by dopamine neurons
#Text=Discrete coding of reward probability and uncertainty by dopamine neurons
#Text=Prefrontal cortical regulation of brainwide circuit dynamics and reward-related behavior
#Text=An Integrative Theory of Prefrontal Cortical Function
#Text=Dorsolateral prefrontal cortex drives mesolimbic dopaminergic regions to initiate motivated behavior
#Text=The nature of adolescent competencies predicted by preschool delay of gratification
#Text=Behavioral and neural correlates of delay of gratification 40 years later
#Text=Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls
#Text=Altered neural reward representations in pathological gamblers revealed by delay and probability discounting
#Text=The behavioral- and neuro-economic process of temporal discounting: A candidate behavioral marker of addiction
#Text=Testing predictions from personality neuroscience.
209-1	45164-45165	A	_	
209-2	45166-45175	skeptical	_	
209-3	45176-45185	appraisal	_	
209-4	45186-45189	The	_	
209-5	45190-45200	adolescent	_	
209-6	45201-45206	brain	_	
209-7	45207-45210	and	_	
209-8	45211-45222	age-related	_	
209-9	45223-45233	behavioral	_	
209-10	45234-45248	manifestations	_	
209-11	45249-45252	The	_	
209-12	45253-45259	social	_	
209-13	45260-45274	re-orientation	_	
209-14	45275-45277	of	_	
209-15	45278-45289	adolescence	_	
209-16	45289-45290	:	_	
209-17	45291-45292	a	_	
209-18	45293-45305	neuroscience	_	
209-19	45306-45317	perspective	_	
209-20	45318-45320	on	_	
209-21	45321-45324	the	_	
209-22	45325-45332	process	_	
209-23	45333-45336	and	_	
209-24	45337-45340	its	_	
209-25	45341-45349	relation	_	
209-26	45350-45352	to	_	
209-27	45353-45368	psychopathology	_	
209-28	45369-45384	Competitiveness	_	
209-29	45384-45385	,	_	
209-30	45386-45390	risk	_	
209-31	45391-45397	taking	_	
209-32	45397-45398	,	_	
209-33	45399-45402	and	_	
209-34	45403-45411	violence	_	
209-35	45411-45412	:	_	
209-36	45413-45416	the	_	
209-37	45417-45422	young	_	
209-38	45423-45427	male	_	
209-39	45428-45436	syndrome	_	
209-40	45437-45451	Disaggregating	_	
209-41	45452-45467	entrepreneurial	_	
209-42	45468-45479	orientation	_	
209-43	45479-45480	:	_	
209-44	45481-45484	the	_	
209-45	45485-45495	non-linear	_	
209-46	45496-45502	impact	_	
209-47	45503-45505	of	_	
209-48	45506-45520	innovativeness	_	
209-49	45520-45521	,	_	
209-50	45522-45535	proactiveness	_	
209-51	45536-45539	and	_	
209-52	45540-45551	risk-taking	_	
209-53	45552-45554	on	_	
209-54	45555-45558	SME	_	
209-55	45559-45570	performance	_	
209-56	45571-45575	FMRI	_	
209-57	45576-45589	visualization	_	
209-58	45590-45592	of	_	
209-59	45593-45598	brain	_	
209-60	45599-45607	activity	_	
209-61	45608-45614	during	_	
209-62	45615-45616	a	_	
209-63	45617-45625	monetary	_	
209-64	45626-45635	incentive	_	
209-65	45636-45641	delay	_	
209-66	45642-45646	task	_	
209-67	45647-45656	Affective	_	
209-68	45657-45663	traits	_	
209-69	45664-45668	link	_	
209-70	45669-45671	to	_	
209-71	45672-45680	reliable	_	
209-72	45681-45687	neural	_	
209-73	45688-45695	markers	_	
209-74	45696-45698	of	_	
209-75	45699-45708	incentive	_	
209-76	45709-45721	anticipation	_	
209-77	45722-45732	Mesolimbic	_	
209-78	45733-45743	functional	_	
209-79	45744-45752	magnetic	_	
209-80	45753-45762	resonance	_	
209-81	45763-45770	imaging	_	
209-82	45771-45782	activations	_	
209-83	45783-45789	during	_	
209-84	45790-45796	reward	_	
209-85	45797-45809	anticipation	_	
209-86	45810-45819	correlate	_	
209-87	45820-45824	with	_	
209-88	45825-45839	reward-related	_	
209-89	45840-45847	ventral	_	
209-90	45848-45856	striatal	_	
209-91	45857-45865	dopamine	_	
209-92	45866-45873	release	_	
209-93	45874-45885	Dysfunction	_	
209-94	45886-45888	of	_	
209-95	45889-45895	reward	_	
209-96	45896-45906	processing	_	
209-97	45907-45917	correlates	_	
209-98	45918-45922	with	_	
209-99	45923-45930	alcohol	_	
209-100	45931-45938	craving	_	
209-101	45939-45941	in	_	
209-102	45942-45952	detoxified	_	
209-103	45953-45963	alcoholics	_	
209-104	45964-45968	Risk	_	
209-105	45969-45975	taking	_	
209-106	45976-45979	and	_	
209-107	45980-45983	the	_	
209-108	45984-45994	adolescent	_	
209-109	45995-46001	reward	_	
209-110	46002-46008	system	_	
209-111	46008-46009	:	_	
209-112	46010-46011	A	_	
209-113	46012-46021	potential	_	
209-114	46022-46028	common	_	
209-115	46029-46033	link	_	
209-116	46034-46036	to	_	
209-117	46037-46046	substance	_	
209-118	46047-46052	abuse	_	
209-119	46053-46062	Decreased	_	
209-120	46063-46071	striatal	_	
209-121	46072-46084	dopaminergic	_	
209-122	46085-46099	responsiveness	_	
209-123	46100-46102	in	_	
209-124	46103-46113	detoxified	_	
209-125	46114-46131	cocaine-dependent	_	
209-126	46132-46140	subjects	_	
209-127	46141-46153	Pathological	_	
209-128	46154-46162	gambling	_	
209-129	46163-46165	is	_	
209-130	46166-46172	linked	_	
209-131	46173-46175	to	_	
209-132	46176-46183	reduced	_	
209-133	46184-46194	activation	_	
209-134	46195-46197	of	_	
209-135	46198-46201	the	_	
209-136	46202-46212	mesolimbic	_	
209-137	46213-46219	reward	_	
209-138	46220-46226	system	_	
209-139	46227-46230	PET	_	
209-140	46231-46238	imaging	_	
209-141	46239-46241	of	_	
209-142	46242-46250	dopamine	_	
209-143	46251-46253	D2	_	
209-144	46254-46263	receptors	_	
209-145	46264-46270	during	_	
209-146	46271-46278	chronic	_	
209-147	46279-46286	cocaine	_	
209-148	46287-46306	self-administration	_	
209-149	46307-46309	in	_	
209-150	46310-46317	monkeys	_	
209-151	46318-46325	Nucleus	_	
209-152	46326-46335	accumbens	_	
209-153	46336-46338	D2	_	
209-154	46338-46339	/	_	
209-155	46339-46340	3	_	
209-156	46341-46350	receptors	_	
209-157	46351-46358	predict	_	
209-158	46359-46364	trait	_	
209-159	46365-46376	impulsivity	_	
209-160	46377-46380	and	_	
209-161	46381-46388	cocaine	_	
209-162	46389-46402	reinforcement	_	
209-163	46403-46414	Dissociable	_	
209-164	46415-46422	systems	_	
209-165	46423-46426	for	_	
209-166	46427-46431	gain	_	
209-167	46431-46432	-	_	
209-168	46433-46436	and	_	
209-169	46437-46449	loss-related	_	
209-170	46450-46455	value	_	
209-171	46456-46467	predictions	_	
209-172	46468-46471	and	_	
209-173	46472-46478	errors	_	
209-174	46479-46481	of	_	
209-175	46482-46492	prediction	_	
209-176	46493-46495	in	_	
209-177	46496-46499	the	_	
209-178	46500-46505	human	_	
209-179	46506-46511	brain	_	
209-180	46512-46520	Adaptive	_	
209-181	46521-46527	coding	_	
209-182	46528-46530	of	_	
209-183	46531-46537	reward	_	
209-184	46538-46543	value	_	
209-185	46544-46546	by	_	
209-186	46547-46555	dopamine	_	
209-187	46556-46563	neurons	_	
209-188	46564-46572	Discrete	_	
209-189	46573-46579	coding	_	
209-190	46580-46582	of	_	
209-191	46583-46589	reward	_	
209-192	46590-46601	probability	_	
209-193	46602-46605	and	_	
209-194	46606-46617	uncertainty	_	
209-195	46618-46620	by	_	
209-196	46621-46629	dopamine	_	
209-197	46630-46637	neurons	_	
209-198	46638-46648	Prefrontal	_	
209-199	46649-46657	cortical	_	
209-200	46658-46668	regulation	_	
209-201	46669-46671	of	_	
209-202	46672-46681	brainwide	_	
209-203	46682-46689	circuit	_	
209-204	46690-46698	dynamics	_	
209-205	46699-46702	and	_	
209-206	46703-46717	reward-related	_	
209-207	46718-46726	behavior	_	
209-208	46727-46729	An	_	
209-209	46730-46741	Integrative	_	
209-210	46742-46748	Theory	_	
209-211	46749-46751	of	_	
209-212	46752-46762	Prefrontal	_	
209-213	46763-46771	Cortical	_	
209-214	46772-46780	Function	_	
209-215	46781-46793	Dorsolateral	_	
209-216	46794-46804	prefrontal	_	
209-217	46805-46811	cortex	_	
209-218	46812-46818	drives	_	
209-219	46819-46829	mesolimbic	_	
209-220	46830-46842	dopaminergic	_	
209-221	46843-46850	regions	_	
209-222	46851-46853	to	_	
209-223	46854-46862	initiate	_	
209-224	46863-46872	motivated	_	
209-225	46873-46881	behavior	_	
209-226	46882-46885	The	_	
209-227	46886-46892	nature	_	
209-228	46893-46895	of	_	
209-229	46896-46906	adolescent	_	
209-230	46907-46919	competencies	_	
209-231	46920-46929	predicted	_	
209-232	46930-46932	by	_	
209-233	46933-46942	preschool	_	
209-234	46943-46948	delay	_	
209-235	46949-46951	of	_	
209-236	46952-46965	gratification	_	
209-237	46966-46976	Behavioral	_	
209-238	46977-46980	and	_	
209-239	46981-46987	neural	_	
209-240	46988-46998	correlates	_	
209-241	46999-47001	of	_	
209-242	47002-47007	delay	_	
209-243	47008-47010	of	_	
209-244	47011-47024	gratification	_	
209-245	47025-47027	40	_	
209-246	47028-47033	years	_	
209-247	47034-47039	later	_	
209-248	47040-47046	Heroin	_	
209-249	47047-47054	addicts	_	
209-250	47055-47059	have	_	
209-251	47060-47066	higher	_	
209-252	47067-47075	discount	_	
209-253	47076-47081	rates	_	
209-254	47082-47085	for	_	
209-255	47086-47093	delayed	_	
209-256	47094-47101	rewards	_	
209-257	47102-47106	than	_	
209-258	47107-47121	non-drug-using	_	
209-259	47122-47130	controls	_	
209-260	47131-47138	Altered	_	
209-261	47139-47145	neural	_	
209-262	47146-47152	reward	_	
209-263	47153-47168	representations	_	
209-264	47169-47171	in	_	
209-265	47172-47184	pathological	_	
209-266	47185-47193	gamblers	_	
209-267	47194-47202	revealed	_	
209-268	47203-47205	by	_	
209-269	47206-47211	delay	_	
209-270	47212-47215	and	_	
209-271	47216-47227	probability	_	
209-272	47228-47239	discounting	_	
209-273	47240-47243	The	_	
209-274	47244-47254	behavioral	_	
209-275	47254-47255	-	_	
209-276	47256-47259	and	_	
209-277	47260-47274	neuro-economic	_	
209-278	47275-47282	process	_	
209-279	47283-47285	of	_	
209-280	47286-47294	temporal	_	
209-281	47295-47306	discounting	_	
209-282	47306-47307	:	_	
209-283	47308-47309	A	_	
209-284	47310-47319	candidate	_	
209-285	47320-47330	behavioral	_	
209-286	47331-47337	marker	_	
209-287	47338-47340	of	_	
209-288	47341-47350	addiction	_	
209-289	47351-47358	Testing	_	
209-290	47359-47370	predictions	_	
209-291	47371-47375	from	_	
209-292	47376-47387	personality	_	
209-293	47388-47400	neuroscience	_	
209-294	47400-47401	.	_	

#Text=Brain structure and the big five
#Text=Conscientiousness and health-related behaviors: a meta-analysis of the leading behavioral contributors to mortality
#Text=Separate neural systems value immediate and delayed monetary rewards
#Text=Dissociable neural representations of future reward magnitude and delay during temporal discounting
#Text=Lateral prefrontal cortex and self-control in intertemporal choice
#Text=Longitudinal changes in prefrontal cortex activation underlie declines in adolescent risk taking
#Text=Identifying adolescents at risk for hard drug use: racial/ethnic variations
#Text=Toward a syndrome model of addiction: multiple expressions, common etiology
#Text=Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: Implications for substance abuse prevention
#Text=Personality traits are differentially linked to mental disorders: a multitrait-multidiagnosis study of an adolescent birth cohort
#Text=Neuromaturation and adolescent risk taking: why development is not determinism
#Text=The IMAGEN study: reinforcement-related behaviour in normal brain function and psychopathology
#Text=A psychobiological model of temperament and character
#Text=
#Text=Domains and facets: hierarchical personality assessment using the revised NEO personality inventory
#Text=The development and well-being assessment: description and initial validation of an integrated assessment of child and adolescent psychopathology
#Text=
#Text=Within-subject comparison of real and hypothetical money rewards in delay discounting
#Text=Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers evidence for monoaminergic mechanisms
#Text=A self-report measure of pubertal status: reliability, validity, and initial norms
#Text=A fast diffeomorphic image registration algorithm
#Text=Dissociable roles of ventral and dorsal striatum in instrumental conditioning
#Text=Anticipatory affect: Neural correlates and consequences for choice
#Text=The dopaminergic midbrain participates in human episodic memory formation: evidence from genetic imaging
#Text=Modulation of emotion by cognition and cognition by emotion
#Text=
#Text=The authors declare no competing financial interests.
210-1	47402-47407	Brain	_	
210-2	47408-47417	structure	_	
210-3	47418-47421	and	_	
210-4	47422-47425	the	_	
210-5	47426-47429	big	_	
210-6	47430-47434	five	_	
210-7	47435-47452	Conscientiousness	_	
210-8	47453-47456	and	_	
210-9	47457-47471	health-related	_	
210-10	47472-47481	behaviors	_	
210-11	47481-47482	:	_	
210-12	47483-47484	a	_	
210-13	47485-47498	meta-analysis	_	
210-14	47499-47501	of	_	
210-15	47502-47505	the	_	
210-16	47506-47513	leading	_	
210-17	47514-47524	behavioral	_	
210-18	47525-47537	contributors	_	
210-19	47538-47540	to	_	
210-20	47541-47550	mortality	_	
210-21	47551-47559	Separate	_	
210-22	47560-47566	neural	_	
210-23	47567-47574	systems	_	
210-24	47575-47580	value	_	
210-25	47581-47590	immediate	_	
210-26	47591-47594	and	_	
210-27	47595-47602	delayed	_	
210-28	47603-47611	monetary	_	
210-29	47612-47619	rewards	_	
210-30	47620-47631	Dissociable	_	
210-31	47632-47638	neural	_	
210-32	47639-47654	representations	_	
210-33	47655-47657	of	_	
210-34	47658-47664	future	_	
210-35	47665-47671	reward	_	
210-36	47672-47681	magnitude	_	
210-37	47682-47685	and	_	
210-38	47686-47691	delay	_	
210-39	47692-47698	during	_	
210-40	47699-47707	temporal	_	
210-41	47708-47719	discounting	_	
210-42	47720-47727	Lateral	_	
210-43	47728-47738	prefrontal	_	
210-44	47739-47745	cortex	_	
210-45	47746-47749	and	_	
210-46	47750-47762	self-control	_	
210-47	47763-47765	in	_	
210-48	47766-47779	intertemporal	_	
210-49	47780-47786	choice	_	
210-50	47787-47799	Longitudinal	_	
210-51	47800-47807	changes	_	
210-52	47808-47810	in	_	
210-53	47811-47821	prefrontal	_	
210-54	47822-47828	cortex	_	
210-55	47829-47839	activation	_	
210-56	47840-47848	underlie	_	
210-57	47849-47857	declines	_	
210-58	47858-47860	in	_	
210-59	47861-47871	adolescent	_	
210-60	47872-47876	risk	_	
210-61	47877-47883	taking	_	
210-62	47884-47895	Identifying	_	
210-63	47896-47907	adolescents	_	
210-64	47908-47910	at	_	
210-65	47911-47915	risk	_	
210-66	47916-47919	for	_	
210-67	47920-47924	hard	_	
210-68	47925-47929	drug	_	
210-69	47930-47933	use	_	
210-70	47933-47934	:	_	
210-71	47935-47941	racial	_	
210-72	47941-47942	/	_	
210-73	47942-47948	ethnic	_	
210-74	47949-47959	variations	_	
210-75	47960-47966	Toward	_	
210-76	47967-47968	a	_	
210-77	47969-47977	syndrome	_	
210-78	47978-47983	model	_	
210-79	47984-47986	of	_	
210-80	47987-47996	addiction	_	
210-81	47996-47997	:	_	
210-82	47998-48006	multiple	_	
210-83	48007-48018	expressions	_	
210-84	48018-48019	,	_	
210-85	48020-48026	common	_	
210-86	48027-48035	etiology	_	
210-87	48036-48040	Risk	_	
210-88	48041-48044	and	_	
210-89	48045-48055	protective	_	
210-90	48056-48063	factors	_	
210-91	48064-48067	for	_	
210-92	48068-48075	alcohol	_	
210-93	48076-48079	and	_	
210-94	48080-48085	other	_	
210-95	48086-48090	drug	_	
210-96	48091-48099	problems	_	
210-97	48100-48102	in	_	
210-98	48103-48114	adolescence	_	
210-99	48115-48118	and	_	
210-100	48119-48124	early	_	
210-101	48125-48134	adulthood	_	
210-102	48134-48135	:	_	
210-103	48136-48148	Implications	_	
210-104	48149-48152	for	_	
210-105	48153-48162	substance	_	
210-106	48163-48168	abuse	_	
210-107	48169-48179	prevention	_	
210-108	48180-48191	Personality	_	
210-109	48192-48198	traits	_	
210-110	48199-48202	are	_	
210-111	48203-48217	differentially	_	
210-112	48218-48224	linked	_	
210-113	48225-48227	to	_	
210-114	48228-48234	mental	_	
210-115	48235-48244	disorders	_	
210-116	48244-48245	:	_	
210-117	48246-48247	a	_	
210-118	48248-48273	multitrait-multidiagnosis	_	
210-119	48274-48279	study	_	
210-120	48280-48282	of	_	
210-121	48283-48285	an	_	
210-122	48286-48296	adolescent	_	
210-123	48297-48302	birth	_	
210-124	48303-48309	cohort	_	
210-125	48310-48325	Neuromaturation	_	
210-126	48326-48329	and	_	
210-127	48330-48340	adolescent	_	
210-128	48341-48345	risk	_	
210-129	48346-48352	taking	_	
210-130	48352-48353	:	_	
210-131	48354-48357	why	_	
210-132	48358-48369	development	_	
210-133	48370-48372	is	_	
210-134	48373-48376	not	_	
210-135	48377-48388	determinism	_	
210-136	48389-48392	The	_	
210-137	48393-48399	IMAGEN	_	
210-138	48400-48405	study	_	
210-139	48405-48406	:	_	
210-140	48407-48428	reinforcement-related	_	
210-141	48429-48438	behaviour	_	
210-142	48439-48441	in	_	
210-143	48442-48448	normal	_	
210-144	48449-48454	brain	_	
210-145	48455-48463	function	_	
210-146	48464-48467	and	_	
210-147	48468-48483	psychopathology	_	
210-148	48484-48485	A	_	
210-149	48486-48502	psychobiological	_	
210-150	48503-48508	model	_	
210-151	48509-48511	of	_	
210-152	48512-48523	temperament	_	
210-153	48524-48527	and	_	
210-154	48528-48537	character	_	
210-155	48539-48546	Domains	_	
210-156	48547-48550	and	_	
210-157	48551-48557	facets	_	
210-158	48557-48558	:	_	
210-159	48559-48571	hierarchical	_	
210-160	48572-48583	personality	_	
210-161	48584-48594	assessment	_	
210-162	48595-48600	using	_	
210-163	48601-48604	the	_	
210-164	48605-48612	revised	_	
210-165	48613-48616	NEO	_	
210-166	48617-48628	personality	_	
210-167	48629-48638	inventory	_	
210-168	48639-48642	The	_	
210-169	48643-48654	development	_	
210-170	48655-48658	and	_	
210-171	48659-48669	well-being	_	
210-172	48670-48680	assessment	_	
210-173	48680-48681	:	_	
210-174	48682-48693	description	_	
210-175	48694-48697	and	_	
210-176	48698-48705	initial	_	
210-177	48706-48716	validation	_	
210-178	48717-48719	of	_	
210-179	48720-48722	an	_	
210-180	48723-48733	integrated	_	
210-181	48734-48744	assessment	_	
210-182	48745-48747	of	_	
210-183	48748-48753	child	_	
210-184	48754-48757	and	_	
210-185	48758-48768	adolescent	_	
210-186	48769-48784	psychopathology	_	
210-187	48786-48800	Within-subject	_	
210-188	48801-48811	comparison	_	
210-189	48812-48814	of	_	
210-190	48815-48819	real	_	
210-191	48820-48823	and	_	
210-192	48824-48836	hypothetical	_	
210-193	48837-48842	money	_	
210-194	48843-48850	rewards	_	
210-195	48851-48853	in	_	
210-196	48854-48859	delay	_	
210-197	48860-48871	discounting	_	
210-198	48872-48883	Dissociable	_	
210-199	48884-48892	deficits	_	
210-200	48893-48895	in	_	
210-201	48896-48899	the	_	
210-202	48900-48915	decision-making	_	
210-203	48916-48925	cognition	_	
210-204	48926-48928	of	_	
210-205	48929-48936	chronic	_	
210-206	48937-48948	amphetamine	_	
210-207	48949-48956	abusers	_	
210-208	48956-48957	,	_	
210-209	48958-48964	opiate	_	
210-210	48965-48972	abusers	_	
210-211	48972-48973	,	_	
210-212	48974-48982	patients	_	
210-213	48983-48987	with	_	
210-214	48988-48993	focal	_	
210-215	48994-49000	damage	_	
210-216	49001-49003	to	_	
210-217	49004-49014	prefrontal	_	
210-218	49015-49021	cortex	_	
210-219	49021-49022	,	_	
210-220	49023-49026	and	_	
210-221	49027-49046	tryptophan-depleted	_	
210-222	49047-49053	normal	_	
210-223	49054-49064	volunteers	_	
210-224	49065-49073	evidence	_	
210-225	49074-49077	for	_	
210-226	49078-49091	monoaminergic	_	
210-227	49092-49102	mechanisms	_	
210-228	49103-49104	A	_	
210-229	49105-49116	self-report	_	
210-230	49117-49124	measure	_	
210-231	49125-49127	of	_	
210-232	49128-49136	pubertal	_	
210-233	49137-49143	status	_	
210-234	49143-49144	:	_	
210-235	49145-49156	reliability	_	
210-236	49156-49157	,	_	
210-237	49158-49166	validity	_	
210-238	49166-49167	,	_	
210-239	49168-49171	and	_	
210-240	49172-49179	initial	_	
210-241	49180-49185	norms	_	
210-242	49186-49187	A	_	
210-243	49188-49192	fast	_	
210-244	49193-49206	diffeomorphic	_	
210-245	49207-49212	image	_	
210-246	49213-49225	registration	_	
210-247	49226-49235	algorithm	_	
210-248	49236-49247	Dissociable	_	
210-249	49248-49253	roles	_	
210-250	49254-49256	of	_	
210-251	49257-49264	ventral	_	
210-252	49265-49268	and	_	
210-253	49269-49275	dorsal	_	
210-254	49276-49284	striatum	_	
210-255	49285-49287	in	_	
210-256	49288-49300	instrumental	_	
210-257	49301-49313	conditioning	_	
210-258	49314-49326	Anticipatory	_	
210-259	49327-49333	affect	_	
210-260	49333-49334	:	_	
210-261	49335-49341	Neural	_	
210-262	49342-49352	correlates	_	
210-263	49353-49356	and	_	
210-264	49357-49369	consequences	_	
210-265	49370-49373	for	_	
210-266	49374-49380	choice	_	
210-267	49381-49384	The	_	
210-268	49385-49397	dopaminergic	_	
210-269	49398-49406	midbrain	_	
210-270	49407-49419	participates	_	
210-271	49420-49422	in	_	
210-272	49423-49428	human	_	
210-273	49429-49437	episodic	_	
210-274	49438-49444	memory	_	
210-275	49445-49454	formation	_	
210-276	49454-49455	:	_	
210-277	49456-49464	evidence	_	
210-278	49465-49469	from	_	
210-279	49470-49477	genetic	_	
210-280	49478-49485	imaging	_	
210-281	49486-49496	Modulation	_	
210-282	49497-49499	of	_	
210-283	49500-49507	emotion	_	
210-284	49508-49510	by	_	
210-285	49511-49520	cognition	_	
210-286	49521-49524	and	_	
210-287	49525-49534	cognition	_	
210-288	49535-49537	by	_	
210-289	49538-49545	emotion	_	
210-290	49547-49550	The	_	
210-291	49551-49558	authors	_	
210-292	49559-49566	declare	_	
210-293	49567-49569	no	_	
210-294	49570-49579	competing	_	
210-295	49580-49589	financial	_	
210-296	49590-49599	interests	_	
210-297	49599-49600	.	_	

#Text=Author contributions All authors designed the study and acquired the data.
211-1	49601-49607	Author	_	
211-2	49608-49621	contributions	_	
211-3	49622-49625	All	_	
211-4	49626-49633	authors	_	
211-5	49634-49642	designed	_	
211-6	49643-49646	the	_	
211-7	49647-49652	study	_	
211-8	49653-49656	and	_	
211-9	49657-49665	acquired	_	
211-10	49666-49669	the	_	
211-11	49670-49674	data	_	
211-12	49674-49675	.	_	

#Text=C.B. and B.K. analysed the data and wrote the manuscript.
#Text=fMRI activity during anticipation of large versus small gains for control and PDU subjects combined (n=144).
212-1	49676-49679	C.B	_	
212-2	49679-49680	.	_	
212-3	49681-49684	and	_	
212-4	49685-49688	B.K	_	
212-5	49688-49689	.	_	
212-6	49690-49698	analysed	_	
212-7	49699-49702	the	_	
212-8	49703-49707	data	_	
212-9	49708-49711	and	_	
212-10	49712-49717	wrote	_	
212-11	49718-49721	the	_	
212-12	49722-49732	manuscript	_	
212-13	49732-49733	.	_	
212-14	49734-49738	fMRI	_	
212-15	49739-49747	activity	_	
212-16	49748-49754	during	_	
212-17	49755-49767	anticipation	_	
212-18	49768-49770	of	_	
212-19	49771-49776	large	_	
212-20	49777-49783	versus	_	
212-21	49784-49789	small	_	
212-22	49790-49795	gains	_	
212-23	49796-49799	for	_	
212-24	49800-49807	control	_	
212-25	49808-49811	and	_	
212-26	49812-49815	PDU	_	
212-27	49816-49824	subjects	_	
212-28	49825-49833	combined	_	
212-29	49834-49835	(	_	
212-30	49835-49836	n	_	
212-31	49836-49837	=	_	
212-32	49837-49840	144	_	
212-33	49840-49841	)	_	
212-34	49841-49842	.	_	

#Text=Overlaid on a mean structural magnetic resonance scan showing a coronal (left) and an axial (right) section, activation display threshold is P<0.05 (whole brain corrected, t-test).
213-1	49843-49851	Overlaid	_	
213-2	49852-49854	on	_	
213-3	49855-49856	a	_	
213-4	49857-49861	mean	_	
213-5	49862-49872	structural	_	
213-6	49873-49881	magnetic	_	
213-7	49882-49891	resonance	_	
213-8	49892-49896	scan	_	
213-9	49897-49904	showing	_	
213-10	49905-49906	a	_	
213-11	49907-49914	coronal	_	
213-12	49915-49916	(	_	
213-13	49916-49920	left	_	
213-14	49920-49921	)	_	
213-15	49922-49925	and	_	
213-16	49926-49928	an	_	
213-17	49929-49934	axial	_	
213-18	49935-49936	(	_	
213-19	49936-49941	right	_	
213-20	49941-49942	)	_	
213-21	49943-49950	section	_	
213-22	49950-49951	,	_	
213-23	49952-49962	activation	_	
213-24	49963-49970	display	_	
213-25	49971-49980	threshold	_	
213-26	49981-49983	is	_	
213-27	49984-49985	P	_	
213-28	49985-49986	<	_	
213-29	49986-49990	0.05	_	
213-30	49991-49992	(	_	
213-31	49992-49997	whole	_	
213-32	49998-50003	brain	_	
213-33	50004-50013	corrected	_	
213-34	50013-50014	,	_	
213-35	50015-50021	t-test	_	
213-36	50021-50022	)	_	
213-37	50022-50023	.	_	

#Text=Subcortical brain activity in anticipation of large versus small gains for control subjects (n=72) versus problematic drug users (n=72).
214-1	50024-50035	Subcortical	_	
214-2	50036-50041	brain	_	
214-3	50042-50050	activity	_	
214-4	50051-50053	in	_	
214-5	50054-50066	anticipation	_	
214-6	50067-50069	of	_	
214-7	50070-50075	large	_	
214-8	50076-50082	versus	_	
214-9	50083-50088	small	_	
214-10	50089-50094	gains	_	
214-11	50095-50098	for	_	
214-12	50099-50106	control	_	
214-13	50107-50115	subjects	_	
214-14	50116-50117	(	_	
214-15	50117-50118	n	_	
214-16	50118-50119	=	_	
214-17	50119-50121	72	_	
214-18	50121-50122	)	_	
214-19	50123-50129	versus	_	
214-20	50130-50141	problematic	_	
214-21	50142-50146	drug	_	
214-22	50147-50152	users	_	
214-23	50153-50154	(	_	
214-24	50154-50155	n	_	
214-25	50155-50156	=	_	
214-26	50156-50158	72	_	
214-27	50158-50159	)	_	
214-28	50159-50160	.	_	

#Text=The PDU group showed decreased activation in bilateral ventral striatum (left, right) and midbrain (bottom).
215-1	50161-50164	The	_	
215-2	50165-50168	PDU	_	
215-3	50169-50174	group	_	
215-4	50175-50181	showed	_	
215-5	50182-50191	decreased	_	
215-6	50192-50202	activation	_	
215-7	50203-50205	in	_	
215-8	50206-50215	bilateral	_	
215-9	50216-50223	ventral	_	
215-10	50224-50232	striatum	_	
215-11	50233-50234	(	_	
215-12	50234-50238	left	_	
215-13	50238-50239	,	_	
215-14	50240-50245	right	_	
215-15	50245-50246	)	_	
215-16	50247-50250	and	_	
215-17	50251-50259	midbrain	_	
215-18	50260-50261	(	_	
215-19	50261-50267	bottom	_	
215-20	50267-50268	)	_	
215-21	50268-50269	.	_	

#Text=Overlaid on a mean structural magnetic resonance scan, activation display threshold is P<0.005 (uncorrected, t-test).
216-1	50270-50278	Overlaid	_	
216-2	50279-50281	on	_	
216-3	50282-50283	a	_	
216-4	50284-50288	mean	_	
216-5	50289-50299	structural	_	
216-6	50300-50308	magnetic	_	
216-7	50309-50318	resonance	_	
216-8	50319-50323	scan	_	
216-9	50323-50324	,	_	
216-10	50325-50335	activation	_	
216-11	50336-50343	display	_	
216-12	50344-50353	threshold	_	
216-13	50354-50356	is	_	
216-14	50357-50358	P	_	
216-15	50358-50359	<	_	
216-16	50359-50364	0.005	_	
216-17	50365-50366	(	_	
216-18	50366-50377	uncorrected	_	
216-19	50377-50378	,	_	
216-20	50379-50385	t-test	_	
216-21	50385-50386	)	_	
216-22	50386-50387	.	_	

#Text=Highlighted areas indicate volumes of interest in the ventral striatum (VS foci: ±14, 8, –8) and midbrain (VTA foci: ±9, –15, –15).
217-1	50388-50399	Highlighted	_	
217-2	50400-50405	areas	_	
217-3	50406-50414	indicate	_	
217-4	50415-50422	volumes	_	
217-5	50423-50425	of	_	
217-6	50426-50434	interest	_	
217-7	50435-50437	in	_	
217-8	50438-50441	the	_	
217-9	50442-50449	ventral	_	
217-10	50450-50458	striatum	_	
217-11	50459-50460	(	_	
217-12	50460-50462	VS	_	
217-13	50463-50467	foci	_	
217-14	50467-50468	:	_	
217-15	50469-50470	±	_	
217-16	50470-50472	14	_	
217-17	50472-50473	,	_	
217-18	50474-50475	8	_	
217-19	50475-50476	,	_	
217-20	50477-50478	–	_	
217-21	50478-50479	8	_	
217-22	50479-50480	)	_	
217-23	50481-50484	and	_	
217-24	50485-50493	midbrain	_	
217-25	50494-50495	(	_	
217-26	50495-50498	VTA	_	
217-27	50499-50503	foci	_	
217-28	50503-50504	:	_	
217-29	50505-50506	±	_	
217-30	50506-50507	9	_	
217-31	50507-50508	,	_	
217-32	50509-50510	–	_	
217-33	50510-50512	15	_	
217-34	50512-50513	,	_	
217-35	50514-50515	–	_	
217-36	50515-50517	15	_	
217-37	50517-50518	)	_	
217-38	50518-50519	.	_	

#Text=Error bars=±s.e.m.
218-1	50520-50525	Error	_	
218-2	50526-50530	bars	_	
218-3	50530-50531	=	_	
218-4	50531-50532	±	_	
218-5	50532-50537	s.e.m	_	
218-6	50537-50538	.	_	

#Text=*Significant at threshold of P<0.0083 uncorrected or P<0.05 corrected (n=144, t-test).
219-1	50539-50540	*	_	
219-2	50540-50551	Significant	_	
219-3	50552-50554	at	_	
219-4	50555-50564	threshold	_	
219-5	50565-50567	of	_	
219-6	50568-50569	P	_	
219-7	50569-50570	<	_	
219-8	50570-50576	0.0083	_	
219-9	50577-50588	uncorrected	_	
219-10	50589-50591	or	_	
219-11	50592-50593	P	_	
219-12	50593-50594	<	_	
219-13	50594-50598	0.05	_	
219-14	50599-50608	corrected	_	
219-15	50609-50610	(	_	
219-16	50610-50611	n	_	
219-17	50611-50612	=	_	
219-18	50612-50615	144	_	
219-19	50615-50616	,	_	
219-20	50617-50623	t-test	_	
219-21	50623-50624	)	_	
219-22	50624-50625	.	_	

#Text=Cortical brain activity in anticipation of large versus small gains for control subjects (n=72) versus problematic drug users (n=72).
220-1	50626-50634	Cortical	_	
220-2	50635-50640	brain	_	
220-3	50641-50649	activity	_	
220-4	50650-50652	in	_	
220-5	50653-50665	anticipation	_	
220-6	50666-50668	of	_	
220-7	50669-50674	large	_	
220-8	50675-50681	versus	_	
220-9	50682-50687	small	_	
220-10	50688-50693	gains	_	
220-11	50694-50697	for	_	
220-12	50698-50705	control	_	
220-13	50706-50714	subjects	_	
220-14	50715-50716	(	_	
220-15	50716-50717	n	_	
220-16	50717-50718	=	_	
220-17	50718-50720	72	_	
220-18	50720-50721	)	_	
220-19	50722-50728	versus	_	
220-20	50729-50740	problematic	_	
220-21	50741-50745	drug	_	
220-22	50746-50751	users	_	
220-23	50752-50753	(	_	
220-24	50753-50754	n	_	
220-25	50754-50755	=	_	
220-26	50755-50757	72	_	
220-27	50757-50758	)	_	
220-28	50758-50759	.	_	

#Text=The PDU group showed decreased activation in the right dorsolateral prefrontal cortex (for VOI-based statistics, see Table 2).
221-1	50760-50763	The	_	
221-2	50764-50767	PDU	_	
221-3	50768-50773	group	_	
221-4	50774-50780	showed	_	
221-5	50781-50790	decreased	_	
221-6	50791-50801	activation	_	
221-7	50802-50804	in	_	
221-8	50805-50808	the	_	
221-9	50809-50814	right	_	
221-10	50815-50827	dorsolateral	_	
221-11	50828-50838	prefrontal	_	
221-12	50839-50845	cortex	_	
221-13	50846-50847	(	_	
221-14	50847-50850	for	_	
221-15	50851-50860	VOI-based	_	
221-16	50861-50871	statistics	_	
221-17	50871-50872	,	_	
221-18	50873-50876	see	_	
221-19	50877-50882	Table	_	
221-20	50883-50884	2	_	
221-21	50884-50885	)	_	
221-22	50885-50886	.	_	

#Text=Overlaid on a mean structural magnetic resonance scan, activation display threshold is P<0.005 (uncorrected, t-test).
222-1	50887-50895	Overlaid	_	
222-2	50896-50898	on	_	
222-3	50899-50900	a	_	
222-4	50901-50905	mean	_	
222-5	50906-50916	structural	_	
222-6	50917-50925	magnetic	_	
222-7	50926-50935	resonance	_	
222-8	50936-50940	scan	_	
222-9	50940-50941	,	_	
222-10	50942-50952	activation	_	
222-11	50953-50960	display	_	
222-12	50961-50970	threshold	_	
222-13	50971-50973	is	_	
222-14	50974-50975	P	_	
222-15	50975-50976	<	_	
222-16	50976-50981	0.005	_	
222-17	50982-50983	(	_	
222-18	50983-50994	uncorrected	_	
222-19	50994-50995	,	_	
222-20	50996-51002	t-test	_	
222-21	51002-51003	)	_	
222-22	51003-51004	.	_	

#Text=Highlighted areas indicate volumes of interest in the dorsolateral prefrontal cortex (PFC foci: ±35, 36, 32).
223-1	51005-51016	Highlighted	_	
223-2	51017-51022	areas	_	
223-3	51023-51031	indicate	_	
223-4	51032-51039	volumes	_	
223-5	51040-51042	of	_	
223-6	51043-51051	interest	_	
223-7	51052-51054	in	_	
223-8	51055-51058	the	_	
223-9	51059-51071	dorsolateral	_	
223-10	51072-51082	prefrontal	_	
223-11	51083-51089	cortex	_	
223-12	51090-51091	(	_	
223-13	51091-51094	PFC	_	
223-14	51095-51099	foci	_	
223-15	51099-51100	:	_	
223-16	51101-51102	±	_	
223-17	51102-51104	35	_	
223-18	51104-51105	,	_	
223-19	51106-51108	36	_	
223-20	51108-51109	,	_	
223-21	51110-51112	32	_	
223-22	51112-51113	)	_	
223-23	51113-51114	.	_	

#Text=Error bars=±s.e.m.
224-1	51115-51120	Error	_	
224-2	51121-51125	bars	_	
224-3	51125-51126	=	_	
224-4	51126-51127	±	_	
224-5	51127-51132	s.e.m	_	
224-6	51132-51133	.	_	

#Text=*Significant at threshold of P<0.0083 uncorrected or P<0.05 corrected (n=144, t-test).
225-1	51134-51135	*	_	
225-2	51135-51146	Significant	_	
225-3	51147-51149	at	_	
225-4	51150-51159	threshold	_	
225-5	51160-51162	of	_	
225-6	51163-51164	P	_	
225-7	51164-51165	<	_	
225-8	51165-51171	0.0083	_	
225-9	51172-51183	uncorrected	_	
225-10	51184-51186	or	_	
225-11	51187-51188	P	_	
225-12	51188-51189	<	_	
225-13	51189-51193	0.05	_	
225-14	51194-51203	corrected	_	
225-15	51204-51205	(	_	
225-16	51205-51206	n	_	
225-17	51206-51207	=	_	
225-18	51207-51210	144	_	
225-19	51210-51211	,	_	
225-20	51212-51218	t-test	_	
225-21	51218-51219	)	_	
225-22	51219-51220	.	_	

#Text=Cortical differences in grey matter volume for control subjects (n=72) versus prospective problematic drug users (PDU) (n=72).
226-1	51221-51229	Cortical	_	
226-2	51230-51241	differences	_	
226-3	51242-51244	in	_	
226-4	51245-51249	grey	_	
226-5	51250-51256	matter	_	
226-6	51257-51263	volume	_	
226-7	51264-51267	for	_	
226-8	51268-51275	control	_	
226-9	51276-51284	subjects	_	
226-10	51285-51286	(	_	
226-11	51286-51287	n	_	
226-12	51287-51288	=	_	
226-13	51288-51290	72	_	
226-14	51290-51291	)	_	
226-15	51292-51298	versus	_	
226-16	51299-51310	prospective	_	
226-17	51311-51322	problematic	_	
226-18	51323-51327	drug	_	
226-19	51328-51333	users	_	
226-20	51334-51335	(	_	
226-21	51335-51338	PDU	_	
226-22	51338-51339	)	_	
226-23	51340-51341	(	_	
226-24	51341-51342	n	_	
226-25	51342-51343	=	_	
226-26	51343-51345	72	_	
226-27	51345-51346	)	_	
226-28	51346-51347	.	_	

#Text=(a) Increased grey matter density was observed for the PDU group in the right dorsolateral prefrontal cortex.
227-1	51348-51349	(	_	
227-2	51349-51350	a	_	
227-3	51350-51351	)	_	
227-4	51352-51361	Increased	_	
227-5	51362-51366	grey	_	
227-6	51367-51373	matter	_	
227-7	51374-51381	density	_	
227-8	51382-51385	was	_	
227-9	51386-51394	observed	_	
227-10	51395-51398	for	_	
227-11	51399-51402	the	_	
227-12	51403-51406	PDU	_	
227-13	51407-51412	group	_	
227-14	51413-51415	in	_	
227-15	51416-51419	the	_	
227-16	51420-51425	right	_	
227-17	51426-51438	dorsolateral	_	
227-18	51439-51449	prefrontal	_	
227-19	51450-51456	cortex	_	
227-20	51456-51457	.	_	

#Text=(b) The location of increased grey matter density (green) lies adjacent to reduced activation in the Monetary Incentive Delay (MID) task for the prospective problematic drug users (red).
228-1	51458-51459	(	_	
228-2	51459-51460	b	_	
228-3	51460-51461	)	_	
228-4	51462-51465	The	_	
228-5	51466-51474	location	_	
228-6	51475-51477	of	_	
228-7	51478-51487	increased	_	
228-8	51488-51492	grey	_	
228-9	51493-51499	matter	_	
228-10	51500-51507	density	_	
228-11	51508-51509	(	_	
228-12	51509-51514	green	_	
228-13	51514-51515	)	_	
228-14	51516-51520	lies	_	
228-15	51521-51529	adjacent	_	
228-16	51530-51532	to	_	
228-17	51533-51540	reduced	_	
228-18	51541-51551	activation	_	
228-19	51552-51554	in	_	
228-20	51555-51558	the	_	
228-21	51559-51567	Monetary	_	
228-22	51568-51577	Incentive	_	
228-23	51578-51583	Delay	_	
228-24	51584-51585	(	_	
228-25	51585-51588	MID	_	
228-26	51588-51589	)	_	
228-27	51590-51594	task	_	
228-28	51595-51598	for	_	
228-29	51599-51602	the	_	
228-30	51603-51614	prospective	_	
228-31	51615-51626	problematic	_	
228-32	51627-51631	drug	_	
228-33	51632-51637	users	_	
228-34	51638-51639	(	_	
228-35	51639-51642	red	_	
228-36	51642-51643	)	_	
228-37	51643-51644	.	_	

#Text=Overlaid on a mean structural magnetic resonance scale, volumetric display threshold is P<0.005 (uncorrected, t-test).
229-1	51645-51653	Overlaid	_	
229-2	51654-51656	on	_	
229-3	51657-51658	a	_	
229-4	51659-51663	mean	_	
229-5	51664-51674	structural	_	
229-6	51675-51683	magnetic	_	
229-7	51684-51693	resonance	_	
229-8	51694-51699	scale	_	
229-9	51699-51700	,	_	
229-10	51701-51711	volumetric	_	
229-11	51712-51719	display	_	
229-12	51720-51729	threshold	_	
229-13	51730-51732	is	_	
229-14	51733-51734	P	_	
229-15	51734-51735	<	_	
229-16	51735-51740	0.005	_	
229-17	51741-51742	(	_	
229-18	51742-51753	uncorrected	_	
229-19	51753-51754	,	_	
229-20	51755-51761	t-test	_	
229-21	51761-51762	)	_	
229-22	51762-51763	.	_	

#Text=Highlighted areas indicate volumes of interest in the prefrontal cortex.
230-1	51764-51775	Highlighted	_	
230-2	51776-51781	areas	_	
230-3	51782-51790	indicate	_	
230-4	51791-51798	volumes	_	
230-5	51799-51801	of	_	
230-6	51802-51810	interest	_	
230-7	51811-51813	in	_	
230-8	51814-51817	the	_	
230-9	51818-51828	prefrontal	_	
230-10	51829-51835	cortex	_	
230-11	51835-51836	.	_	

#Text=Error bars=±s.e.m.
231-1	51837-51842	Error	_	
231-2	51843-51847	bars	_	
231-3	51847-51848	=	_	
231-4	51848-51849	±	_	
231-5	51849-51854	s.e.m	_	
231-6	51854-51855	.	_	

#Text=*Significant at threshold of P<0.0083 uncorrected or P<0.05 corrected (n=144, t-test).
232-1	51856-51857	*	_	
232-2	51857-51868	Significant	_	
232-3	51869-51871	at	_	
232-4	51872-51881	threshold	_	
232-5	51882-51884	of	_	
232-6	51885-51886	P	_	
232-7	51886-51887	<	_	
232-8	51887-51893	0.0083	_	
232-9	51894-51905	uncorrected	_	
232-10	51906-51908	or	_	
232-11	51909-51910	P	_	
232-12	51910-51911	<	_	
232-13	51911-51915	0.05	_	
232-14	51916-51925	corrected	_	
232-15	51926-51927	(	_	
232-16	51927-51928	n	_	
232-17	51928-51929	=	_	
232-18	51929-51932	144	_	
232-19	51932-51933	,	_	
232-20	51934-51940	t-test	_	
232-21	51940-51941	)	_	
232-22	51941-51942	.	_	

#Text=Experimental design diagram depicting subject selection procedure.
233-1	51943-51955	Experimental	_	
233-2	51956-51962	design	_	
233-3	51963-51970	diagram	_	
233-4	51971-51980	depicting	_	
233-5	51981-51988	subject	_	
233-6	51989-51998	selection	_	
233-7	51999-52008	procedure	_	
233-8	52008-52009	.	_	

#Text=Out of 1090 subjects with full datasets, the top quarter of novelty seekers who had not already met criteria for problematic drug use at age 14 were selected.
234-1	52010-52013	Out	_	
234-2	52014-52016	of	_	
234-3	52017-52021	1090	_	
234-4	52022-52030	subjects	_	
234-5	52031-52035	with	_	
234-6	52036-52040	full	_	
234-7	52041-52049	datasets	_	
234-8	52049-52050	,	_	
234-9	52051-52054	the	_	
234-10	52055-52058	top	_	
234-11	52059-52066	quarter	_	
234-12	52067-52069	of	_	
234-13	52070-52077	novelty	_	
234-14	52078-52085	seekers	_	
234-15	52086-52089	who	_	
234-16	52090-52093	had	_	
234-17	52094-52097	not	_	
234-18	52098-52105	already	_	
234-19	52106-52109	met	_	
234-20	52110-52118	criteria	_	
234-21	52119-52122	for	_	
234-22	52123-52134	problematic	_	
234-23	52135-52139	drug	_	
234-24	52140-52143	use	_	
234-25	52144-52146	at	_	
234-26	52147-52150	age	_	
234-27	52151-52153	14	_	
234-28	52154-52158	were	_	
234-29	52159-52167	selected	_	
234-30	52167-52168	.	_	

#Text=Those who showed problematic drug use at age 16 were matched with those who did not with respect to drug use at age 14 (n=72 per group, 144 total).
235-1	52169-52174	Those	_	
235-2	52175-52178	who	_	
235-3	52179-52185	showed	_	
235-4	52186-52197	problematic	_	
235-5	52198-52202	drug	_	
235-6	52203-52206	use	_	
235-7	52207-52209	at	_	
235-8	52210-52213	age	_	
235-9	52214-52216	16	_	
235-10	52217-52221	were	_	
235-11	52222-52229	matched	_	
235-12	52230-52234	with	_	
235-13	52235-52240	those	_	
235-14	52241-52244	who	_	
235-15	52245-52248	did	_	
235-16	52249-52252	not	_	
235-17	52253-52257	with	_	
235-18	52258-52265	respect	_	
235-19	52266-52268	to	_	
235-20	52269-52273	drug	_	
235-21	52274-52277	use	_	
235-22	52278-52280	at	_	
235-23	52281-52284	age	_	
235-24	52285-52287	14	_	
235-25	52288-52289	(	_	
235-26	52289-52290	n	_	
235-27	52290-52291	=	_	
235-28	52291-52293	72	_	
235-29	52294-52297	per	_	
235-30	52298-52303	group	_	
235-31	52303-52304	,	_	
235-32	52305-52308	144	_	
235-33	52309-52314	total	_	
235-34	52314-52315	)	_	
235-35	52315-52316	.	_	

#Text=Adapted Monetary Incentive Delay (MID) task trial structure.
236-1	52317-52324	Adapted	_	
236-2	52325-52333	Monetary	_	
236-3	52334-52343	Incentive	_	
236-4	52344-52349	Delay	_	
236-5	52350-52351	(	_	
236-6	52351-52354	MID	_	
236-7	52354-52355	)	_	
236-8	52356-52360	task	_	
236-9	52361-52366	trial	_	
236-10	52367-52376	structure	_	
236-11	52376-52377	.	_	

#Text=An initial cue signalled potential gain for each trial (no gain: 0 points; small gain: 2 points; or large gain: 10 points).
237-1	52378-52380	An	_	
237-2	52381-52388	initial	_	
237-3	52389-52392	cue	_	
237-4	52393-52402	signalled	_	
237-5	52403-52412	potential	_	
237-6	52413-52417	gain	_	
237-7	52418-52421	for	_	
237-8	52422-52426	each	_	
237-9	52427-52432	trial	_	
237-10	52433-52434	(	_	
237-11	52434-52436	no	_	
237-12	52437-52441	gain	_	
237-13	52441-52442	:	_	
237-14	52443-52444	0	_	
237-15	52445-52451	points	_	
237-16	52451-52452	;	_	
237-17	52453-52458	small	_	
237-18	52459-52463	gain	_	
237-19	52463-52464	:	_	
237-20	52465-52466	2	_	
237-21	52467-52473	points	_	
237-22	52473-52474	;	_	
237-23	52475-52477	or	_	
237-24	52478-52483	large	_	
237-25	52484-52488	gain	_	
237-26	52488-52489	:	_	
237-27	52490-52492	10	_	
237-28	52493-52499	points	_	
237-29	52499-52500	)	_	
237-30	52500-52501	.	_	

#Text=After a variable delay, a target briefly appeared.
238-1	52502-52507	After	_	
238-2	52508-52509	a	_	
238-3	52510-52518	variable	_	
238-4	52519-52524	delay	_	
238-5	52524-52525	,	_	
238-6	52526-52527	a	_	
238-7	52528-52534	target	_	
238-8	52535-52542	briefly	_	
238-9	52543-52551	appeared	_	
238-10	52551-52552	.	_	

#Text=Responding during target display yielded the indicated gain, whereas late or early responses yielded no gain.
239-1	52553-52563	Responding	_	
239-2	52564-52570	during	_	
239-3	52571-52577	target	_	
239-4	52578-52585	display	_	
239-5	52586-52593	yielded	_	
239-6	52594-52597	the	_	
239-7	52598-52607	indicated	_	
239-8	52608-52612	gain	_	
239-9	52612-52613	,	_	
239-10	52614-52621	whereas	_	
239-11	52622-52626	late	_	
239-12	52627-52629	or	_	
239-13	52630-52635	early	_	
239-14	52636-52645	responses	_	
239-15	52646-52653	yielded	_	
239-16	52654-52656	no	_	
239-17	52657-52661	gain	_	
239-18	52661-52662	.	_	

#Text=Target durations adapted to approximate a 66% hit rate for each subject.
240-1	52663-52669	Target	_	
240-2	52670-52679	durations	_	
240-3	52680-52687	adapted	_	
240-4	52688-52690	to	_	
240-5	52691-52702	approximate	_	
240-6	52703-52704	a	_	
240-7	52705-52708	66%	_	
240-8	52709-52712	hit	_	
240-9	52713-52717	rate	_	
240-10	52718-52721	for	_	
240-11	52722-52726	each	_	
240-12	52727-52734	subject	_	
240-13	52734-52735	.	_	

#Text=Subject group characteristics and comparisons.
#Text= 
241-1	52736-52743	Subject	_	
241-2	52744-52749	group	_	
241-3	52750-52765	characteristics	_	
241-4	52766-52769	and	_	
241-5	52770-52781	comparisons	_	
241-6	52781-52782	.	_	
241-7	52783-52784	 	_	

#Text=Control (n=72)\tProblematic drug use (n=72)\tTest\tPvalue\t \tDemographics\t \t Age (days)\t14.48 (0.40)\t14.38 (0.45)\tF(1,142)=1.82\t0.18\t \t Center site\t15 21 5 6 8 8 9\t9 11 10 10 12 12 8\tχ2(6)=8.95\t0.18\t \t PDS score\t2.08 (0.28)\t2.07 (0.26)\tF(1,142)=0.10\t0.76\t \t Gender (F/M)\t45 27\t41 31\tχ2(1)=0.46\t0.50\t \t Handedness (L/R)\t9 63\t6 66\tχ2(1)=0.67\t0.41\t \t Intelligence*\t167.71 (20.09)\t171.29 (18.67)\tF(1,142)=1.23\t0.27\t \t Socioeconomic status composite\t7.21 (3.37)\t7.15 (3.18)\tF(1,142)=0.01\t0.92\t \t ESPAD composite age 14\t6.33 (3.04)\t6.93 (4.97)\tF(1,142)=0.76\t0.39\t \t ESPAD composite age 16\t9.83 (4.66)\t20.24 (5.43)\tF(1,142)=152.19\t0.000**\t \t \t \t \t \t \t \tBehavioural measures\t \t CGT risk taking\t0.56 (0.14)\t0.54 (0.14)\tF(1,142)=0.79\t0.38\t \t MCQ discounting (log)\t−4.55 (1.38)\t−3.99 (1.53)\tF(1,142)=5.23\t0.024*\t \t MID large gain RT\t244.87 (26.55)\t253.89 (31.70)\tF(1,142)=3.43\t0.07\t \t MID small gain RT\t258.53 (35.72)\t263.28 (36.33)\tF(1,142)=0.62\t0.43\t \t MID no gain RT\t284.18 (44.64)\t300.95 (55.75)\tF(1,142)=3.97\t0.048*\t \t MID large gain prob.\t0.70 (0.09)\t0.69 (0.09)\tF(1,142)=0.80\t0.37\t \t MID small gain prob.\t0.70 (0.10)\t0.68 (0.10)\tF(1,142)=1.26\t0.26\t \t MID no gain prob.\t0.61 (0.11)\t0.56 (0.12)\tF(1,142)=5.96\t0.016*\t \t \t \t \t \t \t \tPersonality and psychopathology\t \t TCI novelty seeking\t127.93 (7.04)\t127.42 (6.11)\tF(1,142)=0.22\t0.64\t \t NEO neuroticism\t21.75 (7.98)\t22.24 (8.48)\tF(1,142)=0.13\t0.72\t \t NEO extraversion\t33.22 (4.97)\t32.15 (5.41)\tF(1,142)=1.53\t0.22\t \t NEO openness\t26.67 (5.49)\t26.01 (5.82)\tF(1,142)=0.48\t0.49\t \t NEO agreeableness\t28.21 (4.61)\t26.99 (5.83)\tF(1,142)=1.95\t0.16\t \t NEO conscientiousness\t25.44 (6.20)\t23.13 (6.13)\tF(1,142)=5.09\t0.026*\t \t DAWBA emotional\t65 2 5\t63 7 2\tχ2(2)=4.09\t0.13\t \t DAWBA behavioural\t55 13 4\t54 13 5\tχ2(2)=0.12\t0.94\t \t DAWBA hyperactive\t63 9\t64 8\tχ2(1)=0.07\t0.80\t \t DAWBA any\t47 16 9\t47 18 7\tχ2(2)=0.37\t0.83\t \t
#Text=CGT, Cambridge Gambling Task; DAWBA, Development and Well-Being Assessment; ESPAD, European School Survey Project on Alcohol and other Drugs; MCQ, Monetary-Choice Questionnaire; MID, Monetary Incentive Delay Task; NEO, Neuroticism-Extraversion-Openness Five-Factor Inventory; PDS, Pubertal Development Scale; RT, reaction time; TCI, Temperament and Character Inventory -- Revised.Intelligence reflects the sum of these categories of the Wechsler Intelligence Scale for Children (WISC-IV): Similarities, Vocabulary, Block design, Matrix reasoning, Digit span forward.
242-1	52785-52792	Control	_	
242-2	52793-52794	(	_	
242-3	52794-52795	n	_	
242-4	52795-52796	=	_	
242-5	52796-52798	72	_	
242-6	52798-52799	)	_	
242-7	52800-52811	Problematic	_	
242-8	52812-52816	drug	_	
242-9	52817-52820	use	_	
242-10	52821-52822	(	_	
242-11	52822-52823	n	_	
242-12	52823-52824	=	_	
242-13	52824-52826	72	_	
242-14	52826-52827	)	_	
242-15	52828-52832	Test	_	
242-16	52833-52839	Pvalue	_	
242-17	52842-52854	Demographics	_	
242-18	52858-52861	Age	_	
242-19	52862-52863	(	_	
242-20	52863-52867	days	_	
242-21	52867-52868	)	_	
242-22	52869-52874	14.48	_	
242-23	52875-52876	(	_	
242-24	52876-52880	0.40	_	
242-25	52880-52881	)	_	
242-26	52882-52887	14.38	_	
242-27	52888-52889	(	_	
242-28	52889-52893	0.45	_	
242-29	52893-52894	)	_	
242-30	52895-52896	F	_	
242-31	52896-52897	(	_	
242-32	52897-52902	1,142	_	
242-33	52902-52903	)	_	
242-34	52903-52904	=	_	
242-35	52904-52908	1.82	_	
242-36	52909-52913	0.18	_	
242-37	52917-52923	Center	_	
242-38	52924-52928	site	_	
242-39	52929-52931	15	_	
242-40	52932-52934	21	_	
242-41	52935-52936	5	_	
242-42	52937-52938	6	_	
242-43	52939-52940	8	_	
242-44	52941-52942	8	_	
242-45	52943-52944	9	_	
242-46	52945-52946	9	_	
242-47	52947-52949	11	_	
242-48	52950-52952	10	_	
242-49	52953-52955	10	_	
242-50	52956-52958	12	_	
242-51	52959-52961	12	_	
242-52	52962-52963	8	_	
242-53	52964-52966	χ2	_	
242-54	52966-52967	(	_	
242-55	52967-52968	6	_	
242-56	52968-52969	)	_	
242-57	52969-52970	=	_	
242-58	52970-52974	8.95	_	
242-59	52975-52979	0.18	_	
242-60	52983-52986	PDS	_	
242-61	52987-52992	score	_	
242-62	52993-52997	2.08	_	
242-63	52998-52999	(	_	
242-64	52999-53003	0.28	_	
242-65	53003-53004	)	_	
242-66	53005-53009	2.07	_	
242-67	53010-53011	(	_	
242-68	53011-53015	0.26	_	
242-69	53015-53016	)	_	
242-70	53017-53018	F	_	
242-71	53018-53019	(	_	
242-72	53019-53024	1,142	_	
242-73	53024-53025	)	_	
242-74	53025-53026	=	_	
242-75	53026-53030	0.10	_	
242-76	53031-53035	0.76	_	
242-77	53039-53045	Gender	_	
242-78	53046-53047	(	_	
242-79	53047-53048	F	_	
242-80	53048-53049	/	_	
242-81	53049-53050	M	_	
242-82	53050-53051	)	_	
242-83	53052-53054	45	_	
242-84	53055-53057	27	_	
242-85	53058-53060	41	_	
242-86	53061-53063	31	_	
242-87	53064-53066	χ2	_	
242-88	53066-53067	(	_	
242-89	53067-53068	1	_	
242-90	53068-53069	)	_	
242-91	53069-53070	=	_	
242-92	53070-53074	0.46	_	
242-93	53075-53079	0.50	_	
242-94	53083-53093	Handedness	_	
242-95	53094-53095	(	_	
242-96	53095-53096	L	_	
242-97	53096-53097	/	_	
242-98	53097-53098	R	_	
242-99	53098-53099	)	_	
242-100	53100-53101	9	_	
242-101	53102-53104	63	_	
242-102	53105-53106	6	_	
242-103	53107-53109	66	_	
242-104	53110-53112	χ2	_	
242-105	53112-53113	(	_	
242-106	53113-53114	1	_	
242-107	53114-53115	)	_	
242-108	53115-53116	=	_	
242-109	53116-53120	0.67	_	
242-110	53121-53125	0.41	_	
242-111	53129-53141	Intelligence	_	
242-112	53141-53142	*	_	
242-113	53143-53149	167.71	_	
242-114	53150-53151	(	_	
242-115	53151-53156	20.09	_	
242-116	53156-53157	)	_	
242-117	53158-53164	171.29	_	
242-118	53165-53166	(	_	
242-119	53166-53171	18.67	_	
242-120	53171-53172	)	_	
242-121	53173-53174	F	_	
242-122	53174-53175	(	_	
242-123	53175-53180	1,142	_	
242-124	53180-53181	)	_	
242-125	53181-53182	=	_	
242-126	53182-53186	1.23	_	
242-127	53187-53191	0.27	_	
242-128	53195-53208	Socioeconomic	_	
242-129	53209-53215	status	_	
242-130	53216-53225	composite	_	
242-131	53226-53230	7.21	_	
242-132	53231-53232	(	_	
242-133	53232-53236	3.37	_	
242-134	53236-53237	)	_	
242-135	53238-53242	7.15	_	
242-136	53243-53244	(	_	
242-137	53244-53248	3.18	_	
242-138	53248-53249	)	_	
242-139	53250-53251	F	_	
242-140	53251-53252	(	_	
242-141	53252-53257	1,142	_	
242-142	53257-53258	)	_	
242-143	53258-53259	=	_	
242-144	53259-53263	0.01	_	
242-145	53264-53268	0.92	_	
242-146	53272-53277	ESPAD	_	
242-147	53278-53287	composite	_	
242-148	53288-53291	age	_	
242-149	53292-53294	14	_	
242-150	53295-53299	6.33	_	
242-151	53300-53301	(	_	
242-152	53301-53305	3.04	_	
242-153	53305-53306	)	_	
242-154	53307-53311	6.93	_	
242-155	53312-53313	(	_	
242-156	53313-53317	4.97	_	
242-157	53317-53318	)	_	
242-158	53319-53320	F	_	
242-159	53320-53321	(	_	
242-160	53321-53326	1,142	_	
242-161	53326-53327	)	_	
242-162	53327-53328	=	_	
242-163	53328-53332	0.76	_	
242-164	53333-53337	0.39	_	
242-165	53341-53346	ESPAD	_	
242-166	53347-53356	composite	_	
242-167	53357-53360	age	_	
242-168	53361-53363	16	_	
242-169	53364-53368	9.83	_	
242-170	53369-53370	(	_	
242-171	53370-53374	4.66	_	
242-172	53374-53375	)	_	
242-173	53376-53381	20.24	_	
242-174	53382-53383	(	_	
242-175	53383-53387	5.43	_	
242-176	53387-53388	)	_	
242-177	53389-53390	F	_	
242-178	53390-53391	(	_	
242-179	53391-53396	1,142	_	
242-180	53396-53397	)	_	
242-181	53397-53398	=	_	
242-182	53398-53404	152.19	_	
242-183	53405-53410	0.000	_	
242-184	53410-53411	*	_	
242-185	53411-53412	*	_	
242-186	53415-53424	 	 	 	 	 	_	
242-187	53427-53438	Behavioural	_	
242-188	53439-53447	measures	_	
242-189	53451-53454	CGT	_	
242-190	53455-53459	risk	_	
242-191	53460-53466	taking	_	
242-192	53467-53471	0.56	_	
242-193	53472-53473	(	_	
242-194	53473-53477	0.14	_	
242-195	53477-53478	)	_	
242-196	53479-53483	0.54	_	
242-197	53484-53485	(	_	
242-198	53485-53489	0.14	_	
242-199	53489-53490	)	_	
242-200	53491-53492	F	_	
242-201	53492-53493	(	_	
242-202	53493-53498	1,142	_	
242-203	53498-53499	)	_	
242-204	53499-53500	=	_	
242-205	53500-53504	0.79	_	
242-206	53505-53509	0.38	_	
242-207	53513-53516	MCQ	_	
242-208	53517-53528	discounting	_	
242-209	53529-53530	(	_	
242-210	53530-53533	log	_	
242-211	53533-53534	)	_	
242-212	53535-53536	−	_	
242-213	53536-53540	4.55	_	
242-214	53541-53542	(	_	
242-215	53542-53546	1.38	_	
242-216	53546-53547	)	_	
242-217	53548-53549	−	_	
242-218	53549-53553	3.99	_	
242-219	53554-53555	(	_	
242-220	53555-53559	1.53	_	
242-221	53559-53560	)	_	
242-222	53561-53562	F	_	
242-223	53562-53563	(	_	
242-224	53563-53568	1,142	_	
242-225	53568-53569	)	_	
242-226	53569-53570	=	_	
242-227	53570-53574	5.23	_	
242-228	53575-53580	0.024	_	
242-229	53580-53581	*	_	
242-230	53585-53588	MID	_	
242-231	53589-53594	large	_	
242-232	53595-53599	gain	_	
242-233	53600-53602	RT	_	
242-234	53603-53609	244.87	_	
242-235	53610-53611	(	_	
242-236	53611-53616	26.55	_	
242-237	53616-53617	)	_	
242-238	53618-53624	253.89	_	
242-239	53625-53626	(	_	
242-240	53626-53631	31.70	_	
242-241	53631-53632	)	_	
242-242	53633-53634	F	_	
242-243	53634-53635	(	_	
242-244	53635-53640	1,142	_	
242-245	53640-53641	)	_	
242-246	53641-53642	=	_	
242-247	53642-53646	3.43	_	
242-248	53647-53651	0.07	_	
242-249	53655-53658	MID	_	
242-250	53659-53664	small	_	
242-251	53665-53669	gain	_	
242-252	53670-53672	RT	_	
242-253	53673-53679	258.53	_	
242-254	53680-53681	(	_	
242-255	53681-53686	35.72	_	
242-256	53686-53687	)	_	
242-257	53688-53694	263.28	_	
242-258	53695-53696	(	_	
242-259	53696-53701	36.33	_	
242-260	53701-53702	)	_	
242-261	53703-53704	F	_	
242-262	53704-53705	(	_	
242-263	53705-53710	1,142	_	
242-264	53710-53711	)	_	
242-265	53711-53712	=	_	
242-266	53712-53716	0.62	_	
242-267	53717-53721	0.43	_	
242-268	53725-53728	MID	_	
242-269	53729-53731	no	_	
242-270	53732-53736	gain	_	
242-271	53737-53739	RT	_	
242-272	53740-53746	284.18	_	
242-273	53747-53748	(	_	
242-274	53748-53753	44.64	_	
242-275	53753-53754	)	_	
242-276	53755-53761	300.95	_	
242-277	53762-53763	(	_	
242-278	53763-53768	55.75	_	
242-279	53768-53769	)	_	
242-280	53770-53771	F	_	
242-281	53771-53772	(	_	
242-282	53772-53777	1,142	_	
242-283	53777-53778	)	_	
242-284	53778-53779	=	_	
242-285	53779-53783	3.97	_	
242-286	53784-53789	0.048	_	
242-287	53789-53790	*	_	
242-288	53794-53797	MID	_	
242-289	53798-53803	large	_	
242-290	53804-53808	gain	_	
242-291	53809-53813	prob	_	
242-292	53813-53814	.	_	
242-293	53815-53819	0.70	_	
242-294	53820-53821	(	_	
242-295	53821-53825	0.09	_	
242-296	53825-53826	)	_	
242-297	53827-53831	0.69	_	
242-298	53832-53833	(	_	
242-299	53833-53837	0.09	_	
242-300	53837-53838	)	_	
242-301	53839-53840	F	_	
242-302	53840-53841	(	_	
242-303	53841-53846	1,142	_	
242-304	53846-53847	)	_	
242-305	53847-53848	=	_	
242-306	53848-53852	0.80	_	
242-307	53853-53857	0.37	_	
242-308	53861-53864	MID	_	
242-309	53865-53870	small	_	
242-310	53871-53875	gain	_	
242-311	53876-53880	prob	_	
242-312	53880-53881	.	_	
242-313	53882-53886	0.70	_	
242-314	53887-53888	(	_	
242-315	53888-53892	0.10	_	
242-316	53892-53893	)	_	
242-317	53894-53898	0.68	_	
242-318	53899-53900	(	_	
242-319	53900-53904	0.10	_	
242-320	53904-53905	)	_	
242-321	53906-53907	F	_	
242-322	53907-53908	(	_	
242-323	53908-53913	1,142	_	
242-324	53913-53914	)	_	
242-325	53914-53915	=	_	
242-326	53915-53919	1.26	_	
242-327	53920-53924	0.26	_	
242-328	53928-53931	MID	_	
242-329	53932-53934	no	_	
242-330	53935-53939	gain	_	
242-331	53940-53944	prob	_	
242-332	53944-53945	.	_	
242-333	53946-53950	0.61	_	
242-334	53951-53952	(	_	
242-335	53952-53956	0.11	_	
242-336	53956-53957	)	_	
242-337	53958-53962	0.56	_	
242-338	53963-53964	(	_	
242-339	53964-53968	0.12	_	
242-340	53968-53969	)	_	
242-341	53970-53971	F	_	
242-342	53971-53972	(	_	
242-343	53972-53977	1,142	_	
242-344	53977-53978	)	_	
242-345	53978-53979	=	_	
242-346	53979-53983	5.96	_	
242-347	53984-53989	0.016	_	
242-348	53989-53990	*	_	
242-349	53993-54002	 	 	 	 	 	_	
242-350	54005-54016	Personality	_	
242-351	54017-54020	and	_	
242-352	54021-54036	psychopathology	_	
242-353	54040-54043	TCI	_	
242-354	54044-54051	novelty	_	
242-355	54052-54059	seeking	_	
242-356	54060-54066	127.93	_	
242-357	54067-54068	(	_	
242-358	54068-54072	7.04	_	
242-359	54072-54073	)	_	
242-360	54074-54080	127.42	_	
242-361	54081-54082	(	_	
242-362	54082-54086	6.11	_	
242-363	54086-54087	)	_	
242-364	54088-54089	F	_	
242-365	54089-54090	(	_	
242-366	54090-54095	1,142	_	
242-367	54095-54096	)	_	
242-368	54096-54097	=	_	
242-369	54097-54101	0.22	_	
242-370	54102-54106	0.64	_	
242-371	54110-54113	NEO	_	
242-372	54114-54125	neuroticism	_	
242-373	54126-54131	21.75	_	
242-374	54132-54133	(	_	
242-375	54133-54137	7.98	_	
242-376	54137-54138	)	_	
242-377	54139-54144	22.24	_	
242-378	54145-54146	(	_	
242-379	54146-54150	8.48	_	
242-380	54150-54151	)	_	
242-381	54152-54153	F	_	
242-382	54153-54154	(	_	
242-383	54154-54159	1,142	_	
242-384	54159-54160	)	_	
242-385	54160-54161	=	_	
242-386	54161-54165	0.13	_	
242-387	54166-54170	0.72	_	
242-388	54174-54177	NEO	_	
242-389	54178-54190	extraversion	_	
242-390	54191-54196	33.22	_	
242-391	54197-54198	(	_	
242-392	54198-54202	4.97	_	
242-393	54202-54203	)	_	
242-394	54204-54209	32.15	_	
242-395	54210-54211	(	_	
242-396	54211-54215	5.41	_	
242-397	54215-54216	)	_	
242-398	54217-54218	F	_	
242-399	54218-54219	(	_	
242-400	54219-54224	1,142	_	
242-401	54224-54225	)	_	
242-402	54225-54226	=	_	
242-403	54226-54230	1.53	_	
242-404	54231-54235	0.22	_	
242-405	54239-54242	NEO	_	
242-406	54243-54251	openness	_	
242-407	54252-54257	26.67	_	
242-408	54258-54259	(	_	
242-409	54259-54263	5.49	_	
242-410	54263-54264	)	_	
242-411	54265-54270	26.01	_	
242-412	54271-54272	(	_	
242-413	54272-54276	5.82	_	
242-414	54276-54277	)	_	
242-415	54278-54279	F	_	
242-416	54279-54280	(	_	
242-417	54280-54285	1,142	_	
242-418	54285-54286	)	_	
242-419	54286-54287	=	_	
242-420	54287-54291	0.48	_	
242-421	54292-54296	0.49	_	
242-422	54300-54303	NEO	_	
242-423	54304-54317	agreeableness	_	
242-424	54318-54323	28.21	_	
242-425	54324-54325	(	_	
242-426	54325-54329	4.61	_	
242-427	54329-54330	)	_	
242-428	54331-54336	26.99	_	
242-429	54337-54338	(	_	
242-430	54338-54342	5.83	_	
242-431	54342-54343	)	_	
242-432	54344-54345	F	_	
242-433	54345-54346	(	_	
242-434	54346-54351	1,142	_	
242-435	54351-54352	)	_	
242-436	54352-54353	=	_	
242-437	54353-54357	1.95	_	
242-438	54358-54362	0.16	_	
242-439	54366-54369	NEO	_	
242-440	54370-54387	conscientiousness	_	
242-441	54388-54393	25.44	_	
242-442	54394-54395	(	_	
242-443	54395-54399	6.20	_	
242-444	54399-54400	)	_	
242-445	54401-54406	23.13	_	
242-446	54407-54408	(	_	
242-447	54408-54412	6.13	_	
242-448	54412-54413	)	_	
242-449	54414-54415	F	_	
242-450	54415-54416	(	_	
242-451	54416-54421	1,142	_	
242-452	54421-54422	)	_	
242-453	54422-54423	=	_	
242-454	54423-54427	5.09	_	
242-455	54428-54433	0.026	_	
242-456	54433-54434	*	_	
242-457	54438-54443	DAWBA	_	
242-458	54444-54453	emotional	_	
242-459	54454-54456	65	_	
242-460	54457-54458	2	_	
242-461	54459-54460	5	_	
242-462	54461-54463	63	_	
242-463	54464-54465	7	_	
242-464	54466-54467	2	_	
242-465	54468-54470	χ2	_	
242-466	54470-54471	(	_	
242-467	54471-54472	2	_	
242-468	54472-54473	)	_	
242-469	54473-54474	=	_	
242-470	54474-54478	4.09	_	
242-471	54479-54483	0.13	_	
242-472	54487-54492	DAWBA	_	
242-473	54493-54504	behavioural	_	
242-474	54505-54507	55	_	
242-475	54508-54510	13	_	
242-476	54511-54512	4	_	
242-477	54513-54515	54	_	
242-478	54516-54518	13	_	
242-479	54519-54520	5	_	
242-480	54521-54523	χ2	_	
242-481	54523-54524	(	_	
242-482	54524-54525	2	_	
242-483	54525-54526	)	_	
242-484	54526-54527	=	_	
242-485	54527-54531	0.12	_	
242-486	54532-54536	0.94	_	
242-487	54540-54545	DAWBA	_	
242-488	54546-54557	hyperactive	_	
242-489	54558-54560	63	_	
242-490	54561-54562	9	_	
242-491	54563-54565	64	_	
242-492	54566-54567	8	_	
242-493	54568-54570	χ2	_	
242-494	54570-54571	(	_	
242-495	54571-54572	1	_	
242-496	54572-54573	)	_	
242-497	54573-54574	=	_	
242-498	54574-54578	0.07	_	
242-499	54579-54583	0.80	_	
242-500	54587-54592	DAWBA	_	
242-501	54593-54596	any	_	
242-502	54597-54599	47	_	
242-503	54600-54602	16	_	
242-504	54603-54604	9	_	
242-505	54605-54607	47	_	
242-506	54608-54610	18	_	
242-507	54611-54612	7	_	
242-508	54613-54615	χ2	_	
242-509	54615-54616	(	_	
242-510	54616-54617	2	_	
242-511	54617-54618	)	_	
242-512	54618-54619	=	_	
242-513	54619-54623	0.37	_	
242-514	54624-54628	0.83	_	
242-515	54632-54635	CGT	_	
242-516	54635-54636	,	_	
242-517	54637-54646	Cambridge	_	
242-518	54647-54655	Gambling	_	
242-519	54656-54660	Task	_	
242-520	54660-54661	;	_	
242-521	54662-54667	DAWBA	_	
242-522	54667-54668	,	_	
242-523	54669-54680	Development	_	
242-524	54681-54684	and	_	
242-525	54685-54695	Well-Being	_	
242-526	54696-54706	Assessment	_	
242-527	54706-54707	;	_	
242-528	54708-54713	ESPAD	_	
242-529	54713-54714	,	_	
242-530	54715-54723	European	_	
242-531	54724-54730	School	_	
242-532	54731-54737	Survey	_	
242-533	54738-54745	Project	_	
242-534	54746-54748	on	_	
242-535	54749-54756	Alcohol	_	
242-536	54757-54760	and	_	
242-537	54761-54766	other	_	
242-538	54767-54772	Drugs	_	
242-539	54772-54773	;	_	
242-540	54774-54777	MCQ	_	
242-541	54777-54778	,	_	
242-542	54779-54794	Monetary-Choice	_	
242-543	54795-54808	Questionnaire	_	
242-544	54808-54809	;	_	
242-545	54810-54813	MID	_	
242-546	54813-54814	,	_	
242-547	54815-54823	Monetary	_	
242-548	54824-54833	Incentive	_	
242-549	54834-54839	Delay	_	
242-550	54840-54844	Task	_	
242-551	54844-54845	;	_	
242-552	54846-54849	NEO	_	
242-553	54849-54850	,	_	
242-554	54851-54884	Neuroticism-Extraversion-Openness	_	
242-555	54885-54896	Five-Factor	_	
242-556	54897-54906	Inventory	_	
242-557	54906-54907	;	_	
242-558	54908-54911	PDS	_	
242-559	54911-54912	,	_	
242-560	54913-54921	Pubertal	_	
242-561	54922-54933	Development	_	
242-562	54934-54939	Scale	_	
242-563	54939-54940	;	_	
242-564	54941-54943	RT	_	
242-565	54943-54944	,	_	
242-566	54945-54953	reaction	_	
242-567	54954-54958	time	_	
242-568	54958-54959	;	_	
242-569	54960-54963	TCI	_	
242-570	54963-54964	,	_	
242-571	54965-54976	Temperament	_	
242-572	54977-54980	and	_	
242-573	54981-54990	Character	_	
242-574	54991-55000	Inventory	_	
242-575	55001-55002	-	_	
242-576	55002-55003	-	_	
242-577	55004-55024	Revised.Intelligence	_	
242-578	55025-55033	reflects	_	
242-579	55034-55037	the	_	
242-580	55038-55041	sum	_	
242-581	55042-55044	of	_	
242-582	55045-55050	these	_	
242-583	55051-55061	categories	_	
242-584	55062-55064	of	_	
242-585	55065-55068	the	_	
242-586	55069-55077	Wechsler	_	
242-587	55078-55090	Intelligence	_	
242-588	55091-55096	Scale	_	
242-589	55097-55100	for	_	
242-590	55101-55109	Children	_	
242-591	55110-55111	(	_	
242-592	55111-55118	WISC-IV	_	
242-593	55118-55119	)	_	
242-594	55119-55120	:	_	
242-595	55121-55133	Similarities	_	
242-596	55133-55134	,	_	
242-597	55135-55145	Vocabulary	_	
242-598	55145-55146	,	_	
242-599	55147-55152	Block	_	
242-600	55153-55159	design	_	
242-601	55159-55160	,	_	
242-602	55161-55167	Matrix	_	
242-603	55168-55177	reasoning	_	
242-604	55177-55178	,	_	
242-605	55179-55184	Digit	_	
242-606	55185-55189	span	_	
242-607	55190-55197	forward	_	
242-608	55197-55198	.	_	

#Text=*Significant at uncorrected threshold of P<0.05 (n=144, t-test).
243-1	55199-55200	*	_	
243-2	55200-55211	Significant	_	
243-3	55212-55214	at	_	
243-4	55215-55226	uncorrected	_	
243-5	55227-55236	threshold	_	
243-6	55237-55239	of	_	
243-7	55240-55241	P	_	
243-8	55241-55242	<	_	
243-9	55242-55246	0.05	_	
243-10	55247-55248	(	_	
243-11	55248-55249	n	_	
243-12	55249-55250	=	_	
243-13	55250-55253	144	_	
243-14	55253-55254	,	_	
243-15	55255-55261	t-test	_	
243-16	55261-55262	)	_	
243-17	55262-55263	.	_	

#Text=**Significant at uncorrected threshold of P<0.01 (n=144, t-test).
#Text=fMRI activity for high versus low gain anticipation contrast (PDU>Control).
244-1	55263-55264	*	_	
244-2	55264-55265	*	_	
244-3	55265-55276	Significant	_	
244-4	55277-55279	at	_	
244-5	55280-55291	uncorrected	_	
244-6	55292-55301	threshold	_	
244-7	55302-55304	of	_	
244-8	55305-55306	P	_	
244-9	55306-55307	<	_	
244-10	55307-55311	0.01	_	
244-11	55312-55313	(	_	
244-12	55313-55314	n	_	
244-13	55314-55315	=	_	
244-14	55315-55318	144	_	
244-15	55318-55319	,	_	
244-16	55320-55326	t-test	_	
244-17	55326-55327	)	_	
244-18	55327-55328	.	_	
244-19	55329-55333	fMRI	_	
244-20	55334-55342	activity	_	
244-21	55343-55346	for	_	
244-22	55347-55351	high	_	
244-23	55352-55358	versus	_	
244-24	55359-55362	low	_	
244-25	55363-55367	gain	_	
244-26	55368-55380	anticipation	_	
244-27	55381-55389	contrast	_	
244-28	55390-55391	(	_	
244-29	55391-55394	PDU	_	
244-30	55394-55395	>	_	
244-31	55395-55402	Control	_	
244-32	55402-55403	)	_	
244-33	55403-55404	.	_	

#Text=Volume of interest (VOI)\tRight/Left\tT(126)\tP(uncorrected)\t \tVentral striatum\tR\t−2.66\t0.004*\t \t \tL\t−1.75\t0.042†\t \t \t \t \t \t \tMidbrain\tR\t−1.32\t0.095\t \t \tL\t−2.69\t0.004*\t \t \t \t \t \t \tDorsolateral prefrontal cortex\tR\t−2.48\t0.007*\t \t \tL\t−2.10\t0.019†\t \t
#Text=*Significant at corrected threshold of P≤0.0083 (n=144, t-test corrected for multiple VOIs).
245-1	55405-55411	Volume	_	
245-2	55412-55414	of	_	
245-3	55415-55423	interest	_	
245-4	55424-55425	(	_	
245-5	55425-55428	VOI	_	
245-6	55428-55429	)	_	
245-7	55430-55435	Right	_	
245-8	55435-55436	/	_	
245-9	55436-55440	Left	_	
245-10	55441-55442	T	_	
245-11	55442-55443	(	_	
245-12	55443-55446	126	_	
245-13	55446-55447	)	_	
245-14	55448-55449	P	_	
245-15	55449-55450	(	_	
245-16	55450-55461	uncorrected	_	
245-17	55461-55462	)	_	
245-18	55465-55472	Ventral	_	
245-19	55473-55481	striatum	_	
245-20	55482-55483	R	_	
245-21	55484-55485	−	_	
245-22	55485-55489	2.66	_	
245-23	55490-55495	0.004	_	
245-24	55495-55496	*	_	
245-25	55499-55500	 	_	
245-26	55501-55502	L	_	
245-27	55503-55504	−	_	
245-28	55504-55508	1.75	_	
245-29	55509-55514	0.042	_	
245-30	55514-55515	†	_	
245-31	55518-55525	 	 	 	 	_	
245-32	55528-55536	Midbrain	_	
245-33	55537-55538	R	_	
245-34	55539-55540	−	_	
245-35	55540-55544	1.32	_	
245-36	55545-55550	0.095	_	
245-37	55553-55554	 	_	
245-38	55555-55556	L	_	
245-39	55557-55558	−	_	
245-40	55558-55562	2.69	_	
245-41	55563-55568	0.004	_	
245-42	55568-55569	*	_	
245-43	55572-55579	 	 	 	 	_	
245-44	55582-55594	Dorsolateral	_	
245-45	55595-55605	prefrontal	_	
245-46	55606-55612	cortex	_	
245-47	55613-55614	R	_	
245-48	55615-55616	−	_	
245-49	55616-55620	2.48	_	
245-50	55621-55626	0.007	_	
245-51	55626-55627	*	_	
245-52	55630-55631	 	_	
245-53	55632-55633	L	_	
245-54	55634-55635	−	_	
245-55	55635-55639	2.10	_	
245-56	55640-55645	0.019	_	
245-57	55645-55646	†	_	
245-58	55650-55651	*	_	
245-59	55651-55662	Significant	_	
245-60	55663-55665	at	_	
245-61	55666-55675	corrected	_	
245-62	55676-55685	threshold	_	
245-63	55686-55688	of	_	
245-64	55689-55690	P	_	
245-65	55690-55691	≤	_	
245-66	55691-55697	0.0083	_	
245-67	55698-55699	(	_	
245-68	55699-55700	n	_	
245-69	55700-55701	=	_	
245-70	55701-55704	144	_	
245-71	55704-55705	,	_	
245-72	55706-55712	t-test	_	
245-73	55713-55722	corrected	_	
245-74	55723-55726	for	_	
245-75	55727-55735	multiple	_	
245-76	55736-55740	VOIs	_	
245-77	55740-55741	)	_	
245-78	55741-55742	.	_	

#Text=†Significant at uncorrected threshold of P≤0.05 (n=144, t-test).
246-1	55743-55744	†	_	
246-2	55744-55755	Significant	_	
246-3	55756-55758	at	_	
246-4	55759-55770	uncorrected	_	
246-5	55771-55780	threshold	_	
246-6	55781-55783	of	_	
246-7	55784-55785	P	_	
246-8	55785-55786	≤	_	
246-9	55786-55790	0.05	_	
246-10	55791-55792	(	_	
246-11	55792-55793	n	_	
246-12	55793-55794	=	_	
246-13	55794-55797	144	_	
246-14	55797-55798	,	_	
246-15	55799-55805	t-test	_	
246-16	55805-55806	)	_	
246-17	55806-55807	.	_	

#Text=Structural differences in grey matter density indexed by voxel-based morphometry (PDU>control).
247-1	55808-55818	Structural	_	
247-2	55819-55830	differences	_	
247-3	55831-55833	in	_	
247-4	55834-55838	grey	_	
247-5	55839-55845	matter	_	
247-6	55846-55853	density	_	
247-7	55854-55861	indexed	_	
247-8	55862-55864	by	_	
247-9	55865-55876	voxel-based	_	
247-10	55877-55888	morphometry	_	
247-11	55889-55890	(	_	
247-12	55890-55893	PDU	_	
247-13	55893-55894	>	_	
247-14	55894-55901	control	_	
247-15	55901-55902	)	_	
247-16	55902-55903	.	_	

#Text=Volume of interest (VOI)\tRight/Left\tT(126)\tP(uncorrected)\t \tVentral striatum\tR\t2.25\t0.013†\t \t \tL\t2.51\t0.007*\t \t \t \t \t \t \tMidbrain\tR\t−0.06\t>1\t \t \tL\t2.95\t0.002*\t \t \t \t \t \t \tDorsolateral Prefrontal Cortex\tR\t3.62\t0.001*\t \t \tL\t3.75\t0.001*\t \t
#Text=*Significant at corrected threshold of P<0.0083 (n=144, t-test corrected for multiple VOIs).
248-1	55904-55910	Volume	_	
248-2	55911-55913	of	_	
248-3	55914-55922	interest	_	
248-4	55923-55924	(	_	
248-5	55924-55927	VOI	_	
248-6	55927-55928	)	_	
248-7	55929-55934	Right	_	
248-8	55934-55935	/	_	
248-9	55935-55939	Left	_	
248-10	55940-55941	T	_	
248-11	55941-55942	(	_	
248-12	55942-55945	126	_	
248-13	55945-55946	)	_	
248-14	55947-55948	P	_	
248-15	55948-55949	(	_	
248-16	55949-55960	uncorrected	_	
248-17	55960-55961	)	_	
248-18	55964-55971	Ventral	_	
248-19	55972-55980	striatum	_	
248-20	55981-55982	R	_	
248-21	55983-55987	2.25	_	
248-22	55988-55993	0.013	_	
248-23	55993-55994	†	_	
248-24	55997-55998	 	_	
248-25	55999-56000	L	_	
248-26	56001-56005	2.51	_	
248-27	56006-56011	0.007	_	
248-28	56011-56012	*	_	
248-29	56015-56022	 	 	 	 	_	
248-30	56025-56033	Midbrain	_	
248-31	56034-56035	R	_	
248-32	56036-56037	−	_	
248-33	56037-56041	0.06	_	
248-34	56042-56043	>	_	
248-35	56043-56044	1	_	
248-36	56047-56048	 	_	
248-37	56049-56050	L	_	
248-38	56051-56055	2.95	_	
248-39	56056-56061	0.002	_	
248-40	56061-56062	*	_	
248-41	56065-56072	 	 	 	 	_	
248-42	56075-56087	Dorsolateral	_	
248-43	56088-56098	Prefrontal	_	
248-44	56099-56105	Cortex	_	
248-45	56106-56107	R	_	
248-46	56108-56112	3.62	_	
248-47	56113-56118	0.001	_	
248-48	56118-56119	*	_	
248-49	56122-56123	 	_	
248-50	56124-56125	L	_	
248-51	56126-56130	3.75	_	
248-52	56131-56136	0.001	_	
248-53	56136-56137	*	_	
248-54	56141-56142	*	_	
248-55	56142-56153	Significant	_	
248-56	56154-56156	at	_	
248-57	56157-56166	corrected	_	
248-58	56167-56176	threshold	_	
248-59	56177-56179	of	_	
248-60	56180-56181	P	_	
248-61	56181-56182	<	_	
248-62	56182-56188	0.0083	_	
248-63	56189-56190	(	_	
248-64	56190-56191	n	_	
248-65	56191-56192	=	_	
248-66	56192-56195	144	_	
248-67	56195-56196	,	_	
248-68	56197-56203	t-test	_	
248-69	56204-56213	corrected	_	
248-70	56214-56217	for	_	
248-71	56218-56226	multiple	_	
248-72	56227-56231	VOIs	_	
248-73	56231-56232	)	_	
248-74	56232-56233	.	_	

#Text=†Significant at uncorrected threshold of P<0.05 (n=144, t-test).
249-1	56234-56235	†	_	
249-2	56235-56246	Significant	_	
249-3	56247-56249	at	_	
249-4	56250-56261	uncorrected	_	
249-5	56262-56271	threshold	_	
249-6	56272-56274	of	_	
249-7	56275-56276	P	_	
249-8	56276-56277	<	_	
249-9	56277-56281	0.05	_	
249-10	56282-56283	(	_	
249-11	56283-56284	n	_	
249-12	56284-56285	=	_	
249-13	56285-56288	144	_	
249-14	56288-56289	,	_	
249-15	56290-56296	t-test	_	
249-16	56296-56297	)	_	
249-17	56297-56298	.	_	

#Text=Logistic regression models of psychological and neural features predicting problematic drug use in novelty-seeking adolescents two years later.
#Text= 
250-1	56299-56307	Logistic	_	
250-2	56308-56318	regression	_	
250-3	56319-56325	models	_	
250-4	56326-56328	of	_	
250-5	56329-56342	psychological	_	
250-6	56343-56346	and	_	
250-7	56347-56353	neural	_	
250-8	56354-56362	features	_	
250-9	56363-56373	predicting	_	
250-10	56374-56385	problematic	_	
250-11	56386-56390	drug	_	
250-12	56391-56394	use	_	
250-13	56395-56397	in	_	
250-14	56398-56413	novelty-seeking	_	
250-15	56414-56425	adolescents	_	
250-16	56426-56429	two	_	
250-17	56430-56435	years	_	
250-18	56436-56441	later	_	
250-19	56441-56442	.	_	
250-20	56443-56444	 	_	

#Text=Psychological\tNeural\tCombined\t \tDelay discounting\t0.28 (0.12)*2.30\t \t0.29 (0.13)**2.23\t \tConscientiousness\t−0.07 (0.03)*−2.27\t \t−0.07 (0.03)*−2.12\t \tR ventral striatum\t \t−0.11 (0.05)*−2.09\t−0.12 (0.05)*−2.16\t \tR dorsolateral prefrontal cortex\t \t−0.30 (0.09)**−3.30\t−0.30 (0.10)**−3.07\t \tPseudo R2 (ML)\t0.07\t0.15\t0.20\t \tAIC\t195\t183\t176\t \tClassification %\t58/55\t67/65\t74/66\t \t
#Text=AIC, Akaike Information criterion; ML, maximum likelihood.
251-1	56445-56458	Psychological	_	
251-2	56459-56465	Neural	_	
251-3	56466-56474	Combined	_	
251-4	56477-56482	Delay	_	
251-5	56483-56494	discounting	_	
251-6	56495-56499	0.28	_	
251-7	56500-56501	(	_	
251-8	56501-56505	0.12	_	
251-9	56505-56506	)	_	
251-10	56506-56507	*	_	
251-11	56507-56511	2.30	_	
251-12	56512-56513	 	_	
251-13	56514-56518	0.29	_	
251-14	56519-56520	(	_	
251-15	56520-56524	0.13	_	
251-16	56524-56525	)	_	
251-17	56525-56526	*	_	
251-18	56526-56527	*	_	
251-19	56527-56531	2.23	_	
251-20	56534-56551	Conscientiousness	_	
251-21	56552-56553	−	_	
251-22	56553-56557	0.07	_	
251-23	56558-56559	(	_	
251-24	56559-56563	0.03	_	
251-25	56563-56564	)	_	
251-26	56564-56565	*	_	
251-27	56565-56566	−	_	
251-28	56566-56570	2.27	_	
251-29	56571-56572	 	_	
251-30	56573-56574	−	_	
251-31	56574-56578	0.07	_	
251-32	56579-56580	(	_	
251-33	56580-56584	0.03	_	
251-34	56584-56585	)	_	
251-35	56585-56586	*	_	
251-36	56586-56587	−	_	
251-37	56587-56591	2.12	_	
251-38	56594-56595	R	_	
251-39	56596-56603	ventral	_	
251-40	56604-56612	striatum	_	
251-41	56613-56614	 	_	
251-42	56615-56616	−	_	
251-43	56616-56620	0.11	_	
251-44	56621-56622	(	_	
251-45	56622-56626	0.05	_	
251-46	56626-56627	)	_	
251-47	56627-56628	*	_	
251-48	56628-56629	−	_	
251-49	56629-56633	2.09	_	
251-50	56634-56635	−	_	
251-51	56635-56639	0.12	_	
251-52	56640-56641	(	_	
251-53	56641-56645	0.05	_	
251-54	56645-56646	)	_	
251-55	56646-56647	*	_	
251-56	56647-56648	−	_	
251-57	56648-56652	2.16	_	
251-58	56655-56656	R	_	
251-59	56657-56669	dorsolateral	_	
251-60	56670-56680	prefrontal	_	
251-61	56681-56687	cortex	_	
251-62	56688-56689	 	_	
251-63	56690-56691	−	_	
251-64	56691-56695	0.30	_	
251-65	56696-56697	(	_	
251-66	56697-56701	0.09	_	
251-67	56701-56702	)	_	
251-68	56702-56703	*	_	
251-69	56703-56704	*	_	
251-70	56704-56705	−	_	
251-71	56705-56709	3.30	_	
251-72	56710-56711	−	_	
251-73	56711-56715	0.30	_	
251-74	56716-56717	(	_	
251-75	56717-56721	0.10	_	
251-76	56721-56722	)	_	
251-77	56722-56723	*	_	
251-78	56723-56724	*	_	
251-79	56724-56725	−	_	
251-80	56725-56729	3.07	_	
251-81	56732-56738	Pseudo	_	
251-82	56739-56741	R2	_	
251-83	56742-56743	(	_	
251-84	56743-56745	ML	_	
251-85	56745-56746	)	_	
251-86	56747-56751	0.07	_	
251-87	56752-56756	0.15	_	
251-88	56757-56761	0.20	_	
251-89	56764-56767	AIC	_	
251-90	56768-56771	195	_	
251-91	56772-56775	183	_	
251-92	56776-56779	176	_	
251-93	56782-56796	Classification	_	
251-94	56797-56798	%	_	
251-95	56799-56801	58	_	
251-96	56801-56802	/	_	
251-97	56802-56804	55	_	
251-98	56805-56807	67	_	
251-99	56807-56808	/	_	
251-100	56808-56810	65	_	
251-101	56811-56813	74	_	
251-102	56813-56814	/	_	
251-103	56814-56816	66	_	
251-104	56820-56823	AIC	_	
251-105	56823-56824	,	_	
251-106	56825-56831	Akaike	_	
251-107	56832-56843	Information	_	
251-108	56844-56853	criterion	_	
251-109	56853-56854	;	_	
251-110	56855-56857	ML	_	
251-111	56857-56858	,	_	
251-112	56859-56866	maximum	_	
251-113	56867-56877	likelihood	_	
251-114	56877-56878	.	_	

#Text=Statistics are standardized coefficients, followed by standard errors of the mean in parentheses, and Z-scores (n=144, significance: *P<0.05; **P<0.01, t-test).
252-1	56879-56889	Statistics	_	
252-2	56890-56893	are	_	
252-3	56894-56906	standardized	_	
252-4	56907-56919	coefficients	_	
252-5	56919-56920	,	_	
252-6	56921-56929	followed	_	
252-7	56930-56932	by	_	
252-8	56933-56941	standard	_	
252-9	56942-56948	errors	_	
252-10	56949-56951	of	_	
252-11	56952-56955	the	_	
252-12	56956-56960	mean	_	
252-13	56961-56963	in	_	
252-14	56964-56975	parentheses	_	
252-15	56975-56976	,	_	
252-16	56977-56980	and	_	
252-17	56981-56989	Z-scores	_	
252-18	56990-56991	(	_	
252-19	56991-56992	n	_	
252-20	56992-56993	=	_	
252-21	56993-56996	144	_	
252-22	56996-56997	,	_	
252-23	56998-57010	significance	_	
252-24	57010-57011	:	_	
252-25	57012-57013	*	_	
252-26	57013-57014	P	_	
252-27	57014-57015	<	_	
252-28	57015-57019	0.05	_	
252-29	57019-57020	;	_	
252-30	57021-57022	*	_	
252-31	57022-57023	*	_	
252-32	57023-57024	P	_	
252-33	57024-57025	<	_	
252-34	57025-57029	0.01	_	
252-35	57029-57030	,	_	
252-36	57031-57037	t-test	_	
252-37	57037-57038	)	_	
252-38	57038-57039	.	_	

#Text=Classification was determined using 10-fold cross-validation over fits of a linear support vector machine, with 50% classification representing chance (train/test rates).
253-1	57040-57054	Classification	_	
253-2	57055-57058	was	_	
253-3	57059-57069	determined	_	
253-4	57070-57075	using	_	
253-5	57076-57078	10	_	
253-6	57078-57079	-	_	
253-7	57079-57083	fold	_	
253-8	57084-57100	cross-validation	_	
253-9	57101-57105	over	_	
253-10	57106-57110	fits	_	
253-11	57111-57113	of	_	
253-12	57114-57115	a	_	
253-13	57116-57122	linear	_	
253-14	57123-57130	support	_	
253-15	57131-57137	vector	_	
253-16	57138-57145	machine	_	
253-17	57145-57146	,	_	
253-18	57147-57151	with	_	
253-19	57152-57155	50%	_	
253-20	57156-57170	classification	_	
253-21	57171-57183	representing	_	
253-22	57184-57190	chance	_	
253-23	57191-57192	(	_	
253-24	57192-57197	train	_	
253-25	57197-57198	/	_	
253-26	57198-57202	test	_	
253-27	57203-57208	rates	_	
253-28	57208-57209	)	_	
253-29	57209-57210	.	_	
